
<html lang="en"     class="pb-page"  data-request-id="b37e4191-0514-4096-b0a1-5df93f96d6c2"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b00454;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2019.62.issue-14;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives" /></meta><meta name="dc.Creator" content="Christopher  Heim" /></meta><meta name="dc.Creator" content="Dimanthi  Pliatsika" /></meta><meta name="dc.Creator" content="Farnoush  Mousavizadeh" /></meta><meta name="dc.Creator" content="Kerstin  Bär" /></meta><meta name="dc.Creator" content="Birte  Hernandez Alvarez" /></meta><meta name="dc.Creator" content="Athanassios  Giannis" /></meta><meta name="dc.Creator" content="Marcus D.  Hartmann" /></meta><meta name="dc.Description" content="Targeted protein degradation via cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase complex, is an increasingly important strategy in various clinical settings, in which the substrate ..." /></meta><meta name="Description" content="Targeted protein degradation via cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase complex, is an increasingly important strategy in various clinical settings, in which the substrate ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 28, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00454" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00454" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00454" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00454" /></link>
        
    
    

<title>De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00454" /></meta><meta property="og:title" content="De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0012.jpeg" /></meta><meta property="og:description" content="Targeted protein degradation via cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase complex, is an increasingly important strategy in various clinical settings, in which the substrate specificity of CRBN is altered via the binding of small-molecule effectors. To date, such effectors are derived from thalidomide and confer a broad substrate spectrum that is far from being fully characterized. Here, we employed a rational and modular approach to design novel and minimalistic CRBN effectors. In this approach, we took advantage of the binding modes of hydrolyzed metabolites of several thalidomide-derived effectors, which we elucidated via crystallography. These yielded key insights for the optimization of the minimal core binding moiety and its linkage to a chemical moiety that imparts substrate specificity. Based on this scaffold, we present a first active de-novo CRBN effector that is able to degrade the neo-substrate IKZF3 in the cell culture." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00454"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00454">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00454&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00454&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00454&amp;href=/doi/10.1021/acs.jmedchem.9b00454" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 6615-6629</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00413" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00447" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Christopher Heim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher Heim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Protein Evolution, Max Planck Institute for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++Heim">Christopher Heim</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dimanthi Pliatsika</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dimanthi Pliatsika</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty for Chemistry und Mineralogy, Institute of Organic Chemistry, University of Leipzig, Johannisallee 29, 04103 Leipzig, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dimanthi++Pliatsika">Dimanthi Pliatsika</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Farnoush Mousavizadeh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Farnoush Mousavizadeh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty for Chemistry und Mineralogy, Institute of Organic Chemistry, University of Leipzig, Johannisallee 29, 04103 Leipzig, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Farnoush++Mousavizadeh">Farnoush Mousavizadeh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kerstin Bär</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kerstin Bär</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Protein Evolution, Max Planck Institute for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kerstin++B%C3%A4r">Kerstin Bär</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Birte Hernandez Alvarez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Birte Hernandez Alvarez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Protein Evolution, Max Planck Institute for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Birte++Hernandez+Alvarez">Birte Hernandez Alvarez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Athanassios Giannis</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Athanassios Giannis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty for Chemistry und Mineralogy, Institute of Organic Chemistry, University of Leipzig, Johannisallee 29, 04103 Leipzig, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#ccaba5ada2a2a5bf8cb9a2a5e1a0a9a5bcb6a5abe2a8a9"><span class="__cf_email__" data-cfemail="04636d656a6a6d7744716a6d2968616d747e6d632a6061">[email protected]</span></a> (A.G.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Athanassios++Giannis">Athanassios Giannis</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2203-0959" title="Orcid link">http://orcid.org/0000-0003-2203-0959</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Marcus D. Hartmann</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marcus D. Hartmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Protein Evolution, Max Planck Institute for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#b4d9d5c6d7c1c79adcd5c6c0d9d5dadaf4c0c1d1d6dddad3d1da9ad9c4d39ad0d1"><span class="__cf_email__" data-cfemail="e18c8093829492cf898093958c808f8fa195948483888f86848fcf8c9186cf8584">[email protected]</span></a> (M.D.H.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marcus+D.++Hartmann">Marcus D. Hartmann</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6937-5677" title="Orcid link">http://orcid.org/0000-0001-6937-5677</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00454&amp;href=/doi/10.1021%2Facs.jmedchem.9b00454" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 6615–6629</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 28, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 March 2019</li><li><span class="item_label"><b>Published</b> online</span>28 June 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 July 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00454" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00454</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00454"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5738</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">6</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00454" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;Heim&quot;},{&quot;first_name&quot;:&quot;Dimanthi&quot;,&quot;last_name&quot;:&quot;Pliatsika&quot;},{&quot;first_name&quot;:&quot;Farnoush&quot;,&quot;last_name&quot;:&quot;Mousavizadeh&quot;},{&quot;first_name&quot;:&quot;Kerstin&quot;,&quot;last_name&quot;:&quot;Bär&quot;},{&quot;first_name&quot;:&quot;Birte&quot;,&quot;last_name&quot;:&quot;Hernandez Alvarez&quot;},{&quot;first_name&quot;:&quot;Athanassios&quot;,&quot;last_name&quot;:&quot;Giannis&quot;},{&quot;first_name&quot;:&quot;Marcus&quot;,&quot;last_name&quot;:&quot;D. Hartmann&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;6615-6629&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00454&quot;},&quot;abstract&quot;:&quot;Targeted protein degradation via cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase complex, is an increasingly important strategy in various clinical settings, in which the substrate specificity of CRBN is altered via the binding of small-molecule effectors. To date, such effectors are derived from thalidomide and confer a broad substrate spectrum that is far from being fully characterized. Here, we employed a rational and modular approach to design novel and minimalistic CRBN effectors. In this approach, we took advantage of the binding modes of hydrolyzed metabolites of several thalidomide-derived effectors, which we elucidated via crystallography. These yielded key insights for the optimization of the minimal core binding moiety and its linkage to a chemical moiety that imparts substrate specificity. Based on this scaffold, we present a first active de-novo CRBN effector that is able to degrade the neo-substrate IKZF3 in the cell culture.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00454&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00454" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00454&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00454" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00454&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00454" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00454&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00454&amp;href=/doi/10.1021/acs.jmedchem.9b00454" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00454" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00454" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00454%26sid%3Dliteratum%253Aachs%26pmid%3D31251063%26genre%3Darticle%26aulast%3DHeim%26date%3D2019%26atitle%3DDe-Novo%2BDesign%2Bof%2BCereblon%2B%2528CRBN%2529%2BEffectors%2BGuided%2Bby%2BNatural%2BHydrolysis%2BProducts%2Bof%2BThalidomide%2BDerivatives%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D14%26spage%3D6615%26epage%3D6629%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292580" title="Binding modes">Binding modes</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=291208" title="Hydrolysis">Hydrolysis</a>,</li><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/jmcmar.2019.62.issue-14/20190725/jmcmar.2019.62.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Targeted protein degradation via cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase complex, is an increasingly important strategy in various clinical settings, in which the substrate specificity of CRBN is altered via the binding of small-molecule effectors. To date, such effectors are derived from thalidomide and confer a broad substrate spectrum that is far from being fully characterized. Here, we employed a rational and modular approach to design novel and minimalistic CRBN effectors. In this approach, we took advantage of the binding modes of hydrolyzed metabolites of several thalidomide-derived effectors, which we elucidated via crystallography. These yielded key insights for the optimization of the minimal core binding moiety and its linkage to a chemical moiety that imparts substrate specificity. Based on this scaffold, we present a first active de-novo CRBN effector that is able to degrade the neo-substrate IKZF3 in the cell culture.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Classical immunomodulatory drugs (IMiDs) like thalidomide and its second- and third-generation analogues lenalidomide, pomalidomide, avadomide (CC-122), and iberdomide (CC-220) have constantly emerged to new therapeutic areas. Originally developed as a sedative<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and banned in 1961 for its teratogenic effects when used during pregnancy,<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> thalidomide and a number of newly developed analogues are approved for the treatment of multiple myeloma (MM),<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> erythema nodosum<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and myelodysplastic syndrome (MDS).<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Because of their pleiotropic and especially anti-angiogenic properties, IMiDs have further been reported effective in many off-label indications as for Hodgkin’s lymphoma,<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> light chain-associated (AL) amyloidosis,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and acute myeloid leukemia (AML).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a></div><div class="NLM_p">Currently, IMiDs share a common glutarimide moiety (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which is connected to a second moiety that is typically derived from phthaloyl. Via the glutarimide moiety, they are able to bind to a tri-tryptophan pocket within the thalidomide-binding domain<a onclick="showRef(event, 'ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17">(14−17)</a> of cereblon (CRBN). CRBN is the substrate receptor of the Cullin RING E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (CRL4<sup>CRBN</sup>)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and responsible for the recognition of endogenous substrates such as glutamine synthetase,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> MEIS2,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and amyloid precursor protein (APP).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In the presence of IMiDs, however, its substrate specificity is changed. The solvent-exposed second moiety, the protruding moiety that is unique to each IMiD, recruits novel substrates to the CRBN surface for ubiquitination. The degradation of these neo-substrates accounts for most of the efficacy of IMiDs in MM (IKZF1 and IKZF3),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> 5q-deletion-associated MDS (CK1α),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and AML (GSPT1).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Recently, it has also been shown that the degradation of the neo-substrate SALL4 is linked to developmental malformations caused by thalidomide.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of thalidomide, lenalidomide, pomalidomide, avadomide, and iberdomide with their glutarimide moiety shown in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Crystal structures of the neo-substrate complexes CRBN·lenalidomide·CK1α, CRBN·pomalidomide·IKZF1, and CRBN·pomalidomide·ZNF692 provided first insights into the binding mode of neo-substrates.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> Many of the identified neo-substrates possess no obvious sequence homology, but they all exhibit a structurally analogous β-hairpin, which binds to the surface around the IMiD-binding site, involving interactions with both surface residues and the IMiD itself. A potential prerequisite for the recruitment is the presence of a glycine at the tip of this β-hairpin; this glycine was found to be conserved for many neo-substrates, like CK1α<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and GSPT1,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and appears in the common C-X(2)-C-G motif<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> in many transcription factors belonging to the C<sub>2</sub>H<sub>2</sub> zinc finger class, including IKZF3,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> IKZF1,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> ZFP91,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and SALL4.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> While IMiDs seem to generally recruit several members of the C<sub>2</sub>H<sub>2</sub> zinc finger family, only lenalidomide was proven to recruit CK1α, indicating that the protruding moiety imparts substrate specificity.</div><div class="NLM_p">The CRBN-binding ability of IMiDs has further been exploited for targeted protein degradation in an approach called proteolysis targeting chimera (PROTAC), coined in 2001 by Craig Crews and co-workers.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> PROTACs are bifunctional small molecules with a binding moiety for a target protein linked to a binding moiety for an E3 ubiquitin ligase, thus inducing ubiquitination and proteasomal degradation of the target protein. Recent examples of successful PROTACs target the estrogen<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and the androgen receptor<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> via a von-Hippel-Lindau (VHL) E3 ligase ligand but also BET bromodomains via linkage to thalidomide as a CRBN ligand.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Notably, also PROTACs with a VHL ligand on one and thalidomide as the CRBN ligand on the other end have been tested, leading to unidirectional degradation of CRBN.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In general, also the PROTAC approach has high potential to target the undruggable; a particularly illustrative example for this potential is exemplified by the recent discovery of PROTACs targeting the tau protein.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33−35)</a></div><div class="NLM_p last">To date, essentially all CRBN effectors—IMiDs and CRBN-based PROTACs—are derived from thalidomide and its derivatives. However, the chemical space of CRBN ligands ranges far beyond thalidomide: in first systematic characterization, we have previously revealed that a large variety of lactams and cyclic imides are potent binders, including several marketed drugs.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Specifically, we have shown succinimide to exhibit higher affinity than glutarimide, using the single-domain bacterial CRBN homologue from <i>Magnetospirillum gryphiswaldense</i> (MsCI4) in a FRET assay.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In this study, we set out to further explore and exploit the chemical space of CRBN binding by designing effectors based on succinimide and glutarimide, which we characterize with regard to their affinity, their structural binding mode, and their ability to induce proteasomal degradation of neo-substrates. Guided by hydrolyzed metabolites of thalidomide and of three of our designs, we present novel minimalistic motifs that are able to recruit and degrade neo-substrates and may serve as E3-recruiting ligands for future PROTACs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46708" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46708" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Biophysical and Structural Characterization of IMiD Analogues and Their Hydrolysis Products</h3><div class="NLM_p">As a starting point for new effectors, we chose the classical IMiD scaffold. Based on the finding that succinimide is able to bind to CRBN with a higher affinity than glutarimide (<i>K</i><sub>i</sub> values of 4.3 μM vs 28 μM for MsCI4<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>), we designed a first panel of derivatives based on glutarimide and succinimide, in which we probed the effect of different substitutions in the phthaloyl moiety (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The respective compounds <b>2a–5b</b> were prepared by the synthetic route shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The imides <b>3a</b> and <b>3b</b> were synthesized from the commercially available <i>N</i><sub>α</sub>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-asparagine (<b>1a</b>) and <i>N</i><sub>α</sub>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-glutamine (<b>1b</b>), respectively, via an imide formation using <i>N</i>,<i>N</i>-carbodiimidazole (CDI) and 4-dimethylaminopyridine (4-DMAP) in tetrahydrofuran (THF) as well as a deprotection reaction in the presence of trifluoracetic acid (TFA). Compounds <b>4a–4d</b> were obtained through coupling between the imides <b>3a</b> or <b>3b</b> and the commercially available 3-nitrophthalic anhydride or 4-nitrophthalic anhydride. Catalytic hydrogenation of the molecules <b>4a</b> and <b>4b</b> using 10 wt % Pd/C in EtOAc produced the derivatives <b>5a</b> and <b>5b</b>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The first panel of chemical structures, five- and six-ring based thalidomide analogues and their affinity to MsCI4 determined as <i>K</i><sub>i</sub> values in the FRET assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CDI, 4-DMAP, THF, reflux, 17–48 h; (b) TFA, RT, 30 min; (c) CDI, 4-DMAP, THF, reflux, 5–20 h; and (d) 10 wt % Pd/C, EtOAc, RT, 20 h.</p></p></figure><div class="NLM_p">The binding affinities of these compounds for MsCI4 were assessed in the FRET assay, starting with the glutarimide-based compounds <b>4c</b> and <b>4d</b> in comparison to the commercial thalidomide derivatives, lenalidomide and pomalidomide. Lenalidomide (<i>K</i><sub>i</sub> = 3.1 μM) and pomalidomide (<i>K</i><sub>i</sub> = 0.8 μM), both carrying an additional amino group in the R<sup>2</sup> position, show improved affinity to MsCI4 as compared to thalidomide (<i>K</i><sub>i</sub> = 4.4 μM). When we exchanged this amino group for a nitro group (<b>4c</b>), we saw a significant drop in affinity into a range in which a precise value could not be obtained (<i>K</i><sub>i</sub> > 40 μM);<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> moving this nitro group to the R<sup>1</sup> position (<b>4d</b>) had less impact on the affinity (<i>K</i><sub>i</sub> = 8.9 μM, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). Similar effects were observed in a recent study that was published during the preparation of this manuscript.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> As both compounds, <b>4c</b> and <b>4d</b>, retained affinity to MsCI4, their overall binding mode is supposedly conserved and comparable to thalidomide, which is consistent with previous studies, showing that small modifications on the protruding moiety have little influence on the overall affinity to CRBN.<a onclick="showRef(event, 'ref17 ref37'); return false;" href="javascript:void(0);" class="ref ref17 ref37">(17,37)</a> The binding modes of lenalidomide and pomalidomide have previously been reported to be virtually identical to thalidomide.<a onclick="showRef(event, 'ref14 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref17">(14,17)</a></div><div class="NLM_p">For the succinimide-based compounds <b>4a</b>, <b>4b</b>, <b>5a</b>, and <b>5b</b>, we obtained a similar picture as for the glutarimide-based compounds. Although they showed overall weaker binding in the FRET assay (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B), substitutions in the R<sup>2</sup> position are less favorable for the affinity as substitutions in R<sup>1</sup>. For <b>4a</b> and <b>5a</b>, which have a nitro or an amino group in R<sup>2</sup>, respectively, we obtained <i>K</i><sub>i</sub> values of >40 μM. For <b>4b</b> and <b>5b</b>, which have the respective groups in the R<sup>1</sup> position, the obtained <i>K</i><sub>i</sub> values are 11 and 12 μM, respectively.</div><div class="NLM_p">In a next step, we determined the molecular-binding determinants of the succinimide-based compounds via X-ray crystallography. To this end, crystals of the MsCI4·thalidomide complex were reproduced<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and subsequently used for soaking experiments, in which the thalidomide molecules bound to MsCI4 may be displaced by the compound of interest. There are three chains, that is, three MsCI4·thalidomide complexes, in the asymmetric unit (ASU) of these crystals, in which the bound thalidomide molecules can potentially be displaced. However, as the three chains form different crystal contacts and differ slightly in their conformation, it is possible that thalidomide is only replaced in one or two chains of the ASU, depending on the particular compound.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> These experiments yielded crystal structures for the four compounds tested, <b>4a</b>, <b>4b</b>, <b>5a</b>, and <b>5b</b>, all showing the classical IMiD binding mode with the basal main-chain interactions of the succinimide amino group with F77 and the carbonyl group with W79 of MsCI4. Also, the orientation of the protruding moieties of <b>4a</b>, <b>5a</b>, and <b>5b</b> is very similar to that of thalidomide, despite the different ring size of glutarimide and succinimide. As a result, the hydrogen bond that is typically observed between the conserved N50 and a carbonyl group of the phthaloyl moieties for the classical glutarimide-based compounds is also found for <b>5b</b>.</div><div class="NLM_p">However, the crystal structures also held surprises. They did not only reveal the binding modes of the pure compounds but also that of hydrolysis products of <b>4a</b>, <b>4b</b>, and <b>5a</b> with unambiguous electron density; only <b>5b</b> was exclusively observed in the nonhydrolyzed form (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). For <b>4a</b> and <b>5a</b>, hydrolyzed metabolites were only observed in one chain of the ASU, with the second chain occupied with a nonhydrolyzed version and the third chain with thalidomide. For <b>4b</b>, which showed the highest affinity with a <i>K</i><sub>i</sub> of 11 μM, all three binding pockets in the ASU were occupied by a hydrolyzed metabolite, so the binding mode of nonhydrolyzed <b>4b</b> could not be studied. In all cases, for the hydrolysis products of <b>4a</b>, <b>4b</b>, and <b>5a</b>, ring opening of the phthaloyl group had led to the formation of a secondary amide and a carboxyl group, which are clearly resolved in F<sub>O</sub>–F<sub>C</sub> omit maps (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Both of these form important interactions with the binding pocket: first, the secondary amide rescues the hydrogen bond to the conserved N50, which is typically formed by a carbonyl of the phthaloyl moiety. Second, the additional carboxyl group replaces a conserved water molecule previously coordinated by W99 and engages in direct hydrogen bonding with the W99 side chain. In contrary, the primary amino group of hydrolyzed <b>5a</b> and the solvent-exposed nitro groups of hydrolyzed <b>4a</b> and <b>4b</b> do not show additional interactions.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overview of the thalidomide-binding mode and electron densities of thalidomide analogues and their hydrolysis products bound to MsCI4. Left: Cartoon representation of thalidomide-bound MsCI4 with key residues of the binding pocket shown as sticks. Right: F<sub>O</sub>–F<sub>C</sub> maps of CBG (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0Q">6R0Q</a>), <b>4a</b> and hydrolyzed <b>4a</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0S">6R0S</a>), hydrolyzed <b>4b</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0V">6R0V</a>), <b>5a</b>, and hydrolyzed <b>5a</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0U">6R0U</a>) and <b>5b</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R11">6R11</a>) in the MsCI4-binding pocket, contoured at 2σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding mode of the initial compounds and their hydrolysis products inside the binding pocket. Thalidomide, <b>4a</b>, and <b>5a</b> are shown with their respective hydrolysis products. Ring opening of the phtaloyl moiety that leads to the observed hydrolysis product is indicated in red in the chemical drawings. <b>5b</b> was exclusively found in the nonhydrolyzed form, whereas <b>4b</b> was exclusively found as a hydrolysis product. PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V2Y">4V2Y</a> (thalidomide), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0Q">6R0Q</a> (<b>CBG</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0S">6R0S</a> (<b>4a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0U">6R0U</a> (<b>5a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R11">6R11</a> (<b>5b</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0V">6R0V</a> (<b>4b</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Binding Mode of CBG, a Major Hydrolysis Product of Thalidomide</h3><div class="NLM_p last">Unintentionally, in addition to the hydrolysis products of <b>4a</b>, <b>4b</b>, and <b>5a</b>, we were able to characterize the binding mode of a major hydrolyzed thalidomide metabolite. It is known that IMiDs can rapidly racemize in bodily fluids and water<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and spontaneously hydrolyze under physiological conditions.<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39−41)</a> For thalidomide, being eliminated mainly by spontaneous hydrolysis in blood and tissues, a half-life of about 5.5–7.3 h at the physiological pH of 7.4 was reported.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Among several proposed hydrolysis products, the two main urinary metabolites are 2-phthalimidoglutaramic acid (∼50%) and α-(2-<u class="uu">c</u>arboxy<u class="uu">b</u>enzamido)<u class="uu">g</u>lutarimide (CBG) (∼30%).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Of these, CBG has an unmodified glutarimide moiety and is also one of three major metabolites in human plasma.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> As CBG was also reported to possess a higher TNF-α production-inhibitory activity (80%) than thalidomide (32%) at concentrations of 3 μM,<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> it is of great pharmacological interest, but its mode of interaction remained elusive so far.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> During the course of this study, we obtained a crystal structure of CBG in the complex with a humanized mutant form of MsCI4 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). This structure was the result of a cocrystallization trial of this mutant with thalidomide, which aimed at the characterization of the mutant protein. However, the mutant selectively bound CGB that was presumably present in traces in our crystallization setup with thalidomide. This mutant has a number of nonconserved residues in the direct vicinity of the thalidomide-binding pocket mutated to the residues in the human protein, including the substitution F56H. While this residue is not directly involved in classical IMiD binding in MsCI4 or the human protein, it plays an important role in the binding of CBG: together with N50, it coordinates one oxygen of the carboxyl group in the CBG-protruding moiety; the other oxygen of this carboxyl coordinates the conserved water molecule bound to W99. However, in contrast to the hydrolysis products of the succinimide-based compounds <b>4a</b>, <b>4b</b>, and <b>5a</b>, the amide moiety resulting from ring opening is not found to be involved in defined hydrogen bonding—although superposing approximately with the phthaloyl moiety of thalidomide, it does not form the canonical hydrogen bond with N50, as the latter is engaged in the hydrogen bond to the carboxyl group.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Rational Design of Novel Succinimide Effectors Guided by Hydrolyzed Metabolites</h3><div class="NLM_p">In a next step, we aimed to exploit our knowledge on the binding mode of hydrolyzed metabolites for the design of novel effectors. The fact that the hydrolysis products were selected against their parent compounds in several cocrystallization or soaking experiments suggested that they pose binders of similar, if not superior affinity. Comparing the binding modes of CBG and hydrolyzed <b>4a</b>, <b>4b</b>, and <b>5a</b>, we further hypothesized that the difference seen for the hydrogen bonding of their amide linkers should yield increased affinity for succinimide-based effectors. Consequently, we used this amide linker to connect different functional groups as protruding moieties to succinimide as the binding moiety. To this aim, we prepared derivatives <b>7a–7h</b>, as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, by treating imide <b>3a</b> with the corresponding acyl chlorides <b>6a–6h</b> and <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) in THF.</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CDI, 4-DMAP, THF, reflux, 48 h; (b) TFA, RT, 30 min; (c) <b>6a–h</b>, DIPEA, THF, 0 <sup>o</sup>C to reflux, and 2 h.</p></p></figure><div class="NLM_p">All derivatives of this second panel were tested in the FRET assay. Only for compound <b>7e</b>, with a 3,5-dinitrobenzol group, the affinity was decreased under the detectable levels of the FRET assay. For the compounds with an isobutylene (<b>7a</b>), benzyl (<b>7b</b>), or chlorobenzothiophene group (<b>7g</b>) as the protruding moiety, binding was well detectable but could not be quantified (<i>K</i><sub>i</sub> > 40 μM). Better binding was observed for compounds with a styryl (<b>7f</b>) and dichloro-benzothiophene (<b>7h</b>) group, both showing <i>K</i><sub>i</sub> values of 20 μM (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Finally, the highest affinities were achieved with a 2,4,6-trichlorobenzol moiety (<b>7c</b>, <i>K</i><sub>i</sub> = 9 μM) and benzyloxy group (<b>7d</b>, <i>K</i><sub>i</sub> = 4 μM), rendering <b>7d</b>, the highest-affinity binder in this study, with a <i>K</i><sub>i</sub> value comparable to an unmodified succinimide<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compounds inspired by hydrolysis products of thalidomide analogues and their affinity data. (A) Second panel of compounds, based on the 3-amidosuccinimide scaffold. (B) Third panel of compounds, inspired by <b>7d</b>. * <b>20a</b> could not be purified to satisfactory levels for affinity testing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We continued with characterizing the binding modes of compounds <b>7a–c</b> and <b>7f</b> via crystallography. For the best binder <b>7d</b>, we performed cocrystallization screening, which yielded a new crystal form diffracting to 1.1 Å resolution; the other compounds were successfully evaluated in soaking experiments. All compounds revealed the expected binding mode as observed for the hydrolyzed metabolites of <b>4a</b>, <b>4b</b>, and <b>5a</b>, with the succinimide moiety forming the canonical interaction within the binding pocket, and the amide linker forming the hydrogen bond with N50. Besides these hydrogen bonds of the binding and linking moiety, no defined interactions with the protein were found for the protruding moieties of any of the five compounds, including the best binder <b>7d</b>. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> shows a superposition of the compounds of this panel and their conserved binding mode in the aromatic cage.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding modes of compounds from the second and third panel. (A) Superposition of all compounds bound to MsCI4. (B) Detailed side and top view of bound effectors based on the 3-amidosuccinimide scaffold: <b>7a</b> (yellow, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1X">6R1X</a>), <b>7b</b> (sand, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R12">6R12</a>), <b>7c</b> (pink, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1K">6R1K</a>), <b>7d</b> (green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1D">6R1D</a>), <b>7f</b> (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R13">6R13</a>), and the water soluble <b>11a</b> (cyan, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R18">6R18</a>), and <b>12a</b> (light blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1C">6R1C</a>), indicating interactions with N50. (C) Side and top view of compounds based on 3-amidoglutarimide, <b>16b</b> (brown, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1W">6R1W</a>) and <b>20b</b> (dark green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1A">6R1A</a>). Although the depicted instances for this scaffold do not show the interaction with N50, this interaction was observed in one other instance for <b>16b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on these data, we hypothesized that the planar benzene connected via an oxygen as in <b>7d</b> is favorable for the affinity. Consequently, we designed a third panel of derivatives carrying this feature based on succinimide and glutarimide (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). In this panel, in addition to affinity improvement, we also sought to increase the solubility in water via additional polar or charged groups. As described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, reaction of the intermediates <b>8</b>, <b>13</b>, and <b>17</b> with phosgene solution (15 wt % in toluene) in THF yielded to the corresponding chloroformates <b>9</b>, <b>14</b>, and <b>18</b>. Derivatives <b>11a</b>, <b>11b</b>, <b>16a</b>, <b>16b</b>, <b>20a</b>, and <b>20b</b> were prepared by a coupling reaction between the imides <b>3a</b> or <b>3b</b> and the aforementioned chloroformates <b>9</b>, <b>14</b>, and <b>18</b> using DIPEA in THF followed by deprotection using TFA. Treatment of the derivatives <b>11a</b> and <b>11b</b> with succinic anhydride and triethylamine (Et<sub>3</sub>N) in DMF produced the molecules <b>12a</b> and <b>12b</b>, respectively.</div><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Phosgene solution 15 wt % in toluene, THF, 0 <sup>o</sup>C to RT, 20 h; (b) <b>3a</b> or <b>3b</b>, DIPEA, THF, 0 <sup>o</sup>C to reflux, 20 h; (c) TFA, DCM, 0 <sup>o</sup>C to RT, 2 h; (d) Et<sub>3</sub>N, DMF, 0 <sup>o</sup>C to RT, 20 h. Note that <b>13</b> and thereby also <b>14–16</b> are in cis conformation.</p></p></figure><div class="NLM_p">Indeed, the final compounds with terminal amino groups were water-soluble (<b>11a</b>, <b>11b</b>, <b>16a</b>, <b>16b</b>), while <b>12a</b> and <b>12b</b>, with a terminal succinyl group, were highly soluble in bicarbonate buffer (>200 mM). The compounds were subsequently tested in the FRET assay, apart from <b>20a</b>, which still contained impurities (see Methods). The assay indicated that all derivatives retained high affinity for CRBN independent of the binding moiety and planarity of the substituent; a clear preference for either binding moiety was not recognizable.</div><div class="NLM_p">In soaking experiments, we obtained crystal structures with the 5-ring members <b>11a</b>, <b>12a</b>, and <b>20a</b>, and the 6-ring members <b>16b</b>, and <b>20b</b>, all forming the canonical interactions within the aromatic cage. As expected, the 5-ring effectors form the interaction of the amide linker with N50, which is also observed in one instance for the 6-ring effector <b>16b</b>. Further interactions of the protruding moieties are not observed for any of the compounds. Consequently, the prolonged extensions are less resolved in the electron density map, which is especially evident for <b>12a</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). As these prolonged compounds still retain high affinity, this confirms that the amidosuccinimide scaffold can serve as the universal CRBN-binding moiety, allowing great chemical variability on the protruding moiety.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. F<sub>O</sub>–F<sub>C</sub> maps of bound compounds shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. All compounds are clearly defined by their electron density maps with the exception of the prolonged extension in <b>12a</b>. Crystallographic structures were refined to resolutions between 1.1 and 1.8 Å, and the maps are contoured at 2σ. PDB accession codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1X">6R1X</a> (<b>7a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R12">6R12</a> (<b>7b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1K">6R1K</a> (<b>7c</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1D">6R1D</a> (<b>7d</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R13">6R13</a> (<b>7f</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R18">6R18</a> (<b>11a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1C">6R1C</a> (<b>12a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1W">6R1W</a> (<b>16b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R19">6R19</a> (<b>20a</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1A">6R1A</a> (<b>20b</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Degradation of Neo-Substrates</h3><div class="NLM_p">After assessing the biophysical and structural parameters of our designs, we tested their potential for the degradation of neo-substrates in the MM-derived human cell line OPM-2. To this end, we have selected the established neo-substrates IKZF3, which is targeted via a variety of IMiDs<a onclick="showRef(event, 'ref20 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref20 ref47 ref48 ref49">(20,47−49)</a> and CK1α, which is so far only targeted via lenalidomide,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> as two complementary targets. We treated OPM-2 cells for 24 h with the different compounds and assayed for the endogenous levels of both neo-substrates; for comparison, the classical IMiDs, thalidomide, lenalidomide, and pomalidomide were included in the test set. As anticipated, the results for the two neo-substrates were very different. None of the marketed IMiDs apart from lenalidomide was able to reduce the levels of CK1α significantly,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> but also none of our compounds showed any effect on CK1α. This indicates that our compounds could neither supersede nor sufficiently mimic the interface for CK1α recruitment formed by lenalidomide, substantiating the notion of a very narrow specificity window for this substrate.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><div class="NLM_p">However, the situation was completely different for IKZF3. Here, in addition to all classical IMiDs, multiple of our designs were successful: significant effects were observed for <b>5a</b>, <b>7d</b>, and <b>7f</b>, which are all compounds with a rather compact structure from our first and second panel (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The only successful compound from the first, phthaloyl-based panel, <b>5a</b>, represents a direct succinimide analogue of pomalidomide. It reduced IKZF3 levels by almost 40%. Comparison of its structural binding mode to that of thalidomide or pomalidomide already suggested that it may be a possible functional substitute for pomalidomide. The fact that the other compounds of that panel did not show similar effects indicate that substitutions larger than an amino group in the R<sup>2</sup> position of the phthaloyl moiety, as for <b>4a</b> and <b>4c</b>, or any substitution in R<sup>1</sup>, as for <b>4b</b>, <b>4d</b>, and <b>5b</b>, abolish IKZF3 recruitment.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound-mediated IKFZ3 degradation in OPM-2 cells. (A) Immunoblot analysis of IKZF3 levels after treatment with compounds <b>7d</b>, <b>5a</b>, and <b>7f</b> (100 μM) for 24 h, compared to DMSO (control) and lenalidomide (20 μM) (<i>n</i> = 3). Lenalidomide at 100 μM reduced IKFZ3 levels effectively by 100% (not shown). (B) Averaged IKZF3 levels from the three independent experiments, normalized against total protein loading control (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_001.pdf" class="ext-link">Figure S2</a>). The significance of the data was tested comparing IKZF3 levels in the presence of the compounds and DMSO (<i>p</i> > 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Most interesting is the analysis of the successful compounds of the second panel, <b>7d</b> and <b>7f</b>, which are not derived from classical IMiDs but from the hydrolysis products of the first panel. <b>7d</b>, which is also the highest affinity binder in this study, reduced IKZF3 levels by about 20%. Moreover, the analogous <b>7f</b>, which is a weaker binder that only differs from <b>7d</b> in one heavy atom in the linker, reduced IKZF3 levels by even 40%. Both compounds are more flexible and elongated than <b>5a</b>, so it appears impossible that their protruding moieties adopt a conformation mimicking the classical IMiDs at the interface between CRBN and IKZF3. Their terminal benzyl groups inevitably project further away from the thalidomide-binding pocket, requiring another mode of interaction with the zinc finger motif than characterized for classical IMiDs.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> This interaction mode is also very sensitive to chemical changes: shortening of the linker by only one atom, as for <b>7b</b>, further modifications on the benzyl group, as for <b>11a</b> or <b>12a</b>, or any other variant we designed in the second or third panel abolished IKZF3 recruitment, which is indicative for a highly specific interaction. Therefore, <b>7d</b> and <b>7f</b> are the first representatives of a novel type of CRBN effectors with a recognition mode that is clearly distinct from that of the classical thalidomide-based IMiDs.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67437" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67437" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The development of CRBN effectors is a rapidly growing field, and novel IMiDs and PROTACS are reported frequently. To date, essentially all of these compounds are based on the classical thalidomide scaffold, which significantly restrains the chemical space available for the recruitment of neo-substrates. Here, following on from our previous characterization of CRBN-binding moieties, we have probed the chemical space for the linking and protruding moiety, taking advantage of the structural binding modes of hydrolyzed metabolites. Although not in the focus of this work, the apparent specificity of CRBN for these hydrolysis products, especially for the major thalidomide metabolite CBG, may inspire further research toward the understanding of their pharmacological relevance.</div><div class="NLM_p">As a consensus from the binding modes of our initial designs and their hydrolysis products, we derived an amidosuccinimide scaffold as a minimal binding and linking moiety. 3-Amidosuccinimide can be used to mount almost arbitrary chemistry as the protruding moiety, while retaining affinities to CRBN in the range of classical IMiDs, rendering it an attractive CRBN-binding moiety for future PROTACS.</div><div class="NLM_p last">However, the most relevant aspect of our study concerns the versatility of the 3-amidosuccinimide scaffold for the design of IMiD-like CRBN effectors. As a minimal binding and linking moiety, it does not restrain the chemical space of protruding moieties, allowing for the design of substrate-recruiting motifs that cannot be realized on a classical IMiD scaffold. In our attempt to probe the effect of different protruding moieties mounted on the amidosuccinimide scaffold, two out of twelve compounds were able to recruit the neo-substrate IKZF3 without further optimization. Although we do not have structural insight into the IKZF3-recognition mode of these effectors, it is clearly incompatible with that of the classical IMiDs, which points at a large unexplored chemical space for the recruitment of new therapeutic targets. For the ongoing characterization of the proteome druggable via the IMiD approach, novel CRBN effectors are needed both for probing the space of neo-substrates, as well as for future pharmacological exploitation. With this work, we contribute first steps toward the rational design of a post-thalidomide generation of such effectors, toward unlocking the full potential of the IMiD approach.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55410" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55410" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> General Procedures</h4><div class="NLM_p">Room temperature (RT) refers to 22 °C. Reagents and anhydrous solvents were transferred via an oven-dried syringe or a cannula. Flasks were flame-dried under vacuum and cooled under a constant stream of argon. Anhydrous solvents (toluene, dioxane, and DMF) were purchased from Sigma-Aldrich (anhydrous over molecular sieves). THF was dried over potassium. All other chemicals were purchased from ABCR, Acros, Alfa Aesar, Fluorochem, Merck, Sigma-Aldrich, and TCI Europe at highest commercially available purity and used without further purification. Compound <b>2b</b> and <b>3b</b> were prepared according to the procedures reported by Capitosti et al.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Compounds <b>8</b>, <b>13</b>, and <b>17</b> were prepared according to the procedures previously reported.<a onclick="showRef(event, 'ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54">(51−54)</a> Thin-layer chromatography (TLC) was performed on Merck silica gel 60 F 254 TLC aluminium sheets and visualized by ultraviolet light (254 nm) and/or with ceric ammonium molybdate, potassium permanganate, or ninhydrine staining solution. Flash column chromatography was performed on Acros silica gel 35–70, 60 Å, using a forced flow of eluent (method of Still). Yields refer to chromatographically purified and spectroscopically pure compounds. NMR spectra were recorded on Varian Mercury plus 400 (operating at 400 MHz for <sup>1</sup>H and 100 MHz for <sup>13</sup>C acquisitions), and Varian Mercury plus 300 (operating at 300 MHz for <sup>1</sup>H and 75 MHz for <sup>13</sup>C acquisitions). Chemical shifts are reported in ppm with the solvent resonance as the internal standard (<i>d</i><sub>1</sub>-chloroform: 7.26 (<sup>1</sup>H NMR), 77.16 (<sup>13</sup>C NMR); <i>d</i><sub>6</sub>-dimethylsulfoxide: 2.50 (<sup>1</sup>H NMR), 39.52 (<sup>13</sup>C NMR); (<i>d</i><sub>4</sub>-methanol: 3.31 (<sup>1</sup>H NMR), 49.00 (<sup>13</sup>C NMR); [<i>d</i><sub>6</sub>-acetone: 2.05 (<sup>1</sup>H NMR), and 29.84, 206.26 (<sup>13</sup>C NMR)]. Coupling constants J are reported in Hertz (Hz). Multiplicities are indicated by s = singlet, d = doublet, t = triplet, q = quartet, sep = septet, dd = doublet of doublet, dt = doublet of triplet, m = multiplet, and br = broad resonance. High-resolution mass spectra were obtained on Bruker Daltonics ESI-FT-ICR-MS APEX II. IR spectra were measured on ATI/Mattson Genesis FT-IR as thin film (in CCl<sub>4</sub>) or KBr-disk. Absorbance frequencies are reported in reciprocal centimeters (cm<sup>–1</sup>). Melting points were measured on a Boetius-micro hot stage and are uncorrected. The purity of compounds was analyzed by detecting UV absorbance at 254 nm using a Poroshell 120 EC-C18 column on a 1260 Infinity II system (Agilent Technologies, Inc.) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_001.pdf" class="ext-link">Figure S1</a>). All compounds showed >95% purity with the exception of <b>7a</b> (87.6%), <b>7b</b> (91.5%), <b>7c</b> (88.2%). <b>12a</b> (89.4%), <b>12b</b> (88.2%), and <b>20a</b> (<50%).</div><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i12" class="anchor-spacer"></div><h5 class="article-section__title" id="_i12"> General Procedure A</h5><div class="NLM_p last">Preparation of the compounds <b>4a–d</b>: to a solution of <b>3a</b> or <b>3b</b> (1.0 equiv) in anhydrous THF (4.60 mL/mmol), 4-nitrophthalic anhydride (1.5 equiv) in anhydrous THF (0.5 mL/mmol) was added. CDI (1.7 equiv), Et<sub>3</sub>N (2.9 equiv), and catalytic amounts of 4-DMAP were added, and the reaction mixture was heated to reflux for 5 h. The solvent was evaporated, and the resulting crude oil was purified by column chromatography to give <b>4a–d</b>.</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i13" class="anchor-spacer"></div><h5 class="article-section__title" id="_i13"> General Procedure B</h5><div class="NLM_p last">Reduction of the nitro group: to a solution of <b>4a</b> or <b>4b</b> (1.0 equiv) in EtOAc (100 mL/mmol), 10 wt % Pd/C (27 mol %) was added. The flask was degassed and let to stir under a hydrogen atmosphere for 20 h at RT. After completion of the reaction (TLC control), the mixture was filtered over Celite and washed with copious amounts of acetone. Afterward, the solvent was evaporated and <b>5a</b> or <b>5b</b> was obtained.</div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i14" class="anchor-spacer"></div><h5 class="article-section__title" id="_i14"> General Procedure C</h5><div class="NLM_p last">Preparation of the compounds <b>7a–h</b> (amide bond formation): to a solution of the TFA-salt <b>3a</b> (1.0 equiv) in THF (5 mL/mmol), DIPEA (2.0 equiv) was added. The mixture was cooled down to 0 °C, the acyl chloride <b>6a–h</b> (1.0 equiv) was added, and the reaction mixture was left to stir under reflux for 2 h. Upon completion, the reaction was diluted with EtOAc and washed with 3 M HCl and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated in vacuo. The resulting crude product was purified by flash column chromatography to give <b>7a–h</b>.</div></div><div id="sec4_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15"> General Procedure D</h5><div class="NLM_p last">Phosgenation, carbamate formation, and Boc deprotection: to a 15% wt solution of COCl<sub>2</sub> in toluene (1.3 equiv) was added dry THF (0.58 mL/mmol) under argon. The solution was cooled to 0 °C, and a solution of <b>8</b>, <b>13</b>, or <b>17</b> (1.0 equiv) in dry THF (0.6 mL/mmol) was added over 10 min. The reaction mixture was stirred at 0 °C for 15 min and then warmed up to RT and stirred for two more hours. After completion of the reaction, the volatiles were completely evaporated under reduced pressure to give the chloroformates <b>9</b>, <b>14</b>, or <b>18</b>, respectively, which were used for the next step without further purification. To a stirred suspension of the TFA-salt <b>3a</b> or <b>3b</b> (1.03 equiv) in dry THF (2 mL/mmol), DIPEA (0.35 mL/mmol) was added at 0 °C. Then, a solution of the chloroformate <b>9</b>, <b>14</b>, or <b>18</b> (1.0 equiv) in dry THF (0.35 mL/mmol) was added gradually to the suspension. The reaction was warmed up to RT, stirred for 30 min at RT, and then refluxed overnight. After completion of the reaction, the solvent was evaporated, and the crude product was purified by column chromatography giving the carbamates <b>10a–b</b>, <b>15a–b</b>, or <b>19</b> respectively. To a solution of <b>10a–b</b>, <b>15a–b</b>, or <b>19</b> (1.0 equiv) in DCM (4.5 mL/mmol), TFA (30.0 equiv) was added at 0 °C. The reaction solution was warmed up to RT and stirred for 2 h. After completion of the reaction, the volatiles were completely evaporated to give <b>11a–b</b>, <b>16a–b</b>, or <b>20</b> respectively.</div></div><div id="sec4_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16"> General Procedure E</h5><div class="NLM_p last">Preparation of <b>12a–b</b> (amide bond formation): derivatives <b>11a–b</b> (1.0 equiv) were dissolved in DMF (2.8 mL/mmol), and Et<sub>3</sub>N (2.2 equiv) was added at 0 °C. After 20 min of stirring, succinic anhydride (1.0 equiv) was added, and the reaction mixture was stirred at RT overnight. After the end of the reaction, the solvent was evaporated, and the corresponding acid <b>12a–b</b> was afforded via flash column chromatography.</div></div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> <i>tert</i>-Butyl (<i>S</i>)-(2,5-Dioxopyrrolidin-3-yl)carbamate (<b>2a</b>)</h4><div class="NLM_p last">A mixture of <i>N</i>-Boc-L-asparagin (2 g, 8.61 mmol, 1 equiv), CDI (1.39 g, 8.61 mmol, 1 equiv), and catalytic amounts 4-DMAP in anhydrous THF (21.5 mL) was stirred and heated to reflux for 48 h. After the end of the reaction, the solvent was evaporated, and the crude product was purified by column chromatography (<i>n</i>-hexane/ethyl acetate, 1:1 v/v) to give <b>2a</b> (1.54 g, 6.75 mmol, 78%) as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>f</sub> = 0.48; mp 160–162 °C; IR (KBr) ν̃<sub>max</sub>: 3376.75, 3361.32, 1709.59, 1521.56, 1171.54 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.18 (s, 1H), 7.42 (d, <i>J</i> = 8.1 Hz, 1H), 4.33–4.24 (m, 1H), 2.85 (dd, <i>J</i> = 17.5, 9.4 Hz, 1H), 2.44 (dd, <i>J</i> = 17.5, 5.7 Hz, 1H), 1.37 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO): δ 178.2, 176.5, 155.2, 78.8, 50.3, 36.4, 28.2; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>9</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>Na<sup>+</sup>, 237.08513; found, 237.08513.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 2,5-Dioxopyrrolidin-3-aminium 2,2,2-Trifluoroacetate (<b>3a</b>)</h4><div class="NLM_p last">Compound <b>3a</b> (1.54 g, 6.75 mmol, 1 equiv) was dissolved in TFA (7.8 mL, 101.25 mmol, 15 equiv) and stirred for 30 min. The excess of the acid was removed in vacuo, and the resulting product was dried under vacuum to give <b>3a</b> (1.54 g, 6.75 mmol, quant) as an off-white solid. TLC (EtOAc): <i>R</i><sub>f</sub> = 0.0; mp 109–114 °C; IR (KBr) ν̃<sub>max</sub>: 3446.17, 1665.23, 1617.02, 1593.88, 1207.22, 1181.19, 1149.37, 1137.8, 723.175 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.71 (s, 1H), 8.61 (s, 3H), 4.39–4.26 (m, 1H), 2.95 (d, <i>J</i> = 26.9 Hz, 1H), 2.61 (dd, <i>J</i> = 17.7, 5.5 Hz, 1H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 175.29, 175.14, 158.69 (q, <i>J</i> = 31.8 Hz), 117.08 (q, <i>J</i> = 298.4 Hz), 48.53, 34.73; <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>): δ −73.84; HRMS ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>4</sub>H<sub>7</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup>, 115.05075; found, 115.05142.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 2-(2,5-Dioxopyrrolidin-3-yl)-4-nitroisoindoline-1,3-dione (<b>4a</b>)</h4><div class="NLM_p last">Compound 4a was synthesized according to general procedure A using <b>3b</b> (0.50 g, 2.19 mmol), 3-nitrophthalic anhydride (655.7 mg, 3.29 mmol), CDI (603.2 mg, 3.72 mmol), Et<sub>3</sub>N (0.89 mL, 6.35 mmol), and catalytic amounts of 4-DMAP. After purification via flash column chromatography (<i>n</i>-hexane/EtOAc, 1:1 v/v), compound <b>4a</b> (412 mg, 1.43 mmol 65%) was isolated as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 1:3 v/v): <i>R</i><sub>F</sub> = 0.72; mp 129–131 °C; IR (KBr) ν̃<sub>max</sub>: 3442.31, 1722.12, 1541.81, 1396.21 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.55 (br s, 1H), 8.35–8.28 (m, 1H), 8.28–8.21 (m, 1H), 8.22–8.15 (m, 1H), 5.47 (dd, <i>J</i> = 9.7, 5.9 Hz, 1H), 3.21 (dd, <i>J</i> = 18.0, 9.7 Hz, 1H), 3.05 (dd, <i>J</i> = 18.0, 5.9 Hz, 1H); <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 175.2, 174.9, 165.9, 163.3, 146.0, 137.4, 134.6, 129.7, 128.0, 124.1, 49.5, 35.2; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>12</sub>H<sub>7</sub>N<sub>3</sub>O<sub>6</sub>Na<sup>+</sup>, 312.02325; found, 312.04880.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 2-(2,5-Dioxopyrrolidin-3-yl)-5-nitroisoindoline-1,3-dione (<b>4b</b>)</h4><div class="NLM_p last">Compound <b>4b</b> was synthesized according to general procedure A using <b>3a</b> (0.5 g, 2.19 mmol), 4-nitrophthalic anhydride (656 mg, 3.29 mmol), CDI (603 mg, 3.72 mmol), Et<sub>3</sub>N (0.89 mL, 6.35 mmol), and catalytic amounts of 4-DMAP. After purification via flash column chromatography (<i>n</i>-hexane/EtOAc, 1:1 v/v) compound <b>4b</b> (483 mg, 1.67 mmol 76%) was isolated as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 1:3 v/v): <i>R</i><sub>F</sub> = 0.61; mp 203–204 °C; IR (KBr) ν̃<sub>max</sub>: 3489.56, 1787.69, 1538.92, 1399.1, 1349.93, 722.211 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.55 (br s, 1H), 8.75 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 8.62 (dd, <i>J</i> = 2.0, 0.5 Hz, 1H), 8.21 (dd, <i>J</i> = 8.2, 0.5 Hz, 1H), 5.50 (dd, <i>J</i> = 9.7, 5.9 Hz, 1H), 3.23 (dd, <i>J</i> = 18.0, 9.7 Hz, 1H), 3.06 (dd, <i>J</i> = 18.0, 5.9 Hz, 1H); <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 175.2, 174.9, 166.3, 166.0, 153.1, 137.2, 134.1, 130.8, 125.8, 119.3, 49.5, 35.3; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na + MeOH]<sup>+</sup> calcd for C<sub>13</sub>H<sub>11</sub>N<sub>3</sub>O<sub>7</sub>Na<sup>+</sup>, 344.04947; found, 344.04985.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 2-(2,6-Dioxopiperidin-3-yl)-4-nitroisoindoline-1,3-dione (<b>4c</b>)</h4><div class="NLM_p last">Compound <b>4c</b> was synthesized according to the general procedure A using <b>3b</b> (3.11 g, 12.9 mmol), 3-nitrophthalic anhydride (3.73 g, 19.3 mmol), CDI (3.55 g, 21.9 mmol) Et<sub>3</sub>N (5.2 mL, 37.3 mmol), and catalytic amounts of 4-DMAP. After purification via flash column chromatography (<i>n</i>-hexane/EtOAc, 1:1–1:4 v/v), compound <b>4c</b> (3.48 g, 11.5 mmol, 89%) was isolated as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>F</sub> = 0.40; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.17 (s, 1H), 8.34 (dd, <i>J</i> = 8.1, 0.7 Hz, 1H), 8.23 (dd, <i>J</i> = 7.5, 0.7 Hz, 1H), 8.15–8.08 (m, 1H), 5.19 (dd, <i>J</i> = 12.9, 5.4 Hz, 1H), 2.88 (ddd, <i>J</i> = 17.3, 13.9, 5.4 Hz, 1H), 2.61 (dt, <i>J</i> = 17.0, 2.7 Hz, 1H), 2.56–2.44 (m, 1H), 2.08 (dtd, <i>J</i> = 12.9, 5.3, 2.1 Hz, 1H); <sup>13</sup>C NMR (101 MHz, DMSO): δ 172.8, 169.6, 165.3, 162.6, 144.5, 136.9, 133.1, 129.0, 127.4, 122.6, 49.5, 30.9, 21.8; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na + MeOH]<sup>+</sup> calcd for C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>O<sub>7</sub>Na<sup>+</sup>, 358.06512; found, 358.06703; spectral data were consistent with the literature.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-(2,6-Dioxopiperidin-3-yl)-5-nitroisoindoline-1,3-dione (<b>4d</b>)</h4><div class="NLM_p last">Compound <b>4d</b> was synthesized according to the general procedure A using <b>3b</b> (4.17 g, 17.2 mmol), 4-nitrophthalic anhydride (4.99 g, 25.9 mmol), CDI (4.73 g, 29.1 mmol) Et<sub>3</sub>N (6.97 mL, 50.00 mmol), and catalytic amounts of 4-DMAP. After purification via flash column chromatography (<i>n</i>-hexane/EtOAc, 1:1–1:4 v/v), compound <b>4d</b> (2.35 g, 7.8 mmol, 45%) was isolated as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>f</sub> = 0.50; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.18 (s, 1H), 8.67 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 8.56 (d, <i>J</i> = 2.0 Hz, 1H), 8.19 (d, <i>J</i> = 8.2 Hz, 1H), 5.23 (dd, <i>J</i> = 12.9, 5.4 Hz, 1H), 2.90 (ddd, <i>J</i> = 17.1, 13.9, 5.4 Hz, 1H), 2.63 (ddd, <i>J</i> = 17.1, 4.3, 2.3 Hz, 1H), 2.58–2.47 (m, 1H), 2.10 (dtd, <i>J</i> = 12.9, 5.2, 2.2 Hz, 1H); <sup>13</sup>C NMR (101 MHz, DMSO): δ 172.82, 169.61, 165.63, 165.36, 151.79, 135.80, 132.60, 130.17, 125.09, 118.46, 49.57, 30.95, 21.91; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na + MeOH]<sup>+</sup> calcd for C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>O<sub>7</sub>Na<sup>+</sup>, 358.06512; found, 358.06642; spectral data were consistent with the literature.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-Amino-2-(2,5-dioxopyrrolidin-3-yl)isoindoline-1,3-dione (<b>5a</b>)</h4><div class="NLM_p last">Compound <b>5a</b> was synthesized according to the general procedure B using <b>4a</b> (0.30 g, 1.04 mmol) and 10 wt % Pd/C (0.30 g, 0.28 mmol). Compound <b>5a</b> (0.25 g, 0.95 mmol, 92%) was obtained as a yellow-green solid. TLC (<i>n</i>-hexane/EtOAc, 1:3 v/v): <i>R</i><sub>f</sub> = 0.61; mp 292–295 °C; IR (KBr) ν̃<sub>max</sub>: 3474.13<sub>,</sub> 1727.91, 1702.84, 1632.45 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.45 (br s, 1H), 7.50 (dd, <i>J</i> = 8.4, 7.1 Hz, 1H), 7.07 (dd, <i>J</i> = 10.7, 7.7 Hz, 2H), 6.17 (s, 1H), 5.34 (dd, <i>J</i> = 9.7, 5.9 Hz, 1H), 3.18 (dd, <i>J</i> = 17.9, 9.7 Hz, 1H), 3.02 (dd, <i>J</i> = 17.9, 5.9 Hz, 1H); <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 175.7, 175.5, 170.9, 170.9, 147.8, 136.4, 133.4, 122.5, 122.4, 112.4, 48.7, 35.6; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>O<sub>4</sub>Na<sup>+</sup>, 282.04908; found, 282.04853.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 5-Amino-2-(2,5-dioxopyrrolidin-3-yl)isoindoline-1,3-dione (<b>5b</b>)</h4><div class="NLM_p last">Compound <b>5b</b> was synthesized according to the general procedure B using <b>4a</b> (0.30 g, 1.0 mmol) and 10 wt % Pd/C (0.30 g, 0.3 mmol). Compound <b>5b</b> (0.26 g, 1.0 mmol, 97%) was obtained as a yellow-green solid. TLC (<i>n</i>-hexane/EtOAc, 1:3 v/v): <i>R</i><sub>F</sub> = 0.68; mp 259–260 °C; IR (KBr) ν̃<sub>max</sub>: 3473.17, 3354.57, 1701.87, 1628.59, 1613.16, 1405.85 cm<sup>–1</sup>; <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.40 (br s, 1H), 7.54 (d, <i>J</i> = 8.2 Hz, 1H), 7.07 (d, <i>J</i> = 1.8 Hz, 1H), 6.97 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 6.00 (br s, 2H), 5.32 (dd, <i>J</i> = 9.7, 6.0 Hz, 1H), 3.16 (dd, <i>J</i> = 17.9, 9.7 Hz, 1H), 2.98 (dd, <i>J</i> = 17.9, 6.0 Hz, 1H); <sup>13</sup>C NMR (75 MHz, acetone-<i>d</i><sub>6</sub>): δ 175.8, 175.6, 155.9, 135.6, 126.0, 118.8, 118.4, 108.5, 48.8, 35.6; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>O<sub>4</sub>Na<sup>+</sup>, 282.04908; found, 282.04853.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(2,5-Dioxopyrrolidin-3-yl)-3-methylbut-2-enamide (<b>7a</b>)</h4><div class="NLM_p last">Compound <b>7a</b> was synthesized according to the general procedure C using <b>3a</b> (0.10 g, 0.44 mmol), DIPEA (0.15 mL, 0.88 mmol), and 3, 3-dimethylacryloyl chloride <b>6a</b> (51.9 mg, 0.44 mmol). After purification via flash column chromatography, (<i>n</i>-hexane/EtOAc, 5:5 v/v) compound <b>7a</b> (56.8 mg, 0.29 mmol, 66%) was isolated as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>f</sub> = 0.18; mp 181–188 °C; IR (KBr) ν̃<sub>max</sub>: 3354.57, 1729.83, 1715.37, 1624.73, 1530.24, 1363.43, 1261.22, 1193.72, 1177.33 cm<sup>–1</sup>; <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.04 (s, 1H), 7.63 (s, 1H), 5.72 (s, 1H), 4.54 (ddd, <i>J</i> = 9.3, 7.5, 5.8 Hz, 1H), 2.97 (dd, <i>J</i> = 17.6, 9.3 Hz, 1H), 2.71 (dd, <i>J</i> = 17.6, 5.8 Hz, 1H), 2.11 (d, <i>J</i> = 1.2 Hz, 3H), 1.82 (d, <i>J</i> = 1.2 Hz, 3H); <sup>13</sup>C NMR (75 MHz, acetone-<i>d</i><sub>6</sub>): δ 176.0, 172.1, 167.3, 152.3, 118.6, 51.1, 37.2, 27.1, 19.7; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>9</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>Na<sup>+</sup>, 219.07456; found, 219.07401.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(2,5-Dioxopyrrolidin-3-yl)-2-phenylacetamide (<b>7b</b>)</h4><div class="NLM_p last">Compound <b>7b</b> was synthesized according to the general procedure C using <b>3a</b> (0.10 g, 0.44 mmol), DIPEA (0.15 mL, 0.876 mmol), and phenylacetyl chloride <b>6b</b> (67.7 mg, 0.44 mmol). After purification via flash column chromatography (<i>n</i>-hexane/EtOAc, 1:1 v/v), compound <b>7b</b> (75.9 mg, 0.33 mmol, 75%) was isolated as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>f</sub> = 0.15; mp 181–184 °C; IR (KBr) ν̃<sub>max</sub>: 3502.1, 3259.11, 1731.76, 1715.35, 1654.62, 1542.77, 1358.6, 1196.61, 1172.51 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.02 (br s, 1H), 7.81 (br s, 1H), 7.35–7.18 (m, 5H), 4.57 (ddd, <i>J</i> = 9.3, 7.5, 5.8 Hz, 1H), 3.56 (s, 2H), 2.96 (dd, <i>J</i> = 17.6, 9.4 Hz, 1H), 2.66 (dd, <i>J</i> = 17.6, 5.8 Hz, 1H); <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 176.3, 175.0, 170.7, 135.7, 129.2, 128.3, 126.6, 50.4, 42.2, 36.2; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>12</sub>H<sub>12</sub>N<sub>3</sub>O<sub>6</sub>Na<sup>+</sup>, 255.07456; found, 255.07401.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2,4,6-Trichloro-<i>N</i>-(2,5-dioxopyrrolidin-3-yl)benzamide (<b>7c</b>)</h4><div class="NLM_p last">Compound <b>7c</b> was synthesized according to the general procedure C using <b>3a</b> (0.10 g, 0.438 mmol), DIPEA (0.15 mL, 0.88 mmol), and 2,4,6-trichlorobenzoyl chloride <b>6c</b> (106.8 mg, 0.44 mmol). After purification via flash column chromatography (<i>n</i>-hexane/EtOAc, 5:5 v/v), compound <b>7c</b> (81.7 mg, 0.25 mmol, 58%) was isolated as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>F</sub> = 0.47; mp 210–212 °C; IR (KBr) ν̃<sub>max</sub>: 3450.03, 3249.47, 1717.3, 1640.16, 1582.31, 1547.59 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.35 (s, 1H), 9.37 (d, <i>J</i> = 7.5 Hz, 1H), 7.75 (s, 1H), 4.59 (ddd, <i>J</i> = 9.3, 7.6, 5.3 Hz, 1H), 3.01 (dd, <i>J</i> = 17.6, 9.4 Hz, 1H), 2.59 (dd, <i>J</i> = 17.6, 5.3 Hz, 1H); <sup>13</sup>C NMR (101 MHz, DMSO): δ 176.5, 176.3, 163.3, 134.9, 134.3, 132.3, 128.1, 50.0, 35.9; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>11</sub>H<sub>7</sub>Cl<sub>3</sub>N<sub>2</sub>O<sub>3</sub>Na<sup>+</sup>, 342.94199; found, 342.94145.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Benzyl (2,5-Dioxopyrrolidin-3-yl)carbamate (<b>7d</b>)</h4><div class="NLM_p last">Compound <b>7d</b> was synthesized according to the general procedure C using <b>3a</b> (0.10 g, 0.44 mmol), DIPEA (0.15 mL, 0.876 mmol), and benzyl chloroformate <b>6d</b> (74.7 mg, 0.44 mmol). After purification via flash column chromatography (<i>n</i>-hexane/EtOAc, 5:5 v/v), compound <b>7d</b> (105.9 mg, 0.43 mmol, 98%) was isolated as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>f</sub> = 0.44; mp 93–96 °C; IR (KBr) ν̃<sub>max</sub>: 3363.25, 1718.26, 1532.17, 1267.97, 1203.36, 1177.33 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.09 (br s, 1H), 7.41–7.27 (m, 5H), 7.08 (br s, 1H), 5.10 (s, 2H), 4.63–4.53 (m, 1H), 3.05 (dd, <i>J</i> = 17.6, 9.4 Hz, 1H), 2.74 (dd, <i>J</i> = 17.6, 5.5 Hz, 1H); <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 177.5, 175.8, 156.9, 137.8, 129.2, 128.7, 67.1, 52.0, 37.1; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>4</sub>Na<sup>+</sup>, 271.06948; found, 271.06893.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(2,5-Dioxopyrrolidin-3-yl)-3,5-dinitrobenzamide (<b>7e</b>)</h4><div class="NLM_p last">Compound <b>7e</b> was synthesized according to the general procedure C using <b>3a</b> (0.1 g, 0.44 mmol), DIPEA (0.15 mL, 0.88 mmol), and 3,5-dinitrobenzoyl chloride <b>6e</b> (0.10 g, 0.44 mmol). After purification via flash column chromatography (<i>n</i>-hexane/EtOAc, 5:5 v/v), compound <b>7e</b> (0.10 g, 0.34 mmol, 76%) was isolated as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>f</sub> = 0.28; mp 238–239 °C; IR (KBr) ν̃<sub>max</sub>: 3447.16, 3389.28, 1717.3, 1659.45, 1540.85, 1348, 1188.9 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.24 (br s, 1H), 9.15 (d, <i>J</i> = 7.1 Hz, 1H), 9.12–9.06 (m, 3H), 4.99–4.91 (m, 1H), 3.20–3.11 (m, 1H), 2.93 (dd, <i>J</i> = 17.8, 5.8 Hz, 1H); <sup>13</sup>C NMR (101 MHz, acetone): δ 176.7, 175.7, 163.7, 149.7, 137.6, 128.3, 122.1, 51.8, 36.8; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>11</sub>H<sub>8</sub>N<sub>4</sub>O<sub>7</sub>Na<sup>+</sup>, 331.02907; found, 331.02842.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(2,5-Dioxopyrrolidin-3-yl)cinnamamide (<b>7f</b>)</h4><div class="NLM_p last">Compound <b>7f</b> was synthesized according to the general procedure C using <b>3a</b> (0.10 g, 0.44 mmol), DIPEA (0.15 mL, 0.88 mmol), and cinnamoyl chloride <b>6f</b> (73.0 mg, 0.44 mmol). After purification via flash column chromatography (<i>n</i>-hexane/EtOAc, 1:1 v/v), compound <b>7f</b> (102 mg, 0.42 mmol, 96%) was isolated as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>f</sub> = 0.19; mp 213–214 °C; IR (KBr) ν̃<sub>max</sub>: 3431.71, 1718.26, 2654.62, 1617.02, 1522.52, 1191.79 cm<sup>–1</sup>; <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.11 (s, 1H), 8.01 (d, <i>J</i> = 6.2 Hz, 1H), 7.71–7.33 (m, 6H), 6.71 (d, <i>J</i> = 15.8 Hz, 1H), 4.76–4.63 (m, 1H), 3.10–2.97 (m, 1H), 2.80 (dd, <i>J</i> = 17.6, 5.9 Hz, 1H); <sup>13</sup>C NMR (75 MHz, acetone-<i>d</i><sub>6</sub>): δ 177.3, 175.9, 166.4, 141.5, 136.0, 130.5, 129.7, 128.6, 121.5, 51.5, 37.2; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>Na<sup>+</sup>, 267.07456; found, 267.07401.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-Chloro-<i>N</i>-(2,5-dioxopyrrolidin-3-yl)benzo[<i>b</i>]thiophene-2-carboxamide (<b>7g</b>)</h4><div class="NLM_p last">Compound <b>7g</b> was synthesized according to the general procedure C using <b>3a</b> (100 mg, 0.44 mmol), DIPEA (0.15 mL, 0.88 mmol), and 3-chlorobenzo[<i>b</i>]thiophen-2-carbonyl chloride <b>6g</b> (101 mg, 0.44 mmol). After purification via flash column chromatography (<i>n</i>-hexane/EtOAc, 1:1 v/v), compound <b>7g</b> (128 mg, 0.41 mmol, 94%) was isolated as a colorless solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>f</sub> = 0.46; mp 215–218 °C; IR (KBr) ν̃<sub>max</sub>: 3445.21, 2932.23, 1729.83, 1636.3, 1534.1 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 10.18 (br s, 1H), 8.47 (br d, <i>J</i> = 6.6 Hz, 1H), 8.10–7.98 (m, 1H), 8.00–7.90 (m, 1H), 7.66–7.55 (m, 2H), 4.99 (ddt, <i>J</i> = 10.4, 7.2, 5.2 Hz, 1H), 3.14 (ddd, <i>J</i> = 17.7, 9.5, 3.5 Hz, 1H), 2.92 (dd, <i>J</i> = 17.7, 6.0 Hz, 1H); <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 176.8, 175.8, 161.4, 138.7, 137.7, 133.0, 128.7, 126.7, 124.0, 123.8, 120.6, 51.8, 37.1; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>13</sub>H<sub>9</sub>ClN<sub>2</sub>O<sub>3</sub>SNa, 303.991201; found, 303.99146; [2M + Na]<sup>+</sup> calcd for C<sub>26</sub>H<sub>18</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>6</sub>S<sub>2</sub>Na<sup>+</sup>, 638.99425; found, 638.99370.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3,4-Dichloro-<i>N</i>-(2,5-dioxopyrrolidin-3-yl)benzo[<i>b</i>]thiophene-2-carboxamide (<b>7h</b>)</h4><div class="NLM_p last">Compound <b>7h</b> was synthesized according to the general procedure C using <b>3a</b> (100 mg, 0.44 mmol), DIPEA (0.15 mL, 0.88 mmol), and 3,4-dichlorobenzo[<i>b</i>]thiophene-2-carbonyl chloride <b>6h</b> (116 mg, 0.44 mmol). After purification via flash column chromatography (<i>n</i>-hexane/EtOAc, 1:1 v/v), compound <b>7h</b> (63.6 mg, 0.27 mmol, 62%) was isolated as a light-yellow solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>F</sub> = 0.46; mp 159–162 °C; IR (KBr) ν̃<sub>max</sub>: 3396.03, 3192.58, 1135.62, 1620.88, 1532.17, 1193.72.755.244 cm<sup>–1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.35 (s, 1H), 9.10 (d, <i>J</i> = 7.8 Hz, 1H), 8.10 (dd, <i>J</i> = 7.9, 1.2 Hz, 1H), 7.62–7.48 (m, 2H), 4.83–4.73 (m, 1H), 2.99 (dd, <i>J</i> = 17.6, 9.3 Hz, 1H), 2.67 (dd, <i>J</i> = 17.5, 5.6 Hz, 1H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 177.1, 176.4, 160.3, 139.6, 133.7, 130.6, 128.4, 128.1, 123.1, 118.5, 50.4, 36.1, 30.8; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>13</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub>SNa<sup>+</sup>, 364.95304; found, 364.95249.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>tert</i>-Butyl (4-((((2,5-Dioxopyrrolidin-3-yl)carbamoyl)oxy)methyl)benzyl)carbamate (<b>10a</b>)</h4><div class="NLM_p last">Compound <b>10a</b> was synthesized according to the general procedure D. To a 15% wt solution of COCl<sub>2</sub> in toluene (12.3 mL, 17.29 mmol), a solution of <b>8</b> (3.15 g, 13.3 mmol) in THF was added. After evaporation of the volatiles, compound <b>9</b> was produced. By using <b>3a</b> (2.8 g, 12.4 mmol), DIPEA (4.0 mL, 23.0 mmol), and the chloroformate <b>9</b> (3.6 g, 12.0 mmol), compound <b>10a</b> was synthesized. After purification via flash column chromatography (DCM/MeOH 0–2% v/v), compound <b>10a</b> (4.3 g, 11.4 mmol, 95%) was isolated as a white solid. TLC (DCM/MeOH, 5:0.3 v/v): <i>R</i><sub>f</sub> = 0.81; mp 80–82 °C; IR (KBr) ν̃<sub>max</sub>: 3412, 1718, 1528, 1267, 1170 cm<sup>–1</sup>; <sup>1</sup>H NMR: (300 MHz, CDCl<sub>3</sub>): δ 9.32 (s, 1H), 7.21 (q, <i>J</i> = 8.0 Hz, 4H), 6.20 (s, 1H), 5.14 (s, 1H), 5.02 (s, 2H), 4.24 (s, 3H), 2.90 (d, <i>J</i> = 8.8 Hz, 1H), 2.71 (d, <i>J</i> = 17.6 Hz, 1H), 1.43 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 28.5, 36.7, 44.3, 51.3, 67.3, 79.9, 127.5, 128.6, 134.9, 139.4, 156.3, 175.2, 177.0; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>N<sub>3</sub>O<sub>6</sub>Na<sup>+</sup>, 400.14850; found, 400.14782.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>tert</i>-Butyl (4-((((2,6-Dioxopiperidin-3-yl)carbamoyl)oxy)methyl)benzyl)carbamate (<b>10b</b>)</h4><div class="NLM_p last">Compound <b>10b</b> was synthesized according to the general procedure D. To a 15% wt solution of COCl<sub>2</sub> in toluene (12.3 mL, 17.3 mmol), a solution of <b>8</b> (3.15 g, 13.3 mmol) in THF was added. After evaporation of the volatiles, compound <b>9</b> was produced. By using <b>3b</b> (3.0 mg, 12.4 mmol), DIPEA (4.0 mL, 23 mmol), and the chloroformate <b>9</b> (3.6 g, 12.0 mmol) compound <b>10b</b> was synthesized. After purification via flash column chromatography (DCM/MeOH 0–2% v/v), compound <b>10b</b> (4.23 g, 10.8 mmol, 90%) was isolated as a white solid. TLC (<i>n</i>-hexane/EtOAc, 3:7 v/v): <i>R</i><sub>F</sub> = 0.16; mp 154.4 °C; IR (KBr) ν̃<sub>max</sub>: 3412.42, 3100.01, 2977.55, 2927.41, 2853.17, 1698.98, 1524.45 cm<sup>–1</sup>; <sup>1</sup>H NMR: (300 MHz, CDCl<sub>3</sub>): δ 8.19 (s, 1H), 7.35–7.27 (m, 4H), 5.65 (s, 1H), 5.11 (s, 2H), 4.90 (s, 1H), 4.44–4.20 (m, 3H), 2.90–2.47 (m, 3H), 1.96–1.83 (m, 1H), 1.45 (s, 9H); <sup>13</sup>C NMR: (75 MHz, CDCl<sub>3</sub>): δ 171.1, 171.0, 156.1, 155.9, 139.2, 135.0, 128.5, 127.6, 77.2, 67.0, 52.2, 44.4, 31.2, 28.4, 25.3; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>19</sub>H<sub>25</sub>N<sub>3</sub>O<sub>6</sub>Na<sup>+</sup>, 414.16410; found, 414.16326.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (4-((((2,5-Dioxopyrrolidin-3-yl)carbamoyl)oxy)methyl)phenyl)methanaminium 2,2,2-Trifluoroacetate (<b>11a</b>)</h4><div class="NLM_p last">Compound <b>11a</b> was synthesized according to the general procedure D using <b>10a</b> (3.8 g, 10 mmol) and TFA (23 mL, 300 mmol). Upon completion, the volatiles were completely evaporated to give <b>11a</b> (3.91 g, 10 mmol, quant) as a white solid. TLC (DCM/MeOH, 5:2 v/v): <i>R</i><sub>f</sub> = 0.26; mp 197–200 °C; IR (KBr) ν̃<sub>max</sub>: 3450, 1780, 1719, 1526, 1203, 1180 cm<sup>–1</sup>; <sup>1</sup>H NMR: (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.47 (s, 4H), 5.15 (s, 2H), 4.46 (dd, <i>J</i> = 9.3, 5.9 Hz, 1H), 4.13 (s, 2H), 3.02 (dd, <i>J</i> = 17.8, 9.3 Hz, 1H), 2.68 (dd, <i>J</i> = 17.8, 5.9 Hz, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 179.5, 177.9, 139.3, 134.2, 130.1, 129.5, 67.2, 52.4, 44.0, 37.3, 27.72; <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −73.61.; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>13</sub>H<sub>15</sub>N<sub>3</sub>O<sub>4</sub>Na<sup>+</sup>, 278.11353; found, 278.11345.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (4-((((2,6-Dioxopiperidin-3-yl)carbamoyl)oxy)methyl)phenyl)methanaminium 2,2,2-Trifluoroacetate (<b>11b</b>)</h4><div class="NLM_p last">Compound <b>11b</b> was synthesized according to the general procedure D using (3.91 g, 10 mmol) and TFA (23 mg, 300 mmol). Upon completion, the volatiles were completely evaporated to give <b>11b</b> (4.05 g, 10 mmol, quant) as a white solid. TLC (DCM/MeOH, 5:2 v/v): <i>R</i><sub>F</sub> = 0.3; mp 58–60 °C; IR (KBr) ν̃<sub>max</sub>: 3419.17, 3240.79, 3094.23, 1698.98, 1532.17, 1251.58, 1204.33, 1136.83 cm<sup>–1</sup>; <sup>1</sup>H NMR: (300 MHz, DMSO): δ 7.54–7.38 (m, 4H), 5.24–5.11 (m, 2H), 4.45–4.35 (m, 1H), 4.12 (s, 2H), 2.87–2.61 (m, 2H), 2.24–1.94 (m, 2H); <sup>13</sup>C NMR: (100 MHz, DMSO): δ 173.4, 172.4, 157.1, 138.1, 132.6, 128.7, 128.0, 65.6, 51.3, 42.6, 30.7, 24.4; <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −73.70; HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>14</sub>H<sub>18</sub>N<sub>3</sub>O<sub>4</sub><sup>+</sup>, 292.12973; found, 292.12885.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4-((4-((((2,5-Dioxopyrrolidin-3-yl)carbamoyl)oxy)methyl)benzyl)amino)-4-oxobutanoic Acid (<b>12a</b>)</h4><div class="NLM_p last">Compound <b>12a</b> was synthesized according to the general procedure E using <b>11a</b> (175 mg, 0.45 mmol), succinic anhydride (44.7 mg, 0.45 mmol), and Et<sub>3</sub>N (0.14 mL, 0.98 mmol). After purification via flash column chromatography, (EtOAc/IPA/H<sub>2</sub>O 4:2:1) compound <b>12a</b> (128 mg, 0.34 mmol, 76%) was isolated as a white solid. TLC (EtOAc/iPA/H<sub>2</sub>O<sub>,</sub> 4:3:2 v/v): <i>R</i><sub>f</sub> = 0.45; mp 110 °C; IR (KBr) ν̃<sub>max</sub>: 3747.98, 3739.3, 2922.59, 1649.8, 1555.31, 1539.88, 1520.6, 1511.92 cm<sup>–1</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.53 (t, <i>J</i> = 5.8 Hz, 1H), 7.86 (d, <i>J</i> = 8.2 Hz, 1H), 7.25 (q, <i>J</i> = 8.1 Hz, 4H), 4.99 (s, 2H), 4.42–4.32 (m, 1H), 4.23 (d, <i>J</i> = 5.9 Hz, 2H), 2.94–2.83 (m, 1H), 2.53–2.43 (m, 1H), 2.37–2.25 (m, 4H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 178.1, 176.5, 176.0, 172.6, 155.9, 139.7, 135.2, 128.1, 127.3, 65.8, 50.7, 41.9, 36.3, 32.1, 32.0; HRMS ESI (<i>m</i>/<i>z</i>): [M – H]<sup>−</sup> calcd for C<sub>17</sub>H<sub>18</sub>N<sub>3</sub>O<sub>7</sub><sup>–</sup>, 376.11447; found, 376.11646.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 4-((4-((((2,6-Dioxopiperidin-3-yl)carbamoyl)oxy)methyl)benzyl)amino)-4-oxobutanoic Acid (<b>12b</b>)</h4><div class="NLM_p last">Compound <b>12b</b> was synthesized according to the general procedure E using <b>11b</b> (121 mg, 0.3 mmol), succinic anhydride (30.0 mg, 0.3 mmol), and Et<sub>3</sub>N (0.092 mL, 0.66 mmol). After purification via flash column chromatography, (EtOAc/IPA/H<sub>2</sub>O 4:2:1) compound <b>12a</b> (117 mg, 0.3 mmol, quant) was isolated as a white solid. TLC (EtOAc/iPA/H<sub>2</sub>O, 4:3:2 v/v): <i>R</i><sub>f</sub> = 0.60; mp 129 °C; IR (KBr) ν̃<sub>max</sub>: 3443.28, 1712.48, 1700.91, 1555.31, 1539.88, 1522.52, 1202.4 cm<sup>–1</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.80 (s, 1H), 8.49 (s, 1H), 7.59 (d, <i>J</i> = 8.6 Hz, 1H), 7.38–7.16 (m, 4H), 5.02 (s, 2H), 4.36–4.17 (m, 3H), 2.73 (ddd, <i>J</i> = 18.1, 11.8, 7.1 Hz, 1H), 2.47 (d, <i>J</i> = 3.7 Hz, 1H), 2.32 (dq, <i>J</i> = 12.3, 7.2, 6.5 Hz, 3H), 1.95 (ddt, <i>J</i> = 17.6, 13.4, 5.2 Hz, 2H); <sup>13</sup>C NMR: (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.1, 172.5, 172.3, 156.2, 139.5, 135.4, 127.9, 127.3, 65.5, 50.9, 41.9, 31.9, 31.8, 31.7, 31.0, 24.4; HRMS ESI (<i>m</i>/<i>z</i>): [M – H]<sup>−</sup> calcd for C<sub>18</sub>H<sub>20</sub>N<sub>3</sub>O<sub>7</sub><sup>–</sup>, 390.13013; found, 390.13109.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> ((1<i>s</i>,4<i>s</i>)-4-((<i>tert</i>-Butoxycarbonyl)amino)cyclohexyl)methyl (2,5-Dioxopyrrolidin-3-yl)carbamate (<b>15a</b>)</h4><div class="NLM_p last">Compound <b>15a</b> was synthesized according to the general procedure D. To a 15% wt solution of COCl<sub>2</sub> in toluene (12.3 mL, 17.3 mmol), a solution of <b>13</b> (3.05 g, 13.3 mmol), in THF was added. After evaporation of the volatiles, compound <b>14</b> was produced. By using <b>3a</b> (2.8 mg, 12.4 mmol), DIPEA (4 mL, 23 mmol), and the chloroformate <b>14</b> (3.5 g, 12 mmol), compound <b>15a</b> was synthesized. After purification via flash column chromatography (DCM/MeOH 0–2% v/v), compound <b>15a</b> (3.9 mg, 10.44 mmol, 87%) was isolated as a white solid. TLC (DCM/MeOH, 5:1 v/v): <i>R</i><sub>f</sub> = 0.71; mp 95–97 °C; IR (KBr) ν̃<sub>max</sub>: 3381, 1715, 1523, 1366, 1257, 1172 cm<sup>–1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>): δ 8.97 (s, 1H), 5.77 (s, 1H), 4.76 (s, 1H), 4.40 (s, 1H), 4.00 (s, 2H), 3.74 (s, 1H), 3.12 (dd, <i>J</i> = 18.8, 10.0 Hz, 1H), 2.88 (d, <i>J</i> = 18.0 Hz, 1H), 1.82–1.56 (m, 6H), 1.47 (s, 9H), 1.31 (s, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 177.0, 175.2, 156.5, 155.3, 79.2, 69.1, 51.3, 46.3, 36.7, 35.2, 29.2, 28.4, 24.3; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>17</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>Na<sup>+</sup>, 392.17976; found, 392.18342.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> ((1<i>s</i>,4<i>s</i>)-4-((<i>tert</i>-Butoxycarbonyl)amino)cyclohexyl)methyl (2,6-Dioxopiperidin-3-yl)carbamate (<b>15b</b>)</h4><div class="NLM_p last">Compound <b>15b</b> was synthesized according to the general procedure D. To a 15% wt solution of COCl<sub>2</sub> in toluene (12.3 mL, 17.3 mmol), a solution of <b>13</b> (3.05 g, 13.3 mmol) in THF was added. After evaporation of the volatiles, compound <b>14</b> was produced. By using <b>3b</b> (3.0 mg, 12.4 mmol), DIPEA (4 mL, 23 mmol), and the chloroformate <b>14</b> (3.5 mg, 12 mmol), compound <b>15b</b> was synthesized. After purification via flash column chromatography (DCM/MeOH 0–2% v/v), compound <b>15b</b> (2.99 g, 7.8 mmol, 65%) was isolated as a white solid. TLC (DCM/MeOH, 5:2 v/v): <i>R</i><sub>f</sub> = 0.76; mp 133–137 °C; IR (KBr) ν̃<sub>max</sub>: 3379, 1703, 1523, 1247, 1198, 1171 cm<sup>–1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>): δ 8.33 (s, 1H), 5.57 (s, 1H), 4.50 (d, <i>J</i> = 130.1 Hz, 2H), 3.85 (d, <i>J</i> = 97.0 Hz, 3H), 2.91–2.32 (m, 3H), 1.91–1.13 (m, 18H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.4, 171.3, 156.5, 155.4, 79.5, 69.0, 53.4, 46.4, 35.5, 31.3, 29.3, 28.5, 25.3, 24.3; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>18</sub>H<sub>29</sub>N<sub>3</sub>O<sub>6</sub>Na<sup>+</sup>, 406.19541; found, 406.19381.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> ((1<i>s</i>,4<i>s</i>)-4-((((2,5-Dioxopyrrolidin-3-yl)carbamoyl)oxy)methyl)cyclohexyl)methanaminium 2,2,2-Trifluoroacetate (<b>16a</b>)</h4><div class="NLM_p last">Compound <b>16a</b> was synthesized according to the general procedure D using <b>15a</b> (3.7 g, 10 mmol) and TFA (23 mL, 300 mmol). Upon completion, the volatiles were completely evaporated to give <b>16a</b> (3.83 g, 10 mmol, quant) as a white solid. TLC (DCM/MeOH, 5:1 v/v): <i>R</i><sub>f</sub> = 0.21; mp 74–76 °C; IR (KBr) ν̃<sub>max</sub>: 3447, 1783, 1717, 1629, 1529, 1267, 1203, 1182, 1138 cm<sup>–1</sup>; <sup>1</sup>H NMR: (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.23 (s, 1H), 7.90–7.71 (m, 4H), 4.53–4.21 (m, 1H), 3.98–3.86 (m, 3H), 3.16 (s, 1H), 2.88 (dd, <i>J</i> = 17.5, 9.4 Hz, 1H), 2.45 (d, <i>J</i> = 5.7 Hz, 1H), 1.87–1.35 (m, 9H); <sup>13</sup>C NMR (75 MHz, DMSO): δ 178.3, 176.6, 156.4, 66.6, 50.9, 48.1, 36.6, 33.5, 26.4, 23.6; <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −73.69; HRMS (<i>m</i>/<i>z</i>): [M + 2H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>20</sub>N<sub>3</sub>O<sub>4</sub><sup>+</sup>, 270.14483; found, 270.14076.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> ((1<i>s</i>,4<i>s</i>)-4-((((2,6-Dioxopiperidin-3-yl)carbamoyl)oxy)methyl)cyclohexyl)methanaminium 2,2,2-Trifluoroacetate (<b>16b</b>)</h4><div class="NLM_p last">Compound <b>16b</b> was synthesized according to the general procedure D using <b>15b</b> (3.8 g, 10 mmol) and TFA (23 mL, 300 mmol). Upon completion, the volatiles were completely evaporated to give <b>16b</b> (3.97 g, 10.0 mmol, quant) as a white solid. TLC (DCM/MeOH, 5:1 v/v): <i>R</i><sub>F</sub> = 0.20; mp 189–191 °C; IR (KBr) ν̃<sub>max</sub>: 3454, 1747, 1724, 1677, 1622, 1546, 1248, 1201, 1188, 1137 cm<sup>–1</sup>; <sup>1</sup>H NMR: (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.78 (s, 1H), 7.80 (s, 3H), 7.44 (s, 1H), 4.28 (s, 1H), 3.94 (dd, <i>J</i> = 16.4, 5.5 Hz, 3H), 3.19 (s, 1H), 2.73 (s, 1H), 2.00–1.40 (m, 11H); <sup>13</sup>C NMR (101 MHz, DMSO): 173.4, 172.9, 156.8, 66.4, 51.2, 48.2, 33.6, 31.4, 26.4, 24.8, 23.6; <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −73.96; HRMS (<i>m</i>/<i>z</i>): [M + 2H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub><sup>+</sup>, 284.16048; found, 284.15961.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>tert</i>-Butyl (2<i>S</i>)-2-((((2,6-Dioxopiperidin-3-yl)carbamoyl)oxy)methyl)pyrrolidine-1-carboxylate (<b>19b</b>)</h4><div class="NLM_p last">Compound <b>19b</b> was synthesized according to the general procedure D. To a 15% wt solution of COCl<sub>2</sub> in toluene (12.3 mL, 17.3 mmol), a solution of <b>17</b> (2.68 g, 13.3 mmol) in THF was added. After evaporation of the volatiles, compound <b>18</b> was produced. By using <b>3b</b> (3.0 g, 12.4 mmol), DIPEA (4 mL, 23 mmol), and the chloroformate <b>18</b> (3.16 g, 12 mmol), compound <b>19b</b> was synthesized. After purification via flash column chromatography (DCM/MeOH 0–2% v/v), compound <b>19b</b> (3.07 g, 8.64 mmol, 72%) was isolated as a white solid. TLC (DCM/MeOH, 5:0.5 v/v): <i>R</i><sub>f</sub> = 0.42; mp 81–83 °C; IR (KBr) ν̃<sub>max</sub>: 3437, 1698, 1540, 1403, 1249, 1201, 1171 cm<sup>–1</sup>; <sup>1</sup>H NMR: (400 MHz, CDCl<sub>3</sub>): δ 8.30 (s, 1H), 5.59 (s, 1H), 4.46–3.82 (m, 4H), 3.52–3.10 (m, 2H), 2.94–2.33 (m, 3H), 2.03–1.77 (m, 5H), 1.46 (s, 9H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.2, 156.1, 154.5, 65.7, 55.7, 52.2, 46.7, 46.5, 31.2, 28.5, 27.8, 25.3, 23.7, 22.9; HRMS ESI (<i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>16</sub>H<sub>25</sub>N<sub>3</sub>O<sub>6</sub>Na<sup>+</sup>, 378.16411; found, 378.16862.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (2<i>S</i>)-2-((((2,6-Dioxopiperidin-3-yl)carbamoyl)oxy)methyl)pyrrolidin-1-ium 2,2,2-Trifluoroacetate (<b>20b</b>)</h4><div class="NLM_p last">Compound <b>20b</b> was synthesized according to the general procedure D using <b>19b</b> (3.55 g, 10 mmol) and TFA (23 mL, 300 mmol). Upon completion, the volatiles were completely evaporated to give <b>20b</b> (3.69 g, 10 mmol, quant) as a white solid. TLC (DCM/MeOH, 5:0.5 v/v): <i>R</i><sub>F</sub> = 0.19; mp 149–151 °C; IR (KBr) ν̃<sub>max</sub>: 3479, 1705, 1541, 1253, 1204, 1135 cm<sup>–1</sup>; <sup>1</sup>H NMR: (400 MHz, DMSO): δ 10.82 (s, 1H), 9.24 (s, 1H), 8.74 (s, 1H), 7.62 (d, <i>J</i> = 8.5 Hz, 1H), 4.48–4.04 (m, 3H), 3.76 (s, 1H), 3.19 (s, 2H), 2.74 (ddd, <i>J</i> = 18.2, 12.7, 6.1 Hz, 1H), 2.12–1.81 (m, 5H), 1.79–1.57 (m, 1H); <sup>13</sup>C NMR (101 MHz, DMSO): δ 173.4, 172.7, 156.0, 63.8, 58.2, 51.3, 45.8, 31.4, 26.9, 24.7, 23.7; <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>): δ −74.36; HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>11</sub>H<sub>18</sub>N<sub>3</sub>O<sub>4</sub><sup>+</sup>, 256.12918; found, 256.12905.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Cloning, Expression and Protein Purification</h4><div class="NLM_p last">WT MsCI4 was cloned, expressed, and purified as previously described.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In an additional construct (humanized MsCI4), surface exposed residues were mutated to mimic hCRBN. The gene carrying the mutations A52H, M54Y, F56H, R68N, A72R, I87V, and L89Q was codon optimized for expression in <i>E. coli</i> and synthesized (eurofins). Humanized MsCI4 was cloned via BamHI and XhoI restriction sites into pETHis_1a; expression and purification were performed as described for WT MsCI4.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> FRET Assay</h4><div class="NLM_p last">FRET-based binding assay was performed using WT MsCI4 as described previously.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Compounds were dissolved in DMSO with the exception of <b>11a/b</b>, <b>16a/b</b>, and <b>20a/b</b>, which were water-soluble, and compounds <b>12a/b</b> that were dissolved in bicarbonate buffer. Because of remaining impurities, <b>20a</b> was not tested in this assay and only used for structural studies. For compounds <b>4a</b>, <b>4c</b>, <b>5a</b>, <b>7a</b>, <b>7b</b>, <b>7e</b>, and <b>7g</b>, binding was observed but could not be quantified, as saturation at higher concentrations was not appreciable in their binding curves. <i>K</i><sub>i</sub> values are summarized in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_001.pdf" class="ext-link">Table S1</a>.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Crystallography</h4><div class="NLM_p">For crystallization, MsCI4 and humanized MsCI4 protein solution were concentrated to 17 mg/mL and mixed with either 3 mM thalidomide (MsCI4 and humanized MsCI4) or <b>7d</b> (MsCI4). Crystallization trials for humanized MsCI4·thalidomide, which turned out to be humanized MsCI4·CBG, and MsCI4·<b>7d</b> were performed via the vapor diffusion technique at 294 K in sitting-drops. 400 nL of protein solution was mixed with 400 nL of reservoir solution with the Honeybee 963 robot (Genomic Solutions Ltd.). Diffraction-quality crystals of humanized MsCI4·CBG were obtained in a condition containing 20% PEG 3350 and 0.2 M ammonium acetate, and crystals of MsCI4·<b>7d</b> were obtained using 15% PEG 6 K and 5% glycerol. For all other compounds, crystals were prepared in hanging drop experiments by mixing 1 μL 0.4 M (NH<sub>4</sub>)<sub>2</sub>HPO<sub>4</sub> ground solution with 1 μL MsCI4·thalidomide solution. Crystals grown in this setup were transferred to 3 μL ground solution spiked with individual compounds for soaking. After 36 h, crystals were cryoprotected by streaking through a 50% PEG 3350 solution. Crystals were flash-cooled in liquid nitrogen, and diffraction data were collected at 100 K and a wavelength of 1 Å on beamline X10SA at the Swiss Light Source using a PILATUS 6M-F hybrid pixel detector (Dectris Ltd.). Data were processed and scaled using XDS.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Structures of soaking experiments were solved based on the MsCI4·thalidomide coordinates (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4v2y">4v2y</a>). The cocrystal structures of the complexes with CBG and <b>7d</b> were of other crystal forms and were solved using molrep<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> with 4v2y as a search model, locating four and two chains in the ASU, respectively. All structures were rebuilt using Coot<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and the integrated suite Lidia for chemical structures and generation of restraints. The models were finalized via cyclic modeling in Coot and refinement using REFMAC5. Molecular figures were generated using PyMOL.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Data collection and refinement statistics are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Data Collection and Refinement Statistics</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">MsCI4·<b>4a</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>4b</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>5a</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>5b</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>7a</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>7b</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>7c</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>7d</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>7f</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="10" align="center"><b>Data Collection</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="10" align="center"><b>Unit Cell</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>a</i>, <i>b</i>, <i>c</i> (Å)</td><td class="colsep0 rowsep0" align="left">56.46, 58.82, 88.23</td><td class="colsep0 rowsep0" align="left">56.75, 58.82, 88.57</td><td class="colsep0 rowsep0" align="left">56.95, 59.58, 89.05</td><td class="colsep0 rowsep0" align="left">56.66, 58.71, 88.01</td><td class="colsep0 rowsep0" align="left">56.33, 58.68, 89.27</td><td class="colsep0 rowsep0" align="left">56.42, 58.80, 88.23</td><td class="colsep0 rowsep0" align="left">56.33, 58.68, 89.27</td><td class="colsep0 rowsep0" align="left">31.63, 52.39, 59.29</td><td class="colsep0 rowsep0" align="left">56.87, 58.55, 88.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α, β, γ (deg)</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90.0, 95.8, 90.0</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution range, Å</td><td class="colsep0 rowsep0" align="left">44.1–1.55 (1.64–1.55)</td><td class="colsep0 rowsep0" align="left">44.28–1.6 (1.7–1.6)</td><td class="colsep0 rowsep0" align="left">44.53–1.7 (1.8–1.7)</td><td class="colsep0 rowsep0" align="left">47.64–1.75 (1.85–1.75)</td><td class="colsep0 rowsep0" align="left">49.03–1.8 (1.86–1.8)</td><td class="colsep0 rowsep0" align="left">48.93–1.73 (1.84–1.73)</td><td class="colsep0 rowsep0" align="left">49.03–1.85 (1.96–1.85)</td><td class="colsep0 rowsep0" align="left">39.2–1.1 (1.16–1.1)</td><td class="colsep0 rowsep0" align="left">44.14–1.65 (1.75–1.65)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">redundancy</td><td class="colsep0 rowsep0" align="left">12.7 (11.8)</td><td class="colsep0 rowsep0" align="left">12.9 (12.9)</td><td class="colsep0 rowsep0" align="left">12.4 (12.8)</td><td class="colsep0 rowsep0" align="left">12.8 (12.8)</td><td class="colsep0 rowsep0" align="left">12.86 (12)</td><td class="colsep0 rowsep0" align="left">12.5 (12.0)</td><td class="colsep0 rowsep0" align="left">12.9 (13.0)</td><td class="colsep0 rowsep0" align="left">6.3 (5.3)</td><td class="colsep0 rowsep0" align="left">12.9 (13.2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness %</td><td class="colsep0 rowsep0" align="left">99.8 (98.9)</td><td class="colsep0 rowsep0" align="left">99.9 (99.4)</td><td class="colsep0 rowsep0" align="left">99.0 (98.2)</td><td class="colsep0 rowsep0" align="left">99.6 (97.7)</td><td class="colsep0 rowsep0" align="left">99.6 (97.6)</td><td class="colsep0 rowsep0" align="left">98.8 (92.4)</td><td class="colsep0 rowsep0" align="left">99.8 (98.6)</td><td class="colsep0 rowsep0" align="left">99.1 (95.1)</td><td class="colsep0 rowsep0" align="left">99.9 (99.6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i> merge %</td><td class="colsep0 rowsep0" align="left">9.0 (98.2)</td><td class="colsep0 rowsep0" align="left">5.3 (82.8)</td><td class="colsep0 rowsep0" align="left">7.3 (94.6)</td><td class="colsep0 rowsep0" align="left">6.6 (98.5)</td><td class="colsep0 rowsep0" align="left">7.2 (89.0)</td><td class="colsep0 rowsep0" align="left">14.2 (88.8)</td><td class="colsep0 rowsep0" align="left">6.1 (102.8)</td><td class="colsep0 rowsep0" align="left">5.3 (39.4)</td><td class="colsep0 rowsep0" align="left">6.9 (81.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>CC</i> (1/2)</td><td class="colsep0 rowsep0" align="left">99.9 (85.4)</td><td class="colsep0 rowsep0" align="left">100 (90.4)</td><td class="colsep0 rowsep0" align="left">99.9 (87.8)</td><td class="colsep0 rowsep0" align="left">100 (87.6)</td><td class="colsep0 rowsep0" align="left">100 (84.6)</td><td class="colsep0 rowsep0" align="left">99.6 (85.7)</td><td class="colsep0 rowsep0" align="left">99.9 (78.1)</td><td class="colsep0 rowsep0" align="left">99.8 (92.4)</td><td class="colsep0 rowsep0" align="left">99.9 (86.6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>I</i>/<i>s</i>(<i>I</i>)</td><td class="colsep0 rowsep0" align="left">15.09 (1.78)</td><td class="colsep0 rowsep0" align="left">15.09 (1.78)</td><td class="colsep0 rowsep0" align="left">20.22 (2.02)</td><td class="colsep0 rowsep0" align="left">20.47 (2.27)</td><td class="colsep0 rowsep0" align="left">22.12 (2.39)</td><td class="colsep0 rowsep0" align="left">10.55 (1.73)</td><td class="colsep0 rowsep0" align="left">21.46 (2.25)</td><td class="colsep0 rowsep0" align="left">17.67 (3.64)</td><td class="colsep0 rowsep0" align="left">20.72 (2.35)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="10" align="center"><b>Refinement</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">number of reflections (total/test)</td><td class="colsep0 rowsep0" align="left">43 370 (4254)</td><td class="colsep0 rowsep0" align="left">39 841 (3904)</td><td class="colsep0 rowsep0" align="left">33 803 (3354)</td><td class="colsep0 rowsep0" align="left">30 301 (2985)</td><td class="colsep0 rowsep0" align="left">28 122 (2771)</td><td class="colsep0 rowsep0" align="left">30 582 (2948)</td><td class="colsep0 rowsep0" align="left">28 122 (2771)</td><td class="colsep0 rowsep0" align="left">77 822 (7458)</td><td class="colsep0 rowsep0" align="left">36 182 (3558)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of atoms</td><td class="colsep0 rowsep0" align="left">2871</td><td class="colsep0 rowsep0" align="left">2787</td><td class="colsep0 rowsep0" align="left">2767</td><td class="colsep0 rowsep0" align="left">2709</td><td class="colsep0 rowsep0" align="left">2544</td><td class="colsep0 rowsep0" align="left">2778</td><td class="colsep0 rowsep0" align="left">2675</td><td class="colsep0 rowsep0" align="left">2082</td><td class="colsep0 rowsep0" align="left">2464</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein</td><td class="colsep0 rowsep0" align="left">2572</td><td class="colsep0 rowsep0" align="left">2519</td><td class="colsep0 rowsep0" align="left">2504</td><td class="colsep0 rowsep0" align="left">2523</td><td class="colsep0 rowsep0" align="left">2338</td><td class="colsep0 rowsep0" align="left">2521</td><td class="colsep0 rowsep0" align="left">2468</td><td class="colsep0 rowsep0" align="left">1768</td><td class="colsep0 rowsep0" align="left">2229</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solvent</td><td class="colsep0 rowsep0" align="left">223</td><td class="colsep0 rowsep0" align="left">173</td><td class="colsep0 rowsep0" align="left">185</td><td class="colsep0 rowsep0" align="left">134</td><td class="colsep0 rowsep0" align="left">175</td><td class="colsep0 rowsep0" align="left">187</td><td class="colsep0 rowsep0" align="left">123</td><td class="colsep0 rowsep0" align="left">276</td><td class="colsep0 rowsep0" align="left">166</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ligand</td><td class="colsep0 rowsep0" align="left">76</td><td class="colsep0 rowsep0" align="left">95</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">70</td><td class="colsep0 rowsep0" align="left">84</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i> work %</td><td class="colsep0 rowsep0" align="left">0.17</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">0.17</td><td class="colsep0 rowsep0" align="left">0.17</td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i> free %</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">0.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="10" align="center"><b>Ligand in Chain</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left">hydrolyzed 4b</td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left"><b>7a</b></td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">thalidomide</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="left">hydrolyzed <b>4b</b></td><td class="colsep0 rowsep0" align="left">hydrolyzed <b>5a</b></td><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left"><b>7a</b></td><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="left">co-crystal with <b>7d</b></td><td class="colsep0 rowsep0" align="left"><b>7f</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">hydrolyzed <b>4a</b></td><td class="colsep0 rowsep0" align="left">hydrolyzed <b>4b</b></td><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDB ID</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0S">6R0S</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0V">6R0V</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0U">6R0U</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R11">6R11</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1X">6R1X</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R12">6R12</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1K">6R1K</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1D">6R1D</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R13">6R13</a></td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="center">MsCI4·<b>11a</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>12a</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>16b</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>20a</b></th><th class="colsep0 rowsep0" align="center">MsCI4·<b>20b</b></th><th class="colsep0 rowsep0" align="center">MsCI4·CBG</th><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="left"> </th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="center"><b>Data Collection</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"><i>P</i>2<sub>1</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="center"><b>Unit Cell</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>a</i>, <i>b</i>, <i>c</i> (Å)</td><td class="colsep0 rowsep0" align="left">56.63, 59.59, 88.90</td><td class="colsep0 rowsep0" align="left">56.66, 59.02, 88.59</td><td class="colsep0 rowsep0" align="left">56.53, 59.44, 88.36</td><td class="colsep0 rowsep0" align="left">56.56, 59.23, 88.43</td><td class="colsep0 rowsep0" align="left">56.56, 59.3, 88.0</td><td class="colsep0 rowsep0" align="left">61.7, 59.1, 61.7</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α, β, γ (deg)</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 90, 90</td><td class="colsep0 rowsep0" align="left">90, 105.6, 90</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution range, Å</td><td class="colsep0 rowsep0" align="left">44.45–1.35 (1.43–1.35)</td><td class="colsep0 rowsep0" align="left">49.12–1.5 (1.59–1.5)</td><td class="colsep0 rowsep0" align="left">47.62–1.35 (1.43–1.35)</td><td class="colsep0 rowsep0" align="left">49.21–1.45 (1.50–1.45)</td><td class="colsep0 rowsep0" align="left">49.18–1.54 (1.64–1.54)</td><td class="colsep0 rowsep0" align="left">49.17–1.50 (1.59–1.50)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">redundancy</td><td class="colsep0 rowsep0" align="left">12.7 (12.4)</td><td class="colsep0 rowsep0" align="left">12.6 (12.6)</td><td class="colsep0 rowsep0" align="left">12.6 (12.7)</td><td class="colsep0 rowsep0" align="left">12.8 (12.9)</td><td class="colsep0 rowsep0" align="left">12.6 (12.1)</td><td class="colsep0 rowsep0" align="left">3.4 (3.1)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness %</td><td class="colsep0 rowsep0" align="left">99.9 (99.3)</td><td class="colsep0 rowsep0" align="left">99.5 (97.2)</td><td class="colsep0 rowsep0" align="left">99.8 (99.1)</td><td class="colsep0 rowsep0" align="left">99.8 (98.5)</td><td class="colsep0 rowsep0" align="left">99.5 (96.7)</td><td class="colsep0 rowsep0" align="left">99.0 (97.5)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i> merge %</td><td class="colsep0 rowsep0" align="left">7.4 (96.3)</td><td class="colsep0 rowsep0" align="left">11.4 (78.6)</td><td class="colsep0 rowsep0" align="left">7.9 (98.8)</td><td class="colsep0 rowsep0" align="left">9.5 (89.4)</td><td class="colsep0 rowsep0" align="left">13.1 (81.5)</td><td class="colsep0 rowsep0" align="left">8.0 (88.0)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>CC</i> (1/2)</td><td class="colsep0 rowsep0" align="left">99.9 (83.2)</td><td class="colsep0 rowsep0" align="left">99.8 (86.5)</td><td class="colsep0 rowsep0" align="left">99.9 (84.0)</td><td class="colsep0 rowsep0" align="left">99.8 (86.2)</td><td class="colsep0 rowsep0" align="left">99.7 (83.8)</td><td class="colsep0 rowsep0" align="left">99.7 (83.8)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>I</i>/<i>s</i>(<i>I</i>)</td><td class="colsep0 rowsep0" align="left">17.62 (1.97)</td><td class="colsep0 rowsep0" align="left">14.29 (2.32)</td><td class="colsep0 rowsep0" align="left">16.63 (1.85)</td><td class="colsep0 rowsep0" align="left">14.83 (2.11)</td><td class="colsep0 rowsep0" align="left">10.28 (1.71)</td><td class="colsep0 rowsep0" align="left">9.70 (1.15)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="center"><b>Refinement</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">number of reflections (total/test)</td><td class="colsep0 rowsep0" align="left">66 738 (6544)</td><td class="colsep0 rowsep0" align="left">48 282 (4739)</td><td class="colsep0 rowsep0" align="left">66 083 (6516)</td><td class="colsep0 rowsep0" align="left">53 344 (5211)</td><td class="colsep0 rowsep0" align="left">44 026 (4112)</td><td class="colsep0 rowsep0" align="left">68 399 (6707)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no. of atoms</td><td class="colsep0 rowsep0" align="left">2977</td><td class="colsep0 rowsep0" align="left">2995</td><td class="colsep0 rowsep0" align="left">3057</td><td class="colsep0 rowsep0" align="left">3074</td><td class="colsep0 rowsep0" align="left">2928</td><td class="colsep0 rowsep0" align="left">3985</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein</td><td class="colsep0 rowsep0" align="left">2619</td><td class="colsep0 rowsep0" align="left">2665</td><td class="colsep0 rowsep0" align="left">2638</td><td class="colsep0 rowsep0" align="left">2634</td><td class="colsep0 rowsep0" align="left">2617</td><td class="colsep0 rowsep0" align="left">3480</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solvent</td><td class="colsep0 rowsep0" align="left">281</td><td class="colsep0 rowsep0" align="left">252</td><td class="colsep0 rowsep0" align="left">338</td><td class="colsep0 rowsep0" align="left">339</td><td class="colsep0 rowsep0" align="left">232</td><td class="colsep0 rowsep0" align="left">421</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ligand</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">101</td><td class="colsep0 rowsep0" align="left">79</td><td class="colsep0 rowsep0" align="left">84</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i> work %</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">0.21</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">0.17</td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i> free %</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">0.24</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left">0.21</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="center"><b>Ligand in Chain</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A</td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B</td><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="left"><b>16b</b></td><td class="colsep0 rowsep0" align="left"><b>20a</b></td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left">co-crystal with CBG</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left"><b>16b</b></td><td class="colsep0 rowsep0" align="left">thalidomide</td><td class="colsep0 rowsep0" align="left"><b>20b</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDB ID</td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R18">6R18</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1C">6R1C</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1W">6R1W</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R19">6R19</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1A">6R1A</a></td><td class="colsep0 rowsep0" align="left"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0Q">6R0Q</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div></div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Cell Culture and Western Blot</h4><div class="NLM_p last">OPM-2 cells were routinely cultivated in 90% RPMI 1640 + 10% FBS and 1% penicillin/streptomycin. Cells were split to 0.3 × 10<sup>6</sup> cells/mL 2 days prior to experiments. 4 mL of culture per well was pipetted in a sterile environment. Stock solutions of lenalidomide were prepared at concentrations of 80 and 400 mM and stock solutions of test compounds were prepared at a concentration of 400 mM. For the assay, 10 μL of stock solutions was added to the 4 mL cell culture. DMSO controls were prepared in the same manner, leading to a final DMSO concentration of 0.25%. After 24 h of incubation, cell solution was centrifugated at 500<i>g</i>. After one washing step with ice cold PBS, cell pellets were resuspended in 35 μL of lysis buffer (20 mM Hepes, 175 mM NaCl, 1% NP40, 2 mM MgCl<sub>2</sub>) on ice and supplemented with 0.5 μL Benzonase. Samples were resolved by Mini-PROTEAN TGX gels (Bio-Rad) and activated under UV light, before transfer to low-fluorescence PVDF membranes, according to manufacturer’s protocol. Membranes were imaged before blocking in 5% milk in PBS-T and incubating with primary antibodies anti-IKZF3 (15103S, Cell Signaling Technology, Inc.) and anti-CK1α (ab108296, Abcam plc). After overnight incubation, horseradish peroxidase conjugated secondary antibodies goat anti-rabbit (111-035-144, Jackson Immuno Research) and goat anti-mouse (115-035-003, Jackson Immuno Research) were used at 1:20 000 dilutions for detection of bands by chemiluminescence (ECL Vilbert). Protein bands were detected and integrated using the Bio-Rad analysis suite. Endogenous protein levels were normalized using Stain-Free Technology (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_001.pdf" class="ext-link">Figure S2</a>) and analyzed by one-way ANOVA, according to the Holm-Sidak method integrated into SigmaPlot. The linearity of anti-IKZF3 mAb was tested via serial dilutions of cell extracts (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_001.pdf" class="ext-link">Figure S3</a>).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00454" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53678" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53678" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00454" class="ext-link">10.1021/acs.jmedchem.9b00454</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HPLC traces of tested compounds, western blot quantification and normalization IKZF3, concentration response curve for IKZF3 mAb, and <i>K</i><sub>i</sub> values of tested compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_001.pdf">jm9b00454_si_001.pdf (1.73 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_002.csv">jm9b00454_si_002.csv (1.18 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Crystal structures have been deposited in the protein data bank (PDB) under the accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0S">6R0S</a> (<b>4a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0V">6R0V</a> (<b>4b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0U">6R0U</a> (<b>5a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R11">6R11</a> (<b>5b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1X">6R1X</a> (<b>7a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R12">6R12</a> (<b>7b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1K">6R1K</a> (<b>7c</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1D">6R1D</a> (<b>7d</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R13">6R13</a> (<b>7f</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R18">6R18</a> (<b>11a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1C">6R1C</a> (<b>12a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1W">6R1W</a> (<b>16b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R19">6R19</a> (<b>20a</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1A">6R1A</a> (<b>20b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0Q">6R0Q</a> (CBG). The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00454" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83028" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83028" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Athanassios Giannis</span> - <span class="hlFld-Affiliation affiliation">Faculty
for Chemistry und Mineralogy, Institute of Organic Chemistry, University of Leipzig, Johannisallee 29, 04103 Leipzig, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2203-0959" title="Orcid link">http://orcid.org/0000-0003-2203-0959</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#53343a323d3d3a2013263d3a7e3f363a23293a347d3736"><span class="__cf_email__" data-cfemail="583f31393636312b182d363175343d312822313f763c3d">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcus D. Hartmann</span> - <span class="hlFld-Affiliation affiliation">Department
of Protein Evolution, Max Planck Institute
for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6937-5677" title="Orcid link">http://orcid.org/0000-0001-6937-5677</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c8a5a9baabbdbbe6a0a9babca5a9a6a688bcbdadaaa1a6afada6e6a5b8afe6acad"><span class="__cf_email__" data-cfemail="503d31223325237e383122243d313e3e1024253532393e37353e7e3d20377e3435">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher Heim</span> - <span class="hlFld-Affiliation affiliation">Department
of Protein Evolution, Max Planck Institute
for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dimanthi Pliatsika</span> - <span class="hlFld-Affiliation affiliation">Faculty
for Chemistry und Mineralogy, Institute of Organic Chemistry, University of Leipzig, Johannisallee 29, 04103 Leipzig, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Farnoush Mousavizadeh</span> - <span class="hlFld-Affiliation affiliation">Faculty
for Chemistry und Mineralogy, Institute of Organic Chemistry, University of Leipzig, Johannisallee 29, 04103 Leipzig, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kerstin Bär</span> - <span class="hlFld-Affiliation affiliation">Department
of Protein Evolution, Max Planck Institute
for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Birte Hernandez Alvarez</span> - <span class="hlFld-Affiliation affiliation">Department
of Protein Evolution, Max Planck Institute
for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23555" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23555" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Andrei Lupas for continuing support, Reinhard Albrecht for assistance with crystallization and crystallographic data collection, and the staff of beamline X10SA of the Swiss Light Source (PSI, Villigen, Switzerland) for excellent technical support. This work was supported by institutional funds of the Max Planck Society.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">4-DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">APP</td><td class="NLM_def"><p class="first last">amyloid precursor protein</p></td></tr><tr><td class="NLM_term">ASU</td><td class="NLM_def"><p class="first last">asymmetric unit</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extraterminal domain</p></td></tr><tr><td class="NLM_term">CBG</td><td class="NLM_def"><p class="first last">α-(2-carboxybenzamido)glutarimide</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-carbodiimidazole</p></td></tr><tr><td class="NLM_term">CK1α</td><td class="NLM_def"><p class="first last">casein kinase 1α</p></td></tr><tr><td class="NLM_term">CRBN</td><td class="NLM_def"><p class="first last">cereblon</p></td></tr><tr><td class="NLM_term">CRL4<sup>CRBN</sup></td><td class="NLM_def"><p class="first last">CUL4-RBX1-DDB1-CRBN</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">Et<sub>3</sub>N</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">GSPT1</td><td class="NLM_def"><p class="first last">eukaryotic peptide chain release factor GTP-binding subunit ERF3A</p></td></tr><tr><td class="NLM_term">IKZF1</td><td class="NLM_def"><p class="first last">IKAROS family zinc finger 1</p></td></tr><tr><td class="NLM_term">IKZF3</td><td class="NLM_def"><p class="first last">zinc finger protein Aiolos</p></td></tr><tr><td class="NLM_term">IMiD</td><td class="NLM_def"><p class="first last">immunomodulatory drug</p></td></tr><tr><td class="NLM_term">MDS</td><td class="NLM_def"><p class="first last">myelodysplastic syndrome</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">MsCI4</td><td class="NLM_def"><p class="first last">CRBN homologue from magnetospirillum gryphiswaldense</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis targeting chimera</p></td></tr><tr><td class="NLM_term">SALL4</td><td class="NLM_def"><p class="first last">sal-like protein 4</p></td></tr><tr><td class="NLM_term">VHL</td><td class="NLM_def"><p class="first last">von-Hippel-Lindau</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32234" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32234" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 60 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somers, G. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug</span>. <i>Br. J. Pharmacol. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1960</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1960.tb01217.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1111%2Fj.1476-5381.1960.tb01217.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=13832739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADyaF3cXht1ShtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1960&pages=111-116&author=G.+F.+Somers&title=Pharmacological+properties+of+thalidomide+%28alpha-phthalimido+glutarimide%29%2C+a+new+sedative+hypnotic+drug&doi=10.1111%2Fj.1476-5381.1960.tb01217.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of thalidomide (α-phthalimidoglutarimide), a new sedative hypnotic drug</span></div><div class="casAuthors">Somers, G. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology and Chemotherapy</span>
        (<span class="NLM_cas:date">1960</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-16</span>CODEN:
                <span class="NLM_cas:coden">BJPCAL</span>;
        ISSN:<span class="NLM_cas:issn">0366-0826</span>.
    </div><div class="casAbstract">This new non-toxic non-barbiturate sedative was assayed on male albino rats, mice, rabbits, cats, and guinea pigs for toxicity, effect on motor activity, reflexes, narcosis, analgesis, antipyresis, autonomic system, and gastrointestinal tract.  It was virtually nontoxic, and had no effect on these systems, possibly because of limited absorption.  It potentiated barbiturates, alc., reserpine, chlorpromazine, and counteracted methylamphetamine and methylphenidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1CQ0N3hCBGLVg90H21EOLACvtfcHk0ljuQ_8KrNdO6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXht1ShtLc%253D&md5=4d82cdf61a96c7f74e79fb343f40bafd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1960.tb01217.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1960.tb01217.x%26sid%3Dliteratum%253Aachs%26aulast%3DSomers%26aufirst%3DG.%2BF.%26atitle%3DPharmacological%2520properties%2520of%2520thalidomide%2520%2528alpha-phthalimido%2520glutarimide%2529%252C%2520a%2520new%2520sedative%2520hypnotic%2520drug%26jtitle%3DBr.%2520J.%2520Pharmacol.%2520Chemother.%26date%3D1960%26volume%3D15%26spage%3D111%26epage%3D116%26doi%3D10.1111%2Fj.1476-5381.1960.tb01217.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, W.</span></span> <span> </span><span class="NLM_article-title">A short history of thalidomide embryopathy</span>. <i>Teratology</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1002/tera.1420380303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1002%2Ftera.1420380303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=3067415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADyaL1M7ks1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1988&pages=203-215&author=W.+Lenz&title=A+short+history+of+thalidomide+embryopathy&doi=10.1002%2Ftera.1420380303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A short history of thalidomide embryopathy</span></div><div class="casAuthors">Lenz W</div><div class="citationInfo"><span class="NLM_cas:title">Teratology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-15</span>
        ISSN:<span class="NLM_cas:issn">0040-3709</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4u0Tv59TImfxQvRxYU81tfW6udTcc2eYib6u8-BBCU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1M7ks1Kluw%253D%253D&md5=65dd1712af76e247727c4cf7f528ae51</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Ftera.1420380303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Ftera.1420380303%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DW.%26atitle%3DA%2520short%2520history%2520of%2520thalidomide%2520embryopathy%26jtitle%3DTeratology%26date%3D1988%26volume%3D38%26spage%3D203%26epage%3D215%26doi%3D10.1002%2Ftera.1420380303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vargesson, N.</span></span> <span> </span><span class="NLM_article-title">Thalidomide-induced limb defects: resolving a 50-year-old puzzle</span>. <i>Bioessays</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1336</span>, <span class="refDoi"> DOI: 10.1002/bies.200900103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1002%2Fbies.200900103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=19921660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVamuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2009&pages=1327-1336&author=N.+Vargesson&title=Thalidomide-induced+limb+defects%3A+resolving+a+50-year-old+puzzle&doi=10.1002%2Fbies.200900103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide-induced limb defects: resolving a 50-year-old puzzle</span></div><div class="casAuthors">Vargesson, Neil</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1327-1336</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Despite the recent discovery that thalidomide causes limb defects by targeting highly angiogenic, immature blood vessels, several challenges still remain and new ones have arisen.  These include understanding the drug's species specificity, detg. mol. target(s) in the endothelial cell, shedding light on the mol. basis of phocomelia and producing a form of the drug that is clin. effective without having side effects.  Now that the trigger of thalidomide-induced teratogenesis has been uncovered, a framework is proposed, incorporating and uniting previous models of thalidomide action, explaining how thalidomide causes not just limb defects, but also all the other defects it induces.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiL3Rixd9UzrVg90H21EOLACvtfcHk0liU4Ism-cD14Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVamuw%253D%253D&md5=ca4738ec2192397e2b61142a3eda4f3e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fbies.200900103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.200900103%26sid%3Dliteratum%253Aachs%26aulast%3DVargesson%26aufirst%3DN.%26atitle%3DThalidomide-induced%2520limb%2520defects%253A%2520resolving%2520a%252050-year-old%2520puzzle%26jtitle%3DBioessays%26date%3D2009%26volume%3D31%26spage%3D1327%26epage%3D1336%26doi%3D10.1002%2Fbies.200900103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdalla, S. H.</span></span> <span> </span><span class="NLM_article-title">Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1080/10428190290006143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1080%2F10428190290006143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=11999568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVaqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=351-354&author=R.+E.+Johnstonauthor=S.+H.+Abdalla&title=Thalidomide+in+low+doses+is+effective+for+the+treatment+of+resistant+or+relapsed+multiple+myeloma+and+for+plasma+cell+leukaemia&doi=10.1080%2F10428190290006143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukemia</span></div><div class="casAuthors">Johnston, R. E.; Abdalla, S. H.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">351-354</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Thalidomide is an effective treatment for relapsed multiple myeloma (MM), but is assocd. with a significant side effect profile at higher doses.  In a recent study, only half of the enrolled patients were able to tolerate the max. dose of 800 mg/day [Singhal, S., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", New Engl. J. Med. 341, 1565-1571].  Moreover, the dose-response relationship has not been defined.  We report our use of low dose thalidomide in a small cohort of 12 patients-eight with relapsed or refractory MM and four with plasma cell leukemia (PCL).  Five of the 12 (42%) patients had a partial response, showing a median fall in their PP/BJP of 80% (63-90%) at a median dose of 175 mg (100-300 mg) with negligible side effects.  Three of four patients with PCL showed an impressive response to treatment with thalidomide as a single agent.  No patient who failed to show any evidence of response at low dose (<150 mg/day) responded to higher doses.  In this study, thalidomide induces a similar rate of response at a lower and better tolerated dose than previously reported and produced "best ever" responses in patients with resistant PCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbWYLn9ADiirVg90H21EOLACvtfcHk0liU4Ism-cD14Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVaqs74%253D&md5=fefa82138697984cbc04d8738cfb8bf9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1080%2F10428190290006143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190290006143%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DR.%2BE.%26aulast%3DAbdalla%26aufirst%3DS.%2BH.%26atitle%3DThalidomide%2520in%2520low%2520doses%2520is%2520effective%2520for%2520the%2520treatment%2520of%2520resistant%2520or%2520relapsed%2520multiple%2520myeloma%2520and%2520for%2520plasma%2520cell%2520leukaemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2002%26volume%3D43%26spage%3D351%26epage%3D354%26doi%3D10.1080%2F10428190290006143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span> </span><span class="NLM_article-title">US Thalomid Label</span>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020785s061lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020785s061lbl.pdf</a> (accessed Dec 9, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=US+Thalomid+Label.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F020785s061lbl.pdf+%28accessed+Dec+9%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DUS%2520Thalomid%2520Label%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertolini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mingrone, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alietti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrucci, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocorocchio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peccatori, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cineri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span> <span> </span><span class="NLM_article-title">Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">990</span>, <span class="refDoi"> DOI: 10.1023/a:1011141009812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1023%2Fa%3A1011141009812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=11521807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADC%252BD3MvnvVehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=987-990&author=F.+Bertoliniauthor=W.+Mingroneauthor=A.+Aliettiauthor=P.+F.+Ferrucciauthor=E.+Cocorocchioauthor=F.+Peccatoriauthor=S.+Cineriauthor=P.+Mancusoauthor=C.+Corsiniauthor=A.+Burliniauthor=E.+Zuccaauthor=G.+Martinelli&title=Thalidomide+in+multiple+myeloma%2C+myelodysplastic+syndromes+and+histiocytosis.+Analysis+of+clinical+results+and+of+surrogate+angiogenesis+markers&doi=10.1023%2Fa%3A1011141009812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers</span></div><div class="casAuthors">Bertolini F; Mingrone W; Alietti A; Ferrucci P F; Cocorocchio E; Peccatori F; Cinieri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G; Cineri S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">987-90</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  Thalidomide, as a single agent, has been recently found to induce a clinical response in one third of refractory or relapsed myeloma patients.  Although it has been reported that thalidomide significantly inhibits angiogenesis. it is still unclear whether its clinical effect is mediated, at least in part, by its anti-angiogenic properties.  PATIENTS AND METHODS:  We evaluated thalidomide as a single agent in myeloma, myelodysplastic syndromes (MDS) and histiocytosis, i.e. hematological diseases characterized by increased angiogenesis, and measured prospectively a number of surrogate angiogenesis markers.  RESULTS:  Clinical responses were observed in 7 of 17 myeloma and 2 of 5 MDS patients.  The histiocytosis patient had a partial response.  At the time of the best clinical response, plasma levels of angiogenic growth factors, vascular endothelial growth factor (VEGF) and basic-fibroblast growth factor (b-FGF), were significantly decreased, and flow cytometry indicated a decrease of activated endothelial cells in the bone marrow of responding MDS patients.  CONCLUSIONS:  These observations confirm thalidomide efficacy in myeloma, suggest a possible use in MDS and histiocytosis and may contribute to the prediction of clinical response and to understanding the mechanism of thalidomide's action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMwvoem2ZMpYvKgEt20y1XfW6udTcc2eZxLPT9JbqF0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvnvVehuw%253D%253D&md5=19268541729e2a5d8762802d62ae882c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1023%2Fa%3A1011141009812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252Fa%253A1011141009812%26sid%3Dliteratum%253Aachs%26aulast%3DBertolini%26aufirst%3DF.%26aulast%3DMingrone%26aufirst%3DW.%26aulast%3DAlietti%26aufirst%3DA.%26aulast%3DFerrucci%26aufirst%3DP.%2BF.%26aulast%3DCocorocchio%26aufirst%3DE.%26aulast%3DPeccatori%26aufirst%3DF.%26aulast%3DCineri%26aufirst%3DS.%26aulast%3DMancuso%26aufirst%3DP.%26aulast%3DCorsini%26aufirst%3DC.%26aulast%3DBurlini%26aufirst%3DA.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DMartinelli%26aufirst%3DG.%26atitle%3DThalidomide%2520in%2520multiple%2520myeloma%252C%2520myelodysplastic%2520syndromes%2520and%2520histiocytosis.%2520Analysis%2520of%2520clinical%2520results%2520and%2520of%2520surrogate%2520angiogenesis%2520markers%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26spage%3D987%26epage%3D990%26doi%3D10.1023%2Fa%3A1011141009812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kale, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">List, A.</span></span> <span> </span><span class="NLM_article-title">Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes</span>. <i>Curr. Pharm. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.2174/138920106778521587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.2174%2F138920106778521587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=17076650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVamsLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=339-342&author=V.+Kaleauthor=A.+List&title=Immunomodulatory+drugs+%28IMiDs%29%3A+a+new+treatment+option+for+myelodysplastic+syndromes&doi=10.2174%2F138920106778521587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes</span></div><div class="casAuthors">Kale, Vishakha; List, Alan F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Biotechnology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">339-342</span>CODEN:
                <span class="NLM_cas:coden">CPBUBP</span>;
        ISSN:<span class="NLM_cas:issn">1389-2010</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The IMiDs represent a new proprietary class of thalidomide analogs that possess greater potency and less toxicity than the parent compd.  As a group, these agents share the pharmacol. property of modulating cellular response to ligand activation, the precise biol. effect of which is cell lineage and stimulant-dependent.  Lenalidomide (CC-5013; Revlimid), a second generation IMiD, has shown significant erythropoietic activity in patients with lower risk MDS that have failed or are not candidates for recombinant erythropoietin treatment.  Unlike cytokine therapy, lenalidomide suppresses select MDS clones and enhances erythropoietin receptor signaling to restore erythropoiesis.  Activity is greatest in patients with interstitial deletions involving chromosome 5q31.1.  A multicenter phase II study reported a 76% overall transfusion response rate in transfusion-dependent patients with deletion 5q, with 67% achieving transfusion independence after a median interval of 4.6 wk of treatment.  Cytogenetic responses were obsd. in 73% of patients with complete cytogenetic remission in 45% patients.  Both transfusion response and cytogenetic response frequency were independent of karyotype complexity, raising excitement that this new treatment strategy might favorably alter the natural history of disease in higher risk patients with deletion 5q.  Lenalidomide was approved by the U.S. Food and Drug Administration on Dec. 27, 2005, for the treatment of IPSS Low and intermediate-1 risk MDS patients with del(5q) abnormality.  A phase III Intergroup trial (ECOG 2905) will test the capacity to potentiate erythropoietin response by comparing response to lenalidomide monotherapy to the combination of darbepoetin and lenalidomide in non-deletion 5q MDS patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtP_aXebs15rVg90H21EOLACvtfcHk0lgSqIrF0jqS1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVamsLrN&md5=e1597e6b7cf4543228046753231f2348</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F138920106778521587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920106778521587%26sid%3Dliteratum%253Aachs%26aulast%3DKale%26aufirst%3DV.%26aulast%3DList%26aufirst%3DA.%26atitle%3DImmunomodulatory%2520drugs%2520%2528IMiDs%2529%253A%2520a%2520new%2520treatment%2520option%2520for%2520myelodysplastic%2520syndromes%26jtitle%3DCurr.%2520Pharm.%2520Biotechnol.%26date%3D2006%26volume%3D7%26spage%3D339%26epage%3D342%26doi%3D10.2174%2F138920106778521587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, G.</span></span> <span> </span><span class="NLM_article-title">Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin’s lymphoma: A prospective study of 46 cases</span>. <i>Mol. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.3892/mco.2014.307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.3892%2Fmco.2014.307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25054032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADC%252BC2sbpvFKgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=695-700&author=H.+Wuauthor=C.+Zhaoauthor=K.+Guauthor=Y.+Jiaoauthor=J.+Haoauthor=G.+Sun&title=Thalidomide+plus+chemotherapy+exhibit+enhanced+efficacy+in+the+clinical+treatment+of+T-cell+non-Hodgkin%E2%80%99s+lymphoma%3A+A+prospective+study+of+46+cases&doi=10.3892%2Fmco.2014.307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases</span></div><div class="casAuthors">Wu Hongyang; Zhao Chenchen; Gu Kangsheng; Jiao Yang; Hao Jiqing; Sun Guoping</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and clinical oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">695-700</span>
        ISSN:<span class="NLM_cas:issn">2049-9450</span>.
    </div><div class="casAbstract">The treatment of T-cell non-Hodgkin's lymphoma (T-NHL) remains challenging.  There is currently no standard regimen for the treatment of T-NHL in the first- or second-line setting.  Thalidomide was previously shown to exert antitumor effects through inhibiting angiogenesis, promoting apoptosis and immunomodulatory activity.  However, all the previous studies on the treatment of lymphoma with thalidomide included patient samples of limited size.  In the present study, 46 cases of eligible T-NHL patients were randomized into i) the control group (conventional combined chemotherapy, n=22) and ii) the thalidomide group (thalidomide plus combined chemotherapy, n=24).  The median dose of thalidomide was 200 mg (range, 150-400 mg) every night, without reported severe side effects.  The clinical response to treatment was as follows: Complete response (CR) in 12 cases, partial response (PR) in 7, stable disease (SD) in 1 and progressive disease (PD) in 4 cases in the thalidomide group; and CR in 8 cases, PR in 6, SD in 3 and PD in 5 cases in the control group.  The CR rate was 50.0 and 36.4% in the thalidomide and the control groups, respectively (P<0.05).  The median progression-free and overall survival were 12 and undefined months, respectively, in the thalidomide group and 6 and 17 months, respectively, in the control group.  The toxicity profile was considered acceptable in both groups.  Our results indicated that thalidomide plus combined chemotherapy may exhibit enhanced efficacy in the clinical treatment of T-NHL.  In addition, this type of treatment may reduce the frequency of adverse gastrointestinal reactions and help alleviate fear of chemotherapy.  Therefore, thalidomide plus combined chemotherapy may be a viable option for the clinical treatment of T-NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTb-wRHuM3ThRjv2lLSLOxFfW6udTcc2eZxLPT9JbqF0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbpvFKgtA%253D%253D&md5=f173c9f716db0820c32424792125ff88</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3892%2Fmco.2014.307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmco.2014.307%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DK.%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DG.%26atitle%3DThalidomide%2520plus%2520chemotherapy%2520exhibit%2520enhanced%2520efficacy%2520in%2520the%2520clinical%2520treatment%2520of%2520T-cell%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%253A%2520A%2520prospective%2520study%2520of%252046%2520cases%26jtitle%3DMol.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D2%26spage%3D695%26epage%3D700%26doi%3D10.3892%2Fmco.2014.307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-Sanz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-López, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vázquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermida, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graciani, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, J. F.</span></span> <span> </span><span class="NLM_article-title">The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin’s lymphoma</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0609.2009.01375.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1111%2Fj.1600-0609.2009.01375.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=19912314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlGmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=266-270&author=R.+Garc%C3%ADa-Sanzauthor=T.+J.+Gonz%C3%A1lez-L%C3%B3pezauthor=L.+V%C3%A1zquezauthor=G.+Hermidaauthor=I.+F.+Gracianiauthor=J.+F.+San+Miguel&title=The+combination+of+thalidomide%2C+cyclophosphamide+and+dexamethasone+is+potentially+useful+in+highly+resistant+Hodgkin%E2%80%99s+lymphoma&doi=10.1111%2Fj.1600-0609.2009.01375.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma</span></div><div class="casAuthors">Garcia-Sanz, R.; Gonzalez-Lopez, T. J.; Vazquez, L.; Hermida, G.; Graciani, I. F.; San Miguel, J. F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">266-270</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Few diseases have a prognosis worse than Hodgkin's lymphoma (HL), patients relapsing after autologous or allogeneic stem cell transplantation.  Here, we report two highly refractory patients with HL who successfully responded to a combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex).  Despite the use of a very large no. of different drugs (>5 different schemes) including high-dose therapy and autologous and allogeneic stem cell transplantation, both patients proved to be suffering from a highly resistant disease.  Fortunately, they finally responded to the ThaCyDex combination, achieving sustained complete remission that would support the running of a trial within this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD5zryHnpzqLVg90H21EOLACvtfcHk0lj0FRtieKC0iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlGmtL0%253D&md5=11de756fa308a935acb76c8870c33110</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0609.2009.01375.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0609.2009.01375.x%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Sanz%26aufirst%3DR.%26aulast%3DGonz%25C3%25A1lez-L%25C3%25B3pez%26aufirst%3DT.%2BJ.%26aulast%3DV%25C3%25A1zquez%26aufirst%3DL.%26aulast%3DHermida%26aufirst%3DG.%26aulast%3DGraciani%26aufirst%3DI.%2BF.%26aulast%3DSan%2BMiguel%26aufirst%3DJ.%2BF.%26atitle%3DThe%2520combination%2520of%2520thalidomide%252C%2520cyclophosphamide%2520and%2520dexamethasone%2520is%2520potentially%2520useful%2520in%2520highly%2520resistant%2520Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2010%26volume%3D84%26spage%3D266%26epage%3D270%26doi%3D10.1111%2Fj.1600-0609.2009.01375.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzarella, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCrae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crump, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, A.</span></span> <span> </span><span class="NLM_article-title">A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin’s lymphoma</span>. <i>Hematology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1080/10245330500276592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1080%2F10245330500276592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=16522545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVOhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=25-29&author=J.+Kuruvillaauthor=K.+Songauthor=P.+Molleeauthor=T.+Panzarellaauthor=J.+McCraeauthor=T.+Nagyauthor=M.+Crumpauthor=A.+Keating&title=A+phase+II+study+of+thalidomide+and+vinblastine+for+palliative+patients+with+Hodgkin%E2%80%99s+lymphoma&doi=10.1080%2F10245330500276592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma</span></div><div class="casAuthors">Kuruvilla, John; Song, Kevin; Mollee, Peter; Panzarella, Tony; McCrae, Jan; Nagy, Tracy; Crump, Michael; Keating, Armand</div><div class="citationInfo"><span class="NLM_cas:title">Hematology (Abingdon, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-29</span>CODEN:
                <span class="NLM_cas:coden">HMATFL</span>;
        ISSN:<span class="NLM_cas:issn">1024-5332</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Patients with Hodgkin's Lymphoma (HL) who relapse or progress after primary therapy and subsequent high dose chemotherapy with autologous stem cell transplantation (ASCT) cannot be cured with conventional treatment.  We combined thalidomide (THAL), an agent with anti-angiogenic and immunomodulatory properties, with vinblastine, which is active after ASCT, to det. the objective response rate, improvement in B symptoms and toxicity in patients with refractory HD.  Methods: Patients were eligible if they HD that progressed after chemotherapy and ASCT or had declined or were ineligible for curative therapy.  Treatment consisted of THAL 200 mg orally given daily.  After 2 wk, VBL 6 mg IV was given weekly × 6 doses on an eight-week cycle.  Response and toxicity assessment occurred following each cycle. Results: Eleven patients were enrolled, 1 progressed within 6 days of study enrollment and was subsequently treated with alternative palliative therapy and thus 11 patients are response evaluable and 10 are evaluable for toxicity.  Patient characteristics: relapsed after ASCT: 7; median no. of prior chemotherapy regimens: 3 (range 1-5); median time to progression post-ASCT: 7 mo (range 2-29).  Four patients had a partial response to treatment (response rate 36%); two patients had stable disease.  B symptoms were present at enrollment in four patients and resolved completely on treatment in two patients.  Five had disease progression within 3 mo of starting treatment.  The median duration of response was 9 mo (range 0-22 mo).  Toxicity was mild and limited to grade 2 neuropathy in 6 patients and grade 2 or 3 neutropenia in 4 patients.  Conclusions: In this small study in chemotherapy- refractory HL, THAL and VBL demonstrated encouraging activity with some durable responses and acceptable toxicity.  These results suggest that chronic low dose chemotherapy combined with less toxic immunomodulatory or anti-angiogenic drugs warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUGJwJvjl5v7Vg90H21EOLACvtfcHk0lj0FRtieKC0iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVOhu74%253D&md5=7e23a9439d19a069125052db1c1c64b7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F10245330500276592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10245330500276592%26sid%3Dliteratum%253Aachs%26aulast%3DKuruvilla%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DMollee%26aufirst%3DP.%26aulast%3DPanzarella%26aufirst%3DT.%26aulast%3DMcCrae%26aufirst%3DJ.%26aulast%3DNagy%26aufirst%3DT.%26aulast%3DCrump%26aufirst%3DM.%26aulast%3DKeating%26aufirst%3DA.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520thalidomide%2520and%2520vinblastine%2520for%2520palliative%2520patients%2520with%2520Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DHematology%26date%3D2006%26volume%3D11%26spage%3D25%26epage%3D29%26doi%3D10.1080%2F10245330500276592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seldin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choufani, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dember, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berk, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennessey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchorawala, V.</span></span> <span> </span><span class="NLM_article-title">Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis</span>. <i>Clin. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.3816/clm.2003.n.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.3816%2Fclm.2003.n.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=12672274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVSjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=241-246&author=D.+C.+Seldinauthor=E.+B.+Choufaniauthor=L.+M.+Demberauthor=J.+F.+Wiesmanauthor=J.+L.+Berkauthor=R.+H.+Falkauthor=C.+O%E2%80%99Haraauthor=S.+Fennesseyauthor=K.+T.+Finnauthor=D.+G.+Wrightauthor=M.+Skinnerauthor=V.+Sanchorawala&title=Tolerability+and+efficacy+of+thalidomide+for+the+treatment+of+patients+with+light+chain-associated+%28AL%29+amyloidosis&doi=10.3816%2Fclm.2003.n.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Tolerability and efficacy of thalidomide for the treatment of patients with light-chain-associated (AL) amyloidosis</span></div><div class="casAuthors">Seldin, David C.; Choufani, Elie B.; Dember, Laura M.; Wiesman, Janice F.; Berk, John L.; Falk, Rodney H.; O'Hara, Carl; Fennessey, Salli; Finn, Kathleen T.; Wright, Daniel G.; Skinner, Martha; Sanchorawala, Vaishali</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lymphoma</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">241-246</span>CODEN:
                <span class="NLM_cas:coden">CLLYAO</span>;
        ISSN:<span class="NLM_cas:issn">1526-9655</span>.
    
            (<span class="NLM_cas:orgname">Cancer Information Group</span>)
        </div><div class="casAbstract">A phase I/II trial was carried out with patients with AL amyloidosis, most of whom had failed prior therapy with high-dose melphalan and autologous stem cell transplantation.  This trial was designed as an individualized 6-mo dose-escalation study with re-evaluation of bone marrow plasmacytosis and serum and urine monoclonal proteins after 3 and 6 mo.  Sixteen patients with a median age of 62 yr (range, 37-70 yr) were enrolled.  Fourteen of the patients had renal involvement, 4 had cardiac involvement, 4 had liver involvement, and 2 had predominant soft tissue or lymph node involvement.  The median max. tolerated dose was 300 mg, with fatigue and other central nervous system side effects being the major dose-limiting toxicities.  Side effects not frequently reported for other patient populations included exacerbation of peripheral and pulmonary edema and worsening azotemia.  In all, 50% of the patients experienced grade 3/4 toxicity, and 25% had to discontinue the drug.  No complete hematol. responses were seen, but 25% of the patients had a significant redn. in Bence-Jones proteinuria.  Thus, while thalidomide has activity in AL amyloidosis, it also has significant toxicity in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgze0jQtI1pLVg90H21EOLACvtfcHk0lj0FRtieKC0iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVSjtrk%253D&md5=b15425f1d8d306ab1f9bb1375a49e40b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3816%2Fclm.2003.n.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252Fclm.2003.n.005%26sid%3Dliteratum%253Aachs%26aulast%3DSeldin%26aufirst%3DD.%2BC.%26aulast%3DChoufani%26aufirst%3DE.%2BB.%26aulast%3DDember%26aufirst%3DL.%2BM.%26aulast%3DWiesman%26aufirst%3DJ.%2BF.%26aulast%3DBerk%26aufirst%3DJ.%2BL.%26aulast%3DFalk%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Hara%26aufirst%3DC.%26aulast%3DFennessey%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DK.%2BT.%26aulast%3DWright%26aufirst%3DD.%2BG.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DSanchorawala%26aufirst%3DV.%26atitle%3DTolerability%2520and%2520efficacy%2520of%2520thalidomide%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520light%2520chain-associated%2520%2528AL%2529%2520amyloidosis%26jtitle%3DClin.%2520Lymphoma%26date%3D2003%26volume%3D3%26spage%3D241%26epage%3D246%26doi%3D10.3816%2Fclm.2003.n.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zyl-Smit, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iveson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassam, S. M.</span></span> <span> </span><span class="NLM_article-title">Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1080/1042819031000149412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1080%2F1042819031000149412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=15061217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADC%252BD2c7mslehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=179-181&author=R.+Bairdauthor=R.+N.+van+Zyl-Smitauthor=A.+Ivesonauthor=J.+Duddyauthor=S.+M.+Rassam&title=Thalidomide+is+highly+effective+in+a+patient+with+meningeal+acute+myeloid+leukaemia&doi=10.1080%2F1042819031000149412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia</span></div><div class="casAuthors">Baird Richard; van Zyl-Smit Richard Nellis; Iveson Anne; Duddy James; Rassam Saad M B</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & lymphoma</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">179-81</span>
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    </div><div class="casAbstract">We report a case of secondary acute myeloid leukaemia (AML) following high dose therapy for diffuse large B-cell non-Hodgkin's lymphoma (NHL) who developed meningeal leukaemia.  This was refractory to systemic and intrathecal chemotherapy and cranial irradiation.  Thalidomide has been reported to have anti-AML activity and appears to cross the blood brain barrier (BBB).  We, therefore, attempted a trial of oral Thalidomide and achieved rapid biochemical and cytological remission with a short course.  The patient, however, progressed systemically and succumbed to her illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxkV8URyRmx825P7XSLhESfW6udTcc2eYMxo1Bshed77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7mslehtw%253D%253D&md5=31006e0dbe0fb3cf55bcd7198fc8ef2a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F1042819031000149412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1042819031000149412%26sid%3Dliteratum%253Aachs%26aulast%3DBaird%26aufirst%3DR.%26aulast%3Dvan%2BZyl-Smit%26aufirst%3DR.%2BN.%26aulast%3DIveson%26aufirst%3DA.%26aulast%3DDuddy%26aufirst%3DJ.%26aulast%3DRassam%26aufirst%3DS.%2BM.%26atitle%3DThalidomide%2520is%2520highly%2520effective%2520in%2520a%2520patient%2520with%2520meningeal%2520acute%2520myeloid%2520leukaemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2004%26volume%3D45%26spage%3D179%26epage%3D181%26doi%3D10.1080%2F1042819031000149412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faderl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albitar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span> <span> </span><span class="NLM_article-title">Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2141.2003.04639.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1046%2Fj.1365-2141.2003.04639.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=14617002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsFChs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2003&pages=436-441&author=D.+A.+Thomasauthor=E.+Esteyauthor=F.+J.+Gilesauthor=S.+Faderlauthor=J.+Cortesauthor=M.+Keatingauthor=S.+O%E2%80%99Brienauthor=M.+Albitarauthor=H.+Kantarjian&title=Single+agent+thalidomide+in+patients+with+relapsed+or+refractory+acute+myeloid+leukaemia&doi=10.1046%2Fj.1365-2141.2003.04639.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia</span></div><div class="casAuthors">Thomas, Deborah A.; Estey, Elihu; Giles, Francis J.; Faderi, Stefan; Cortes, Jorge; Keating, Michael; O'Brien, Susan; Albitar, Maher; Kantarjian, Hagop</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">436-441</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Thalidomide is a putative anti-angiogenesis agent that has significant anti-tumor activity in haematol. malignancies with increased bone marrow angiogenesis, including multiple myeloma (MM) and myelodysplastic syndromes (MDS).  Increased levels of the mitogen for angiogenesis, vascular endothelial growth factor (VEGF), correlate with worse survival in acute myeloid leukemia (AML).  A phase II trial of thalidomide was conducted in patients with relapsed- or refractory-AML previously treated with cytarabine-contg. regimens.  A total of 16 patients with refractory- or relapsed-AML were treated with thalidomide 200-800 mg orally daily (median dose 400 mg daily) for a median of 27 d (range, 3-94 d).  Overall, one patient (6%) achieved complete remission (CR) lasting for 36 mo, and two patients had a transient redn. in marrow blasts from 8% and 7% to less than 5% in both cases.  There was no correlation between redn. in levels of angiogenesis markers and response.  Toxicities related to thalidomide were significant, and precluded dose escalation beyond 400 mg orally daily in most patients.  Although there appears to be some evidence of biol. activity, single agent thalidomide is not an optimal choice of therapy for salvaging patients with relapsed- or refractory-AML.  Thalidomide analogs with more potent immunomodulatory activities and more favorable toxicity profiles may offer more promise as anti-AML therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXd9innVXxwrVg90H21EOLACvtfcHk0ljkvoK0L-clBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsFChs70%253D&md5=28de5d4f924d2b35a000096ceb1f5be7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2141.2003.04639.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2141.2003.04639.x%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKeating%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DSingle%2520agent%2520thalidomide%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2003%26volume%3D123%26spage%3D436%26epage%3D441%26doi%3D10.1046%2Fj.1365-2141.2003.04639.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boichenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupas, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez
Alvarez, B.</span></span> <span> </span><span class="NLM_article-title">Thalidomide mimics uridine binding to an aromatic cage in cereblon</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2014.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1016%2Fj.jsb.2014.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25448889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFSnu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2014&pages=225-232&author=M.+D.+Hartmannauthor=I.+Boichenkoauthor=M.+Colesauthor=F.+Zaniniauthor=A.+N.+Lupasauthor=B.+Hernandez%0AAlvarez&title=Thalidomide+mimics+uridine+binding+to+an+aromatic+cage+in+cereblon&doi=10.1016%2Fj.jsb.2014.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide mimics uridine binding to an aromatic cage in cereblon</span></div><div class="casAuthors">Hartmann, Marcus D.; Boichenko, Iuliia; Coles, Murray; Zanini, Fabio; Lupas, Andrei N.; Hernandez Alvarez, Birte</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-232</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Thalidomide and its derivs. lenalidomide and pomalidomide are important anticancer agents but can cause severe birth defects via an interaction with the protein cereblon.  The ligand-binding domain of cereblon is found, with a high degree of conservation, in both bacteria and eukaryotes.  Using a bacterial model system, we reveal the structural determinants of cereblon substrate recognition, based on a series of high-resoln. crystal structures.  For the first time, we identify a cellular ligand that is universally present: we show that thalidomide and its derivs. mimic and compete for the binding of uridine, and validate these findings in vivo.  The nature of the binding pocket, an arom. cage of three tryptophan residues, further suggests a role in the recognition of cationic ligands.  Our results allow for general evaluation of pharmaceuticals for potential cereblon-dependent teratogenicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTvANwpl9hTbVg90H21EOLACvtfcHk0ljkvoK0L-clBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFSnu7jI&md5=e601c6e1091deea840f9738fb30fa7bb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2014.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2014.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DM.%2BD.%26aulast%3DBoichenko%26aufirst%3DI.%26aulast%3DColes%26aufirst%3DM.%26aulast%3DZanini%26aufirst%3DF.%26aulast%3DLupas%26aufirst%3DA.%2BN.%26aulast%3DHernandez%2BAlvarez%26aufirst%3DB.%26atitle%3DThalidomide%2520mimics%2520uridine%2520binding%2520to%2520an%2520aromatic%2520cage%2520in%2520cereblon%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2014%26volume%3D188%26spage%3D225%26epage%3D232%26doi%3D10.1016%2Fj.jsb.2014.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boichenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupas, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez
Alvarez, B.</span></span> <span> </span><span class="NLM_article-title">Structural dynamics of the cereblon ligand binding domain</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0128342</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0128342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1371%2Fjournal.pone.0128342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=26024445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGru77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=M.+D.+Hartmannauthor=I.+Boichenkoauthor=M.+Colesauthor=A.+N.+Lupasauthor=B.+Hernandez%0AAlvarez&title=Structural+dynamics+of+the+cereblon+ligand+binding+domain&doi=10.1371%2Fjournal.pone.0128342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structural dynamics of the cereblon ligand binding domain</span></div><div class="casAuthors">Hartmann, Marcus D.; Boichenko, Iuliia; Coles, Murray; Lupas, Andrei N.; Alvarez, Birte Hernandez</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e0128342/1-e0128342/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Cereblon, a primary target of thalidomide and its derivs., has been characterized structurally from both bacteria and animals.  Esp. well studied is the thalidomide binding domain, CULT, which shows an invariable structure across different organisms and in complex with different ligands.  Here, based on a series of crystal structures of a bacterial representative, we reveal the conformational flexibility and structural dynamics of this domain.  In particular, we follow the unfolding of large fractions of the domain upon release of thalidomide in the cryst. state.  Our results imply that a third of the domain, including the thalidomide binding pocket, only folds upon ligand binding.  We further characterize the structural effect of the C-terminal truncation resulting from the mental-retardation linked R419X nonsense mutation in vitro and offer a mechanistic hypothesis for its irresponsiveness to thalidomide.  At 1.2Å resoln., our data provide a view of thalidomide binding at at. resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocnADN6zO_LrVg90H21EOLACvtfcHk0lhY7oHzf1nLSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGru77F&md5=525f48f454c54c466360231d1ab3330a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0128342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0128342%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DM.%2BD.%26aulast%3DBoichenko%26aufirst%3DI.%26aulast%3DColes%26aufirst%3DM.%26aulast%3DLupas%26aufirst%3DA.%2BN.%26aulast%3DHernandez%2BAlvarez%26aufirst%3DB.%26atitle%3DStructural%2520dynamics%2520of%2520the%2520cereblon%2520ligand%2520binding%2520domain%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0128342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Girona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chie-Leon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakoshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span> <span> </span><span class="NLM_article-title">Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnsmb.2874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25108355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlahurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=803-809&author=P.+P.+Chamberlainauthor=A.+Lopez-Gironaauthor=K.+Millerauthor=G.+Carmelauthor=B.+Pagariganauthor=B.+Chie-Leonauthor=E.+Rychakauthor=L.+G.+Corralauthor=Y.+J.+Renauthor=M.+Wangauthor=M.+Rileyauthor=S.+L.+Delkerauthor=T.+Itoauthor=H.+Andoauthor=T.+Moriauthor=Y.+Hiranoauthor=H.+Handaauthor=T.+Hakoshimaauthor=T.+O.+Danielauthor=B.+E.+Cathers&title=Structure+of+the+human+cereblon-DDB1-lenalidomide+complex+reveals+basis+for+responsiveness+to+thalidomide+analogs&doi=10.1038%2Fnsmb.2874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs</span></div><div class="casAuthors">Chamberlain, Philip P.; Lopez-Girona, Antonia; Miller, Karen; Carmel, Gilles; Pagarigan, Barbra; Chie-Leon, Barbara; Rychak, Emily; Corral, Laura G.; Ren, Yan J.; Wang, Maria; Riley, Mariko; Delker, Silvia L.; Ito, Takumi; Ando, Hideki; Mori, Tomoyuki; Hirano, Yoshinori; Handa, Hiroshi; Hakoshima, Toshio; Daniel, Thomas O.; Cathers, Brian E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">803-809</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Cul4-Rbx1-DDB1-Cereblon E3 ubiquitin ligase complex is the target of thalidomide, lenalidomide and pomalidomide, therapeutically important drugs for multiple myeloma and other B-cell malignancies.  These drugs directly bind Cereblon (CRBN) and promote the recruitment of substrates Ikaros (IKZF1) and Aiolos (IKZF3) to the E3 complex, thus leading to substrate ubiquitination and degrdn.  Here we present the crystal structure of human CRBN bound to DDB1 and the drug lenalidomide.  A hydrophobic pocket in the thalidomide-binding domain (TBD) of CRBN accommodates the glutarimide moiety of lenalidomide, whereas the isoindolinone ring is exposed to solvent.  We also solved the structures of the mouse TBD in the apo state and with thalidomide or pomalidomide.  Site-directed mutagenesis in lentiviral-expression myeloma models showed that key drug-binding residues are crit. for antiproliferative effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtN-ZCacB1m7Vg90H21EOLACvtfcHk0lhY7oHzf1nLSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlahurjI&md5=627fc3c8eae320059ca1cdc173bb56ed</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2874%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DLopez-Girona%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DChie-Leon%26aufirst%3DB.%26aulast%3DRychak%26aufirst%3DE.%26aulast%3DCorral%26aufirst%3DL.%2BG.%26aulast%3DRen%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DDelker%26aufirst%3DS.%2BL.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DHirano%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DHakoshima%26aufirst%3DT.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26atitle%3DStructure%2520of%2520the%2520human%2520cereblon-DDB1-lenalidomide%2520complex%2520reveals%2520basis%2520for%2520responsiveness%2520to%2520thalidomide%2520analogs%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D803%26epage%3D809%26doi%3D10.1038%2Fnsmb.2874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydeard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavadini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serluca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraju, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schebesta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassiepen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hild, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckwith, R. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomä, N. H.</span></span> <span> </span><span class="NLM_article-title">Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>512</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1038/nature13527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnature13527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25043012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12ms7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2014&pages=49-53&author=E.+S.+Fischerauthor=K.+B%C3%B6hmauthor=J.+R.+Lydeardauthor=H.+Yangauthor=M.+B.+Stadlerauthor=S.+Cavadiniauthor=J.+Nagelauthor=F.+Serlucaauthor=V.+Ackerauthor=G.+M.+Lingarajuauthor=R.+B.+Tichkuleauthor=M.+Schebestaauthor=W.+C.+Forresterauthor=M.+Schirleauthor=U.+Hassiepenauthor=J.+Ottlauthor=M.+Hildauthor=R.+E.+J.+Beckwithauthor=J.+W.+Harperauthor=J.+L.+Jenkinsauthor=N.+H.+Thom%C3%A4&title=Structure+of+the+DDB1-CRBN+E3+ubiquitin+ligase+in+complex+with+thalidomide&doi=10.1038%2Fnature13527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide</span></div><div class="casAuthors">Fischer, Eric S.; Bohm, Kerstin; Lydeard, John R.; Yang, Haidi; Stadler, Michael B.; Cavadini, Simone; Nagel, Jane; Serluca, Fabrizio; Acker, Vincent; Lingaraju, Gondichatnahalli M.; Tichkule, Ritesh B.; Schebesta, Michael; Forrester, William C.; Schirle, Markus; Hassiepen, Ulrich; Ottl, Johannes; Hild, Marc; Beckwith, Rohan E. J.; Harper, J. Wade; Jenkins, Jeremy L.; Thoma, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">7512</span>),
    <span class="NLM_cas:pages">49-53</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects.  Despite the teratogenicity of thalidomide and its derivs. lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recently emerged as effective treatments for multiple myeloma and 5q-deletion-assocd. dysplasia.  IMiDs target the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4CRBN) and promote the ubiquitination of the IKAROS family transcription factors IKZF1 and IKZF3 by CRL4CRBN.  Here we present crystal structures of the DDB1-CRBN complex bound to thalidomide, lenalidomide and pomalidomide.  The structure establishes that CRBN is a substrate receptor within CRL4CRBN and enantioselectively binds IMiDs.  Using an unbiased screen, we identified the homeobox transcription factor MEIS2 as an endogenous substrate of CRL4CRBN.  Our studies suggest that IMiDs block endogenous substrates (MEIS2) from binding to CRL4CRBN while the ligase complex is recruiting IKZF1 or IKZF3 for degrdn.  This dual activity implies that small mols. can modulate an E3 ubiquitin ligase and thereby upregulate or downregulate the ubiquitination of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGt2Y9GecKr7Vg90H21EOLACvtfcHk0lhY7oHzf1nLSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12ms7%252FP&md5=1c1eaa48bef87463cdd3f2b1e1bd400d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature13527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13527%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DB%25C3%25B6hm%26aufirst%3DK.%26aulast%3DLydeard%26aufirst%3DJ.%2BR.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DStadler%26aufirst%3DM.%2BB.%26aulast%3DCavadini%26aufirst%3DS.%26aulast%3DNagel%26aufirst%3DJ.%26aulast%3DSerluca%26aufirst%3DF.%26aulast%3DAcker%26aufirst%3DV.%26aulast%3DLingaraju%26aufirst%3DG.%2BM.%26aulast%3DTichkule%26aufirst%3DR.%2BB.%26aulast%3DSchebesta%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DW.%2BC.%26aulast%3DSchirle%26aufirst%3DM.%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DOttl%26aufirst%3DJ.%26aulast%3DHild%26aufirst%3DM.%26aulast%3DBeckwith%26aufirst%3DR.%2BE.%2BJ.%26aulast%3DHarper%26aufirst%3DJ.%2BW.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DThom%25C3%25A4%26aufirst%3DN.%2BH.%26atitle%3DStructure%2520of%2520the%2520DDB1-CRBN%2520E3%2520ubiquitin%2520ligase%2520in%2520complex%2520with%2520thalidomide%26jtitle%3DNature%26date%3D2014%26volume%3D512%26spage%3D49%26epage%3D53%26doi%3D10.1038%2Fnature13527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweredoski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitsma, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshaies, R. J.</span></span> <span> </span><span class="NLM_article-title">Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2016.02.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1016%2Fj.molcel.2016.02.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=26990986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1OqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=809-820&author=T.+V.+Nguyenauthor=J.+E.+Leeauthor=M.+J.+Sweredoskiauthor=S.+J.+Yangauthor=S.+J.+Jeonauthor=J.+S.+Harrisonauthor=J.+H.+Yimauthor=S.+G.+Leeauthor=H.+Handaauthor=B.+Kuhlmanauthor=J.+S.+Jeongauthor=J.+M.+Reitsmaauthor=C.+S.+Parkauthor=S.+Hessauthor=R.+J.+Deshaies&title=Glutamine+triggers+acetylation-dependent+degradation+of+glutamine+synthetase+via+the+thalidomide+receptor+cereblon&doi=10.1016%2Fj.molcel.2016.02.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon</span></div><div class="casAuthors">Nguyen, T. Van; Lee, J. Eugene; Sweredoski, Michael J.; Yang, Seung-Joo; Jeon, Seung-Je; Harrison, Joseph S.; Yim, Jung-Hyuk; Lee, Sang Ghil; Handa, Hiroshi; Kuhlman, Brian; Jeong, Ji-Seon; Reitsma, Justin M.; Park, Chul-Seung; Hess, Sonja; Deshaies, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">809-820</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cereblon (CRBN), a substrate receptor for the cullin-RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).  Here we report that glutamine synthetase (GS) is an endogenous substrate of CRL4CRBN.  Upon exposing cells to high glutamine concn., GS is acetylated at lysines 11 and 14, yielding a degron that is necessary and sufficient for binding and ubiquitylation by CRL4CRBN and degrdn. by the proteasome.  Binding of acetylated degron peptides to CRBN depends on an intact thalidomide-binding pocket but is not competitive with IMiDs.  These findings reveal a feedback loop involving CRL4CRBN that adjusts GS protein levels in response to glutamine and uncover a new function for lysine acetylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSanlZNHndMrVg90H21EOLACvtfcHk0ljhcyrk1hTWhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1OqsL0%253D&md5=641527ec1a6c97d1800e3e393582c07f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2016.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2016.02.032%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%2BV.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DSweredoski%26aufirst%3DM.%2BJ.%26aulast%3DYang%26aufirst%3DS.%2BJ.%26aulast%3DJeon%26aufirst%3DS.%2BJ.%26aulast%3DHarrison%26aufirst%3DJ.%2BS.%26aulast%3DYim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DS.%2BG.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DKuhlman%26aufirst%3DB.%26aulast%3DJeong%26aufirst%3DJ.%2BS.%26aulast%3DReitsma%26aufirst%3DJ.%2BM.%26aulast%3DPark%26aufirst%3DC.%2BS.%26aulast%3DHess%26aufirst%3DS.%26aulast%3DDeshaies%26aufirst%3DR.%2BJ.%26atitle%3DGlutamine%2520triggers%2520acetylation-dependent%2520degradation%2520of%2520glutamine%2520synthetase%2520via%2520the%2520thalidomide%2520receptor%2520cereblon%26jtitle%3DMol.%2520Cell%26date%3D2016%26volume%3D61%26spage%3D809%26epage%3D820%26doi%3D10.1016%2Fj.molcel.2016.02.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del
Prete, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajadhyaksha, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Adamio, L.</span></span> <span> </span><span class="NLM_article-title">Amyloid precursor protein (APP) may act as a substrate and a recognition unit for CRL4(CRBN) and Stub1 E3 ligases facilitating ubiquitination of proteins involved in presynaptic functions and neurodegeneration</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">17209</span>– <span class="NLM_lpage">17227</span>, <span class="refDoi"> DOI: 10.1074/jbc.m116.733626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1074%2Fjbc.m116.733626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=27325702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslaktLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=17209-17227&author=D.+Del%0APreteauthor=R.+C.+Riceauthor=A.+M.+Rajadhyakshaauthor=L.+D%E2%80%99Adamio&title=Amyloid+precursor+protein+%28APP%29+may+act+as+a+substrate+and+a+recognition+unit+for+CRL4%28CRBN%29+and+Stub1+E3+ligases+facilitating+ubiquitination+of+proteins+involved+in+presynaptic+functions+and+neurodegeneration&doi=10.1074%2Fjbc.m116.733626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid precursor protein (APP) may act as a substrate and a recognition unit for CRL4CRBN and Stub1 E3 ligases facilitating ubiquitination of proteins involved in presynaptic functions and neurodegeneration</span></div><div class="casAuthors">Del Prete, Dolores; Rice, Richard C.; Rajadhyaksha, Anjali M.; D'Adamio, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">17209-17227</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The amyloid precursor protein (APP), whose mutations cause Alzheimer disease, plays an important in vivo role and facilitates transmitter release.  Because the APP cytosolic region (ACR) is essential for these functions, we have characterized its brain interactome.  We found that the ACR interacts with proteins that regulate the ubiquitin-proteasome system, predominantly with the E3 ubiquitin-protein ligases Stub1, which binds the N-terminus of the ACR, and CRL4CRBN, which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the C-terminus of the ACR via Crbn.  APP shares essential functions with APP-like protein-2 (APLP2) but not APP-like protein-1 (APLP1).  Noteworthy, APLP2, but not APLP1, interacts with Stub1 and CRL4CRBN, pointing to a functional pathway shared only by APP and APLP2.  In vitro ubiquitination/ubiquitome anal. indicates that these E3 ligases are enzymically active and ubiquitinated the ACR residues Lys649/650/651/676/688.  Deletion of Crbn reduces ubiquitination of Lys676 suggesting that Lys676 is physiol. ubiquitinated by CRL4CRBN.  The ACR facilitated in vitro ubiquitination of presynaptic proteins that regulate exocytosis, suggesting a mechanism by which APP tunes transmitter release.  Other dementia-related proteins, namely Tau and apoE, interact with and are ubiquitinated via the ACR in vitro.  This, and the evidence that CRBN and CUL4B are linked to intellectual disability, prompts us to hypothesize a pathogenic mechanism, in which APP acts as a modulator of E3 ubiquitin-protein ligase(s), shared by distinct neuronal disorders.  The well described accumulation of ubiquitinated protein inclusions in neurodegenerative diseases and the link between the ubiquitin-proteasome system and neurodegeneration make this concept plausible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk1X5MYxG30bVg90H21EOLACvtfcHk0ljx92q6M749GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslaktLrF&md5=b4cfc53ded92c62aa868a17e28929986</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1074%2Fjbc.m116.733626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.m116.733626%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BPrete%26aufirst%3DD.%26aulast%3DRice%26aufirst%3DR.%2BC.%26aulast%3DRajadhyaksha%26aufirst%3DA.%2BM.%26aulast%3DD%25E2%2580%2599Adamio%26aufirst%3DL.%26atitle%3DAmyloid%2520precursor%2520protein%2520%2528APP%2529%2520may%2520act%2520as%2520a%2520substrate%2520and%2520a%2520recognition%2520unit%2520for%2520CRL4%2528CRBN%2529%2520and%2520Stub1%2520E3%2520ligases%2520facilitating%2520ubiquitination%2520of%2520proteins%2520involved%2520in%2520presynaptic%2520functions%2520and%2520neurodegeneration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D17209%26epage%3D17227%26doi%3D10.1074%2Fjbc.m116.733626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kronke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svinkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarlo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1126/science.1244851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1126%2Fscience.1244851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=24292625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=301-305&author=J.+Kronkeauthor=N.+D.+Udeshiauthor=A.+Narlaauthor=P.+Graumanauthor=S.+N.+Hurstauthor=M.+McConkeyauthor=T.+Svinkinaauthor=D.+Hecklauthor=E.+Comerauthor=X.+Liauthor=C.+Ciarloauthor=E.+Hartmanauthor=N.+Munshiauthor=M.+Schenoneauthor=S.+L.+Schreiberauthor=S.+A.+Carrauthor=B.+L.+Ebert&title=Lenalidomide+causes+selective+degradation+of+IKZF1+and+IKZF3+in+multiple+myeloma+cells&doi=10.1126%2Fscience.1244851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</span></div><div class="casAuthors">Kronke Jan; Udeshi Namrata D; Narla Anupama; Grauman Peter; Hurst Slater N; McConkey Marie; Svinkina Tanya; Heckl Dirk; Comer Eamon; Li Xiaoyu; Ciarlo Christie; Hartman Emily; Munshi Nikhil; Schenone Monica; Schreiber Stuart L; Carr Steven A; Ebert Benjamin L</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">301-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown.  Using quantitative proteomics, we found that lenalidomide causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.  IKZF1 and IKZF3 are essential transcription factors in multiple myeloma.  A single amino acid substitution of IKZF3 conferred resistance to lenalidomide-induced degradation and rescued lenalidomide-induced inhibition of cell growth.  Similarly, we found that lenalidomide-induced interleukin-2 production in T cells is due to depletion of IKZF1 and IKZF3.  These findings reveal a previously unknown mechanism of action for a therapeutic agent: alteration of the activity of an E3 ubiquitin ligase, leading to selective degradation of specific targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiiGR0Yx7nuYFEOhA_Im3cfW6udTcc2eaYEtJK2cq1mrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D&md5=8cae3e554399308493aa38f0d05ed610</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244851%26sid%3Dliteratum%253Aachs%26aulast%3DKronke%26aufirst%3DJ.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DNarla%26aufirst%3DA.%26aulast%3DGrauman%26aufirst%3DP.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DMcConkey%26aufirst%3DM.%26aulast%3DSvinkina%26aufirst%3DT.%26aulast%3DHeckl%26aufirst%3DD.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCiarlo%26aufirst%3DC.%26aulast%3DHartman%26aufirst%3DE.%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DSchenone%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520causes%2520selective%2520degradation%2520of%2520IKZF1%2520and%2520IKZF3%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D301%26epage%3D305%26doi%3D10.1126%2Fscience.1244851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacBeth, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svinkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järås, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>523</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1038/nature14610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnature14610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=26131937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1entr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=523&publication_year=2015&pages=183-188&author=J.+Kr%C3%B6nkeauthor=E.+C.+Finkauthor=P.+W.+Hollenbachauthor=K.+J.+MacBethauthor=S.+N.+Hurstauthor=N.+D.+Udeshiauthor=P.+P.+Chamberlainauthor=D.+R.+Maniauthor=H.+W.+Manauthor=A.+K.+Gandhiauthor=T.+Svinkinaauthor=R.+K.+Schneiderauthor=M.+McConkeyauthor=M.+J%C3%A4r%C3%A5sauthor=E.+Griffithsauthor=M.+Wetzlerauthor=L.+Bullingerauthor=B.+E.+Cathersauthor=S.+A.+Carrauthor=R.+Chopraauthor=B.+L.+Ebert&title=Lenalidomide+induces+ubiquitination+and+degradation+of+CK1alpha+in+del%285q%29+MDS&doi=10.1038%2Fnature14610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS</span></div><div class="casAuthors">Kronke, Jan; Fink, Emma C.; Hollenbach, Paul W.; MacBeth, Kyle J.; Hurst, Slater N.; Udeshi, Namrata D.; Chamberlain, Philip P.; Mani, D. R.; Man, Hon Wah; Gandhi, Anita K.; Svinkina, Tanya; Schneider, Rebekka K.; McConkey, Marie; Jaras, Marcus; Griffiths, Elizabeth; Wetzler, Meir; Bullinger, Lars; Cathers, Brian E.; Carr, Steven A.; Chopra, Rajesh; Ebert, Benjamin L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">523</span>
        (<span class="NLM_cas:issue">7559</span>),
    <span class="NLM_cas:pages">183-188</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)).  Lenalidomide induces the ubiquitination of casein kinase 1A1 (CK1α) by the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4CRBN), resulting in CK1α degrdn.  CK1α is encoded by a gene within the common deleted region for del(5q) MDS and haplo-insufficient expression sensitizes cells to lenalidomide therapy, providing a mechanistic basis for the therapeutic window of lenalidomide in del(5q) MDS.  The authors found that mouse cells are resistant to lenalidomide but that changing a single amino acid in mouse Crbn to the corresponding human residue enables lenalidomide-dependent degrdn. of CK1α.  The authors further demonstrate that minor side chain modifications in thalidomide and a novel analog, CC-122, can modulate the spectrum of substrates targeted by CRL4CRBN.  These findings have implications for the clin. activity of lenalidomide and related compds., and demonstrate the therapeutic potential of novel modulators of E3 ubiquitin ligases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLiHx3FKesbVg90H21EOLACvtfcHk0lh7yn4K-ssAvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1entr%252FN&md5=9b20a91c13e888e6569223ffa25af2cd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature14610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14610%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26aulast%3DFink%26aufirst%3DE.%2BC.%26aulast%3DHollenbach%26aufirst%3DP.%2BW.%26aulast%3DMacBeth%26aufirst%3DK.%2BJ.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DMani%26aufirst%3DD.%2BR.%26aulast%3DMan%26aufirst%3DH.%2BW.%26aulast%3DGandhi%26aufirst%3DA.%2BK.%26aulast%3DSvinkina%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DR.%2BK.%26aulast%3DMcConkey%26aufirst%3DM.%26aulast%3DJ%25C3%25A4r%25C3%25A5s%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DE.%26aulast%3DWetzler%26aufirst%3DM.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520induces%2520ubiquitination%2520and%2520degradation%2520of%2520CK1alpha%2520in%2520del%25285q%2529%2520MDS%26jtitle%3DNature%26date%3D2015%26volume%3D523%26spage%3D183%26epage%3D188%26doi%3D10.1038%2Fnature14610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchelman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Girona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span> <span> </span><span class="NLM_article-title">A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1038/nature18611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnature18611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=27338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=252-257&author=M.+E.+Matyskielaauthor=G.+Luauthor=T.+Itoauthor=B.+Pagariganauthor=C.-C.+Luauthor=K.+Millerauthor=W.+Fangauthor=N.-Y.+Wangauthor=D.+Nguyenauthor=J.+Houstonauthor=G.+Carmelauthor=T.+Tranauthor=M.+Rileyauthor=L.+A.+Nosakaauthor=G.+C.+Landerauthor=S.+Gaidarovaauthor=S.+Xuauthor=A.+L.+Ruchelmanauthor=H.+Handaauthor=J.+Carmichaelauthor=T.+O.+Danielauthor=B.+E.+Cathersauthor=A.+Lopez-Gironaauthor=P.+P.+Chamberlain&title=A+novel+cereblon+modulator+recruits+GSPT1+to+the+CRL4%28CRBN%29+ubiquitin+ligase&doi=10.1038%2Fnature18611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Matyskiela, Mary E.; Lu, Gang; Ito, Takumi; Pagarigan, Barbra; Lu, Chin-Chun; Miller, Karen; Fang, Wei; Wang, Nai-Yu; Nguyen, Derek; Houston, Jack; Carmel, Gilles; Tran, Tam; Riley, Mariko; Nosaka, Lyn'Al; Lander, Gabriel C.; Gaidarova, Svetlana; Xu, Shuichan; Ruchelman, Alexander L.; Handa, Hiroshi; Carmichael, James; Daniel, Thomas O.; Cathers, Brian E.; Lopez-Girona, Antonia; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7611</span>),
    <span class="NLM_cas:pages">252-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Immunomodulatory drugs bind to cereblon (CRBN) to confer differentiated substrate specificity on the CRL4CRBN E3 ubiquitin ligase.  Here we report the identification of a new cereblon modulator, CC-885, with potent anti-tumor activity.  The anti-tumor activity of CC-885 is mediated through the cereblon-dependent ubiquitination and degrdn. of the translation termination factor GSPT1.  Patient-derived acute myeloid leukemia tumor cells exhibit high sensitivity to CC-885, indicating the clin. potential of this mechanism.  Crystallog. studies of the CRBN-DDB1-CC-885-GSPT1 complex reveal that GSPT1 binds to cereblon through a surface turn contg. a glycine residue at a key position, interacting with both CC-885 and a 'hotspot' on the cereblon surface.  Although GSPT1 possesses no obvious structural, sequence or functional homol. to previously known cereblon substrates, mutational anal. and modeling indicate that the cereblon substrate Ikaros uses a similar structural feature to bind cereblon, suggesting a common motif for substrate recruitment.  These findings define a structural degron underlying cereblon 'neosubstrate' selectivity, and identify an anti-tumor target rendered druggable by cereblon modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgAWiXdlJgYLVg90H21EOLACvtfcHk0lh7yn4K-ssAvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI&md5=1d4e340416aa0b08fc0f123faf638c3f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature18611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18611%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DC.-C.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DFang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DN.-Y.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DHouston%26aufirst%3DJ.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DNosaka%26aufirst%3DL.%2BA.%26aulast%3DLander%26aufirst%3DG.%2BC.%26aulast%3DGaidarova%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DRuchelman%26aufirst%3DA.%2BL.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DLopez-Girona%26aufirst%3DA.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26atitle%3DA%2520novel%2520cereblon%2520modulator%2520recruits%2520GSPT1%2520to%2520the%2520CRL4%2528CRBN%2529%2520ubiquitin%2520ligase%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D252%26epage%3D257%26doi%3D10.1038%2Fnature18611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdubek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blease, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vessey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span> <span> </span><span class="NLM_article-title">SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1038/s41589-018-0129-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fs41589-018-0129-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=30190590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kgu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=981-987&author=M.+E.+Matyskielaauthor=S.+Coutoauthor=X.+Zhengauthor=G.+Luauthor=J.+Huiauthor=K.+Stampauthor=C.+Drewauthor=Y.+Renauthor=M.+Wangauthor=A.+Carpenterauthor=C.-W.+Leeauthor=T.+Claytonauthor=W.+Fangauthor=C.-C.+Luauthor=M.+Rileyauthor=P.+Abdubekauthor=K.+Bleaseauthor=J.+Hartkeauthor=G.+Kumarauthor=R.+Vesseyauthor=M.+Rolfeauthor=L.+G.+Hamannauthor=P.+P.+Chamberlain&title=SALL4+mediates+teratogenicity+as+a+thalidomide-dependent+cereblon+substrate&doi=10.1038%2Fs41589-018-0129-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate</span></div><div class="casAuthors">Matyskiela, Mary E.; Couto, Suzana; Zheng, Xinde; Lu, Gang; Hui, Julia; Stamp, Katie; Drew, Clifton; Ren, Yan; Wang, Maria; Carpenter, Aaron; Lee, Chung-Wein; Clayton, Thomas; Fang, Wei; Lu, Chin-Chun; Riley, Mariko; Abdubek, Polat; Blease, Kate; Hartke, James; Kumar, Gondi; Vessey, Rupert; Rolfe, Mark; Hamann, Lawrence G.; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">981-987</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Targeted protein degrdn. via small-mol. modulation of cereblon offers vast potential for the development of new therapeutics.  Cereblon-binding therapeutics carry the safety risks of thalidomide, which caused an epidemic of severe birth defects characterized by forelimb shortening or phocomelia.  Here we show that thalidomide is not teratogenic in transgenic mice expressing human cereblon, indicating that binding to cereblon is not sufficient to cause birth defects.  Instead, we identify SALL4 as a thalidomide-dependent cereblon neosubstrate.  Human mutations in SALL4 cause Duane-radial ray, IVIC, and acro-renal-ocular syndromes with overlapping clin. presentations to thalidomide embryopathy, including phocomelia.  SALL4 is degraded in rabbits but not in resistant organisms such as mice because of SALL4 sequence variations.  This work expands the scope of cereblon neosubstrate activity within the formerly 'undruggable' C2H2 zinc finger family and offers a path toward safer therapeutics through an improved understanding of the mol. basis of thalidomide-induced teratogenicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpePTE78HX85rVg90H21EOLACvtfcHk0lh7yn4K-ssAvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kgu7nM&md5=7530c3850ed7a763b30cba44dab640ac</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0129-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0129-x%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DCouto%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DHui%26aufirst%3DJ.%26aulast%3DStamp%26aufirst%3DK.%26aulast%3DDrew%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DCarpenter%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.-W.%26aulast%3DClayton%26aufirst%3DT.%26aulast%3DFang%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DC.-C.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DAbdubek%26aufirst%3DP.%26aulast%3DBlease%26aufirst%3DK.%26aulast%3DHartke%26aufirst%3DJ.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DVessey%26aufirst%3DR.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26atitle%3DSALL4%2520mediates%2520teratogenicity%2520as%2520a%2520thalidomide-dependent%2520cereblon%2520substrate%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D981%26epage%3D987%26doi%3D10.1038%2Fs41589-018-0129-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span>; <span class="NLM_string-name">An, J.</span>; <span class="NLM_string-name">Nowak, R. P.</span>; <span class="NLM_string-name">Yuan, J. C.</span>; <span class="NLM_string-name">Fink, E. C.</span>; <span class="NLM_string-name">Berry, B. C.</span>; <span class="NLM_string-name">Ebert, B. L.</span>; <span class="NLM_string-name">Fischer, E. S.</span></span>, <span> </span><span class="NLM_article-title">Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray Syndrome</span>.  <i>Elife</i> <span class="NLM_year" style="font-weight: bold;">2018</span><b>,</b>  <span class="NLM_volume">7</span>.<span class="refDoi"> DOI: 10.7554/elife.38430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.7554%2Felife.38430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=30067223" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&author=K.+A.+Donovan&author=J.+An&author=R.+P.+Nowak&author=J.+C.+Yuan&author=E.+C.+Fink&author=B.+C.+Berry&author=B.+L.+Ebert&author=E.+S.+Fischer&title=Thalidomide+promotes+degradation+of+SALL4%2C+a+transcription+factor+implicated+in+Duane+Radial+Ray+Syndrome&doi=10.7554%2Felife.38430"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.7554%2Felife.38430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252Felife.38430%26sid%3Dliteratum%253Aachs%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26atitle%3DThalidomide%2520promotes%2520degradation%2520of%2520SALL4%252C%2520a%2520transcription%2520factor%2520implicated%2520in%2520Duane%2520Radial%2520Ray%2520Syndrome%26jtitle%3DElife%26date%3D2018%26volume%3D7%26doi%3D10.7554%2Felife.38430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petzold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomä, N. H.</span></span> <span> </span><span class="NLM_article-title">Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1038/nature16979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnature16979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=26909574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=127-130&author=G.+Petzoldauthor=E.+S.+Fischerauthor=N.+H.+Thom%C3%A4&title=Structural+basis+of+lenalidomide-induced+CK1alpha+degradation+by+the+CRL4%28CRBN%29+ubiquitin+ligase&doi=10.1038%2Fnature16979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Petzold, Georg; Fischer, Eric S.; Thoma, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7597</span>),
    <span class="NLM_cas:pages">127-130</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thalidomide and its derivs., lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of hematol. malignancies.  IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4CRBN) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous CRL4CRBN substrates.  Unexpectedly, IMiDs also repurpose the ligase to target new proteins for degrdn.  Lenalidomide induces degrdn. of the lymphoid transcription factors Ikaros and Aiolos (also known as IKZF1 and IKZF3), and casein kinase 1α (CK1α), which contributes to its clin. efficacy in the treatment of multiple myeloma and 5q-deletion assocd. myelodysplastic syndrome (del(5q) MDS), resp.  How lenalidomide alters the specificity of the ligase to degrade these proteins remains elusive.  Here we present the 2.45 Å crystal structure of DDB1-CRBN bound to lenalidomide and CK1α.  CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop located in the kinase N-lobe.  We show that CK1α binding to CRL4CRBN is strictly dependent on the presence of an IMiD.  Binding of IKZF1 to CRBN similarly requires the compd. and both, IKZF1 and CK1α, use a related binding mode.  Our study provides a mechanistic explanation for the selective efficacy of lenalidomide in del(5q) MDS therapy.  We anticipate that high-affinity protein-protein interactions induced by small mols. will provide opportunities for drug development, particularly for targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs4FxWriI1ObVg90H21EOLACvtfcHk0lhJI9BnImbT5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D&md5=320fc6ff811da335fa8e02feab2d702d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature16979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16979%26sid%3Dliteratum%253Aachs%26aulast%3DPetzold%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DThom%25C3%25A4%26aufirst%3DN.%2BH.%26atitle%3DStructural%2520basis%2520of%2520lenalidomide-induced%2520CK1alpha%2520degradation%2520by%2520the%2520CRL4%2528CRBN%2529%2520ubiquitin%2520ligase%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D127%26epage%3D130%26doi%3D10.1038%2Fnature16979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, Q. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renneville, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Słabicki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddicoat, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdulrahman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomä, N. H.</span></span> <span> </span><span class="NLM_article-title">Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>362</i></span>, <span class="NLM_elocation-id">eaat0572</span> <span class="refDoi"> DOI: 10.1126/science.aat0572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1126%2Fscience.aat0572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=30385546" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2018&author=Q.+L.+Sieversauthor=G.+Petzoldauthor=R.+D.+Bunkerauthor=A.+Rennevilleauthor=M.+S%C5%82abickiauthor=B.+J.+Liddicoatauthor=W.+Abdulrahmanauthor=T.+Mikkelsenauthor=B.+L.+Ebertauthor=N.+H.+Thom%C3%A4&title=Defining+the+human+C2H2+zinc+finger+degrome+targeted+by+thalidomide+analogs+through+CRBN&doi=10.1126%2Fscience.aat0572"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1126%2Fscience.aat0572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aat0572%26sid%3Dliteratum%253Aachs%26aulast%3DSievers%26aufirst%3DQ.%2BL.%26aulast%3DPetzold%26aufirst%3DG.%26aulast%3DBunker%26aufirst%3DR.%2BD.%26aulast%3DRenneville%26aufirst%3DA.%26aulast%3DS%25C5%2582abicki%26aufirst%3DM.%26aulast%3DLiddicoat%26aufirst%3DB.%2BJ.%26aulast%3DAbdulrahman%26aufirst%3DW.%26aulast%3DMikkelsen%26aufirst%3DT.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DThom%25C3%25A4%26aufirst%3DN.%2BH.%26atitle%3DDefining%2520the%2520human%2520C2H2%2520zinc%2520finger%2520degrome%2520targeted%2520by%2520thalidomide%2520analogs%2520through%2520CRBN%26jtitle%3DScience%26date%3D2018%26volume%3D362%26doi%3D10.1126%2Fscience.aat0572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0lhJI9BnImbT5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshaies, R. J.</span></span> <span> </span><span class="NLM_article-title">Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">8554</span>– <span class="NLM_lpage">8559</span>, <span class="refDoi"> DOI: 10.1073/pnas.141230798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1073%2Fpnas.141230798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=11438690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD3MXls1Wisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=8554-8559&author=K.+M.+Sakamotoauthor=K.+B.+Kimauthor=A.+Kumagaiauthor=F.+Mercurioauthor=C.+M.+Crewsauthor=R.+J.+Deshaies&title=Protacs%3A+Chimeric+molecules+that+target+proteins+to+the+Skp1%E2%80%93Cullin%E2%80%93F+box+complex+for+ubiquitination+and+degradation&doi=10.1073%2Fpnas.141230798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation</span></div><div class="casAuthors">Sakamoto, Kathleen M.; Kim, Kyung B.; Kumagai, Akiko; Mercurio, Frank; Crews, Craig M.; Deshaies, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8554-8559</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The intracellular levels of many proteins are regulated by ubiquitin-dependent proteolysis.  One of the best-characterized enzymes that catalyzes the attachment of ubiquitin to proteins is a ubiquitin ligase complex, Skp1-Cullin-F box complex contg. Hrt1 (SCF).  We sought to artificially target a protein to the SCF complex for ubiquitination and degrdn.  To this end, we tested methionine aminopeptidase-2 (MetAP-2), which covalently binds the angiogenesis inhibitor ovalicin.  A chimeric compd., protein-targeting chimeric mol. 1 (Protac-1), was synthesized to recruit MetAP-2 to SCF.  One domain of Protac-1 contains the IκBα phosphopeptide that is recognized by the F-box protein β-TRCP, whereas the other domain is composed of ovalicin.  We show that MetAP-2 can be tethered to SCFβ-TRCP, ubiquitinated, and degraded in a Protac-1-dependent manner.  In the future, this approach may be useful for conditional inactivation of proteins, and for targeting disease-causing proteins for destruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp49fYtuEVlJrVg90H21EOLACvtfcHk0ljpczoCrhchNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXls1Wisbk%253D&md5=540358035222f745f7b6367b38781a21</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1073%2Fpnas.141230798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.141230798%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DKumagai%26aufirst%3DA.%26aulast%3DMercurio%26aufirst%3DF.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26aulast%3DDeshaies%26aufirst%3DR.%2BJ.%26atitle%3DProtacs%253A%2520Chimeric%2520molecules%2520that%2520target%2520proteins%2520to%2520the%2520Skp1%25E2%2580%2593Cullin%25E2%2580%2593F%2520box%2520complex%2520for%2520ubiquitination%2520and%2520degradation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D8554%26epage%3D8559%26doi%3D10.1073%2Fpnas.141230798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delproposto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1420</span>– <span class="NLM_lpage">1442</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Cqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1420-1442&author=J.+Huauthor=B.+Huauthor=M.+Wangauthor=F.+Xuauthor=B.+Miaoauthor=C.-Y.+Yangauthor=M.+Wangauthor=Z.+Liuauthor=D.+F.+Hayesauthor=K.+Chinnaswamyauthor=J.+Delpropostoauthor=J.+Stuckeyauthor=S.+Wang&title=Discovery+of+ERD-308+as+a+Highly+Potent+Proteolysis+Targeting+Chimera+%28PROTAC%29+Degrader+of+Estrogen+Receptor+%28ER%29&doi=10.1021%2Facs.jmedchem.8b01572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)</span></div><div class="casAuthors">Hu, Jiantao; Hu, Biao; Wang, Mingliang; Xu, Fuming; Miao, Bukeyan; Yang, Chao-Yie; Wang, Mi; Liu, Zhaomin; Hayes, Daniel F.; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1420-1442</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-pos. (ER+) breast cancer.  Here, we describe the design, synthesis, and extensive structure-activity relationship (SAR) studies of small-mol. ERα degraders based on the proteolysis targeting chimeras (PROTAC) concept.  Our efforts have resulted in the discovery of highly potent and effective PROTAC ER degraders, as exemplified by ERD-308 I.  I achieves DC50 (concn. causing 50% of protein degrdn.) values of 0.17 and 0.43 nM in MCF-7 and T47D ER+ breast cancer cell lines, resp., and induces >95% of ER degrdn. at concns. as low as 5 nM in both cell lines.  Significantly, I induces more complete ER degrdn. than fulvestrant, the only approved selective ER degrader (SERD), and is more effective in inhibition of cell proliferation than fulvestrant in MCF-7 cells.  Further optimization of I may lead to a new therapy for advanced ER+ breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHRlcISYyFXLVg90H21EOLACvtfcHk0ljpczoCrhchNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Cqs7s%253D&md5=678e82dd460c065e2054ba18ea8af18a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01572%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DMiao%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DDelproposto%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520ERD-308%2520as%2520a%2520Highly%2520Potent%2520Proteolysis%2520Targeting%2520Chimera%2520%2528PROTAC%2529%2520Degrader%2520of%2520Estrogen%2520Receptor%2520%2528ER%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1420%26epage%3D1442%26doi%3D10.1021%2Facs.jmedchem.8b01572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delproposto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01631</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01631" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=941-964&author=X.+Hanauthor=C.+Wangauthor=C.+Qinauthor=W.+Xiangauthor=E.+Fernandez-Salasauthor=C.-Y.+Yangauthor=M.+Wangauthor=L.+Zhaoauthor=T.+Xuauthor=K.+Chinnaswamyauthor=J.+Delpropostoauthor=J.+Stuckeyauthor=S.+Wang&title=Discovery+of+ARD-69+as+a+highly+potent+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+androgen+receptor+%28AR%29+for+the+treatment+of+prostate+cancer&doi=10.1021%2Facs.jmedchem.8b01631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span></div><div class="casAuthors">Han, Xin; Wang, Chao; Qin, Chong; Xiang, Weiguo; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Mi; Zhao, Lijie; Xu, Tianfeng; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">941-964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by IARD-69.  I induces degrdn. of AR protein in AR-pos. prostate cancer cell lines in a dose- and time-dependent manner.  I achieves DC50 values of 0.86, 0.76, and 10.4 nM in LNCaP, VCaP, and 22Rv1 AR+ prostate cancer cell lines, resp.  I is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.  I potently inhibits cell growth in these AR-pos. prostate cancer cell lines and is >100 times more potent than AR antagonists.  A single dose of I effectively reduces the level of AR protein in xenograft tumor tissue in mice.  Further optimization of I may ultimately lead to a new therapy for AR+, castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTlOD69tfhtbVg90H21EOLACvtfcHk0ljpczoCrhchNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D&md5=2376573fb1a1e19c517d64c70199700a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01631%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DDelproposto%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520ARD-69%2520as%2520a%2520highly%2520potent%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520androgen%2520receptor%2520%2528AR%2529%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D941%26epage%3D964%26doi%3D10.1021%2Facs.jmedchem.8b01631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Phthalimide conjugation as a strategy for in vivo target protein degradation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">1376</span>– <span class="NLM_lpage">1381</span>, <span class="refDoi"> DOI: 10.1126/science.aab1433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1126%2Fscience.aab1433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25999370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=1376-1381&author=G.+E.+Winterauthor=D.+L.+Buckleyauthor=J.+Paulkauthor=J.+M.+Robertsauthor=A.+Souzaauthor=S.+Dhe-Paganonauthor=J.+E.+Bradner&title=Phthalimide+conjugation+as+a+strategy+for+in+vivo+target+protein+degradation&doi=10.1126%2Fscience.aab1433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phthalimide conjugation as a strategy for in vivo target protein degradation</span></div><div class="casAuthors">Winter, Georg E.; Buckley, Dennis L.; Paulk, Joshiawa; Roberts, Justin M.; Souza, Amanda; Dhe-Paganon, Sirano; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6241</span>),
    <span class="NLM_cas:pages">1376-1381</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The development of effective pharmacol. inhibitors of multidomain scaffold proteins, notably transcription factors, is a particularly challenging problem.  In part, this is because many small-mol. antagonists disrupt the activity of only one domain in the target protein.  The authors devised a chem. strategy that promotes ligand-dependent target protein degrdn. using as an example the transcriptional coactivator BRD4, a protein crit. for cancer cell growth and survival.  The authors appended a competitive antagonist of BET bromodomains to a phthalimide moiety to hijack the cereblon E3 ubiquitin ligase complex.  The resultant compd., dBET1, induced highly selective cereblon-dependent BET protein degrdn. in vitro and in vivo and delayed leukemia progression in mice.  A second series of probes resulted in selective degrdn. of the cytosolic protein FKBP12.  This chem. strategy for controlling target protein stability may have implications for therapeutically targeting previously intractable proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZW4zjRjXi7Vg90H21EOLACvtfcHk0lj9kBsEzU0T2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D&md5=b0277cc95d318d926b96e7a119066e3b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1126%2Fscience.aab1433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aab1433%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DSouza%26aufirst%3DA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DPhthalimide%2520conjugation%2520as%2520a%2520strategy%2520for%2520in%2520vivo%2520target%2520protein%2520degradation%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D1376%26epage%3D1381%26doi%3D10.1126%2Fscience.aab1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinebach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köpff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López Mármol, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichenzeller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gütschow, M.</span></span> <span> </span><span class="NLM_article-title">PROTAC-mediated crosstalk between E3 ligases</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1821</span>– <span class="NLM_lpage">1824</span>, <span class="refDoi"> DOI: 10.1039/c8cc09541h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1039%2FC8CC09541H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=30672516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFSmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=1821-1824&author=C.+Steinebachauthor=H.+Kehmauthor=S.+Lindnerauthor=L.+P.+Vuauthor=S.+K%C3%B6pffauthor=%C3%81.+L%C3%B3pez+M%C3%A1rmolauthor=C.+Weilerauthor=K.+G.+Wagnerauthor=M.+Reichenzellerauthor=J.+Kr%C3%B6nkeauthor=M.+G%C3%BCtschow&title=PROTAC-mediated+crosstalk+between+E3+ligases&doi=10.1039%2Fc8cc09541h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-mediated crosstalk between E3 ligases</span></div><div class="casAuthors">Steinebach, Christian; Kehm, Hannes; Lindner, Stefanie; Vu, Lan Phuong; Koepff, Simon; Lopez Marmol, Alvaro; Weiler, Corinna; Wagner, Karl G.; Reichenzeller, Michaela; Kroenke, Jan; Guetschow, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1821-1824</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Small-mol. heterobifunctional degraders can effectively control protein levels and are useful research tools.  We assembled proteolysis targeting chimeras (PROTACs) from a cereblon (CRBN) and a von-Hippel-Lindau (VHL) ligase ligand and demonstrated a PROTAC-induced heterodimerization of the two E3 ligases leading to unidirectional and efficient degrdn. of CRBN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofM8Lun8SiSLVg90H21EOLACvtfcHk0lj9kBsEzU0T2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFSmtLY%253D&md5=17ed8abc73d45081c73f1995205713cf</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1039%2FC8CC09541H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CC09541H%26sid%3Dliteratum%253Aachs%26aulast%3DSteinebach%26aufirst%3DC.%26aulast%3DKehm%26aufirst%3DH.%26aulast%3DLindner%26aufirst%3DS.%26aulast%3DVu%26aufirst%3DL.%2BP.%26aulast%3DK%25C3%25B6pff%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez%2BM%25C3%25A1rmol%26aufirst%3D%25C3%2581.%26aulast%3DWeiler%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DK.%2BG.%26aulast%3DReichenzeller%26aufirst%3DM.%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26atitle%3DPROTAC-mediated%2520crosstalk%2520between%2520E3%2520ligases%26jtitle%3DChem.%2520Commun.%26date%3D2019%26volume%3D55%26spage%3D1821%26epage%3D1824%26doi%3D10.1039%2Fc8cc09541h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1016%2Fj.ejmech.2018.01.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=29407955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFehsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=251-259&author=M.+Luauthor=T.+Liuauthor=Q.+Jiaoauthor=J.+Jiauthor=M.+Taoauthor=Y.+Liuauthor=Q.+Youauthor=Z.+Jiang&title=Discovery+of+a+Keap1-dependent+peptide+PROTAC+to+knockdown+Tau+by+ubiquitination-proteasome+degradation+pathway&doi=10.1016%2Fj.ejmech.2018.01.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway</span></div><div class="casAuthors">Lu, Mengchen; Liu, Tian; Jiao, Qiong; Ji, Jianai; Tao, Mengmin; Liu, Yijun; You, Qidong; Jiang, Zhengyu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">251-259</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Induced protein degrdn. by PROTACs has emerged as a promising strategy to target nonenzymic proteins inside the cell.  The aim of this study was to identify Keap1, a substrate adaptor protein for ubiquitin E3 ligase involved in oxidative stress regulation, as a novel candidate for PROTACs that can be applied in the degrdn. of the nonenzymic protein Tau.  A peptide PROTAC by recruiting Keap1-Cul3 ubiquitin E3 ligase was developed and applied in the degrdn. of intracellular Tau.  Peptide 1 showed strong in vitro binding with Keap1 and Tau.  With proper cell permeability, peptide 1 was found to colocalize with cellular Keap1 and resulted in the coimmunopptn. of Tau and Keap1.  The results of flow cytometry and western blotting assays showed that peptide 1 can downregulate the intracellular Tau level in both time- and concn.-dependent manner.  The application of Keap1 siRNA silencing and the proteasome inhibitor MG132 confirmed that peptide 1 could promote the Keap1-dependent poly-ubiquitination and proteasome-dependent degrdn. of Tau.  The results suggested that using PROTACs to recruit Keap1 to induce the degrdn. of Tau may show promising character in the treatment of neurodegenerative disease.  In addn., our research demonstrated that Keap1 should be a promising E3 ligase adaptor to be used in the design of novel PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9KC7pnPqlL7Vg90H21EOLACvtfcHk0lj9kBsEzU0T2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFehsbY%253D&md5=165e6f510e4e2024aca6c4135d2840b2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.063%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DJiao%26aufirst%3DQ.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYou%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520a%2520Keap1-dependent%2520peptide%2520PROTAC%2520to%2520knockdown%2520Tau%2520by%2520ubiquitination-proteasome%2520degradation%2520pathway%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D251%26epage%3D259%26doi%3D10.1016%2Fj.ejmech.2018.01.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kargbo, R. B.</span></span> <span> </span><span class="NLM_article-title">Treatment of Alzheimer’s by PROTAC-Tau protein degradation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVSnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=699-700&author=R.+B.+Kargbo&title=Treatment+of+Alzheimer%E2%80%99s+by+PROTAC-Tau+protein+degradation&doi=10.1021%2Facsmedchemlett.9b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Alzheimer's by PROTAC-Tau Protein Degradation</span></div><div class="casAuthors">Kargbo, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">699-700</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfHxe_Dk7zBrVg90H21EOLACvtfcHk0lgeK1NVUNbMzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVSnu70%253D&md5=7d4254b26c56f6401c16e6d100ddf0bd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00083%26sid%3Dliteratum%253Aachs%26aulast%3DKargbo%26aufirst%3DR.%2BB.%26atitle%3DTreatment%2520of%2520Alzheimer%25E2%2580%2599s%2520by%2520PROTAC-Tau%2520protein%2520degradation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D699%26epage%3D700%26doi%3D10.1021%2Facsmedchemlett.9b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-M.</span></span> <span> </span><span class="NLM_article-title">Specific knockdown of endogenous Tau protein by peptide-directed ubiquitin-proteasome degradation</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1016%2Fj.chembiol.2016.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=27105281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlSqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=453-461&author=T.-T.+Chuauthor=N.+Gaoauthor=Q.-Q.+Liauthor=P.-G.+Chenauthor=X.-F.+Yangauthor=Y.-X.+Chenauthor=Y.-F.+Zhaoauthor=Y.-M.+Li&title=Specific+knockdown+of+endogenous+Tau+protein+by+peptide-directed+ubiquitin-proteasome+degradation&doi=10.1016%2Fj.chembiol.2016.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation</span></div><div class="casAuthors">Chu, Ting-Ting; Gao, Na; Li, Qian-Qian; Chen, Pu-Guang; Yang, Xi-Fei; Chen, Yong-Xiang; Zhao, Yu-Fen; Li, Yan-Mei</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">453-461</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tau, an important pathol. protein of Alzheimer's disease (AD), can mediate the toxicity of amyloid β (Aβ).  Thus, redn. of Tau with chem. mols. may offer a novel strategy for treating AD.  Here, we designed and synthesized a series of multifunctional mols. that contained Tau-recognition moieties and E3 ligase-binding moieties to enhance Tau degrdn.  Among these mols., TH006 had the highest activity of inducing Tau degrdn. by increasing its poly-ubiquitination.  The decrement in Tau induced by TH006 could decrease the cytotoxicity caused by Aβ.  Furthermore, TH006 could regulate the Tau level in the brain of an AD mouse model.  Therefore, partial redn. of Tau with such multifunctional peptides may open up a novel therapeutic strategy for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnG14J2STP7Vg90H21EOLACvtfcHk0lgeK1NVUNbMzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlSqtbg%253D&md5=d965c74777427dfa9b6068f4f51a0f12</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DT.-T.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DQ.-Q.%26aulast%3DChen%26aufirst%3DP.-G.%26aulast%3DYang%26aufirst%3DX.-F.%26aulast%3DChen%26aufirst%3DY.-X.%26aulast%3DZhao%26aufirst%3DY.-F.%26aulast%3DLi%26aufirst%3DY.-M.%26atitle%3DSpecific%2520knockdown%2520of%2520endogenous%2520Tau%2520protein%2520by%2520peptide-directed%2520ubiquitin-proteasome%2520degradation%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D453%26epage%3D461%26doi%3D10.1016%2Fj.chembiol.2016.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boichenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bär, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupas, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez Alvarez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M. D.</span></span> <span> </span><span class="NLM_article-title">Chemical ligand space of cereblon</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">11163</span>– <span class="NLM_lpage">11171</span>, <span class="refDoi"> DOI: 10.1021/acsomega.8b00959</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.8b00959" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSku7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=11163-11171&author=I.+Boichenkoauthor=K.+B%C3%A4rauthor=S.+Deissauthor=C.+Heimauthor=R.+Albrechtauthor=A.+N.+Lupasauthor=B.+Hernandez+Alvarezauthor=M.+D.+Hartmann&title=Chemical+ligand+space+of+cereblon&doi=10.1021%2Facsomega.8b00959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Ligand Space of Cereblon</span></div><div class="casAuthors">Boichenko, Iuliia; Baer, Kerstin; Deiss, Silvia; Heim, Christopher; Albrecht, Reinhard; Lupas, Andrei N.; Hernandez Alvarez, Birte; Hartmann, Marcus D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">11163-11171</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The protein, cereblon, serves as a substrate receptor of a ubiquitin ligase complex that can be tuned toward different target proteins by cereblon-binding agents.  This approach to targeted protein degrdn. is exploited in different clin. settings and has sparked the development of a growing no. of thalidomide derivs.  Here, we probed the chem. space of cereblon binding beyond such derivs. and worked out a simple set of chem. requirements, delineating the metaclass of cereblon effectors.  We report co-crystal structures of Magnetospirillum gryphiswaldense cereblon isoform 4 with a diverse set of compds., including commonly used pharmaceuticals, but we also found that already minimalistic cereblon-binding moieties might exert teratogenic effects in zebrafish.  These results may guide the design of a post-thalidomide generation of therapeutic cereblon effectors, and provide a framework for the circumvention of unintended cereblon-binding by neg. design for future pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-HgXkEOEEXrVg90H21EOLACvtfcHk0lgeK1NVUNbMzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSku7bO&md5=b0fee25453d5ec83098ac0cf28575d44</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsomega.8b00959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.8b00959%26sid%3Dliteratum%253Aachs%26aulast%3DBoichenko%26aufirst%3DI.%26aulast%3DB%25C3%25A4r%26aufirst%3DK.%26aulast%3DDeiss%26aufirst%3DS.%26aulast%3DHeim%26aufirst%3DC.%26aulast%3DAlbrecht%26aufirst%3DR.%26aulast%3DLupas%26aufirst%3DA.%2BN.%26aulast%3DHernandez%2BAlvarez%26aufirst%3DB.%26aulast%3DHartmann%26aufirst%3DM.%2BD.%26atitle%3DChemical%2520ligand%2520space%2520of%2520cereblon%26jtitle%3DACS%2520Omega%26date%3D2018%26volume%3D3%26spage%3D11163%26epage%3D11171%26doi%3D10.1021%2Facsomega.8b00959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromm, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Efficient synthesis of immunomodulatory drug analogues enables exploration of structure-degradation relationships</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1508</span>– <span class="NLM_lpage">1512</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1002%2Fcmdc.201800271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=29870139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1KntL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1508-1512&author=G.+M.+Burslemauthor=P.+Ottisauthor=S.+Jaime-Figueroaauthor=A.+Morganauthor=P.+M.+Crommauthor=M.+Toureauthor=C.+M.+Crews&title=Efficient+synthesis+of+immunomodulatory+drug+analogues+enables+exploration+of+structure-degradation+relationships&doi=10.1002%2Fcmdc.201800271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships</span></div><div class="casAuthors">Burslem, George M.; Ottis, Philipp; Jaime-Figueroa, Saul; Morgan, Alicia; Cromm, Philipp M.; Toure, Momar; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1508-1512</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The immunomodulatory drugs (IMiDs) thalidomide, pomalidomide, and lenalidomide have been approved for the treatment of multiple myeloma for many years.  Recently, their use as E3 ligase recruiting elements for small-mol.-induced protein degrdn. has led to a resurgence in interest in IMiD synthesis and functionalization.  Traditional IMiD synthesis follows a stepwise route with multiple purifn. steps.  Herein we describe a novel one-pot synthesis without purifn. that provides rapid access to a multitude of IMiD analogs.  Binding studies with the IMiD target protein cereblon (CRBN) reveals a narrow structure-activity relationship with only a few compds. showing sub-micromolar binding affinity in the range of pomalidomide and lenalidomide.  However, anti-proliferative activity as well as Aiolos degrdn. could be identified for two IMiD analogs.  This study provides useful insight into the structure-degrdn. relationships for mols. of this type as well as a rapid and robust method for IMiD synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXV1lRMrjBNrVg90H21EOLACvtfcHk0lj8Uw6vM9Qw9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1KntL7O&md5=74ada081313c4e01b430fb6014441e2e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800271%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DOttis%26aufirst%3DP.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DMorgan%26aufirst%3DA.%26aulast%3DCromm%26aufirst%3DP.%2BM.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DEfficient%2520synthesis%2520of%2520immunomodulatory%2520drug%2520analogues%2520enables%2520exploration%2520of%2520structure-degradation%2520relationships%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D1508%26epage%3D1512%26doi%3D10.1002%2Fcmdc.201800271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dredge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgleish, A. G.</span></span> <span> </span><span class="NLM_article-title">The evolution of thalidomide and its IMiD derivatives as anticancer agents</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1038/nrc1323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnrc1323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=15057291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=314-322&author=J.+B.+Bartlettauthor=K.+Dredgeauthor=A.+G.+Dalgleish&title=The+evolution+of+thalidomide+and+its+IMiD+derivatives+as+anticancer+agents&doi=10.1038%2Fnrc1323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The evolution of thalidomide and its IMiD derivatives as anticancer agents</span></div><div class="casAuthors">Bartlett, J. Blake; Dredge, Keith; Dalgleish, Angus G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">314-322</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Thalidomide was originally used to treat morning sickness, but was banned in the 1960s for causing serious congenital birth defects.  Remarkably, thalidomide was subsequently discovered to have anti-inflammatory and anti-angiogenic properties, and was identified as an effective treatment for multiple myeloma.  A series of immunomodulatory drugs - created by chem. modification of thalidomide - have been developed to overcome the original devastating side effects.  Their powerful anticancer properties mean that these drugs are now emerging from thalidomide's shadow as useful anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4ahyYZGz7MbVg90H21EOLACvtfcHk0lj8Uw6vM9Qw9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt7k%253D&md5=99d2ac4c0f6d6d1dac5547e5360dd74f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrc1323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1323%26sid%3Dliteratum%253Aachs%26aulast%3DBartlett%26aufirst%3DJ.%2BB.%26aulast%3DDredge%26aufirst%3DK.%26aulast%3DDalgleish%26aufirst%3DA.%2BG.%26atitle%3DThe%2520evolution%2520of%2520thalidomide%2520and%2520its%2520IMiD%2520derivatives%2520as%2520anticancer%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D314%26epage%3D322%26doi%3D10.1038%2Fnrc1323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrupt, P.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francotte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, B.</span></span> <span> </span><span class="NLM_article-title">Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1521</span>– <span class="NLM_lpage">1528</span>, <span class="refDoi"> DOI: 10.1021/tx9801817</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx9801817" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADyaK1cXntFens7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1998&pages=1521-1528&author=M.+Reistauthor=P.-A.+Carruptauthor=E.+Francotteauthor=B.+Testa&title=Chiral+inversion+and+hydrolysis+of+thalidomide%3A+mechanisms+and+catalysis+by+bases+and+serum+albumin%2C+and+chiral+stability+of+teratogenic+metabolites&doi=10.1021%2Ftx9801817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral Inversion and Hydrolysis of Thalidomide: Mechanisms and Catalysis by Bases and Serum Albumin, and Chiral Stability of Teratogenic Metabolites</span></div><div class="casAuthors">Reist, Marianne; Carrupt, Pierre-Alain; Francotte, Eric; Testa, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1521-1528</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The chiral inversion and hydrolysis of thalidomide and the catalysis by bases and human serum albumin were investigated by using a stereoselective HPLC assay.  Chiral inversion was catalyzed by albumin, hydroxyl ions, phosphate, and amino acids.  Basic amino acids (Arg and Lys) had a superior potency in catalyzing chiral inversion compared to acid and neutral ones.  The chiral inversion of thalidomide is thus subject to specific and general base catalysis, and it is suggested that the ability of HSA to catalyze the reaction is due to the basic groups of the amino acids Arg and Lys and not to a single catalytic site on the macromol.  The hydrolysis of thalidomide was also base-catalyzed.  However, albumin had no effect on hydrolysis, and there was no difference between the catalytic potencies of acidic, neutral, and basic amino acids.  This may be explained by different reaction mechanisms of the chiral inversion and hydrolysis of thalidomide.  Chiral inversion is deduced to occur by electrophilic substitution involving specific and general base catalysis, whereas hydrolysis is thought to occur by nucleophilic substitution involving specific and general base as well as nucleophilic catalysis.  As nucleophilic attack is sensitive to steric properties of the catalyst, steric hindrance might be the reason albumin is not able to catalyze hydrolysis.  1H NMR expts. revealed that the three teratogenic metabolites of thalidomide, in sharp contrast to the drug itself, had complete chiral stability.  This leads to the speculation that, were some enantioselectivity to exist in the teratogenicity of thalidomide, it could result from fast hydrolysis to chirally stable teratogenic metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfmXgvPgsp8rVg90H21EOLACvtfcHk0lj8Uw6vM9Qw9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntFens7s%253D&md5=1952fa00825e6791eeb8388419f3cc09</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Ftx9801817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9801817%26sid%3Dliteratum%253Aachs%26aulast%3DReist%26aufirst%3DM.%26aulast%3DCarrupt%26aufirst%3DP.-A.%26aulast%3DFrancotte%26aufirst%3DE.%26aulast%3DTesta%26aufirst%3DB.%26atitle%3DChiral%2520inversion%2520and%2520hydrolysis%2520of%2520thalidomide%253A%2520mechanisms%2520and%2520catalysis%2520by%2520bases%2520and%2520serum%2520albumin%252C%2520and%2520chiral%2520stability%2520of%2520teratogenic%2520metabolites%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1998%26volume%3D11%26spage%3D1521%26epage%3D1528%26doi%3D10.1021%2Ftx9801817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelsang, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petty, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brundrett, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colvin, O. M.</span></span> <span> </span><span class="NLM_article-title">Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers</span>. <i>Drug Metab Dispos</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=2571480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADyaL1MXlt1KnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1989&pages=402-405&author=T.+L.+Chenauthor=G.+B.+Vogelsangauthor=B.+G.+Pettyauthor=R.+B.+Brundrettauthor=D.+A.+Noeauthor=G.+W.+Santosauthor=O.+M.+Colvin&title=Plasma+pharmacokinetics+and+urinary+excretion+of+thalidomide+after+oral+dosing+in+healthy+male+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers</span></div><div class="casAuthors">Chen, Tian Ling; Vogelsang, Georgia B.; Petty, Brent G.; Brundrett, Robert B.; Noe, Dennis A.; Santos, George W.; Colvin, O. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-5</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">The plasma pharmacokinetics and urinary excretion of thalidomide were evaluated in healthy male volunteers receiving a single oral dose of 200 mg.  Concns. of thalidomide were detd. by a new HPLC assay.  Plasma concn. vs. time data were well fit by a 1-compartment model.  The mean peak concn., 1.15 μg/mL, was achieved at 4.39 h.  Absorption and elimination half-lives were 1.70 and 8.70 h, resp., with a lag time of 0.41 h obsd. in 6 of 8 subjects.  The apparent vol. of distribution and total body clearance rate, based on assumed complete bioavailability, were 120.69 L and 10.41 L/h.  The urinary excretion of thalidomide accounted for only 0.6% of the total dose administered over 24 h, and the renal clearance rate was 0.08 L/h.  Thus, the major route of elimination of thalidomide is nonrenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo27dR99aSZ8rVg90H21EOLACvtfcHk0ljtoTyZwqYn_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlt1KnsLY%253D&md5=e171e48357c05ea8fedbc2979293650e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%2BL.%26aulast%3DVogelsang%26aufirst%3DG.%2BB.%26aulast%3DPetty%26aufirst%3DB.%2BG.%26aulast%3DBrundrett%26aufirst%3DR.%2BB.%26aulast%3DNoe%26aufirst%3DD.%2BA.%26aulast%3DSantos%26aufirst%3DG.%2BW.%26aulast%3DColvin%26aufirst%3DO.%2BM.%26atitle%3DPlasma%2520pharmacokinetics%2520and%2520urinary%2520excretion%2520of%2520thalidomide%2520after%2520oral%2520dosing%2520in%2520healthy%2520male%2520volunteers%26jtitle%3DDrug%2520Metab%2520Dispos%26date%3D1989%26volume%3D17%26spage%3D402%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. T.</span></span> <span> </span><span class="NLM_article-title">The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species</span>. <i>Br. J. Pharmacol. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1965.tb02054.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1111%2Fj.1476-5381.1965.tb02054.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=5866716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADyaF28Xhtl2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1965&pages=338-351&author=H.+Schumacherauthor=R.+L.+Smithauthor=R.+T.+Williams&title=The+metabolism+of+thalidomide%3A+the+fate+of+thalidomide+and+some+of+its+hydrolysis+products+in+various+species&doi=10.1111%2Fj.1476-5381.1965.tb02054.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of thalidomide. The fate of thalidomide and some of its hydrolysis products in various species</span></div><div class="casAuthors">Schumacher, H.; Smith, R. L.; Williams, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology and Chemotherapy</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">338-51</span>CODEN:
                <span class="NLM_cas:coden">BJPCAL</span>;
        ISSN:<span class="NLM_cas:issn">0366-0826</span>.
    </div><div class="casAbstract">cf. preceding abstr.  The metabolism of thalidomide in the rabbit, rat, mouse, and guinea pig was investigated.  The metabolites of thalidomide present in the urine, blood, and tissues of various species dosed with the drug were characterized by comparing their chromatographic mobility and color reactions with those given by authentic samples of the compds.  The rabbit urinary metabolites were isolated in cryst. form by solvent extn. and adsorption chromatography, and their identity was established by analysis, m.p. behavior, and comparison of their ir spectra with those of the authentic compds.  When thalidomide is fed to rabbits, rats, mice, and guinea pigs a no. of hydrolysis products appear in the urine.  These hydrolysis products are formed by the spontaneous hydrolysis of thalidomide.  In addn. the urine of rabbits dosed with thalidomide contains derivs. of 3- and 4-hydroxyphthalic acid; these minor metabolites were not identified.  The hydrolysis products appear to be derived by spontaneous breakdown of thalidomide in the body, although it is possible that any of the hydrolytic reactions of thalidomide may be assisted by hydrolases in the body.  In rats, some breakdown of thalidomide occurs in the gut before absorption; hydrolysis products are present in the gastrointestinal tract following the oral administration of the drug.  Thalidomide and some of its hydrolysis products can be detected in the plasma and brain of rats dosed orally with thalidomide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonBmF6EIEpPrVg90H21EOLACvtfcHk0ljtoTyZwqYn_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF28Xhtl2rsA%253D%253D&md5=cb686e6f49ced088a96fc32b61f2256b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1965.tb02054.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1965.tb02054.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DR.%2BL.%26aulast%3DWilliams%26aufirst%3DR.%2BT.%26atitle%3DThe%2520metabolism%2520of%2520thalidomide%253A%2520the%2520fate%2520of%2520thalidomide%2520and%2520some%2520of%2520its%2520hydrolysis%2520products%2520in%2520various%2520species%26jtitle%3DBr.%2520J.%2520Pharmacol.%2520Chemother.%26date%3D1965%26volume%3D25%26spage%3D338%26epage%3D351%26doi%3D10.1111%2Fj.1476-5381.1965.tb02054.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teo, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colburn, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracewell, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kook, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaworsky, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laskin, O. L.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of thalidomide</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.2165/00003088-200443050-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.2165%2F00003088-200443050-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=15080764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFOqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=311-327&author=S.+K.+Teoauthor=W.+A.+Colburnauthor=W.+G.+Tracewellauthor=K.+A.+Kookauthor=D.+I.+Stirlingauthor=M.+S.+Jaworskyauthor=M.+A.+Schefflerauthor=S.+D.+Thomasauthor=O.+L.+Laskin&title=Clinical+pharmacokinetics+of+thalidomide&doi=10.2165%2F00003088-200443050-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of thalidomide</span></div><div class="casAuthors">Teo, Steve K.; Colburn, Wayne A.; Tracewell, William G.; Kook, Karin A.; Stirling, David I.; Jaworsky, Markian S.; Scheffler, Michael A.; Thomas, Steve D.; Laskin, Oscar L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">311-327</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Thalidomide is a racemic glutamic acid deriv. approved in the US for erythema nodosum leprosum, a complication of leprosy.  In addn., its use in various inflammatory and oncol. conditions is being investigated.  Thalidomide interconverts between the (R)- and (S)-enantiomers in plasma, with protein binding of 55% and 65%, resp.  More than 90% of the absorbed drug is excreted in the urine and feces within 48 h.  Thalidomide is minimally metabolized by the liver, but is spontaneously hydrolyzed into numerous renally excreted products.  After a single oral dose of thalidomide 200mg (as the US-approved capsule formulation) in healthy volunteers, absorption is slow and extensive, resulting in a peak concn. (Cmax) of 1-2 mg/L at 3-4 h after administration, absorption lag time of 30 min, total exposure (AUC∞) of 18 mg • h/L, apparent elimination half-life of 6 h and apparent systemic clearance of 10 L/h.  Thalidomide pharmacokinetics are best described by a one-compartment model with first-order absorption and elimination.  Because of the low soly. of the drug in the gastrointestinal tract, thalidomide exhibits absorption rate-limited pharmacokinetics (the "flip-flop" phenomenon), with its elimination rate being faster than its absorption rate.  The apparent elimination half-life of 6 h therefore represents absorption, not elimination.  The "true" apparent vol. of distribution was estd. to be 16L by use of the faster elimination-rate half-life.  Multiple doses of thalidomide 200 mg/day over 21 days cause no change in the pharmacokinetics, with a steady-state Cmax (Cssmax) of 1.2 mg/L.  Simulation of 400 and 800 mg/day also shows no accumulation, with Cssmax of 3.5 and 6.0 mg/L, resp.  Multiple-dose studies in cancer patients show pharmacokinetics comparable with those in healthy populations at similar dosages.  Thalidomide exhibits a dose-proportional increase in AUC at doses from 50 to 400mg.  Because of the low soly. of thalidomide, Cmax is less than proportional to dose, and tmax is prolonged with increasing dose.  Age, sex and smoking have no effect on the pharmacokinetics of thalidomide, and the effect of food is minimal.  Thalidomide does not alter the pharmacokinetics of oral contraceptives, and is also unlikely to interact with warfarin and grapefruit juice.  Since thalidomide is mainly hydrolyzed and passively excreted, its pharmacokinetics are not expected to change in patients with impaired liver or kidney function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqliBDHYhKycbVg90H21EOLACvtfcHk0ljtoTyZwqYn_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFOqtbg%253D&md5=aa199f0c21a3fdb952fccde4059b71ec</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2165%2F00003088-200443050-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200443050-00004%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DS.%2BK.%26aulast%3DColburn%26aufirst%3DW.%2BA.%26aulast%3DTracewell%26aufirst%3DW.%2BG.%26aulast%3DKook%26aufirst%3DK.%2BA.%26aulast%3DStirling%26aufirst%3DD.%2BI.%26aulast%3DJaworsky%26aufirst%3DM.%2BS.%26aulast%3DScheffler%26aufirst%3DM.%2BA.%26aulast%3DThomas%26aufirst%3DS.%2BD.%26aulast%3DLaskin%26aufirst%3DO.%2BL.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520thalidomide%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2004%26volume%3D43%26spage%3D311%26epage%3D327%26doi%3D10.2165%2F00003088-200443050-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, R.</span></span> <span> </span><span class="NLM_article-title">Ueber das Verhalten von Thalidomid im Organismus</span>. <i>Arzneimittelforschung</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=13970176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADyaF387mtF2mug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1963&pages=185-191&author=R.+Beckmann&title=Ueber+das+Verhalten+von+Thalidomid+im+Organismus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">C-14])</span></div><div class="casAuthors">BECKMANN R</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">1963</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185-91</span>
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkR3GXTV6hukwlCcfExbvbfW6udTcc2ebmaHfd6mjmj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF387mtF2mug%253D%253D&md5=211cb3a294eb7d33c0cfd689bb37d2bc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeckmann%26aufirst%3DR.%26atitle%3DUeber%2520das%2520Verhalten%2520von%2520Thalidomid%2520im%2520Organismus%26jtitle%3DArzneimittelforschung%26date%3D1963%26volume%3D13%26spage%3D185%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kestell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tingle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ching, L. M.</span></span> <span> </span><span class="NLM_article-title">Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">5949</span>– <span class="NLM_lpage">5956</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-04-0421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1158%2F1078-0432.ccr-04-0421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=15355928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlyjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=5949-5956&author=F.+Chungauthor=J.+Luauthor=B.+D.+Palmerauthor=P.+Kestellauthor=P.+Browettauthor=B.+C.+Baguleyauthor=M.+Tingleauthor=L.+M.+Ching&title=Thalidomide+pharmacokinetics+and+metabolite+formation+in+mice%2C+rabbits%2C+and+multiple+myeloma+patients&doi=10.1158%2F1078-0432.ccr-04-0421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients</span></div><div class="casAuthors">Chung, Francisco; Lu, Jun; Palmer, Brian D.; Kestell, Philip; Browett, Peter; Baguley, Bruce C.; Tingle, Malcolm; Ching, Lai-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5949-5956</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thalidomide has a variety of biol. effects that vary considerably according to the species tested.  The authors sought to establish whether differences in pharmacokinetics could form a basis for the species-specific effects of thalidomide.  Mice and rabbits were administered thalidomide (2 mg/kg) p.o. or i.v., and plasma concns. of thalidomide were measured after drug administration using high performance liq. chromatog.  Plasma samples from five multiple myeloma patients over 24 h after their first dose of thalidomide (200 mg) were similarly analyzed and all data were fitted to a one-compartment model.  Metabolites of thalidomide in plasma were identified simultaneously using liq. chromatog.-mass spectrometry.  Plasma concn.-time profiles for the individual patients were very similar to each other, but widely different pharmacokinetic properties were found between patients compared with those in mice or rabbits.  Area under the concn. curve values for mice, rabbits, and multiple myeloma patients were 4, 8, and 81 μmol/L · hour, resp., and corresponding elimination half-lives were 0.5, 2.2, and 7.3 h, resp.  Large differences were also obsd. between the metabolite profiles from the three species.  Hydrolysis products were detected for all species, and the proportion of hydroxylated metabolites was higher in mice than in rabbits and undetectable in patients.  Our results show major interspecies differences in the pharmacokinetics of thalidomide that are related to the altered degree of metab.  The authors suggest that the interspecies differences in biol. effects of thalidomide may be attributable, at least in part, to the differences in its metab. and hence pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_L7cwpcdbcLVg90H21EOLACvtfcHk0lhVuVkEJj4n5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlyjtLw%253D&md5=51bea71546be92322a511405e004aa80</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-04-0421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-04-0421%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DKestell%26aufirst%3DP.%26aulast%3DBrowett%26aufirst%3DP.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DTingle%26aufirst%3DM.%26aulast%3DChing%26aufirst%3DL.%2BM.%26atitle%3DThalidomide%2520pharmacokinetics%2520and%2520metabolite%2520formation%2520in%2520mice%252C%2520rabbits%252C%2520and%2520multiple%2520myeloma%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D5949%26epage%3D5956%26doi%3D10.1158%2F1078-0432.ccr-04-0421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Hydrolyzed metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1248/cpb.55.651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1248%2Fcpb.55.651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=17409565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1arsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2007&pages=651-654&author=T.+Nakamuraauthor=T.+Noguchiauthor=H.+Miyachiauthor=Y.+Hashimoto&title=Hydrolyzed+metabolites+of+thalidomide%3A+synthesis+and+TNF-alpha+production-inhibitory+activity&doi=10.1248%2Fcpb.55.651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrolyzed metabolites of thalidomide: synthesis and TNF-α production-inhibitory activity</span></div><div class="casAuthors">Nakamura, Takanori; Noguchi, Tomomi; Miyachi, Hiroyuki; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">651-654</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Putative hydrolyzed metabolites of thalidomide (I) were prepd. and characterized, and their inhibitory activity on tumor necrosis factor (TNF)-α prodn. in the human monocytic leukemia cell line THP-1 was evaluated.  α-(2-Carboxybenzamido)glutarimide (II) was a more potent TNF-α prodn. inhibitor than I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW3FV9YCmOprVg90H21EOLACvtfcHk0lhVuVkEJj4n5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1arsLc%253D&md5=32f1066b688a9de33e9dbf5da42ec514</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1248%2Fcpb.55.651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.55.651%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DT.%26aulast%3DMiyachi%26aufirst%3DH.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DHydrolyzed%2520metabolites%2520of%2520thalidomide%253A%2520synthesis%2520and%2520TNF-alpha%2520production-inhibitory%2520activity%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2007%26volume%3D55%26spage%3D651%26epage%3D654%26doi%3D10.1248%2Fcpb.55.651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asahi, T.</span></span> <span> </span><span class="NLM_article-title">Structural and thermal analyses of a hydrolysis compound of thalidomide</span>. <i>Acta Crystallogr., Sect. A: Found. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">C113</span>, <span class="refDoi"> DOI: 10.1107/s2053273314098866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1107%2Fs2053273314098866" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=C113&author=K.+Otogawaauthor=Y.+Oginoauthor=K.+Ishikawaauthor=M.+Tanakaauthor=M.+Shiroauthor=T.+Osakaauthor=T.+Asahi&title=Structural+and+thermal+analyses+of+a+hydrolysis+compound+of+thalidomide&doi=10.1107%2Fs2053273314098866"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2Fs2053273314098866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs2053273314098866%26sid%3Dliteratum%253Aachs%26aulast%3DOtogawa%26aufirst%3DK.%26aulast%3DOgino%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DShiro%26aufirst%3DM.%26aulast%3DOsaka%26aufirst%3DT.%26aulast%3DAsahi%26aufirst%3DT.%26atitle%3DStructural%2520and%2520thermal%2520analyses%2520of%2520a%2520hydrolysis%2520compound%2520of%2520thalidomide%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Adv.%26date%3D2014%26volume%3D70%26spage%3DC113%26doi%3D10.1107%2Fs2053273314098866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide induces degradation of IKZF1 and IKZF3</span>. <i>OncoImmunology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e941742</span> <span class="refDoi"> DOI: 10.4161/21624011.2014.941742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.4161%2F21624011.2014.941742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25610725" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&author=J.+Kr%C3%B6nkeauthor=S.+N.+Hurstauthor=B.+L.+Ebert&title=Lenalidomide+induces+degradation+of+IKZF1+and+IKZF3&doi=10.4161%2F21624011.2014.941742"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.4161%2F21624011.2014.941742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F21624011.2014.941742%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520induces%2520degradation%2520of%2520IKZF1%2520and%2520IKZF3%26jtitle%3DOncoImmunology%26date%3D2014%26volume%3D3%26doi%3D10.4161%2F21624011.2014.941742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringheim, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span> <span> </span><span class="NLM_article-title">Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1516</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2017-212916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1136%2Fannrheumdis-2017-212916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=29945920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVektbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2018&pages=1516-1523&author=P.+H.+Schaferauthor=Y.+Yeauthor=L.+Wuauthor=J.+Kosekauthor=G.+Ringheimauthor=Z.+Yangauthor=L.+Liuauthor=M.+Thomasauthor=M.+Palmisanoauthor=R.+Chopra&title=Cereblon+modulator+iberdomide+induces+degradation+of+the+transcription+factors+Ikaros+and+Aiolos%3A+immunomodulation+in+healthy+volunteers+and+relevance+to+systemic+lupus+erythematosus&doi=10.1136%2Fannrheumdis-2017-212916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus</span></div><div class="casAuthors">Schafer, Peter H.; Ye, Ying; Wu, Lei; Kosek, Jolanta; Ringheim, Garth; Yang, Zhihong; Liu, Liangang; Thomas, Michael; Palmisano, Maria; Chopra, Rajesh</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1516-1523</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">ObjectivesIKZF1 and IKZF3 (encoding transcription factors Ikaros and Aiolos) are susceptibility loci for systemic lupus erythematosus (SLE).  The pharmacol. of iberdomide (CC-220), a cereblon (CRBN) modulator targeting Ikaros and Aiolos, was studied in SLE patient cells and in a phase 1 healthy volunteer study.  MethodsCRBN, IKZF1 and IKZF3 gene expression was measured in peripheral blood mononuclear cells (PBMC) from patients with SLE and healthy volunteers.  Ikaros and Aiolos protein levels were measured by Western blot and flow cytometry.  Anti-dsDNA and anti-phospholipid autoantibodies were measured in SLE PBMC cultures treated for 7 days with iberdomide.  Fiftysix healthy volunteers were randomised to a single dose of iberdomide (0.03-6mg, n=6 across seven cohorts) or placebo (n=2/cohort).  CD19+ B cells, CD3+ T cells and intracellular Aiolos were measured by flow cytometry.  Interleukin (IL)-2 and IL-1β prodn. was stimulated with anti-CD3 and lipopolysaccharide, resp., in an ex vivo whole blood assay.  Results SLE patient PBMCs expressed significantly higher CRBN (1.5-fold), IKZF1 (2.1-fold) and IKZF3 (4.1- fold) mRNA levels compared with healthy volunteers.  Iberdomide significantly reduced Ikaros and Aiolos protein levels in B cells, T cells and monocytes.  In SLE PBMC cultures, iberdomide inhibited anti-dsDNA and anti-phospholipid autoantibody prodn. (IC50 ≈10 nM).  Single doses of iberdomide (0.3-6mg) in healthy volunteers decreased intracellular Aiolos (min. mean per cent of baseline: ≈12%-28% (B cells); ≈0%-33% (T cells)), decreased abs. CD19+ B cells, increased IL-2 and decreased IL-1β prodn. ex vivo.  Conclusions These findings demonstrate pharmacodynamic activity of iberdomide and support its further clin. development for the treatment of SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRD6MltUiWQ7Vg90H21EOLACvtfcHk0lglN8ACjr5u6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVektbw%253D&md5=200098adf4787ee935df528d18a5508d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2017-212916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2017-212916%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DKosek%26aufirst%3DJ.%26aulast%3DRingheim%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DPalmisano%26aufirst%3DM.%26aulast%3DChopra%26aufirst%3DR.%26atitle%3DCereblon%2520modulator%2520iberdomide%2520induces%2520degradation%2520of%2520the%2520transcription%2520factors%2520Ikaros%2520and%2520Aiolos%253A%2520immunomodulation%2520in%2520healthy%2520volunteers%2520and%2520relevance%2520to%2520systemic%2520lupus%2520erythematosus%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2018%26volume%3D77%26spage%3D1516%26epage%3D1523%26doi%3D10.1136%2Fannrheumdis-2017-212916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baculi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBrun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span> <span> </span><span class="NLM_article-title">A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1KqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=535-542&author=M.+E.+Matyskielaauthor=W.+Zhangauthor=H.-W.+Manauthor=G.+Mullerauthor=G.+Khambattaauthor=F.+Baculiauthor=M.+Hickmanauthor=L.+LeBrunauthor=B.+Pagariganauthor=G.+Carmelauthor=C.-C.+Luauthor=G.+Luauthor=M.+Rileyauthor=Y.+Satohauthor=P.+Schaferauthor=T.+O.+Danielauthor=J.+Carmichaelauthor=B.+E.+Cathersauthor=P.+P.+Chamberlain&title=A+Cereblon+Modulator+%28CC-220%29+with+Improved+Degradation+of+Ikaros+and+Aiolos&doi=10.1021%2Facs.jmedchem.6b01921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos</span></div><div class="casAuthors">Matyskiela, Mary E.; Zhang, Weihong; Man, Hon-Wah; Muller, George; Khambatta, Godrej; Baculi, Frans; Hickman, Matthew; LeBrun, Laurie; Pagarigan, Barbra; Carmel, Gilles; Lu, Chin-Chun; Lu, Gang; Riley, Mariko; Satoh, Yoshitaka; Schafer, Peter; Daniel, Thomas O.; Carmichael, James; Cathers, Brian E.; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">535-542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The drugs lenalidomide and pomalidomide bind to the protein cereblon, directing the CRL4-CRBN E3 ligase toward the transcription factors Ikaros and Aiolos to cause their ubiquitination and degrdn.  Here we describe CC-220 (compd. 6), a cereblon modulator in clin. development for systemic lupus erythematosis and relapsed/refractory multiple myeloma.  Compd. 6 binds cereblon with a higher affinity than lenalidomide or pomalidomide.  Consistent with this, the cellular degrdn. of Ikaros and Aiolos is more potent and the extent of substrate depletion is greater.  The crystal structure of cereblon in complex with DDB1 and compd. 6 reveals that the increase in potency correlates with increased contacts between compd. 6 and cereblon away from the modeled binding site for Ikaros/Aiolos.  These results describe a new cereblon modulator which achieves greater substrate degrdn. via tighter binding to the cereblon E3 ligase and provides an example of the effect of E3 ligase binding affinity with relevance to other drug discovery efforts in targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGropbvYIxr5j7Vg90H21EOLACvtfcHk0lglN8ACjr5u6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1KqsLs%253D&md5=8358ae8563f8f2c09dbf68683e5e4008</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01921%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMan%26aufirst%3DH.-W.%26aulast%3DMuller%26aufirst%3DG.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DBaculi%26aufirst%3DF.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DLeBrun%26aufirst%3DL.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DC.-C.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DSchafer%26aufirst%3DP.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26atitle%3DA%2520Cereblon%2520Modulator%2520%2528CC-220%2529%2520with%2520Improved%2520Degradation%2520of%2520Ikaros%2520and%2520Aiolos%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D535%26epage%3D542%26doi%3D10.1021%2Facs.jmedchem.6b01921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capitosti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. L.</span></span> <span> </span><span class="NLM_article-title">Facile synthesis of an azido-labeled thalidomide analogue</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2865</span>– <span class="NLM_lpage">2867</span>, <span class="refDoi"> DOI: 10.1021/ol034906w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol034906w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1Cgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=2865-2867&author=S.+M.+Capitostiauthor=T.+P.+Hansenauthor=M.+L.+Brown&title=Facile+synthesis+of+an+azido-labeled+thalidomide+analogue&doi=10.1021%2Fol034906w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Synthesis of an Azido-Labeled Thalidomide Analogue</span></div><div class="casAuthors">Capitosti, Scott M.; Hansen, Todd P.; Brown, Milton L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2865-2867</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A five-step synthesis of an azido-thalidomide analog I is presented.  The sequence requires cheap and readily available starting materials and reagents, and only two steps require purifn.  Addnl., I possesses activity comparable to that of thalidomide in inhibiting the proliferation of human microvascular endothelial cells, thus providing impetus for its use as a potential photoaffinity label of thalidomide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquqM8L-K7ZtrVg90H21EOLACvtfcHk0lglN8ACjr5u6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1Cgs70%253D&md5=fdefbdcf05d15f638e322bc9e5687ebb</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fol034906w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol034906w%26sid%3Dliteratum%253Aachs%26aulast%3DCapitosti%26aufirst%3DS.%2BM.%26aulast%3DHansen%26aufirst%3DT.%2BP.%26aulast%3DBrown%26aufirst%3DM.%2BL.%26atitle%3DFacile%2520synthesis%2520of%2520an%2520azido-labeled%2520thalidomide%2520analogue%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D2865%26epage%3D2867%26doi%3D10.1021%2Fol034906w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeir, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haemers, A.</span></span> <span> </span><span class="NLM_article-title">Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2411</span>– <span class="NLM_lpage">2413</span>, <span class="refDoi"> DOI: 10.1021/jm0499209</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0499209" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisl2it7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2411-2413&author=J.+Joossensauthor=P.+Van+der+Vekenauthor=A.-M.+Lambeirauthor=K.+Augustynsauthor=A.+Haemers&title=Development+of+irreversible+diphenyl+phosphonate+inhibitors+for+urokinase+plasminogen+activator&doi=10.1021%2Fjm0499209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Irreversible Diphenyl Phosphonate Inhibitors for Urokinase Plasminogen Activator</span></div><div class="casAuthors">Joossens, J.; Van der Veken, P.; Lambeir, A.-M.; Augustyns, K.; Haemers, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2411-2413</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report the synthesis and biochem. evaluation of selective, irreversible di-Ph phosphonate inhibitors for urokinase plasminogen activator (uPA).  A di-Ph phosphonate group was introduced on the substrate-like peptide Z-D-Ser-Ala-Arg, and modification of the guanidine side chain was investigated.  A guanylated benzyl group appeared the most promising side chain modification.  A kapp value in the 103 M-1 s-1 range for uPA was obtained, together with a selectivity index higher than 240 toward other trypsin-like proteases such as tPA, thrombin, plasmin, and FXa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreVabGd76ZqrVg90H21EOLACvtfcHk0liohn4Z59hqVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisl2it7k%253D&md5=a5e0eb9791dc09a1ac71b6cf8415af29</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm0499209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0499209%26sid%3Dliteratum%253Aachs%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DHaemers%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520irreversible%2520diphenyl%2520phosphonate%2520inhibitors%2520for%2520urokinase%2520plasminogen%2520activator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2411%26epage%3D2413%26doi%3D10.1021%2Fjm0499209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omodera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funakoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3307</span>– <span class="NLM_lpage">3319</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.12.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1016%2Fj.bmc.2005.12.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=16434202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFGjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=3307-3319&author=K.+Kanumaauthor=K.+Omoderaauthor=M.+Nishiguchiauthor=T.+Funakoshiauthor=S.+Chakiauthor=Y.+Nagaseauthor=I.+Iidaauthor=J.-i.+Yamaguchiauthor=G.+Sempleauthor=T.-A.+Tranauthor=Y.+Sekiguchi&title=Identification+of+4-amino-2-cyclohexylaminoquinazolines+as+metabolically+stable+melanin-concentrating+hormone+receptor+1+antagonists&doi=10.1016%2Fj.bmc.2005.12.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists</span></div><div class="casAuthors">Kanuma, Kosuke; Omodera, Katsunori; Nishiguchi, Mariko; Funakoshi, Takeo; Chaki, Shigeyuki; Nagase, Yasuko; Iida, Izumi; Yamaguchi, Jun-ichi; Semple, Graeme; Tran, Thuy-Anh; Sekiguchi, Yoshinori</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3307-3319</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of the distance between two key pharmacophore features within our first hit compds. led to the identification of a new class of potent non-peptidic antagonists for the MCH-R1, based around 4-amino-2-cyclohexylaminoquinazolines.  In particular, ATC0065, N 2-[cis-4-({2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl}amino)cyclohexyl]-N4,N4-dimethylquinazoline-2,4-diamine dihydrochloride, bound with high affinity to the MCH-R1 (IC50 value of 16 nM) and showed good metabolic stability in liver microsomes from human and rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5kEHF1eMMQrVg90H21EOLACvtfcHk0liohn4Z59hqVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFGjtb4%253D&md5=99bcc1d1e058b4c8e5baa2efcbae7447</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.12.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.12.052%26sid%3Dliteratum%253Aachs%26aulast%3DKanuma%26aufirst%3DK.%26aulast%3DOmodera%26aufirst%3DK.%26aulast%3DNishiguchi%26aufirst%3DM.%26aulast%3DFunakoshi%26aufirst%3DT.%26aulast%3DChaki%26aufirst%3DS.%26aulast%3DNagase%26aufirst%3DY.%26aulast%3DIida%26aufirst%3DI.%26aulast%3DYamaguchi%26aufirst%3DJ.-i.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DT.-A.%26aulast%3DSekiguchi%26aufirst%3DY.%26atitle%3DIdentification%2520of%25204-amino-2-cyclohexylaminoquinazolines%2520as%2520metabolically%2520stable%2520melanin-concentrating%2520hormone%2520receptor%25201%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D3307%26epage%3D3319%26doi%3D10.1016%2Fj.bmc.2005.12.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nouch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pàmies, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, W.</span></span> <span> </span><span class="NLM_article-title">Enantioselective synthesis of 6,6-disubstituted pentafulvenes containing a chiral pendant hydroxy group</span>. <i>Chem.—Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">17195</span>– <span class="NLM_lpage">17198</span>, <span class="refDoi"> DOI: 10.1002/chem.201704247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1002%2Fchem.201704247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=29083067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKmurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=17195-17198&author=R.+Nouchauthor=M.+Ciniauthor=M.+Magreauthor=M.+Abidauthor=M.+Di%C3%A9guezauthor=O.+P%C3%A0miesauthor=S.+Woodwardauthor=W.+Lewis&title=Enantioselective+synthesis+of+6%2C6-disubstituted+pentafulvenes+containing+a+chiral+pendant+hydroxy+group&doi=10.1002%2Fchem.201704247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Synthesis of 6,6-Disubstituted Pentafulvenes Containing a Chiral Pendant Hydroxy Group</span></div><div class="casAuthors">Nouch, Ryan; Cini, Melchior; Magre, Marc; Abid, Mohammed; Dieguez, Montserrat; Pamies, Oscar; Woodward, Simon; Lewis, William</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">68</span>),
    <span class="NLM_cas:pages">17195-17198</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Simple enantioselective synthesis of 6,6-disubstituted pentafulvenes bearing chiral pendant hydroxy groups are attained by cascade reactivity using com. available proline-based organocatalysts.  Condensation of cyclopentadiene with the acetyl function of a 1,2-formylacetophenone, followed by cyclization of a resulting fulvene-stabilized carbanion with the formyl group, generates bicyclic chiral alcs. with initial er values up to 94:6.  Exceptional enantio-enrichment of the resultant alcs. results upon crystn.-even near racemic samples spontaneously de-racemize.  This enables new families of substituted cyclopentadienes that are both enantiomerically and diastereomerically pure to be rapidly attained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_gTS4C30u6LVg90H21EOLACvtfcHk0liohn4Z59hqVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKmurjI&md5=ed815c390637d2d2ca7c6322180f583b</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fchem.201704247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201704247%26sid%3Dliteratum%253Aachs%26aulast%3DNouch%26aufirst%3DR.%26aulast%3DCini%26aufirst%3DM.%26aulast%3DMagre%26aufirst%3DM.%26aulast%3DAbid%26aufirst%3DM.%26aulast%3DDi%25C3%25A9guez%26aufirst%3DM.%26aulast%3DP%25C3%25A0mies%26aufirst%3DO.%26aulast%3DWoodward%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DW.%26atitle%3DEnantioselective%2520synthesis%2520of%25206%252C6-disubstituted%2520pentafulvenes%2520containing%2520a%2520chiral%2520pendant%2520hydroxy%2520group%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D17195%26epage%3D17198%26doi%3D10.1002%2Fchem.201704247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Tripodal tris-tacn and tris-dpa platforms for assembling phosphate-templated trimetallic centers</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">17366</span>– <span class="NLM_lpage">17369</span>, <span class="refDoi"> DOI: 10.1021/ja108212v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja108212v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGksbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=17366-17369&author=R.+Caoauthor=P.+M%C3%BCllerauthor=S.+J.+Lippard&title=Tripodal+tris-tacn+and+tris-dpa+platforms+for+assembling+phosphate-templated+trimetallic+centers&doi=10.1021%2Fja108212v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Tripodal Tris-tacn and Tris-dpa Platforms for Assembling Phosphate-Templated Trimetallic Centers</span></div><div class="casAuthors">Cao, Rui; Muller, Peter; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">17366-17369</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidentate tripodal ligands, N(CH2-m-C6H4-CH2tacn)3 (L1) and N(CH2-o-C6H4-CH2N(CH2py)2)3 (L2), were devised for assembling high-nuclearity metal clusters.  By using the same tripodal platform with different ligand appendages, either triazacyclononanes or dipicolylamines, and functionalizing either the ortho or the meta positions on the tris(xylyl) linker arms, discrete trimetal phosphate units of relevance to phosphate-metabolizing trimetallic centers in biol. were prepd.  Four such compds., [(CuIICl)3(HPO4)L1](PF6) (1), [(CuIICl)3(HAsO4)L1](PF6) (2), Na2[MnIII6MnII2(H2O)2(HPO4)6(PO4)4(L1)2] (3), and [CoII3(H2PO4)Cl2(MeCN)L2](PF6)3 (4), all contg. three metal centers bound to a central phosphate or arsenate unit bridging oxygen atoms, were synthesized and structurally characterized.  These results demonstrate the propensity of this novel tripodal ligand platform, in the presence of phosphate or arsenate, to assemble {M3(EO4)} units and thus structurally mimic trimetallic active sites of proteins involved in phosphate metab.  Reactivity studies reveal that the tricopper complex 1 is more efficient than monocopper analogs in catalyzing the hydrolysis of 4-nitrophenyl phosphate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNiyoN_nHxgLVg90H21EOLACvtfcHk0lhrFZLW1FecwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGksbzJ&md5=26ced8d2ad3686926092f1940b96a9cc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fja108212v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja108212v%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DTripodal%2520tris-tacn%2520and%2520tris-dpa%2520platforms%2520for%2520assembling%2520phosphate-templated%2520trimetallic%2520centers%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D17366%26epage%3D17369%26doi%3D10.1021%2Fja108212v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinebach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köpff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gütschow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span> <span> </span><span class="NLM_article-title">Homo-PROTACs for the chemical knockdown of cereblon</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2782</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFejsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2771-2782&author=C.+Steinebachauthor=S.+Lindnerauthor=N.+D.+Udeshiauthor=D.+C.+Maniauthor=H.+Kehmauthor=S.+K%C3%B6pffauthor=S.+A.+Carrauthor=M.+G%C3%BCtschowauthor=J.+Kr%C3%B6nke&title=Homo-PROTACs+for+the+chemical+knockdown+of+cereblon&doi=10.1021%2Facschembio.8b00693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Homo-PROTACs for the Chemical Knockdown of Cereblon</span></div><div class="casAuthors">Steinebach, Christian; Lindner, Stefanie; Udeshi, Namrata D.; Mani, Deepak C.; Kehm, Hannes; Koepff, Simon; Carr, Steven A.; Guetschow, Michael; Kroenke, Jan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2771-2782</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide, all approved for the treatment of multiple myeloma, induce targeted ubiquitination and degrdn. of Ikaros (IKZF1) and Aiolos (IKZF3) via the cereblon (CRBN) E3 ubiquitin ligase.  IMiD-based proteolysis-targeting chimeras (PROTACs) can efficiently recruit CRBN to a protein of interest, leading to its ubiquitination and proteasomal degrdn.  By linking two pomalidomide mols., we designed homobifunctional, so-called homo-PROTACs and investigated their ability to induce self-directed ubiquitination and degrdn.  The homodimerized compd. I was characterized as a highly potent and efficient CRBN degrader with only minimal effects on IKZF1 and IKZF3.  The cellular selectivity of I for CRBN degrdn. was confirmed at the proteome level by quant. mass spectrometry.  Inactivation by compd. I did not affect proliferation of different cell lines, prevented pomalidomide-induced degrdn. of IKZF1 and IKZF3, and antagonized the effects of pomalidomide on multiple myeloma cells.  Homobifunctional CRBN degraders will be useful tools for future biomedical investigations of CRBN-related signaling and may help to further elucidate the mol. mechanism of thalidomide analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosUoD-BkTUibVg90H21EOLACvtfcHk0lhrFZLW1FecwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFejsLrO&md5=71bf2d53ad23c2b873f754de5144883c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00693%26sid%3Dliteratum%253Aachs%26aulast%3DSteinebach%26aufirst%3DC.%26aulast%3DLindner%26aufirst%3DS.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DMani%26aufirst%3DD.%2BC.%26aulast%3DKehm%26aufirst%3DH.%26aulast%3DK%25C3%25B6pff%26aufirst%3DS.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26atitle%3DHomo-PROTACs%2520for%2520the%2520chemical%2520knockdown%2520of%2520cereblon%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D2771%26epage%3D2782%26doi%3D10.1021%2Facschembio.8b00693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boichenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bär, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez
Alvarez, B.</span></span> <span> </span><span class="NLM_article-title">A FRET-based assay for the identification and characterization of cereblon ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">770</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01735</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01735" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=770-774&author=I.+Boichenkoauthor=S.+Deissauthor=K.+B%C3%A4rauthor=M.+D.+Hartmannauthor=B.+Hernandez%0AAlvarez&title=A+FRET-based+assay+for+the+identification+and+characterization+of+cereblon+ligands&doi=10.1021%2Facs.jmedchem.5b01735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands</span></div><div class="casAuthors">Boichenko, Iuliia; Deiss, Silvia; Baer, Kerstin; Hartmann, Marcus D.; Hernandez Alvarez, Birte</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">770-774</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cereblon serves as an ubiquitin ligase substrate receptor that can be tuned toward different target proteins by various cereblon-binding agents.  This offers one of the most promising avenues for targeted protein degrdn. in cancer therapy, but cereblon binding can also mediate teratogenic effects.  We present an effective assay that is suited for high-throughput screening of compd. libraries for off-target cereblon interactions but also can guide lead optimization and rational design of novel cereblon effector mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzkRpBLlhlVbVg90H21EOLACvtfcHk0lhrFZLW1FecwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yktg%253D%253D&md5=f0400506428f439e81f579204e0bd39d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01735%26sid%3Dliteratum%253Aachs%26aulast%3DBoichenko%26aufirst%3DI.%26aulast%3DDeiss%26aufirst%3DS.%26aulast%3DB%25C3%25A4r%26aufirst%3DK.%26aulast%3DHartmann%26aufirst%3DM.%2BD.%26aulast%3DHernandez%2BAlvarez%26aufirst%3DB.%26atitle%3DA%2520FRET-based%2520assay%2520for%2520the%2520identification%2520and%2520characterization%2520of%2520cereblon%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D770%26epage%3D774%26doi%3D10.1021%2Facs.jmedchem.5b01735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">Xds</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/s0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=Xds&doi=10.1107%2Fs0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0lhrFZLW1FecwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXds%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2Fs0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplyakov, A.</span></span> <span> </span><span class="NLM_article-title">Molecular replacement with MOLREP</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1107/s0907444909042589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1107%2Fs0907444909042589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=20057045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=22-25&author=A.+Vaginauthor=A.+Teplyakov&title=Molecular+replacement+with+MOLREP&doi=10.1107%2Fs0907444909042589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular replacement with MOLREP</span></div><div class="casAuthors">Vagin, Alexei; Teplyakov, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-25</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MOLREP is an automated program for mol. replacement that utilizes a no. of original approaches to rotational and translational search and data prepn.  Since the first publication describing the program, MOLREP has acquired a variety of features that include weighting of the X-ray data and search models, multi-copy search, fitting the model into electron d., structural superposition of two models and rigid-body refinement.  The program can run in a fully automatic mode using optimized parameters calcd. from the input data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzj5SzYvyu_7Vg90H21EOLACvtfcHk0lhcZ0HkU-UVEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktw%253D%253D&md5=820d114719aca209994ffb0403e3b20d</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1107%2Fs0907444909042589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs0907444909042589%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DTeplyakov%26aufirst%3DA.%26atitle%3DMolecular%2520replacement%2520with%2520MOLREP%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D22%26epage%3D25%26doi%3D10.1107%2Fs0907444909042589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of <i>Coot</i></span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/s0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2Fs0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lhcZ0HkU-UVEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2Fs0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Schrodinger,
LLC</span>.  <i>The PyMOL Molecular Graphics
System</i>, Version 2.2.1.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schrodinger%2C%0ALLC.+The+PyMOL+Molecular+Graphics%0ASystem%2C+Version+2.2.1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%250ASystem" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 6 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Samuel Maiwald, Christopher Heim, Birte Hernandez Alvarez, <span class="NLM_string-name hlFld-ContribAuthor">Marcus D. Hartmann</span>. </span><span class="cited-content_cbyCitation_article-title">Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 74-81. <a href="https://doi.org/10.1021/acsmedchemlett.0c00440" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00440</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00440%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSweet%252Band%252BBlind%252BSpots%252Bin%252BE3%252BLigase%252BLigand%252BSpace%252BRevealed%252Bby%252Ba%252BThermophoresis-Based%252BAssay%26aulast%3DMaiwald%26aufirst%3DSamuel%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12082020%26date%3D25112020%26date%3D04122020%26volume%3D12%26issue%3D1%26spage%3D74%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhiwen  Qi</span>, <span class="hlFld-ContribAuthor ">Guliang  Yang</span>, <span class="hlFld-ContribAuthor ">Tao  Deng</span>, <span class="hlFld-ContribAuthor ">Jianmin  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Zhou</span>, <span class="hlFld-ContribAuthor ">Sergey A.  Popov</span>, <span class="hlFld-ContribAuthor ">Elvira E.  Shults</span>, <span class="hlFld-ContribAuthor ">Chengzhang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>111 </em>, 104901. <a href="https://doi.org/10.1016/j.bioorg.2021.104901" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104901</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104901%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Blinkage%252Boptimization%252Bof%252Bursane-thalidomide-based%252BPROTACs%252Band%252Bidentification%252Bof%252Btheir%252Btargeted-degradation%252Bproperties%252Bto%252BMDM2%252Bprotein%26aulast%3DQi%26aufirst%3DZhiwen%26date%3D2021%26volume%3D111%26spage%3D104901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shelton R.  Boyd</span>, <span class="hlFld-ContribAuthor ">Lyra  Chang</span>, <span class="hlFld-ContribAuthor ">Wanderson  Rezende</span>, <span class="hlFld-ContribAuthor ">Idris O.  Raji</span>, <span class="hlFld-ContribAuthor ">Prasanna  Kandel</span>, <span class="hlFld-ContribAuthor ">Secondra L.  Holmes</span>, <span class="hlFld-ContribAuthor ">Damian W.  Young</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Applications of Bifunctional Small Molecules in Biology. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics</span><span> <strong>2021,</strong> <em>1869 </em>
                                    (1)
                                     , 140534. <a href="https://doi.org/10.1016/j.bbapap.2020.140534" title="DOI URL">https://doi.org/10.1016/j.bbapap.2020.140534</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbapap.2020.140534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbapap.2020.140534%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Proteins%2520and%2520Proteomics%26atitle%3DDesign%252Band%252BApplications%252Bof%252BBifunctional%252BSmall%252BMolecules%252Bin%252BBiology%26aulast%3DBoyd%26aufirst%3DShelton%2BR.%26date%3D2021%26volume%3D1869%26issue%3D1%26spage%3D140534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher  Heim</span>, <span class="hlFld-ContribAuthor ">Samuel  Maiwald</span>, <span class="hlFld-ContribAuthor ">Christian  Steinebach</span>, <span class="hlFld-ContribAuthor ">Matthew K.  Collins</span>, <span class="hlFld-ContribAuthor ">Jonathan  Strope</span>, <span class="hlFld-ContribAuthor ">Cindy H.  Chau</span>, <span class="hlFld-ContribAuthor ">William D.  Figg</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">Marcus D.  Hartmann</span>. </span><span class="cited-content_cbyCitation_article-title">On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2021,</strong> <em>534 </em>, 67-72. <a href="https://doi.org/10.1016/j.bbrc.2020.11.117" title="DOI URL">https://doi.org/10.1016/j.bbrc.2020.11.117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2020.11.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2020.11.117%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DOn%252Bthe%252Bcorrelation%252Bof%252Bcereblon%252Bbinding%25252C%252Bfluorination%252Band%252Bantiangiogenic%252Bproperties%252Bof%252Bimmunomodulatory%252Bdrugs%26aulast%3DHeim%26aufirst%3DChristopher%26date%3D2021%26volume%3D534%26spage%3D67%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taku  Shoji</span>, <span class="hlFld-ContribAuthor ">Nanami  Iida</span>, <span class="hlFld-ContribAuthor ">Akari  Yamazaki</span>, <span class="hlFld-ContribAuthor ">Yukino  Ariga</span>, <span class="hlFld-ContribAuthor ">Akira  Ohta</span>, <span class="hlFld-ContribAuthor ">Ryuta  Sekiguchi</span>, <span class="hlFld-ContribAuthor ">Tatsuki  Nagahata</span>, <span class="hlFld-ContribAuthor ">Takuya  Nagasawa</span>, <span class="hlFld-ContribAuthor ">Shunji  Ito</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of phthalimides cross-conjugated with an azulene ring, and their structural, optical and electrochemical properties. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (12)
                                     , 2274-2282. <a href="https://doi.org/10.1039/D0OB00164C" title="DOI URL">https://doi.org/10.1039/D0OB00164C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00164C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00164C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bphthalimides%252Bcross-conjugated%252Bwith%252Ban%252Bazulene%252Bring%25252C%252Band%252Btheir%252Bstructural%25252C%252Boptical%252Band%252Belectrochemical%252Bproperties%26aulast%3DShoji%26aufirst%3DTaku%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D12%26spage%3D2274%26epage%3D2282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Zhou</span>, <span class="hlFld-ContribAuthor ">Wenming  Chen</span>, <span class="hlFld-ContribAuthor ">Chenyang  Cao</span>, <span class="hlFld-ContribAuthor ">Yonghui  Shi</span>, <span class="hlFld-ContribAuthor ">Wenchong  Ye</span>, <span class="hlFld-ContribAuthor ">Jiliang  Hu</span>, <span class="hlFld-ContribAuthor ">LingLi  Wang</span>, <span class="hlFld-ContribAuthor ">Wen  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>189 </em>, 112028. <a href="https://doi.org/10.1016/j.ejmech.2019.112028" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.112028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.112028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.112028%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B%2525CE%2525B1-naphthoflavone%252Bchimera%252Bderivatives%252Bable%252Bto%252Beliminate%252Bcytochrome%252BP450%252B%252528CYP%2525291B1-mediated%252Bdrug%252Bresistance%252Bvia%252Btargeted%252BCYP1B1%252Bdegradation%26aulast%3DZhou%26aufirst%3DLi%26date%3D2020%26volume%3D189%26spage%3D112028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of thalidomide, lenalidomide, pomalidomide, avadomide, and iberdomide with their glutarimide moiety shown in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. The first panel of chemical structures, five- and six-ring based thalidomide analogues and their affinity to MsCI4 determined as <i>K</i><sub>i</sub> values in the FRET assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CDI, 4-DMAP, THF, reflux, 17–48 h; (b) TFA, RT, 30 min; (c) CDI, 4-DMAP, THF, reflux, 5–20 h; and (d) 10 wt % Pd/C, EtOAc, RT, 20 h.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overview of the thalidomide-binding mode and electron densities of thalidomide analogues and their hydrolysis products bound to MsCI4. Left: Cartoon representation of thalidomide-bound MsCI4 with key residues of the binding pocket shown as sticks. Right: F<sub>O</sub>–F<sub>C</sub> maps of CBG (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0Q">6R0Q</a>), <b>4a</b> and hydrolyzed <b>4a</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0S">6R0S</a>), hydrolyzed <b>4b</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0V">6R0V</a>), <b>5a</b>, and hydrolyzed <b>5a</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0U">6R0U</a>) and <b>5b</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R11">6R11</a>) in the MsCI4-binding pocket, contoured at 2σ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding mode of the initial compounds and their hydrolysis products inside the binding pocket. Thalidomide, <b>4a</b>, and <b>5a</b> are shown with their respective hydrolysis products. Ring opening of the phtaloyl moiety that leads to the observed hydrolysis product is indicated in red in the chemical drawings. <b>5b</b> was exclusively found in the nonhydrolyzed form, whereas <b>4b</b> was exclusively found as a hydrolysis product. PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V2Y">4V2Y</a> (thalidomide), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0Q">6R0Q</a> (<b>CBG</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0S">6R0S</a> (<b>4a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0U">6R0U</a> (<b>5a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R11">6R11</a> (<b>5b</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0V">6R0V</a> (<b>4b</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CDI, 4-DMAP, THF, reflux, 48 h; (b) TFA, RT, 30 min; (c) <b>6a–h</b>, DIPEA, THF, 0 <sup>o</sup>C to reflux, and 2 h.</p></p></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compounds inspired by hydrolysis products of thalidomide analogues and their affinity data. (A) Second panel of compounds, based on the 3-amidosuccinimide scaffold. (B) Third panel of compounds, inspired by <b>7d</b>. * <b>20a</b> could not be purified to satisfactory levels for affinity testing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binding modes of compounds from the second and third panel. (A) Superposition of all compounds bound to MsCI4. (B) Detailed side and top view of bound effectors based on the 3-amidosuccinimide scaffold: <b>7a</b> (yellow, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1X">6R1X</a>), <b>7b</b> (sand, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R12">6R12</a>), <b>7c</b> (pink, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1K">6R1K</a>), <b>7d</b> (green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1D">6R1D</a>), <b>7f</b> (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R13">6R13</a>), and the water soluble <b>11a</b> (cyan, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R18">6R18</a>), and <b>12a</b> (light blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1C">6R1C</a>), indicating interactions with N50. (C) Side and top view of compounds based on 3-amidoglutarimide, <b>16b</b> (brown, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1W">6R1W</a>) and <b>20b</b> (dark green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1A">6R1A</a>). Although the depicted instances for this scaffold do not show the interaction with N50, this interaction was observed in one other instance for <b>16b</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Phosgene solution 15 wt % in toluene, THF, 0 <sup>o</sup>C to RT, 20 h; (b) <b>3a</b> or <b>3b</b>, DIPEA, THF, 0 <sup>o</sup>C to reflux, 20 h; (c) TFA, DCM, 0 <sup>o</sup>C to RT, 2 h; (d) Et<sub>3</sub>N, DMF, 0 <sup>o</sup>C to RT, 20 h. Note that <b>13</b> and thereby also <b>14–16</b> are in cis conformation.</p></p></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. F<sub>O</sub>–F<sub>C</sub> maps of bound compounds shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. All compounds are clearly defined by their electron density maps with the exception of the prolonged extension in <b>12a</b>. Crystallographic structures were refined to resolutions between 1.1 and 1.8 Å, and the maps are contoured at 2σ. PDB accession codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1X">6R1X</a> (<b>7a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R12">6R12</a> (<b>7b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1K">6R1K</a> (<b>7c</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1D">6R1D</a> (<b>7d</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R13">6R13</a> (<b>7f</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R18">6R18</a> (<b>11a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1C">6R1C</a> (<b>12a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1W">6R1W</a> (<b>16b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R19">6R19</a> (<b>20a</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1A">6R1A</a> (<b>20b</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/medium/jm-2019-00454a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound-mediated IKFZ3 degradation in OPM-2 cells. (A) Immunoblot analysis of IKZF3 levels after treatment with compounds <b>7d</b>, <b>5a</b>, and <b>7f</b> (100 μM) for 24 h, compared to DMSO (control) and lenalidomide (20 μM) (<i>n</i> = 3). Lenalidomide at 100 μM reduced IKFZ3 levels effectively by 100% (not shown). (B) Averaged IKZF3 levels from the three independent experiments, normalized against total protein loading control (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_001.pdf" class="ext-link">Figure S2</a>). The significance of the data was tested comparing IKZF3 levels in the presence of the compounds and DMSO (<i>p</i> > 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-14/acs.jmedchem.9b00454/20190719/images/large/jm-2019-00454a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00454&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i54">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80655" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80655" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 60 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somers, G. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug</span>. <i>Br. J. Pharmacol. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1960</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1960.tb01217.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1111%2Fj.1476-5381.1960.tb01217.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=13832739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADyaF3cXht1ShtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1960&pages=111-116&author=G.+F.+Somers&title=Pharmacological+properties+of+thalidomide+%28alpha-phthalimido+glutarimide%29%2C+a+new+sedative+hypnotic+drug&doi=10.1111%2Fj.1476-5381.1960.tb01217.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological properties of thalidomide (α-phthalimidoglutarimide), a new sedative hypnotic drug</span></div><div class="casAuthors">Somers, G. F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology and Chemotherapy</span>
        (<span class="NLM_cas:date">1960</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-16</span>CODEN:
                <span class="NLM_cas:coden">BJPCAL</span>;
        ISSN:<span class="NLM_cas:issn">0366-0826</span>.
    </div><div class="casAbstract">This new non-toxic non-barbiturate sedative was assayed on male albino rats, mice, rabbits, cats, and guinea pigs for toxicity, effect on motor activity, reflexes, narcosis, analgesis, antipyresis, autonomic system, and gastrointestinal tract.  It was virtually nontoxic, and had no effect on these systems, possibly because of limited absorption.  It potentiated barbiturates, alc., reserpine, chlorpromazine, and counteracted methylamphetamine and methylphenidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1CQ0N3hCBGLVg90H21EOLACvtfcHk0lg3GoZ-RDvYHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXht1ShtLc%253D&md5=4d82cdf61a96c7f74e79fb343f40bafd</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1960.tb01217.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1960.tb01217.x%26sid%3Dliteratum%253Aachs%26aulast%3DSomers%26aufirst%3DG.%2BF.%26atitle%3DPharmacological%2520properties%2520of%2520thalidomide%2520%2528alpha-phthalimido%2520glutarimide%2529%252C%2520a%2520new%2520sedative%2520hypnotic%2520drug%26jtitle%3DBr.%2520J.%2520Pharmacol.%2520Chemother.%26date%3D1960%26volume%3D15%26spage%3D111%26epage%3D116%26doi%3D10.1111%2Fj.1476-5381.1960.tb01217.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, W.</span></span> <span> </span><span class="NLM_article-title">A short history of thalidomide embryopathy</span>. <i>Teratology</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1002/tera.1420380303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1002%2Ftera.1420380303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=3067415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADyaL1M7ks1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1988&pages=203-215&author=W.+Lenz&title=A+short+history+of+thalidomide+embryopathy&doi=10.1002%2Ftera.1420380303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A short history of thalidomide embryopathy</span></div><div class="casAuthors">Lenz W</div><div class="citationInfo"><span class="NLM_cas:title">Teratology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-15</span>
        ISSN:<span class="NLM_cas:issn">0040-3709</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR4u0Tv59TImfxQvRxYU81tfW6udTcc2eaIge6HEN98Frntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1M7ks1Kluw%253D%253D&md5=65dd1712af76e247727c4cf7f528ae51</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Ftera.1420380303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Ftera.1420380303%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DW.%26atitle%3DA%2520short%2520history%2520of%2520thalidomide%2520embryopathy%26jtitle%3DTeratology%26date%3D1988%26volume%3D38%26spage%3D203%26epage%3D215%26doi%3D10.1002%2Ftera.1420380303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vargesson, N.</span></span> <span> </span><span class="NLM_article-title">Thalidomide-induced limb defects: resolving a 50-year-old puzzle</span>. <i>Bioessays</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1336</span>, <span class="refDoi"> DOI: 10.1002/bies.200900103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1002%2Fbies.200900103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=19921660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisVamuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2009&pages=1327-1336&author=N.+Vargesson&title=Thalidomide-induced+limb+defects%3A+resolving+a+50-year-old+puzzle&doi=10.1002%2Fbies.200900103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide-induced limb defects: resolving a 50-year-old puzzle</span></div><div class="casAuthors">Vargesson, Neil</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1327-1336</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Despite the recent discovery that thalidomide causes limb defects by targeting highly angiogenic, immature blood vessels, several challenges still remain and new ones have arisen.  These include understanding the drug's species specificity, detg. mol. target(s) in the endothelial cell, shedding light on the mol. basis of phocomelia and producing a form of the drug that is clin. effective without having side effects.  Now that the trigger of thalidomide-induced teratogenesis has been uncovered, a framework is proposed, incorporating and uniting previous models of thalidomide action, explaining how thalidomide causes not just limb defects, but also all the other defects it induces.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiL3Rixd9UzrVg90H21EOLACvtfcHk0lgYEPcxD58VIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisVamuw%253D%253D&md5=ca4738ec2192397e2b61142a3eda4f3e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fbies.200900103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.200900103%26sid%3Dliteratum%253Aachs%26aulast%3DVargesson%26aufirst%3DN.%26atitle%3DThalidomide-induced%2520limb%2520defects%253A%2520resolving%2520a%252050-year-old%2520puzzle%26jtitle%3DBioessays%26date%3D2009%26volume%3D31%26spage%3D1327%26epage%3D1336%26doi%3D10.1002%2Fbies.200900103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdalla, S. H.</span></span> <span> </span><span class="NLM_article-title">Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1080/10428190290006143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1080%2F10428190290006143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=11999568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVaqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=351-354&author=R.+E.+Johnstonauthor=S.+H.+Abdalla&title=Thalidomide+in+low+doses+is+effective+for+the+treatment+of+resistant+or+relapsed+multiple+myeloma+and+for+plasma+cell+leukaemia&doi=10.1080%2F10428190290006143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukemia</span></div><div class="casAuthors">Johnston, R. E.; Abdalla, S. H.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">351-354</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Thalidomide is an effective treatment for relapsed multiple myeloma (MM), but is assocd. with a significant side effect profile at higher doses.  In a recent study, only half of the enrolled patients were able to tolerate the max. dose of 800 mg/day [Singhal, S., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", New Engl. J. Med. 341, 1565-1571].  Moreover, the dose-response relationship has not been defined.  We report our use of low dose thalidomide in a small cohort of 12 patients-eight with relapsed or refractory MM and four with plasma cell leukemia (PCL).  Five of the 12 (42%) patients had a partial response, showing a median fall in their PP/BJP of 80% (63-90%) at a median dose of 175 mg (100-300 mg) with negligible side effects.  Three of four patients with PCL showed an impressive response to treatment with thalidomide as a single agent.  No patient who failed to show any evidence of response at low dose (<150 mg/day) responded to higher doses.  In this study, thalidomide induces a similar rate of response at a lower and better tolerated dose than previously reported and produced "best ever" responses in patients with resistant PCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbWYLn9ADiirVg90H21EOLACvtfcHk0lgYEPcxD58VIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVaqs74%253D&md5=fefa82138697984cbc04d8738cfb8bf9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1080%2F10428190290006143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190290006143%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DR.%2BE.%26aulast%3DAbdalla%26aufirst%3DS.%2BH.%26atitle%3DThalidomide%2520in%2520low%2520doses%2520is%2520effective%2520for%2520the%2520treatment%2520of%2520resistant%2520or%2520relapsed%2520multiple%2520myeloma%2520and%2520for%2520plasma%2520cell%2520leukaemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2002%26volume%3D43%26spage%3D351%26epage%3D354%26doi%3D10.1080%2F10428190290006143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span> </span><span class="NLM_article-title">US Thalomid Label</span>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020785s061lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020785s061lbl.pdf</a> (accessed Dec 9, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=US+Thalomid+Label.+https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F020785s061lbl.pdf+%28accessed+Dec+9%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DUS%2520Thalomid%2520Label%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertolini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mingrone, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alietti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrucci, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocorocchio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peccatori, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cineri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corsini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span> <span> </span><span class="NLM_article-title">Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">990</span>, <span class="refDoi"> DOI: 10.1023/a:1011141009812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1023%2Fa%3A1011141009812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=11521807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADC%252BD3MvnvVehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=987-990&author=F.+Bertoliniauthor=W.+Mingroneauthor=A.+Aliettiauthor=P.+F.+Ferrucciauthor=E.+Cocorocchioauthor=F.+Peccatoriauthor=S.+Cineriauthor=P.+Mancusoauthor=C.+Corsiniauthor=A.+Burliniauthor=E.+Zuccaauthor=G.+Martinelli&title=Thalidomide+in+multiple+myeloma%2C+myelodysplastic+syndromes+and+histiocytosis.+Analysis+of+clinical+results+and+of+surrogate+angiogenesis+markers&doi=10.1023%2Fa%3A1011141009812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers</span></div><div class="casAuthors">Bertolini F; Mingrone W; Alietti A; Ferrucci P F; Cocorocchio E; Peccatori F; Cinieri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G; Cineri S</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">987-90</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  Thalidomide, as a single agent, has been recently found to induce a clinical response in one third of refractory or relapsed myeloma patients.  Although it has been reported that thalidomide significantly inhibits angiogenesis. it is still unclear whether its clinical effect is mediated, at least in part, by its anti-angiogenic properties.  PATIENTS AND METHODS:  We evaluated thalidomide as a single agent in myeloma, myelodysplastic syndromes (MDS) and histiocytosis, i.e. hematological diseases characterized by increased angiogenesis, and measured prospectively a number of surrogate angiogenesis markers.  RESULTS:  Clinical responses were observed in 7 of 17 myeloma and 2 of 5 MDS patients.  The histiocytosis patient had a partial response.  At the time of the best clinical response, plasma levels of angiogenic growth factors, vascular endothelial growth factor (VEGF) and basic-fibroblast growth factor (b-FGF), were significantly decreased, and flow cytometry indicated a decrease of activated endothelial cells in the bone marrow of responding MDS patients.  CONCLUSIONS:  These observations confirm thalidomide efficacy in myeloma, suggest a possible use in MDS and histiocytosis and may contribute to the prediction of clinical response and to understanding the mechanism of thalidomide's action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMwvoem2ZMpYvKgEt20y1XfW6udTcc2eYV2TMlW31T7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvnvVehuw%253D%253D&md5=19268541729e2a5d8762802d62ae882c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1023%2Fa%3A1011141009812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252Fa%253A1011141009812%26sid%3Dliteratum%253Aachs%26aulast%3DBertolini%26aufirst%3DF.%26aulast%3DMingrone%26aufirst%3DW.%26aulast%3DAlietti%26aufirst%3DA.%26aulast%3DFerrucci%26aufirst%3DP.%2BF.%26aulast%3DCocorocchio%26aufirst%3DE.%26aulast%3DPeccatori%26aufirst%3DF.%26aulast%3DCineri%26aufirst%3DS.%26aulast%3DMancuso%26aufirst%3DP.%26aulast%3DCorsini%26aufirst%3DC.%26aulast%3DBurlini%26aufirst%3DA.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DMartinelli%26aufirst%3DG.%26atitle%3DThalidomide%2520in%2520multiple%2520myeloma%252C%2520myelodysplastic%2520syndromes%2520and%2520histiocytosis.%2520Analysis%2520of%2520clinical%2520results%2520and%2520of%2520surrogate%2520angiogenesis%2520markers%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26spage%3D987%26epage%3D990%26doi%3D10.1023%2Fa%3A1011141009812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kale, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">List, A.</span></span> <span> </span><span class="NLM_article-title">Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes</span>. <i>Curr. Pharm. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.2174/138920106778521587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.2174%2F138920106778521587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=17076650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVamsLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=339-342&author=V.+Kaleauthor=A.+List&title=Immunomodulatory+drugs+%28IMiDs%29%3A+a+new+treatment+option+for+myelodysplastic+syndromes&doi=10.2174%2F138920106778521587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes</span></div><div class="casAuthors">Kale, Vishakha; List, Alan F.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Biotechnology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">339-342</span>CODEN:
                <span class="NLM_cas:coden">CPBUBP</span>;
        ISSN:<span class="NLM_cas:issn">1389-2010</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The IMiDs represent a new proprietary class of thalidomide analogs that possess greater potency and less toxicity than the parent compd.  As a group, these agents share the pharmacol. property of modulating cellular response to ligand activation, the precise biol. effect of which is cell lineage and stimulant-dependent.  Lenalidomide (CC-5013; Revlimid), a second generation IMiD, has shown significant erythropoietic activity in patients with lower risk MDS that have failed or are not candidates for recombinant erythropoietin treatment.  Unlike cytokine therapy, lenalidomide suppresses select MDS clones and enhances erythropoietin receptor signaling to restore erythropoiesis.  Activity is greatest in patients with interstitial deletions involving chromosome 5q31.1.  A multicenter phase II study reported a 76% overall transfusion response rate in transfusion-dependent patients with deletion 5q, with 67% achieving transfusion independence after a median interval of 4.6 wk of treatment.  Cytogenetic responses were obsd. in 73% of patients with complete cytogenetic remission in 45% patients.  Both transfusion response and cytogenetic response frequency were independent of karyotype complexity, raising excitement that this new treatment strategy might favorably alter the natural history of disease in higher risk patients with deletion 5q.  Lenalidomide was approved by the U.S. Food and Drug Administration on Dec. 27, 2005, for the treatment of IPSS Low and intermediate-1 risk MDS patients with del(5q) abnormality.  A phase III Intergroup trial (ECOG 2905) will test the capacity to potentiate erythropoietin response by comparing response to lenalidomide monotherapy to the combination of darbepoetin and lenalidomide in non-deletion 5q MDS patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtP_aXebs15rVg90H21EOLACvtfcHk0lg8rmoz4vRX5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVamsLrN&md5=e1597e6b7cf4543228046753231f2348</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F138920106778521587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920106778521587%26sid%3Dliteratum%253Aachs%26aulast%3DKale%26aufirst%3DV.%26aulast%3DList%26aufirst%3DA.%26atitle%3DImmunomodulatory%2520drugs%2520%2528IMiDs%2529%253A%2520a%2520new%2520treatment%2520option%2520for%2520myelodysplastic%2520syndromes%26jtitle%3DCurr.%2520Pharm.%2520Biotechnol.%26date%3D2006%26volume%3D7%26spage%3D339%26epage%3D342%26doi%3D10.2174%2F138920106778521587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, G.</span></span> <span> </span><span class="NLM_article-title">Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin’s lymphoma: A prospective study of 46 cases</span>. <i>Mol. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">695</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.3892/mco.2014.307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.3892%2Fmco.2014.307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25054032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADC%252BC2sbpvFKgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=695-700&author=H.+Wuauthor=C.+Zhaoauthor=K.+Guauthor=Y.+Jiaoauthor=J.+Haoauthor=G.+Sun&title=Thalidomide+plus+chemotherapy+exhibit+enhanced+efficacy+in+the+clinical+treatment+of+T-cell+non-Hodgkin%E2%80%99s+lymphoma%3A+A+prospective+study+of+46+cases&doi=10.3892%2Fmco.2014.307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin's lymphoma: A prospective study of 46 cases</span></div><div class="casAuthors">Wu Hongyang; Zhao Chenchen; Gu Kangsheng; Jiao Yang; Hao Jiqing; Sun Guoping</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and clinical oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">695-700</span>
        ISSN:<span class="NLM_cas:issn">2049-9450</span>.
    </div><div class="casAbstract">The treatment of T-cell non-Hodgkin's lymphoma (T-NHL) remains challenging.  There is currently no standard regimen for the treatment of T-NHL in the first- or second-line setting.  Thalidomide was previously shown to exert antitumor effects through inhibiting angiogenesis, promoting apoptosis and immunomodulatory activity.  However, all the previous studies on the treatment of lymphoma with thalidomide included patient samples of limited size.  In the present study, 46 cases of eligible T-NHL patients were randomized into i) the control group (conventional combined chemotherapy, n=22) and ii) the thalidomide group (thalidomide plus combined chemotherapy, n=24).  The median dose of thalidomide was 200 mg (range, 150-400 mg) every night, without reported severe side effects.  The clinical response to treatment was as follows: Complete response (CR) in 12 cases, partial response (PR) in 7, stable disease (SD) in 1 and progressive disease (PD) in 4 cases in the thalidomide group; and CR in 8 cases, PR in 6, SD in 3 and PD in 5 cases in the control group.  The CR rate was 50.0 and 36.4% in the thalidomide and the control groups, respectively (P<0.05).  The median progression-free and overall survival were 12 and undefined months, respectively, in the thalidomide group and 6 and 17 months, respectively, in the control group.  The toxicity profile was considered acceptable in both groups.  Our results indicated that thalidomide plus combined chemotherapy may exhibit enhanced efficacy in the clinical treatment of T-NHL.  In addition, this type of treatment may reduce the frequency of adverse gastrointestinal reactions and help alleviate fear of chemotherapy.  Therefore, thalidomide plus combined chemotherapy may be a viable option for the clinical treatment of T-NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTb-wRHuM3ThRjv2lLSLOxFfW6udTcc2eaioy_NbgjUlbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbpvFKgtA%253D%253D&md5=f173c9f716db0820c32424792125ff88</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3892%2Fmco.2014.307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmco.2014.307%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DK.%26aulast%3DJiao%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DG.%26atitle%3DThalidomide%2520plus%2520chemotherapy%2520exhibit%2520enhanced%2520efficacy%2520in%2520the%2520clinical%2520treatment%2520of%2520T-cell%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%253A%2520A%2520prospective%2520study%2520of%252046%2520cases%26jtitle%3DMol.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D2%26spage%3D695%26epage%3D700%26doi%3D10.3892%2Fmco.2014.307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">García-Sanz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-López, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vázquez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermida, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graciani, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, J. F.</span></span> <span> </span><span class="NLM_article-title">The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin’s lymphoma</span>. <i>Eur. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0609.2009.01375.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1111%2Fj.1600-0609.2009.01375.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=19912314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtlGmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=266-270&author=R.+Garc%C3%ADa-Sanzauthor=T.+J.+Gonz%C3%A1lez-L%C3%B3pezauthor=L.+V%C3%A1zquezauthor=G.+Hermidaauthor=I.+F.+Gracianiauthor=J.+F.+San+Miguel&title=The+combination+of+thalidomide%2C+cyclophosphamide+and+dexamethasone+is+potentially+useful+in+highly+resistant+Hodgkin%E2%80%99s+lymphoma&doi=10.1111%2Fj.1600-0609.2009.01375.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma</span></div><div class="casAuthors">Garcia-Sanz, R.; Gonzalez-Lopez, T. J.; Vazquez, L.; Hermida, G.; Graciani, I. F.; San Miguel, J. F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">266-270</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Few diseases have a prognosis worse than Hodgkin's lymphoma (HL), patients relapsing after autologous or allogeneic stem cell transplantation.  Here, we report two highly refractory patients with HL who successfully responded to a combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex).  Despite the use of a very large no. of different drugs (>5 different schemes) including high-dose therapy and autologous and allogeneic stem cell transplantation, both patients proved to be suffering from a highly resistant disease.  Fortunately, they finally responded to the ThaCyDex combination, achieving sustained complete remission that would support the running of a trial within this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD5zryHnpzqLVg90H21EOLACvtfcHk0lj2DNAH2x8EDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtlGmtL0%253D&md5=11de756fa308a935acb76c8870c33110</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0609.2009.01375.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0609.2009.01375.x%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Sanz%26aufirst%3DR.%26aulast%3DGonz%25C3%25A1lez-L%25C3%25B3pez%26aufirst%3DT.%2BJ.%26aulast%3DV%25C3%25A1zquez%26aufirst%3DL.%26aulast%3DHermida%26aufirst%3DG.%26aulast%3DGraciani%26aufirst%3DI.%2BF.%26aulast%3DSan%2BMiguel%26aufirst%3DJ.%2BF.%26atitle%3DThe%2520combination%2520of%2520thalidomide%252C%2520cyclophosphamide%2520and%2520dexamethasone%2520is%2520potentially%2520useful%2520in%2520highly%2520resistant%2520Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2010%26volume%3D84%26spage%3D266%26epage%3D270%26doi%3D10.1111%2Fj.1600-0609.2009.01375.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzarella, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCrae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crump, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, A.</span></span> <span> </span><span class="NLM_article-title">A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin’s lymphoma</span>. <i>Hematology</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1080/10245330500276592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1080%2F10245330500276592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=16522545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVOhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2006&pages=25-29&author=J.+Kuruvillaauthor=K.+Songauthor=P.+Molleeauthor=T.+Panzarellaauthor=J.+McCraeauthor=T.+Nagyauthor=M.+Crumpauthor=A.+Keating&title=A+phase+II+study+of+thalidomide+and+vinblastine+for+palliative+patients+with+Hodgkin%E2%80%99s+lymphoma&doi=10.1080%2F10245330500276592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma</span></div><div class="casAuthors">Kuruvilla, John; Song, Kevin; Mollee, Peter; Panzarella, Tony; McCrae, Jan; Nagy, Tracy; Crump, Michael; Keating, Armand</div><div class="citationInfo"><span class="NLM_cas:title">Hematology (Abingdon, United Kingdom)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-29</span>CODEN:
                <span class="NLM_cas:coden">HMATFL</span>;
        ISSN:<span class="NLM_cas:issn">1024-5332</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Patients with Hodgkin's Lymphoma (HL) who relapse or progress after primary therapy and subsequent high dose chemotherapy with autologous stem cell transplantation (ASCT) cannot be cured with conventional treatment.  We combined thalidomide (THAL), an agent with anti-angiogenic and immunomodulatory properties, with vinblastine, which is active after ASCT, to det. the objective response rate, improvement in B symptoms and toxicity in patients with refractory HD.  Methods: Patients were eligible if they HD that progressed after chemotherapy and ASCT or had declined or were ineligible for curative therapy.  Treatment consisted of THAL 200 mg orally given daily.  After 2 wk, VBL 6 mg IV was given weekly × 6 doses on an eight-week cycle.  Response and toxicity assessment occurred following each cycle. Results: Eleven patients were enrolled, 1 progressed within 6 days of study enrollment and was subsequently treated with alternative palliative therapy and thus 11 patients are response evaluable and 10 are evaluable for toxicity.  Patient characteristics: relapsed after ASCT: 7; median no. of prior chemotherapy regimens: 3 (range 1-5); median time to progression post-ASCT: 7 mo (range 2-29).  Four patients had a partial response to treatment (response rate 36%); two patients had stable disease.  B symptoms were present at enrollment in four patients and resolved completely on treatment in two patients.  Five had disease progression within 3 mo of starting treatment.  The median duration of response was 9 mo (range 0-22 mo).  Toxicity was mild and limited to grade 2 neuropathy in 6 patients and grade 2 or 3 neutropenia in 4 patients.  Conclusions: In this small study in chemotherapy- refractory HL, THAL and VBL demonstrated encouraging activity with some durable responses and acceptable toxicity.  These results suggest that chronic low dose chemotherapy combined with less toxic immunomodulatory or anti-angiogenic drugs warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUGJwJvjl5v7Vg90H21EOLACvtfcHk0lj2DNAH2x8EDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVOhu74%253D&md5=7e23a9439d19a069125052db1c1c64b7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F10245330500276592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10245330500276592%26sid%3Dliteratum%253Aachs%26aulast%3DKuruvilla%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DMollee%26aufirst%3DP.%26aulast%3DPanzarella%26aufirst%3DT.%26aulast%3DMcCrae%26aufirst%3DJ.%26aulast%3DNagy%26aufirst%3DT.%26aulast%3DCrump%26aufirst%3DM.%26aulast%3DKeating%26aufirst%3DA.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520thalidomide%2520and%2520vinblastine%2520for%2520palliative%2520patients%2520with%2520Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DHematology%26date%3D2006%26volume%3D11%26spage%3D25%26epage%3D29%26doi%3D10.1080%2F10245330500276592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seldin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choufani, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dember, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesman, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berk, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falk, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fennessey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchorawala, V.</span></span> <span> </span><span class="NLM_article-title">Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis</span>. <i>Clin. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.3816/clm.2003.n.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.3816%2Fclm.2003.n.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=12672274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtVSjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=241-246&author=D.+C.+Seldinauthor=E.+B.+Choufaniauthor=L.+M.+Demberauthor=J.+F.+Wiesmanauthor=J.+L.+Berkauthor=R.+H.+Falkauthor=C.+O%E2%80%99Haraauthor=S.+Fennesseyauthor=K.+T.+Finnauthor=D.+G.+Wrightauthor=M.+Skinnerauthor=V.+Sanchorawala&title=Tolerability+and+efficacy+of+thalidomide+for+the+treatment+of+patients+with+light+chain-associated+%28AL%29+amyloidosis&doi=10.3816%2Fclm.2003.n.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Tolerability and efficacy of thalidomide for the treatment of patients with light-chain-associated (AL) amyloidosis</span></div><div class="casAuthors">Seldin, David C.; Choufani, Elie B.; Dember, Laura M.; Wiesman, Janice F.; Berk, John L.; Falk, Rodney H.; O'Hara, Carl; Fennessey, Salli; Finn, Kathleen T.; Wright, Daniel G.; Skinner, Martha; Sanchorawala, Vaishali</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lymphoma</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">241-246</span>CODEN:
                <span class="NLM_cas:coden">CLLYAO</span>;
        ISSN:<span class="NLM_cas:issn">1526-9655</span>.
    
            (<span class="NLM_cas:orgname">Cancer Information Group</span>)
        </div><div class="casAbstract">A phase I/II trial was carried out with patients with AL amyloidosis, most of whom had failed prior therapy with high-dose melphalan and autologous stem cell transplantation.  This trial was designed as an individualized 6-mo dose-escalation study with re-evaluation of bone marrow plasmacytosis and serum and urine monoclonal proteins after 3 and 6 mo.  Sixteen patients with a median age of 62 yr (range, 37-70 yr) were enrolled.  Fourteen of the patients had renal involvement, 4 had cardiac involvement, 4 had liver involvement, and 2 had predominant soft tissue or lymph node involvement.  The median max. tolerated dose was 300 mg, with fatigue and other central nervous system side effects being the major dose-limiting toxicities.  Side effects not frequently reported for other patient populations included exacerbation of peripheral and pulmonary edema and worsening azotemia.  In all, 50% of the patients experienced grade 3/4 toxicity, and 25% had to discontinue the drug.  No complete hematol. responses were seen, but 25% of the patients had a significant redn. in Bence-Jones proteinuria.  Thus, while thalidomide has activity in AL amyloidosis, it also has significant toxicity in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgze0jQtI1pLVg90H21EOLACvtfcHk0lhHAaRCgZVBew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtVSjtrk%253D&md5=b15425f1d8d306ab1f9bb1375a49e40b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3816%2Fclm.2003.n.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252Fclm.2003.n.005%26sid%3Dliteratum%253Aachs%26aulast%3DSeldin%26aufirst%3DD.%2BC.%26aulast%3DChoufani%26aufirst%3DE.%2BB.%26aulast%3DDember%26aufirst%3DL.%2BM.%26aulast%3DWiesman%26aufirst%3DJ.%2BF.%26aulast%3DBerk%26aufirst%3DJ.%2BL.%26aulast%3DFalk%26aufirst%3DR.%2BH.%26aulast%3DO%25E2%2580%2599Hara%26aufirst%3DC.%26aulast%3DFennessey%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DK.%2BT.%26aulast%3DWright%26aufirst%3DD.%2BG.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DSanchorawala%26aufirst%3DV.%26atitle%3DTolerability%2520and%2520efficacy%2520of%2520thalidomide%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520light%2520chain-associated%2520%2528AL%2529%2520amyloidosis%26jtitle%3DClin.%2520Lymphoma%26date%3D2003%26volume%3D3%26spage%3D241%26epage%3D246%26doi%3D10.3816%2Fclm.2003.n.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Zyl-Smit, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iveson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassam, S. M.</span></span> <span> </span><span class="NLM_article-title">Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1080/1042819031000149412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1080%2F1042819031000149412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=15061217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADC%252BD2c7mslehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=179-181&author=R.+Bairdauthor=R.+N.+van+Zyl-Smitauthor=A.+Ivesonauthor=J.+Duddyauthor=S.+M.+Rassam&title=Thalidomide+is+highly+effective+in+a+patient+with+meningeal+acute+myeloid+leukaemia&doi=10.1080%2F1042819031000149412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia</span></div><div class="casAuthors">Baird Richard; van Zyl-Smit Richard Nellis; Iveson Anne; Duddy James; Rassam Saad M B</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & lymphoma</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">179-81</span>
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    </div><div class="casAbstract">We report a case of secondary acute myeloid leukaemia (AML) following high dose therapy for diffuse large B-cell non-Hodgkin's lymphoma (NHL) who developed meningeal leukaemia.  This was refractory to systemic and intrathecal chemotherapy and cranial irradiation.  Thalidomide has been reported to have anti-AML activity and appears to cross the blood brain barrier (BBB).  We, therefore, attempted a trial of oral Thalidomide and achieved rapid biochemical and cytological remission with a short course.  The patient, however, progressed systemically and succumbed to her illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxkV8URyRmx825P7XSLhESfW6udTcc2eZGHh6XqTTj27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7mslehtw%253D%253D&md5=31006e0dbe0fb3cf55bcd7198fc8ef2a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1080%2F1042819031000149412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1042819031000149412%26sid%3Dliteratum%253Aachs%26aulast%3DBaird%26aufirst%3DR.%26aulast%3Dvan%2BZyl-Smit%26aufirst%3DR.%2BN.%26aulast%3DIveson%26aufirst%3DA.%26aulast%3DDuddy%26aufirst%3DJ.%26aulast%3DRassam%26aufirst%3DS.%2BM.%26atitle%3DThalidomide%2520is%2520highly%2520effective%2520in%2520a%2520patient%2520with%2520meningeal%2520acute%2520myeloid%2520leukaemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2004%26volume%3D45%26spage%3D179%26epage%3D181%26doi%3D10.1080%2F1042819031000149412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faderl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albitar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span> <span> </span><span class="NLM_article-title">Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2141.2003.04639.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1046%2Fj.1365-2141.2003.04639.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=14617002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsFChs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2003&pages=436-441&author=D.+A.+Thomasauthor=E.+Esteyauthor=F.+J.+Gilesauthor=S.+Faderlauthor=J.+Cortesauthor=M.+Keatingauthor=S.+O%E2%80%99Brienauthor=M.+Albitarauthor=H.+Kantarjian&title=Single+agent+thalidomide+in+patients+with+relapsed+or+refractory+acute+myeloid+leukaemia&doi=10.1046%2Fj.1365-2141.2003.04639.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia</span></div><div class="casAuthors">Thomas, Deborah A.; Estey, Elihu; Giles, Francis J.; Faderi, Stefan; Cortes, Jorge; Keating, Michael; O'Brien, Susan; Albitar, Maher; Kantarjian, Hagop</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">436-441</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Thalidomide is a putative anti-angiogenesis agent that has significant anti-tumor activity in haematol. malignancies with increased bone marrow angiogenesis, including multiple myeloma (MM) and myelodysplastic syndromes (MDS).  Increased levels of the mitogen for angiogenesis, vascular endothelial growth factor (VEGF), correlate with worse survival in acute myeloid leukemia (AML).  A phase II trial of thalidomide was conducted in patients with relapsed- or refractory-AML previously treated with cytarabine-contg. regimens.  A total of 16 patients with refractory- or relapsed-AML were treated with thalidomide 200-800 mg orally daily (median dose 400 mg daily) for a median of 27 d (range, 3-94 d).  Overall, one patient (6%) achieved complete remission (CR) lasting for 36 mo, and two patients had a transient redn. in marrow blasts from 8% and 7% to less than 5% in both cases.  There was no correlation between redn. in levels of angiogenesis markers and response.  Toxicities related to thalidomide were significant, and precluded dose escalation beyond 400 mg orally daily in most patients.  Although there appears to be some evidence of biol. activity, single agent thalidomide is not an optimal choice of therapy for salvaging patients with relapsed- or refractory-AML.  Thalidomide analogs with more potent immunomodulatory activities and more favorable toxicity profiles may offer more promise as anti-AML therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXd9innVXxwrVg90H21EOLACvtfcHk0lhN5i2FKhJu9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsFChs70%253D&md5=28de5d4f924d2b35a000096ceb1f5be7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2141.2003.04639.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2141.2003.04639.x%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKeating%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DSingle%2520agent%2520thalidomide%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2003%26volume%3D123%26spage%3D436%26epage%3D441%26doi%3D10.1046%2Fj.1365-2141.2003.04639.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boichenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupas, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez
Alvarez, B.</span></span> <span> </span><span class="NLM_article-title">Thalidomide mimics uridine binding to an aromatic cage in cereblon</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2014.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1016%2Fj.jsb.2014.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25448889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFSnu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2014&pages=225-232&author=M.+D.+Hartmannauthor=I.+Boichenkoauthor=M.+Colesauthor=F.+Zaniniauthor=A.+N.+Lupasauthor=B.+Hernandez%0AAlvarez&title=Thalidomide+mimics+uridine+binding+to+an+aromatic+cage+in+cereblon&doi=10.1016%2Fj.jsb.2014.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide mimics uridine binding to an aromatic cage in cereblon</span></div><div class="casAuthors">Hartmann, Marcus D.; Boichenko, Iuliia; Coles, Murray; Zanini, Fabio; Lupas, Andrei N.; Hernandez Alvarez, Birte</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-232</span>CODEN:
                <span class="NLM_cas:coden">JSBIEM</span>;
        ISSN:<span class="NLM_cas:issn">1047-8477</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Thalidomide and its derivs. lenalidomide and pomalidomide are important anticancer agents but can cause severe birth defects via an interaction with the protein cereblon.  The ligand-binding domain of cereblon is found, with a high degree of conservation, in both bacteria and eukaryotes.  Using a bacterial model system, we reveal the structural determinants of cereblon substrate recognition, based on a series of high-resoln. crystal structures.  For the first time, we identify a cellular ligand that is universally present: we show that thalidomide and its derivs. mimic and compete for the binding of uridine, and validate these findings in vivo.  The nature of the binding pocket, an arom. cage of three tryptophan residues, further suggests a role in the recognition of cationic ligands.  Our results allow for general evaluation of pharmaceuticals for potential cereblon-dependent teratogenicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTvANwpl9hTbVg90H21EOLACvtfcHk0lhN5i2FKhJu9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFSnu7jI&md5=e601c6e1091deea840f9738fb30fa7bb</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2014.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2014.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DM.%2BD.%26aulast%3DBoichenko%26aufirst%3DI.%26aulast%3DColes%26aufirst%3DM.%26aulast%3DZanini%26aufirst%3DF.%26aulast%3DLupas%26aufirst%3DA.%2BN.%26aulast%3DHernandez%2BAlvarez%26aufirst%3DB.%26atitle%3DThalidomide%2520mimics%2520uridine%2520binding%2520to%2520an%2520aromatic%2520cage%2520in%2520cereblon%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2014%26volume%3D188%26spage%3D225%26epage%3D232%26doi%3D10.1016%2Fj.jsb.2014.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boichenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupas, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez
Alvarez, B.</span></span> <span> </span><span class="NLM_article-title">Structural dynamics of the cereblon ligand binding domain</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0128342</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0128342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1371%2Fjournal.pone.0128342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=26024445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGru77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=M.+D.+Hartmannauthor=I.+Boichenkoauthor=M.+Colesauthor=A.+N.+Lupasauthor=B.+Hernandez%0AAlvarez&title=Structural+dynamics+of+the+cereblon+ligand+binding+domain&doi=10.1371%2Fjournal.pone.0128342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structural dynamics of the cereblon ligand binding domain</span></div><div class="casAuthors">Hartmann, Marcus D.; Boichenko, Iuliia; Coles, Murray; Lupas, Andrei N.; Alvarez, Birte Hernandez</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e0128342/1-e0128342/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Cereblon, a primary target of thalidomide and its derivs., has been characterized structurally from both bacteria and animals.  Esp. well studied is the thalidomide binding domain, CULT, which shows an invariable structure across different organisms and in complex with different ligands.  Here, based on a series of crystal structures of a bacterial representative, we reveal the conformational flexibility and structural dynamics of this domain.  In particular, we follow the unfolding of large fractions of the domain upon release of thalidomide in the cryst. state.  Our results imply that a third of the domain, including the thalidomide binding pocket, only folds upon ligand binding.  We further characterize the structural effect of the C-terminal truncation resulting from the mental-retardation linked R419X nonsense mutation in vitro and offer a mechanistic hypothesis for its irresponsiveness to thalidomide.  At 1.2Å resoln., our data provide a view of thalidomide binding at at. resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocnADN6zO_LrVg90H21EOLACvtfcHk0lhN5i2FKhJu9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGru77F&md5=525f48f454c54c466360231d1ab3330a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0128342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0128342%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DM.%2BD.%26aulast%3DBoichenko%26aufirst%3DI.%26aulast%3DColes%26aufirst%3DM.%26aulast%3DLupas%26aufirst%3DA.%2BN.%26aulast%3DHernandez%2BAlvarez%26aufirst%3DB.%26atitle%3DStructural%2520dynamics%2520of%2520the%2520cereblon%2520ligand%2520binding%2520domain%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0128342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Girona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chie-Leon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakoshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span> <span> </span><span class="NLM_article-title">Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnsmb.2874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25108355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlahurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=803-809&author=P.+P.+Chamberlainauthor=A.+Lopez-Gironaauthor=K.+Millerauthor=G.+Carmelauthor=B.+Pagariganauthor=B.+Chie-Leonauthor=E.+Rychakauthor=L.+G.+Corralauthor=Y.+J.+Renauthor=M.+Wangauthor=M.+Rileyauthor=S.+L.+Delkerauthor=T.+Itoauthor=H.+Andoauthor=T.+Moriauthor=Y.+Hiranoauthor=H.+Handaauthor=T.+Hakoshimaauthor=T.+O.+Danielauthor=B.+E.+Cathers&title=Structure+of+the+human+cereblon-DDB1-lenalidomide+complex+reveals+basis+for+responsiveness+to+thalidomide+analogs&doi=10.1038%2Fnsmb.2874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs</span></div><div class="casAuthors">Chamberlain, Philip P.; Lopez-Girona, Antonia; Miller, Karen; Carmel, Gilles; Pagarigan, Barbra; Chie-Leon, Barbara; Rychak, Emily; Corral, Laura G.; Ren, Yan J.; Wang, Maria; Riley, Mariko; Delker, Silvia L.; Ito, Takumi; Ando, Hideki; Mori, Tomoyuki; Hirano, Yoshinori; Handa, Hiroshi; Hakoshima, Toshio; Daniel, Thomas O.; Cathers, Brian E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">803-809</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Cul4-Rbx1-DDB1-Cereblon E3 ubiquitin ligase complex is the target of thalidomide, lenalidomide and pomalidomide, therapeutically important drugs for multiple myeloma and other B-cell malignancies.  These drugs directly bind Cereblon (CRBN) and promote the recruitment of substrates Ikaros (IKZF1) and Aiolos (IKZF3) to the E3 complex, thus leading to substrate ubiquitination and degrdn.  Here we present the crystal structure of human CRBN bound to DDB1 and the drug lenalidomide.  A hydrophobic pocket in the thalidomide-binding domain (TBD) of CRBN accommodates the glutarimide moiety of lenalidomide, whereas the isoindolinone ring is exposed to solvent.  We also solved the structures of the mouse TBD in the apo state and with thalidomide or pomalidomide.  Site-directed mutagenesis in lentiviral-expression myeloma models showed that key drug-binding residues are crit. for antiproliferative effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtN-ZCacB1m7Vg90H21EOLACvtfcHk0lhN5i2FKhJu9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlahurjI&md5=627fc3c8eae320059ca1cdc173bb56ed</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2874%26sid%3Dliteratum%253Aachs%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DLopez-Girona%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DChie-Leon%26aufirst%3DB.%26aulast%3DRychak%26aufirst%3DE.%26aulast%3DCorral%26aufirst%3DL.%2BG.%26aulast%3DRen%26aufirst%3DY.%2BJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DDelker%26aufirst%3DS.%2BL.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DHirano%26aufirst%3DY.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DHakoshima%26aufirst%3DT.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26atitle%3DStructure%2520of%2520the%2520human%2520cereblon-DDB1-lenalidomide%2520complex%2520reveals%2520basis%2520for%2520responsiveness%2520to%2520thalidomide%2520analogs%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D803%26epage%3D809%26doi%3D10.1038%2Fnsmb.2874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böhm, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydeard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadler, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavadini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serluca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acker, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraju, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schebesta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassiepen, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hild, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckwith, R. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomä, N. H.</span></span> <span> </span><span class="NLM_article-title">Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>512</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1038/nature13527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnature13527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25043012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12ms7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=512&publication_year=2014&pages=49-53&author=E.+S.+Fischerauthor=K.+B%C3%B6hmauthor=J.+R.+Lydeardauthor=H.+Yangauthor=M.+B.+Stadlerauthor=S.+Cavadiniauthor=J.+Nagelauthor=F.+Serlucaauthor=V.+Ackerauthor=G.+M.+Lingarajuauthor=R.+B.+Tichkuleauthor=M.+Schebestaauthor=W.+C.+Forresterauthor=M.+Schirleauthor=U.+Hassiepenauthor=J.+Ottlauthor=M.+Hildauthor=R.+E.+J.+Beckwithauthor=J.+W.+Harperauthor=J.+L.+Jenkinsauthor=N.+H.+Thom%C3%A4&title=Structure+of+the+DDB1-CRBN+E3+ubiquitin+ligase+in+complex+with+thalidomide&doi=10.1038%2Fnature13527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide</span></div><div class="casAuthors">Fischer, Eric S.; Bohm, Kerstin; Lydeard, John R.; Yang, Haidi; Stadler, Michael B.; Cavadini, Simone; Nagel, Jane; Serluca, Fabrizio; Acker, Vincent; Lingaraju, Gondichatnahalli M.; Tichkule, Ritesh B.; Schebesta, Michael; Forrester, William C.; Schirle, Markus; Hassiepen, Ulrich; Ottl, Johannes; Hild, Marc; Beckwith, Rohan E. J.; Harper, J. Wade; Jenkins, Jeremy L.; Thoma, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">512</span>
        (<span class="NLM_cas:issue">7512</span>),
    <span class="NLM_cas:pages">49-53</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects.  Despite the teratogenicity of thalidomide and its derivs. lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recently emerged as effective treatments for multiple myeloma and 5q-deletion-assocd. dysplasia.  IMiDs target the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4CRBN) and promote the ubiquitination of the IKAROS family transcription factors IKZF1 and IKZF3 by CRL4CRBN.  Here we present crystal structures of the DDB1-CRBN complex bound to thalidomide, lenalidomide and pomalidomide.  The structure establishes that CRBN is a substrate receptor within CRL4CRBN and enantioselectively binds IMiDs.  Using an unbiased screen, we identified the homeobox transcription factor MEIS2 as an endogenous substrate of CRL4CRBN.  Our studies suggest that IMiDs block endogenous substrates (MEIS2) from binding to CRL4CRBN while the ligase complex is recruiting IKZF1 or IKZF3 for degrdn.  This dual activity implies that small mols. can modulate an E3 ubiquitin ligase and thereby upregulate or downregulate the ubiquitination of proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGt2Y9GecKr7Vg90H21EOLACvtfcHk0lh8MnulRj_D6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12ms7%252FP&md5=1c1eaa48bef87463cdd3f2b1e1bd400d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature13527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13527%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DB%25C3%25B6hm%26aufirst%3DK.%26aulast%3DLydeard%26aufirst%3DJ.%2BR.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DStadler%26aufirst%3DM.%2BB.%26aulast%3DCavadini%26aufirst%3DS.%26aulast%3DNagel%26aufirst%3DJ.%26aulast%3DSerluca%26aufirst%3DF.%26aulast%3DAcker%26aufirst%3DV.%26aulast%3DLingaraju%26aufirst%3DG.%2BM.%26aulast%3DTichkule%26aufirst%3DR.%2BB.%26aulast%3DSchebesta%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DW.%2BC.%26aulast%3DSchirle%26aufirst%3DM.%26aulast%3DHassiepen%26aufirst%3DU.%26aulast%3DOttl%26aufirst%3DJ.%26aulast%3DHild%26aufirst%3DM.%26aulast%3DBeckwith%26aufirst%3DR.%2BE.%2BJ.%26aulast%3DHarper%26aufirst%3DJ.%2BW.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DThom%25C3%25A4%26aufirst%3DN.%2BH.%26atitle%3DStructure%2520of%2520the%2520DDB1-CRBN%2520E3%2520ubiquitin%2520ligase%2520in%2520complex%2520with%2520thalidomide%26jtitle%3DNature%26date%3D2014%26volume%3D512%26spage%3D49%26epage%3D53%26doi%3D10.1038%2Fnature13527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweredoski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitsma, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshaies, R. J.</span></span> <span> </span><span class="NLM_article-title">Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">820</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2016.02.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1016%2Fj.molcel.2016.02.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=26990986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1OqsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=809-820&author=T.+V.+Nguyenauthor=J.+E.+Leeauthor=M.+J.+Sweredoskiauthor=S.+J.+Yangauthor=S.+J.+Jeonauthor=J.+S.+Harrisonauthor=J.+H.+Yimauthor=S.+G.+Leeauthor=H.+Handaauthor=B.+Kuhlmanauthor=J.+S.+Jeongauthor=J.+M.+Reitsmaauthor=C.+S.+Parkauthor=S.+Hessauthor=R.+J.+Deshaies&title=Glutamine+triggers+acetylation-dependent+degradation+of+glutamine+synthetase+via+the+thalidomide+receptor+cereblon&doi=10.1016%2Fj.molcel.2016.02.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon</span></div><div class="casAuthors">Nguyen, T. Van; Lee, J. Eugene; Sweredoski, Michael J.; Yang, Seung-Joo; Jeon, Seung-Je; Harrison, Joseph S.; Yim, Jung-Hyuk; Lee, Sang Ghil; Handa, Hiroshi; Kuhlman, Brian; Jeong, Ji-Seon; Reitsma, Justin M.; Park, Chul-Seung; Hess, Sonja; Deshaies, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">809-820</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cereblon (CRBN), a substrate receptor for the cullin-RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).  Here we report that glutamine synthetase (GS) is an endogenous substrate of CRL4CRBN.  Upon exposing cells to high glutamine concn., GS is acetylated at lysines 11 and 14, yielding a degron that is necessary and sufficient for binding and ubiquitylation by CRL4CRBN and degrdn. by the proteasome.  Binding of acetylated degron peptides to CRBN depends on an intact thalidomide-binding pocket but is not competitive with IMiDs.  These findings reveal a feedback loop involving CRL4CRBN that adjusts GS protein levels in response to glutamine and uncover a new function for lysine acetylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSanlZNHndMrVg90H21EOLACvtfcHk0lh8MnulRj_D6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1OqsL0%253D&md5=641527ec1a6c97d1800e3e393582c07f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2016.02.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2016.02.032%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%2BV.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DSweredoski%26aufirst%3DM.%2BJ.%26aulast%3DYang%26aufirst%3DS.%2BJ.%26aulast%3DJeon%26aufirst%3DS.%2BJ.%26aulast%3DHarrison%26aufirst%3DJ.%2BS.%26aulast%3DYim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DS.%2BG.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DKuhlman%26aufirst%3DB.%26aulast%3DJeong%26aufirst%3DJ.%2BS.%26aulast%3DReitsma%26aufirst%3DJ.%2BM.%26aulast%3DPark%26aufirst%3DC.%2BS.%26aulast%3DHess%26aufirst%3DS.%26aulast%3DDeshaies%26aufirst%3DR.%2BJ.%26atitle%3DGlutamine%2520triggers%2520acetylation-dependent%2520degradation%2520of%2520glutamine%2520synthetase%2520via%2520the%2520thalidomide%2520receptor%2520cereblon%26jtitle%3DMol.%2520Cell%26date%3D2016%26volume%3D61%26spage%3D809%26epage%3D820%26doi%3D10.1016%2Fj.molcel.2016.02.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Del
Prete, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajadhyaksha, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Adamio, L.</span></span> <span> </span><span class="NLM_article-title">Amyloid precursor protein (APP) may act as a substrate and a recognition unit for CRL4(CRBN) and Stub1 E3 ligases facilitating ubiquitination of proteins involved in presynaptic functions and neurodegeneration</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">17209</span>– <span class="NLM_lpage">17227</span>, <span class="refDoi"> DOI: 10.1074/jbc.m116.733626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1074%2Fjbc.m116.733626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=27325702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslaktLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=17209-17227&author=D.+Del%0APreteauthor=R.+C.+Riceauthor=A.+M.+Rajadhyakshaauthor=L.+D%E2%80%99Adamio&title=Amyloid+precursor+protein+%28APP%29+may+act+as+a+substrate+and+a+recognition+unit+for+CRL4%28CRBN%29+and+Stub1+E3+ligases+facilitating+ubiquitination+of+proteins+involved+in+presynaptic+functions+and+neurodegeneration&doi=10.1074%2Fjbc.m116.733626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid precursor protein (APP) may act as a substrate and a recognition unit for CRL4CRBN and Stub1 E3 ligases facilitating ubiquitination of proteins involved in presynaptic functions and neurodegeneration</span></div><div class="casAuthors">Del Prete, Dolores; Rice, Richard C.; Rajadhyaksha, Anjali M.; D'Adamio, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">17209-17227</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The amyloid precursor protein (APP), whose mutations cause Alzheimer disease, plays an important in vivo role and facilitates transmitter release.  Because the APP cytosolic region (ACR) is essential for these functions, we have characterized its brain interactome.  We found that the ACR interacts with proteins that regulate the ubiquitin-proteasome system, predominantly with the E3 ubiquitin-protein ligases Stub1, which binds the N-terminus of the ACR, and CRL4CRBN, which is formed by Cul4a/b, Ddb1, and Crbn, and interacts with the C-terminus of the ACR via Crbn.  APP shares essential functions with APP-like protein-2 (APLP2) but not APP-like protein-1 (APLP1).  Noteworthy, APLP2, but not APLP1, interacts with Stub1 and CRL4CRBN, pointing to a functional pathway shared only by APP and APLP2.  In vitro ubiquitination/ubiquitome anal. indicates that these E3 ligases are enzymically active and ubiquitinated the ACR residues Lys649/650/651/676/688.  Deletion of Crbn reduces ubiquitination of Lys676 suggesting that Lys676 is physiol. ubiquitinated by CRL4CRBN.  The ACR facilitated in vitro ubiquitination of presynaptic proteins that regulate exocytosis, suggesting a mechanism by which APP tunes transmitter release.  Other dementia-related proteins, namely Tau and apoE, interact with and are ubiquitinated via the ACR in vitro.  This, and the evidence that CRBN and CUL4B are linked to intellectual disability, prompts us to hypothesize a pathogenic mechanism, in which APP acts as a modulator of E3 ubiquitin-protein ligase(s), shared by distinct neuronal disorders.  The well described accumulation of ubiquitinated protein inclusions in neurodegenerative diseases and the link between the ubiquitin-proteasome system and neurodegeneration make this concept plausible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk1X5MYxG30bVg90H21EOLACvtfcHk0ljKxLpwQHCxJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslaktLrF&md5=b4cfc53ded92c62aa868a17e28929986</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1074%2Fjbc.m116.733626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.m116.733626%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BPrete%26aufirst%3DD.%26aulast%3DRice%26aufirst%3DR.%2BC.%26aulast%3DRajadhyaksha%26aufirst%3DA.%2BM.%26aulast%3DD%25E2%2580%2599Adamio%26aufirst%3DL.%26atitle%3DAmyloid%2520precursor%2520protein%2520%2528APP%2529%2520may%2520act%2520as%2520a%2520substrate%2520and%2520a%2520recognition%2520unit%2520for%2520CRL4%2528CRBN%2529%2520and%2520Stub1%2520E3%2520ligases%2520facilitating%2520ubiquitination%2520of%2520proteins%2520involved%2520in%2520presynaptic%2520functions%2520and%2520neurodegeneration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D17209%26epage%3D17227%26doi%3D10.1074%2Fjbc.m116.733626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kronke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svinkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciarlo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1126/science.1244851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1126%2Fscience.1244851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=24292625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=301-305&author=J.+Kronkeauthor=N.+D.+Udeshiauthor=A.+Narlaauthor=P.+Graumanauthor=S.+N.+Hurstauthor=M.+McConkeyauthor=T.+Svinkinaauthor=D.+Hecklauthor=E.+Comerauthor=X.+Liauthor=C.+Ciarloauthor=E.+Hartmanauthor=N.+Munshiauthor=M.+Schenoneauthor=S.+L.+Schreiberauthor=S.+A.+Carrauthor=B.+L.+Ebert&title=Lenalidomide+causes+selective+degradation+of+IKZF1+and+IKZF3+in+multiple+myeloma+cells&doi=10.1126%2Fscience.1244851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells</span></div><div class="casAuthors">Kronke Jan; Udeshi Namrata D; Narla Anupama; Grauman Peter; Hurst Slater N; McConkey Marie; Svinkina Tanya; Heckl Dirk; Comer Eamon; Li Xiaoyu; Ciarlo Christie; Hartman Emily; Munshi Nikhil; Schenone Monica; Schreiber Stuart L; Carr Steven A; Ebert Benjamin L</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6168</span>),
    <span class="NLM_cas:pages">301-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown.  Using quantitative proteomics, we found that lenalidomide causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.  IKZF1 and IKZF3 are essential transcription factors in multiple myeloma.  A single amino acid substitution of IKZF3 conferred resistance to lenalidomide-induced degradation and rescued lenalidomide-induced inhibition of cell growth.  Similarly, we found that lenalidomide-induced interleukin-2 production in T cells is due to depletion of IKZF1 and IKZF3.  These findings reveal a previously unknown mechanism of action for a therapeutic agent: alteration of the activity of an E3 ubiquitin ligase, leading to selective degradation of specific targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiiGR0Yx7nuYFEOhA_Im3cfW6udTcc2eZA1Jj4akApibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3itFajsQ%253D%253D&md5=8cae3e554399308493aa38f0d05ed610</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1126%2Fscience.1244851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1244851%26sid%3Dliteratum%253Aachs%26aulast%3DKronke%26aufirst%3DJ.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DNarla%26aufirst%3DA.%26aulast%3DGrauman%26aufirst%3DP.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DMcConkey%26aufirst%3DM.%26aulast%3DSvinkina%26aufirst%3DT.%26aulast%3DHeckl%26aufirst%3DD.%26aulast%3DComer%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCiarlo%26aufirst%3DC.%26aulast%3DHartman%26aufirst%3DE.%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DSchenone%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520causes%2520selective%2520degradation%2520of%2520IKZF1%2520and%2520IKZF3%2520in%2520multiple%2520myeloma%2520cells%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D301%26epage%3D305%26doi%3D10.1126%2Fscience.1244851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacBeth, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svinkina, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConkey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järås, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullinger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>523</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1038/nature14610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnature14610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=26131937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1entr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=523&publication_year=2015&pages=183-188&author=J.+Kr%C3%B6nkeauthor=E.+C.+Finkauthor=P.+W.+Hollenbachauthor=K.+J.+MacBethauthor=S.+N.+Hurstauthor=N.+D.+Udeshiauthor=P.+P.+Chamberlainauthor=D.+R.+Maniauthor=H.+W.+Manauthor=A.+K.+Gandhiauthor=T.+Svinkinaauthor=R.+K.+Schneiderauthor=M.+McConkeyauthor=M.+J%C3%A4r%C3%A5sauthor=E.+Griffithsauthor=M.+Wetzlerauthor=L.+Bullingerauthor=B.+E.+Cathersauthor=S.+A.+Carrauthor=R.+Chopraauthor=B.+L.+Ebert&title=Lenalidomide+induces+ubiquitination+and+degradation+of+CK1alpha+in+del%285q%29+MDS&doi=10.1038%2Fnature14610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS</span></div><div class="casAuthors">Kronke, Jan; Fink, Emma C.; Hollenbach, Paul W.; MacBeth, Kyle J.; Hurst, Slater N.; Udeshi, Namrata D.; Chamberlain, Philip P.; Mani, D. R.; Man, Hon Wah; Gandhi, Anita K.; Svinkina, Tanya; Schneider, Rebekka K.; McConkey, Marie; Jaras, Marcus; Griffiths, Elizabeth; Wetzler, Meir; Bullinger, Lars; Cathers, Brian E.; Carr, Steven A.; Chopra, Rajesh; Ebert, Benjamin L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">523</span>
        (<span class="NLM_cas:issue">7559</span>),
    <span class="NLM_cas:pages">183-188</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)).  Lenalidomide induces the ubiquitination of casein kinase 1A1 (CK1α) by the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4CRBN), resulting in CK1α degrdn.  CK1α is encoded by a gene within the common deleted region for del(5q) MDS and haplo-insufficient expression sensitizes cells to lenalidomide therapy, providing a mechanistic basis for the therapeutic window of lenalidomide in del(5q) MDS.  The authors found that mouse cells are resistant to lenalidomide but that changing a single amino acid in mouse Crbn to the corresponding human residue enables lenalidomide-dependent degrdn. of CK1α.  The authors further demonstrate that minor side chain modifications in thalidomide and a novel analog, CC-122, can modulate the spectrum of substrates targeted by CRL4CRBN.  These findings have implications for the clin. activity of lenalidomide and related compds., and demonstrate the therapeutic potential of novel modulators of E3 ubiquitin ligases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLiHx3FKesbVg90H21EOLACvtfcHk0ljKxLpwQHCxJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1entr%252FN&md5=9b20a91c13e888e6569223ffa25af2cd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature14610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14610%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26aulast%3DFink%26aufirst%3DE.%2BC.%26aulast%3DHollenbach%26aufirst%3DP.%2BW.%26aulast%3DMacBeth%26aufirst%3DK.%2BJ.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26aulast%3DMani%26aufirst%3DD.%2BR.%26aulast%3DMan%26aufirst%3DH.%2BW.%26aulast%3DGandhi%26aufirst%3DA.%2BK.%26aulast%3DSvinkina%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DR.%2BK.%26aulast%3DMcConkey%26aufirst%3DM.%26aulast%3DJ%25C3%25A4r%25C3%25A5s%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DE.%26aulast%3DWetzler%26aufirst%3DM.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520induces%2520ubiquitination%2520and%2520degradation%2520of%2520CK1alpha%2520in%2520del%25285q%2529%2520MDS%26jtitle%3DNature%26date%3D2015%26volume%3D523%26spage%3D183%26epage%3D188%26doi%3D10.1038%2Fnature14610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosaka, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchelman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Girona, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span> <span> </span><span class="NLM_article-title">A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>535</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1038/nature18611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnature18611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=27338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=535&publication_year=2016&pages=252-257&author=M.+E.+Matyskielaauthor=G.+Luauthor=T.+Itoauthor=B.+Pagariganauthor=C.-C.+Luauthor=K.+Millerauthor=W.+Fangauthor=N.-Y.+Wangauthor=D.+Nguyenauthor=J.+Houstonauthor=G.+Carmelauthor=T.+Tranauthor=M.+Rileyauthor=L.+A.+Nosakaauthor=G.+C.+Landerauthor=S.+Gaidarovaauthor=S.+Xuauthor=A.+L.+Ruchelmanauthor=H.+Handaauthor=J.+Carmichaelauthor=T.+O.+Danielauthor=B.+E.+Cathersauthor=A.+Lopez-Gironaauthor=P.+P.+Chamberlain&title=A+novel+cereblon+modulator+recruits+GSPT1+to+the+CRL4%28CRBN%29+ubiquitin+ligase&doi=10.1038%2Fnature18611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Matyskiela, Mary E.; Lu, Gang; Ito, Takumi; Pagarigan, Barbra; Lu, Chin-Chun; Miller, Karen; Fang, Wei; Wang, Nai-Yu; Nguyen, Derek; Houston, Jack; Carmel, Gilles; Tran, Tam; Riley, Mariko; Nosaka, Lyn'Al; Lander, Gabriel C.; Gaidarova, Svetlana; Xu, Shuichan; Ruchelman, Alexander L.; Handa, Hiroshi; Carmichael, James; Daniel, Thomas O.; Cathers, Brian E.; Lopez-Girona, Antonia; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">535</span>
        (<span class="NLM_cas:issue">7611</span>),
    <span class="NLM_cas:pages">252-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Immunomodulatory drugs bind to cereblon (CRBN) to confer differentiated substrate specificity on the CRL4CRBN E3 ubiquitin ligase.  Here we report the identification of a new cereblon modulator, CC-885, with potent anti-tumor activity.  The anti-tumor activity of CC-885 is mediated through the cereblon-dependent ubiquitination and degrdn. of the translation termination factor GSPT1.  Patient-derived acute myeloid leukemia tumor cells exhibit high sensitivity to CC-885, indicating the clin. potential of this mechanism.  Crystallog. studies of the CRBN-DDB1-CC-885-GSPT1 complex reveal that GSPT1 binds to cereblon through a surface turn contg. a glycine residue at a key position, interacting with both CC-885 and a 'hotspot' on the cereblon surface.  Although GSPT1 possesses no obvious structural, sequence or functional homol. to previously known cereblon substrates, mutational anal. and modeling indicate that the cereblon substrate Ikaros uses a similar structural feature to bind cereblon, suggesting a common motif for substrate recruitment.  These findings define a structural degron underlying cereblon 'neosubstrate' selectivity, and identify an anti-tumor target rendered druggable by cereblon modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgAWiXdlJgYLVg90H21EOLACvtfcHk0ljfYLZ7aL79fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCltbnI&md5=1d4e340416aa0b08fc0f123faf638c3f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature18611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature18611%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DC.-C.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DFang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DN.-Y.%26aulast%3DNguyen%26aufirst%3DD.%26aulast%3DHouston%26aufirst%3DJ.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DNosaka%26aufirst%3DL.%2BA.%26aulast%3DLander%26aufirst%3DG.%2BC.%26aulast%3DGaidarova%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DRuchelman%26aufirst%3DA.%2BL.%26aulast%3DHanda%26aufirst%3DH.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DLopez-Girona%26aufirst%3DA.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26atitle%3DA%2520novel%2520cereblon%2520modulator%2520recruits%2520GSPT1%2520to%2520the%2520CRL4%2528CRBN%2529%2520ubiquitin%2520ligase%26jtitle%3DNature%26date%3D2016%26volume%3D535%26spage%3D252%26epage%3D257%26doi%3D10.1038%2Fnature18611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drew, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdubek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blease, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vessey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span> <span> </span><span class="NLM_article-title">SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1038/s41589-018-0129-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fs41589-018-0129-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=30190590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kgu7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=981-987&author=M.+E.+Matyskielaauthor=S.+Coutoauthor=X.+Zhengauthor=G.+Luauthor=J.+Huiauthor=K.+Stampauthor=C.+Drewauthor=Y.+Renauthor=M.+Wangauthor=A.+Carpenterauthor=C.-W.+Leeauthor=T.+Claytonauthor=W.+Fangauthor=C.-C.+Luauthor=M.+Rileyauthor=P.+Abdubekauthor=K.+Bleaseauthor=J.+Hartkeauthor=G.+Kumarauthor=R.+Vesseyauthor=M.+Rolfeauthor=L.+G.+Hamannauthor=P.+P.+Chamberlain&title=SALL4+mediates+teratogenicity+as+a+thalidomide-dependent+cereblon+substrate&doi=10.1038%2Fs41589-018-0129-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate</span></div><div class="casAuthors">Matyskiela, Mary E.; Couto, Suzana; Zheng, Xinde; Lu, Gang; Hui, Julia; Stamp, Katie; Drew, Clifton; Ren, Yan; Wang, Maria; Carpenter, Aaron; Lee, Chung-Wein; Clayton, Thomas; Fang, Wei; Lu, Chin-Chun; Riley, Mariko; Abdubek, Polat; Blease, Kate; Hartke, James; Kumar, Gondi; Vessey, Rupert; Rolfe, Mark; Hamann, Lawrence G.; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">981-987</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Targeted protein degrdn. via small-mol. modulation of cereblon offers vast potential for the development of new therapeutics.  Cereblon-binding therapeutics carry the safety risks of thalidomide, which caused an epidemic of severe birth defects characterized by forelimb shortening or phocomelia.  Here we show that thalidomide is not teratogenic in transgenic mice expressing human cereblon, indicating that binding to cereblon is not sufficient to cause birth defects.  Instead, we identify SALL4 as a thalidomide-dependent cereblon neosubstrate.  Human mutations in SALL4 cause Duane-radial ray, IVIC, and acro-renal-ocular syndromes with overlapping clin. presentations to thalidomide embryopathy, including phocomelia.  SALL4 is degraded in rabbits but not in resistant organisms such as mice because of SALL4 sequence variations.  This work expands the scope of cereblon neosubstrate activity within the formerly 'undruggable' C2H2 zinc finger family and offers a path toward safer therapeutics through an improved understanding of the mol. basis of thalidomide-induced teratogenicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpePTE78HX85rVg90H21EOLACvtfcHk0ljfYLZ7aL79fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kgu7nM&md5=7530c3850ed7a763b30cba44dab640ac</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0129-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0129-x%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DCouto%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DHui%26aufirst%3DJ.%26aulast%3DStamp%26aufirst%3DK.%26aulast%3DDrew%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DCarpenter%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.-W.%26aulast%3DClayton%26aufirst%3DT.%26aulast%3DFang%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DC.-C.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DAbdubek%26aufirst%3DP.%26aulast%3DBlease%26aufirst%3DK.%26aulast%3DHartke%26aufirst%3DJ.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DVessey%26aufirst%3DR.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26atitle%3DSALL4%2520mediates%2520teratogenicity%2520as%2520a%2520thalidomide-dependent%2520cereblon%2520substrate%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2018%26volume%3D14%26spage%3D981%26epage%3D987%26doi%3D10.1038%2Fs41589-018-0129-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span>; <span class="NLM_string-name">An, J.</span>; <span class="NLM_string-name">Nowak, R. P.</span>; <span class="NLM_string-name">Yuan, J. C.</span>; <span class="NLM_string-name">Fink, E. C.</span>; <span class="NLM_string-name">Berry, B. C.</span>; <span class="NLM_string-name">Ebert, B. L.</span>; <span class="NLM_string-name">Fischer, E. S.</span></span>, <span> </span><span class="NLM_article-title">Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray Syndrome</span>.  <i>Elife</i> <span class="NLM_year" style="font-weight: bold;">2018</span><b>,</b>  <span class="NLM_volume">7</span>.<span class="refDoi"> DOI: 10.7554/elife.38430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.7554%2Felife.38430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=30067223" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&author=K.+A.+Donovan&author=J.+An&author=R.+P.+Nowak&author=J.+C.+Yuan&author=E.+C.+Fink&author=B.+C.+Berry&author=B.+L.+Ebert&author=E.+S.+Fischer&title=Thalidomide+promotes+degradation+of+SALL4%2C+a+transcription+factor+implicated+in+Duane+Radial+Ray+Syndrome&doi=10.7554%2Felife.38430"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.7554%2Felife.38430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252Felife.38430%26sid%3Dliteratum%253Aachs%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26atitle%3DThalidomide%2520promotes%2520degradation%2520of%2520SALL4%252C%2520a%2520transcription%2520factor%2520implicated%2520in%2520Duane%2520Radial%2520Ray%2520Syndrome%26jtitle%3DElife%26date%3D2018%26volume%3D7%26doi%3D10.7554%2Felife.38430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petzold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomä, N. H.</span></span> <span> </span><span class="NLM_article-title">Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1038/nature16979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnature16979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=26909574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=127-130&author=G.+Petzoldauthor=E.+S.+Fischerauthor=N.+H.+Thom%C3%A4&title=Structural+basis+of+lenalidomide-induced+CK1alpha+degradation+by+the+CRL4%28CRBN%29+ubiquitin+ligase&doi=10.1038%2Fnature16979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase</span></div><div class="casAuthors">Petzold, Georg; Fischer, Eric S.; Thoma, Nicolas H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7597</span>),
    <span class="NLM_cas:pages">127-130</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thalidomide and its derivs., lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of hematol. malignancies.  IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4CRBN) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous CRL4CRBN substrates.  Unexpectedly, IMiDs also repurpose the ligase to target new proteins for degrdn.  Lenalidomide induces degrdn. of the lymphoid transcription factors Ikaros and Aiolos (also known as IKZF1 and IKZF3), and casein kinase 1α (CK1α), which contributes to its clin. efficacy in the treatment of multiple myeloma and 5q-deletion assocd. myelodysplastic syndrome (del(5q) MDS), resp.  How lenalidomide alters the specificity of the ligase to degrade these proteins remains elusive.  Here we present the 2.45 Å crystal structure of DDB1-CRBN bound to lenalidomide and CK1α.  CRBN and lenalidomide jointly provide the binding interface for a CK1α β-hairpin-loop located in the kinase N-lobe.  We show that CK1α binding to CRL4CRBN is strictly dependent on the presence of an IMiD.  Binding of IKZF1 to CRBN similarly requires the compd. and both, IKZF1 and CK1α, use a related binding mode.  Our study provides a mechanistic explanation for the selective efficacy of lenalidomide in del(5q) MDS therapy.  We anticipate that high-affinity protein-protein interactions induced by small mols. will provide opportunities for drug development, particularly for targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs4FxWriI1ObVg90H21EOLACvtfcHk0ljqU-ODl_SJ5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFOis78%253D&md5=320fc6ff811da335fa8e02feab2d702d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature16979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature16979%26sid%3Dliteratum%253Aachs%26aulast%3DPetzold%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DThom%25C3%25A4%26aufirst%3DN.%2BH.%26atitle%3DStructural%2520basis%2520of%2520lenalidomide-induced%2520CK1alpha%2520degradation%2520by%2520the%2520CRL4%2528CRBN%2529%2520ubiquitin%2520ligase%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D127%26epage%3D130%26doi%3D10.1038%2Fnature16979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sievers, Q. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petzold, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunker, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renneville, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Słabicki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddicoat, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdulrahman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomä, N. H.</span></span> <span> </span><span class="NLM_article-title">Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>362</i></span>, <span class="NLM_elocation-id">eaat0572</span> <span class="refDoi"> DOI: 10.1126/science.aat0572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1126%2Fscience.aat0572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=30385546" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2018&author=Q.+L.+Sieversauthor=G.+Petzoldauthor=R.+D.+Bunkerauthor=A.+Rennevilleauthor=M.+S%C5%82abickiauthor=B.+J.+Liddicoatauthor=W.+Abdulrahmanauthor=T.+Mikkelsenauthor=B.+L.+Ebertauthor=N.+H.+Thom%C3%A4&title=Defining+the+human+C2H2+zinc+finger+degrome+targeted+by+thalidomide+analogs+through+CRBN&doi=10.1126%2Fscience.aat0572"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1126%2Fscience.aat0572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aat0572%26sid%3Dliteratum%253Aachs%26aulast%3DSievers%26aufirst%3DQ.%2BL.%26aulast%3DPetzold%26aufirst%3DG.%26aulast%3DBunker%26aufirst%3DR.%2BD.%26aulast%3DRenneville%26aufirst%3DA.%26aulast%3DS%25C5%2582abicki%26aufirst%3DM.%26aulast%3DLiddicoat%26aufirst%3DB.%2BJ.%26aulast%3DAbdulrahman%26aufirst%3DW.%26aulast%3DMikkelsen%26aufirst%3DT.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26aulast%3DThom%25C3%25A4%26aufirst%3DN.%2BH.%26atitle%3DDefining%2520the%2520human%2520C2H2%2520zinc%2520finger%2520degrome%2520targeted%2520by%2520thalidomide%2520analogs%2520through%2520CRBN%26jtitle%3DScience%26date%3D2018%26volume%3D362%26doi%3D10.1126%2Fscience.aat0572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0ljqU-ODl_SJ5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercurio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshaies, R. J.</span></span> <span> </span><span class="NLM_article-title">Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">8554</span>– <span class="NLM_lpage">8559</span>, <span class="refDoi"> DOI: 10.1073/pnas.141230798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1073%2Fpnas.141230798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=11438690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD3MXls1Wisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=8554-8559&author=K.+M.+Sakamotoauthor=K.+B.+Kimauthor=A.+Kumagaiauthor=F.+Mercurioauthor=C.+M.+Crewsauthor=R.+J.+Deshaies&title=Protacs%3A+Chimeric+molecules+that+target+proteins+to+the+Skp1%E2%80%93Cullin%E2%80%93F+box+complex+for+ubiquitination+and+degradation&doi=10.1073%2Fpnas.141230798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation</span></div><div class="casAuthors">Sakamoto, Kathleen M.; Kim, Kyung B.; Kumagai, Akiko; Mercurio, Frank; Crews, Craig M.; Deshaies, Raymond J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8554-8559</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The intracellular levels of many proteins are regulated by ubiquitin-dependent proteolysis.  One of the best-characterized enzymes that catalyzes the attachment of ubiquitin to proteins is a ubiquitin ligase complex, Skp1-Cullin-F box complex contg. Hrt1 (SCF).  We sought to artificially target a protein to the SCF complex for ubiquitination and degrdn.  To this end, we tested methionine aminopeptidase-2 (MetAP-2), which covalently binds the angiogenesis inhibitor ovalicin.  A chimeric compd., protein-targeting chimeric mol. 1 (Protac-1), was synthesized to recruit MetAP-2 to SCF.  One domain of Protac-1 contains the IκBα phosphopeptide that is recognized by the F-box protein β-TRCP, whereas the other domain is composed of ovalicin.  We show that MetAP-2 can be tethered to SCFβ-TRCP, ubiquitinated, and degraded in a Protac-1-dependent manner.  In the future, this approach may be useful for conditional inactivation of proteins, and for targeting disease-causing proteins for destruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp49fYtuEVlJrVg90H21EOLACvtfcHk0lj7UbjxS9YI9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXls1Wisbk%253D&md5=540358035222f745f7b6367b38781a21</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1073%2Fpnas.141230798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.141230798%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DKumagai%26aufirst%3DA.%26aulast%3DMercurio%26aufirst%3DF.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26aulast%3DDeshaies%26aufirst%3DR.%2BJ.%26atitle%3DProtacs%253A%2520Chimeric%2520molecules%2520that%2520target%2520proteins%2520to%2520the%2520Skp1%25E2%2580%2593Cullin%25E2%2580%2593F%2520box%2520complex%2520for%2520ubiquitination%2520and%2520degradation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D8554%26epage%3D8559%26doi%3D10.1073%2Fpnas.141230798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delproposto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1420</span>– <span class="NLM_lpage">1442</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Cqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1420-1442&author=J.+Huauthor=B.+Huauthor=M.+Wangauthor=F.+Xuauthor=B.+Miaoauthor=C.-Y.+Yangauthor=M.+Wangauthor=Z.+Liuauthor=D.+F.+Hayesauthor=K.+Chinnaswamyauthor=J.+Delpropostoauthor=J.+Stuckeyauthor=S.+Wang&title=Discovery+of+ERD-308+as+a+Highly+Potent+Proteolysis+Targeting+Chimera+%28PROTAC%29+Degrader+of+Estrogen+Receptor+%28ER%29&doi=10.1021%2Facs.jmedchem.8b01572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)</span></div><div class="casAuthors">Hu, Jiantao; Hu, Biao; Wang, Mingliang; Xu, Fuming; Miao, Bukeyan; Yang, Chao-Yie; Wang, Mi; Liu, Zhaomin; Hayes, Daniel F.; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1420-1442</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-pos. (ER+) breast cancer.  Here, we describe the design, synthesis, and extensive structure-activity relationship (SAR) studies of small-mol. ERα degraders based on the proteolysis targeting chimeras (PROTAC) concept.  Our efforts have resulted in the discovery of highly potent and effective PROTAC ER degraders, as exemplified by ERD-308 I.  I achieves DC50 (concn. causing 50% of protein degrdn.) values of 0.17 and 0.43 nM in MCF-7 and T47D ER+ breast cancer cell lines, resp., and induces >95% of ER degrdn. at concns. as low as 5 nM in both cell lines.  Significantly, I induces more complete ER degrdn. than fulvestrant, the only approved selective ER degrader (SERD), and is more effective in inhibition of cell proliferation than fulvestrant in MCF-7 cells.  Further optimization of I may lead to a new therapy for advanced ER+ breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHRlcISYyFXLVg90H21EOLACvtfcHk0lj7UbjxS9YI9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Cqs7s%253D&md5=678e82dd460c065e2054ba18ea8af18a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01572%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DMiao%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DDelproposto%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520ERD-308%2520as%2520a%2520Highly%2520Potent%2520Proteolysis%2520Targeting%2520Chimera%2520%2528PROTAC%2529%2520Degrader%2520of%2520Estrogen%2520Receptor%2520%2528ER%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1420%26epage%3D1442%26doi%3D10.1021%2Facs.jmedchem.8b01572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delproposto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01631</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01631" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=941-964&author=X.+Hanauthor=C.+Wangauthor=C.+Qinauthor=W.+Xiangauthor=E.+Fernandez-Salasauthor=C.-Y.+Yangauthor=M.+Wangauthor=L.+Zhaoauthor=T.+Xuauthor=K.+Chinnaswamyauthor=J.+Delpropostoauthor=J.+Stuckeyauthor=S.+Wang&title=Discovery+of+ARD-69+as+a+highly+potent+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+androgen+receptor+%28AR%29+for+the+treatment+of+prostate+cancer&doi=10.1021%2Facs.jmedchem.8b01631"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</span></div><div class="casAuthors">Han, Xin; Wang, Chao; Qin, Chong; Xiang, Weiguo; Fernandez-Salas, Ester; Yang, Chao-Yie; Wang, Mi; Zhao, Lijie; Xu, Tianfeng; Chinnaswamy, Krishnapriya; Delproposto, James; Stuckey, Jeanne; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">941-964</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the discovery of highly potent PROTAC degraders of androgen receptor (AR), as exemplified by IARD-69.  I induces degrdn. of AR protein in AR-pos. prostate cancer cell lines in a dose- and time-dependent manner.  I achieves DC50 values of 0.86, 0.76, and 10.4 nM in LNCaP, VCaP, and 22Rv1 AR+ prostate cancer cell lines, resp.  I is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.  I potently inhibits cell growth in these AR-pos. prostate cancer cell lines and is >100 times more potent than AR antagonists.  A single dose of I effectively reduces the level of AR protein in xenograft tumor tissue in mice.  Further optimization of I may ultimately lead to a new therapy for AR+, castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTlOD69tfhtbVg90H21EOLACvtfcHk0lj7UbjxS9YI9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFCjtQ%253D%253D&md5=2376573fb1a1e19c517d64c70199700a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01631&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01631%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DDelproposto%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520ARD-69%2520as%2520a%2520highly%2520potent%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520androgen%2520receptor%2520%2528AR%2529%2520for%2520the%2520treatment%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D941%26epage%3D964%26doi%3D10.1021%2Facs.jmedchem.8b01631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Phthalimide conjugation as a strategy for in vivo target protein degradation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">1376</span>– <span class="NLM_lpage">1381</span>, <span class="refDoi"> DOI: 10.1126/science.aab1433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1126%2Fscience.aab1433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25999370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=1376-1381&author=G.+E.+Winterauthor=D.+L.+Buckleyauthor=J.+Paulkauthor=J.+M.+Robertsauthor=A.+Souzaauthor=S.+Dhe-Paganonauthor=J.+E.+Bradner&title=Phthalimide+conjugation+as+a+strategy+for+in+vivo+target+protein+degradation&doi=10.1126%2Fscience.aab1433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phthalimide conjugation as a strategy for in vivo target protein degradation</span></div><div class="casAuthors">Winter, Georg E.; Buckley, Dennis L.; Paulk, Joshiawa; Roberts, Justin M.; Souza, Amanda; Dhe-Paganon, Sirano; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6241</span>),
    <span class="NLM_cas:pages">1376-1381</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The development of effective pharmacol. inhibitors of multidomain scaffold proteins, notably transcription factors, is a particularly challenging problem.  In part, this is because many small-mol. antagonists disrupt the activity of only one domain in the target protein.  The authors devised a chem. strategy that promotes ligand-dependent target protein degrdn. using as an example the transcriptional coactivator BRD4, a protein crit. for cancer cell growth and survival.  The authors appended a competitive antagonist of BET bromodomains to a phthalimide moiety to hijack the cereblon E3 ubiquitin ligase complex.  The resultant compd., dBET1, induced highly selective cereblon-dependent BET protein degrdn. in vitro and in vivo and delayed leukemia progression in mice.  A second series of probes resulted in selective degrdn. of the cytosolic protein FKBP12.  This chem. strategy for controlling target protein stability may have implications for therapeutically targeting previously intractable proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1ZW4zjRjXi7Vg90H21EOLACvtfcHk0lgowc06SqSDpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFansLk%253D&md5=b0277cc95d318d926b96e7a119066e3b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1126%2Fscience.aab1433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aab1433%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DRoberts%26aufirst%3DJ.%2BM.%26aulast%3DSouza%26aufirst%3DA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DPhthalimide%2520conjugation%2520as%2520a%2520strategy%2520for%2520in%2520vivo%2520target%2520protein%2520degradation%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D1376%26epage%3D1381%26doi%3D10.1126%2Fscience.aab1433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinebach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köpff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López Mármol, Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichenzeller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gütschow, M.</span></span> <span> </span><span class="NLM_article-title">PROTAC-mediated crosstalk between E3 ligases</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1821</span>– <span class="NLM_lpage">1824</span>, <span class="refDoi"> DOI: 10.1039/c8cc09541h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1039%2FC8CC09541H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=30672516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFSmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=1821-1824&author=C.+Steinebachauthor=H.+Kehmauthor=S.+Lindnerauthor=L.+P.+Vuauthor=S.+K%C3%B6pffauthor=%C3%81.+L%C3%B3pez+M%C3%A1rmolauthor=C.+Weilerauthor=K.+G.+Wagnerauthor=M.+Reichenzellerauthor=J.+Kr%C3%B6nkeauthor=M.+G%C3%BCtschow&title=PROTAC-mediated+crosstalk+between+E3+ligases&doi=10.1039%2Fc8cc09541h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-mediated crosstalk between E3 ligases</span></div><div class="casAuthors">Steinebach, Christian; Kehm, Hannes; Lindner, Stefanie; Vu, Lan Phuong; Koepff, Simon; Lopez Marmol, Alvaro; Weiler, Corinna; Wagner, Karl G.; Reichenzeller, Michaela; Kroenke, Jan; Guetschow, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1821-1824</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Small-mol. heterobifunctional degraders can effectively control protein levels and are useful research tools.  We assembled proteolysis targeting chimeras (PROTACs) from a cereblon (CRBN) and a von-Hippel-Lindau (VHL) ligase ligand and demonstrated a PROTAC-induced heterodimerization of the two E3 ligases leading to unidirectional and efficient degrdn. of CRBN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofM8Lun8SiSLVg90H21EOLACvtfcHk0lgowc06SqSDpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFSmtLY%253D&md5=17ed8abc73d45081c73f1995205713cf</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1039%2FC8CC09541H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CC09541H%26sid%3Dliteratum%253Aachs%26aulast%3DSteinebach%26aufirst%3DC.%26aulast%3DKehm%26aufirst%3DH.%26aulast%3DLindner%26aufirst%3DS.%26aulast%3DVu%26aufirst%3DL.%2BP.%26aulast%3DK%25C3%25B6pff%26aufirst%3DS.%26aulast%3DL%25C3%25B3pez%2BM%25C3%25A1rmol%26aufirst%3D%25C3%2581.%26aulast%3DWeiler%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DK.%2BG.%26aulast%3DReichenzeller%26aufirst%3DM.%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26atitle%3DPROTAC-mediated%2520crosstalk%2520between%2520E3%2520ligases%26jtitle%3DChem.%2520Commun.%26date%3D2019%26volume%3D55%26spage%3D1821%26epage%3D1824%26doi%3D10.1039%2Fc8cc09541h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1016%2Fj.ejmech.2018.01.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=29407955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFehsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=251-259&author=M.+Luauthor=T.+Liuauthor=Q.+Jiaoauthor=J.+Jiauthor=M.+Taoauthor=Y.+Liuauthor=Q.+Youauthor=Z.+Jiang&title=Discovery+of+a+Keap1-dependent+peptide+PROTAC+to+knockdown+Tau+by+ubiquitination-proteasome+degradation+pathway&doi=10.1016%2Fj.ejmech.2018.01.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway</span></div><div class="casAuthors">Lu, Mengchen; Liu, Tian; Jiao, Qiong; Ji, Jianai; Tao, Mengmin; Liu, Yijun; You, Qidong; Jiang, Zhengyu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">251-259</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Induced protein degrdn. by PROTACs has emerged as a promising strategy to target nonenzymic proteins inside the cell.  The aim of this study was to identify Keap1, a substrate adaptor protein for ubiquitin E3 ligase involved in oxidative stress regulation, as a novel candidate for PROTACs that can be applied in the degrdn. of the nonenzymic protein Tau.  A peptide PROTAC by recruiting Keap1-Cul3 ubiquitin E3 ligase was developed and applied in the degrdn. of intracellular Tau.  Peptide 1 showed strong in vitro binding with Keap1 and Tau.  With proper cell permeability, peptide 1 was found to colocalize with cellular Keap1 and resulted in the coimmunopptn. of Tau and Keap1.  The results of flow cytometry and western blotting assays showed that peptide 1 can downregulate the intracellular Tau level in both time- and concn.-dependent manner.  The application of Keap1 siRNA silencing and the proteasome inhibitor MG132 confirmed that peptide 1 could promote the Keap1-dependent poly-ubiquitination and proteasome-dependent degrdn. of Tau.  The results suggested that using PROTACs to recruit Keap1 to induce the degrdn. of Tau may show promising character in the treatment of neurodegenerative disease.  In addn., our research demonstrated that Keap1 should be a promising E3 ligase adaptor to be used in the design of novel PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9KC7pnPqlL7Vg90H21EOLACvtfcHk0lgowc06SqSDpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFehsbY%253D&md5=165e6f510e4e2024aca6c4135d2840b2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.063%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DJiao%26aufirst%3DQ.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYou%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520a%2520Keap1-dependent%2520peptide%2520PROTAC%2520to%2520knockdown%2520Tau%2520by%2520ubiquitination-proteasome%2520degradation%2520pathway%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D251%26epage%3D259%26doi%3D10.1016%2Fj.ejmech.2018.01.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kargbo, R. B.</span></span> <span> </span><span class="NLM_article-title">Treatment of Alzheimer’s by PROTAC-Tau protein degradation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVSnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=699-700&author=R.+B.+Kargbo&title=Treatment+of+Alzheimer%E2%80%99s+by+PROTAC-Tau+protein+degradation&doi=10.1021%2Facsmedchemlett.9b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of Alzheimer's by PROTAC-Tau Protein Degradation</span></div><div class="casAuthors">Kargbo, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">699-700</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfHxe_Dk7zBrVg90H21EOLACvtfcHk0ljZfErP9Ummww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVSnu70%253D&md5=7d4254b26c56f6401c16e6d100ddf0bd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00083%26sid%3Dliteratum%253Aachs%26aulast%3DKargbo%26aufirst%3DR.%2BB.%26atitle%3DTreatment%2520of%2520Alzheimer%25E2%2580%2599s%2520by%2520PROTAC-Tau%2520protein%2520degradation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D699%26epage%3D700%26doi%3D10.1021%2Facsmedchemlett.9b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-M.</span></span> <span> </span><span class="NLM_article-title">Specific knockdown of endogenous Tau protein by peptide-directed ubiquitin-proteasome degradation</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1016%2Fj.chembiol.2016.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=27105281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlSqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=453-461&author=T.-T.+Chuauthor=N.+Gaoauthor=Q.-Q.+Liauthor=P.-G.+Chenauthor=X.-F.+Yangauthor=Y.-X.+Chenauthor=Y.-F.+Zhaoauthor=Y.-M.+Li&title=Specific+knockdown+of+endogenous+Tau+protein+by+peptide-directed+ubiquitin-proteasome+degradation&doi=10.1016%2Fj.chembiol.2016.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation</span></div><div class="casAuthors">Chu, Ting-Ting; Gao, Na; Li, Qian-Qian; Chen, Pu-Guang; Yang, Xi-Fei; Chen, Yong-Xiang; Zhao, Yu-Fen; Li, Yan-Mei</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">453-461</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tau, an important pathol. protein of Alzheimer's disease (AD), can mediate the toxicity of amyloid β (Aβ).  Thus, redn. of Tau with chem. mols. may offer a novel strategy for treating AD.  Here, we designed and synthesized a series of multifunctional mols. that contained Tau-recognition moieties and E3 ligase-binding moieties to enhance Tau degrdn.  Among these mols., TH006 had the highest activity of inducing Tau degrdn. by increasing its poly-ubiquitination.  The decrement in Tau induced by TH006 could decrease the cytotoxicity caused by Aβ.  Furthermore, TH006 could regulate the Tau level in the brain of an AD mouse model.  Therefore, partial redn. of Tau with such multifunctional peptides may open up a novel therapeutic strategy for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnG14J2STP7Vg90H21EOLACvtfcHk0ljZfErP9Ummww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlSqtbg%253D&md5=d965c74777427dfa9b6068f4f51a0f12</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DT.-T.%26aulast%3DGao%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DQ.-Q.%26aulast%3DChen%26aufirst%3DP.-G.%26aulast%3DYang%26aufirst%3DX.-F.%26aulast%3DChen%26aufirst%3DY.-X.%26aulast%3DZhao%26aufirst%3DY.-F.%26aulast%3DLi%26aufirst%3DY.-M.%26atitle%3DSpecific%2520knockdown%2520of%2520endogenous%2520Tau%2520protein%2520by%2520peptide-directed%2520ubiquitin-proteasome%2520degradation%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D453%26epage%3D461%26doi%3D10.1016%2Fj.chembiol.2016.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boichenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bär, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupas, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez Alvarez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M. D.</span></span> <span> </span><span class="NLM_article-title">Chemical ligand space of cereblon</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">11163</span>– <span class="NLM_lpage">11171</span>, <span class="refDoi"> DOI: 10.1021/acsomega.8b00959</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.8b00959" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSku7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=11163-11171&author=I.+Boichenkoauthor=K.+B%C3%A4rauthor=S.+Deissauthor=C.+Heimauthor=R.+Albrechtauthor=A.+N.+Lupasauthor=B.+Hernandez+Alvarezauthor=M.+D.+Hartmann&title=Chemical+ligand+space+of+cereblon&doi=10.1021%2Facsomega.8b00959"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Ligand Space of Cereblon</span></div><div class="casAuthors">Boichenko, Iuliia; Baer, Kerstin; Deiss, Silvia; Heim, Christopher; Albrecht, Reinhard; Lupas, Andrei N.; Hernandez Alvarez, Birte; Hartmann, Marcus D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">11163-11171</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The protein, cereblon, serves as a substrate receptor of a ubiquitin ligase complex that can be tuned toward different target proteins by cereblon-binding agents.  This approach to targeted protein degrdn. is exploited in different clin. settings and has sparked the development of a growing no. of thalidomide derivs.  Here, we probed the chem. space of cereblon binding beyond such derivs. and worked out a simple set of chem. requirements, delineating the metaclass of cereblon effectors.  We report co-crystal structures of Magnetospirillum gryphiswaldense cereblon isoform 4 with a diverse set of compds., including commonly used pharmaceuticals, but we also found that already minimalistic cereblon-binding moieties might exert teratogenic effects in zebrafish.  These results may guide the design of a post-thalidomide generation of therapeutic cereblon effectors, and provide a framework for the circumvention of unintended cereblon-binding by neg. design for future pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-HgXkEOEEXrVg90H21EOLACvtfcHk0ljZfErP9Ummww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSku7bO&md5=b0fee25453d5ec83098ac0cf28575d44</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsomega.8b00959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.8b00959%26sid%3Dliteratum%253Aachs%26aulast%3DBoichenko%26aufirst%3DI.%26aulast%3DB%25C3%25A4r%26aufirst%3DK.%26aulast%3DDeiss%26aufirst%3DS.%26aulast%3DHeim%26aufirst%3DC.%26aulast%3DAlbrecht%26aufirst%3DR.%26aulast%3DLupas%26aufirst%3DA.%2BN.%26aulast%3DHernandez%2BAlvarez%26aufirst%3DB.%26aulast%3DHartmann%26aufirst%3DM.%2BD.%26atitle%3DChemical%2520ligand%2520space%2520of%2520cereblon%26jtitle%3DACS%2520Omega%26date%3D2018%26volume%3D3%26spage%3D11163%26epage%3D11171%26doi%3D10.1021%2Facsomega.8b00959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cromm, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Efficient synthesis of immunomodulatory drug analogues enables exploration of structure-degradation relationships</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1508</span>– <span class="NLM_lpage">1512</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201800271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1002%2Fcmdc.201800271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=29870139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1KntL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1508-1512&author=G.+M.+Burslemauthor=P.+Ottisauthor=S.+Jaime-Figueroaauthor=A.+Morganauthor=P.+M.+Crommauthor=M.+Toureauthor=C.+M.+Crews&title=Efficient+synthesis+of+immunomodulatory+drug+analogues+enables+exploration+of+structure-degradation+relationships&doi=10.1002%2Fcmdc.201800271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships</span></div><div class="casAuthors">Burslem, George M.; Ottis, Philipp; Jaime-Figueroa, Saul; Morgan, Alicia; Cromm, Philipp M.; Toure, Momar; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1508-1512</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The immunomodulatory drugs (IMiDs) thalidomide, pomalidomide, and lenalidomide have been approved for the treatment of multiple myeloma for many years.  Recently, their use as E3 ligase recruiting elements for small-mol.-induced protein degrdn. has led to a resurgence in interest in IMiD synthesis and functionalization.  Traditional IMiD synthesis follows a stepwise route with multiple purifn. steps.  Herein we describe a novel one-pot synthesis without purifn. that provides rapid access to a multitude of IMiD analogs.  Binding studies with the IMiD target protein cereblon (CRBN) reveals a narrow structure-activity relationship with only a few compds. showing sub-micromolar binding affinity in the range of pomalidomide and lenalidomide.  However, anti-proliferative activity as well as Aiolos degrdn. could be identified for two IMiD analogs.  This study provides useful insight into the structure-degrdn. relationships for mols. of this type as well as a rapid and robust method for IMiD synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXV1lRMrjBNrVg90H21EOLACvtfcHk0ljBCUOELOgjvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1KntL7O&md5=74ada081313c4e01b430fb6014441e2e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201800271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201800271%26sid%3Dliteratum%253Aachs%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DOttis%26aufirst%3DP.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DMorgan%26aufirst%3DA.%26aulast%3DCromm%26aufirst%3DP.%2BM.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DEfficient%2520synthesis%2520of%2520immunomodulatory%2520drug%2520analogues%2520enables%2520exploration%2520of%2520structure-degradation%2520relationships%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D1508%26epage%3D1512%26doi%3D10.1002%2Fcmdc.201800271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dredge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgleish, A. G.</span></span> <span> </span><span class="NLM_article-title">The evolution of thalidomide and its IMiD derivatives as anticancer agents</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1038/nrc1323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1038%2Fnrc1323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=15057291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=314-322&author=J.+B.+Bartlettauthor=K.+Dredgeauthor=A.+G.+Dalgleish&title=The+evolution+of+thalidomide+and+its+IMiD+derivatives+as+anticancer+agents&doi=10.1038%2Fnrc1323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The evolution of thalidomide and its IMiD derivatives as anticancer agents</span></div><div class="casAuthors">Bartlett, J. Blake; Dredge, Keith; Dalgleish, Angus G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">314-322</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Thalidomide was originally used to treat morning sickness, but was banned in the 1960s for causing serious congenital birth defects.  Remarkably, thalidomide was subsequently discovered to have anti-inflammatory and anti-angiogenic properties, and was identified as an effective treatment for multiple myeloma.  A series of immunomodulatory drugs - created by chem. modification of thalidomide - have been developed to overcome the original devastating side effects.  Their powerful anticancer properties mean that these drugs are now emerging from thalidomide's shadow as useful anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4ahyYZGz7MbVg90H21EOLACvtfcHk0ljBCUOELOgjvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt7k%253D&md5=99d2ac4c0f6d6d1dac5547e5360dd74f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrc1323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1323%26sid%3Dliteratum%253Aachs%26aulast%3DBartlett%26aufirst%3DJ.%2BB.%26aulast%3DDredge%26aufirst%3DK.%26aulast%3DDalgleish%26aufirst%3DA.%2BG.%26atitle%3DThe%2520evolution%2520of%2520thalidomide%2520and%2520its%2520IMiD%2520derivatives%2520as%2520anticancer%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D314%26epage%3D322%26doi%3D10.1038%2Fnrc1323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrupt, P.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francotte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, B.</span></span> <span> </span><span class="NLM_article-title">Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1521</span>– <span class="NLM_lpage">1528</span>, <span class="refDoi"> DOI: 10.1021/tx9801817</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx9801817" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADyaK1cXntFens7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1998&pages=1521-1528&author=M.+Reistauthor=P.-A.+Carruptauthor=E.+Francotteauthor=B.+Testa&title=Chiral+inversion+and+hydrolysis+of+thalidomide%3A+mechanisms+and+catalysis+by+bases+and+serum+albumin%2C+and+chiral+stability+of+teratogenic+metabolites&doi=10.1021%2Ftx9801817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral Inversion and Hydrolysis of Thalidomide: Mechanisms and Catalysis by Bases and Serum Albumin, and Chiral Stability of Teratogenic Metabolites</span></div><div class="casAuthors">Reist, Marianne; Carrupt, Pierre-Alain; Francotte, Eric; Testa, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1521-1528</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The chiral inversion and hydrolysis of thalidomide and the catalysis by bases and human serum albumin were investigated by using a stereoselective HPLC assay.  Chiral inversion was catalyzed by albumin, hydroxyl ions, phosphate, and amino acids.  Basic amino acids (Arg and Lys) had a superior potency in catalyzing chiral inversion compared to acid and neutral ones.  The chiral inversion of thalidomide is thus subject to specific and general base catalysis, and it is suggested that the ability of HSA to catalyze the reaction is due to the basic groups of the amino acids Arg and Lys and not to a single catalytic site on the macromol.  The hydrolysis of thalidomide was also base-catalyzed.  However, albumin had no effect on hydrolysis, and there was no difference between the catalytic potencies of acidic, neutral, and basic amino acids.  This may be explained by different reaction mechanisms of the chiral inversion and hydrolysis of thalidomide.  Chiral inversion is deduced to occur by electrophilic substitution involving specific and general base catalysis, whereas hydrolysis is thought to occur by nucleophilic substitution involving specific and general base as well as nucleophilic catalysis.  As nucleophilic attack is sensitive to steric properties of the catalyst, steric hindrance might be the reason albumin is not able to catalyze hydrolysis.  1H NMR expts. revealed that the three teratogenic metabolites of thalidomide, in sharp contrast to the drug itself, had complete chiral stability.  This leads to the speculation that, were some enantioselectivity to exist in the teratogenicity of thalidomide, it could result from fast hydrolysis to chirally stable teratogenic metabolites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfmXgvPgsp8rVg90H21EOLACvtfcHk0ljBCUOELOgjvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntFens7s%253D&md5=1952fa00825e6791eeb8388419f3cc09</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Ftx9801817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx9801817%26sid%3Dliteratum%253Aachs%26aulast%3DReist%26aufirst%3DM.%26aulast%3DCarrupt%26aufirst%3DP.-A.%26aulast%3DFrancotte%26aufirst%3DE.%26aulast%3DTesta%26aufirst%3DB.%26atitle%3DChiral%2520inversion%2520and%2520hydrolysis%2520of%2520thalidomide%253A%2520mechanisms%2520and%2520catalysis%2520by%2520bases%2520and%2520serum%2520albumin%252C%2520and%2520chiral%2520stability%2520of%2520teratogenic%2520metabolites%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1998%26volume%3D11%26spage%3D1521%26epage%3D1528%26doi%3D10.1021%2Ftx9801817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelsang, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petty, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brundrett, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colvin, O. M.</span></span> <span> </span><span class="NLM_article-title">Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers</span>. <i>Drug Metab Dispos</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">405</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=2571480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADyaL1MXlt1KnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1989&pages=402-405&author=T.+L.+Chenauthor=G.+B.+Vogelsangauthor=B.+G.+Pettyauthor=R.+B.+Brundrettauthor=D.+A.+Noeauthor=G.+W.+Santosauthor=O.+M.+Colvin&title=Plasma+pharmacokinetics+and+urinary+excretion+of+thalidomide+after+oral+dosing+in+healthy+male+volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers</span></div><div class="casAuthors">Chen, Tian Ling; Vogelsang, Georgia B.; Petty, Brent G.; Brundrett, Robert B.; Noe, Dennis A.; Santos, George W.; Colvin, O. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-5</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    </div><div class="casAbstract">The plasma pharmacokinetics and urinary excretion of thalidomide were evaluated in healthy male volunteers receiving a single oral dose of 200 mg.  Concns. of thalidomide were detd. by a new HPLC assay.  Plasma concn. vs. time data were well fit by a 1-compartment model.  The mean peak concn., 1.15 μg/mL, was achieved at 4.39 h.  Absorption and elimination half-lives were 1.70 and 8.70 h, resp., with a lag time of 0.41 h obsd. in 6 of 8 subjects.  The apparent vol. of distribution and total body clearance rate, based on assumed complete bioavailability, were 120.69 L and 10.41 L/h.  The urinary excretion of thalidomide accounted for only 0.6% of the total dose administered over 24 h, and the renal clearance rate was 0.08 L/h.  Thus, the major route of elimination of thalidomide is nonrenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo27dR99aSZ8rVg90H21EOLACvtfcHk0ljxhtD-jgbPGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlt1KnsLY%253D&md5=e171e48357c05ea8fedbc2979293650e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%2BL.%26aulast%3DVogelsang%26aufirst%3DG.%2BB.%26aulast%3DPetty%26aufirst%3DB.%2BG.%26aulast%3DBrundrett%26aufirst%3DR.%2BB.%26aulast%3DNoe%26aufirst%3DD.%2BA.%26aulast%3DSantos%26aufirst%3DG.%2BW.%26aulast%3DColvin%26aufirst%3DO.%2BM.%26atitle%3DPlasma%2520pharmacokinetics%2520and%2520urinary%2520excretion%2520of%2520thalidomide%2520after%2520oral%2520dosing%2520in%2520healthy%2520male%2520volunteers%26jtitle%3DDrug%2520Metab%2520Dispos%26date%3D1989%26volume%3D17%26spage%3D402%26epage%3D405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. T.</span></span> <span> </span><span class="NLM_article-title">The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species</span>. <i>Br. J. Pharmacol. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1965.tb02054.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1111%2Fj.1476-5381.1965.tb02054.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=5866716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADyaF28Xhtl2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1965&pages=338-351&author=H.+Schumacherauthor=R.+L.+Smithauthor=R.+T.+Williams&title=The+metabolism+of+thalidomide%3A+the+fate+of+thalidomide+and+some+of+its+hydrolysis+products+in+various+species&doi=10.1111%2Fj.1476-5381.1965.tb02054.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of thalidomide. The fate of thalidomide and some of its hydrolysis products in various species</span></div><div class="casAuthors">Schumacher, H.; Smith, R. L.; Williams, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology and Chemotherapy</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">338-51</span>CODEN:
                <span class="NLM_cas:coden">BJPCAL</span>;
        ISSN:<span class="NLM_cas:issn">0366-0826</span>.
    </div><div class="casAbstract">cf. preceding abstr.  The metabolism of thalidomide in the rabbit, rat, mouse, and guinea pig was investigated.  The metabolites of thalidomide present in the urine, blood, and tissues of various species dosed with the drug were characterized by comparing their chromatographic mobility and color reactions with those given by authentic samples of the compds.  The rabbit urinary metabolites were isolated in cryst. form by solvent extn. and adsorption chromatography, and their identity was established by analysis, m.p. behavior, and comparison of their ir spectra with those of the authentic compds.  When thalidomide is fed to rabbits, rats, mice, and guinea pigs a no. of hydrolysis products appear in the urine.  These hydrolysis products are formed by the spontaneous hydrolysis of thalidomide.  In addn. the urine of rabbits dosed with thalidomide contains derivs. of 3- and 4-hydroxyphthalic acid; these minor metabolites were not identified.  The hydrolysis products appear to be derived by spontaneous breakdown of thalidomide in the body, although it is possible that any of the hydrolytic reactions of thalidomide may be assisted by hydrolases in the body.  In rats, some breakdown of thalidomide occurs in the gut before absorption; hydrolysis products are present in the gastrointestinal tract following the oral administration of the drug.  Thalidomide and some of its hydrolysis products can be detected in the plasma and brain of rats dosed orally with thalidomide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonBmF6EIEpPrVg90H21EOLACvtfcHk0ljxhtD-jgbPGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF28Xhtl2rsA%253D%253D&md5=cb686e6f49ced088a96fc32b61f2256b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1965.tb02054.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1965.tb02054.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DR.%2BL.%26aulast%3DWilliams%26aufirst%3DR.%2BT.%26atitle%3DThe%2520metabolism%2520of%2520thalidomide%253A%2520the%2520fate%2520of%2520thalidomide%2520and%2520some%2520of%2520its%2520hydrolysis%2520products%2520in%2520various%2520species%26jtitle%3DBr.%2520J.%2520Pharmacol.%2520Chemother.%26date%3D1965%26volume%3D25%26spage%3D338%26epage%3D351%26doi%3D10.1111%2Fj.1476-5381.1965.tb02054.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teo, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colburn, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracewell, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kook, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirling, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaworsky, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laskin, O. L.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of thalidomide</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.2165/00003088-200443050-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.2165%2F00003088-200443050-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=15080764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFOqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=311-327&author=S.+K.+Teoauthor=W.+A.+Colburnauthor=W.+G.+Tracewellauthor=K.+A.+Kookauthor=D.+I.+Stirlingauthor=M.+S.+Jaworskyauthor=M.+A.+Schefflerauthor=S.+D.+Thomasauthor=O.+L.+Laskin&title=Clinical+pharmacokinetics+of+thalidomide&doi=10.2165%2F00003088-200443050-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of thalidomide</span></div><div class="casAuthors">Teo, Steve K.; Colburn, Wayne A.; Tracewell, William G.; Kook, Karin A.; Stirling, David I.; Jaworsky, Markian S.; Scheffler, Michael A.; Thomas, Steve D.; Laskin, Oscar L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">311-327</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Thalidomide is a racemic glutamic acid deriv. approved in the US for erythema nodosum leprosum, a complication of leprosy.  In addn., its use in various inflammatory and oncol. conditions is being investigated.  Thalidomide interconverts between the (R)- and (S)-enantiomers in plasma, with protein binding of 55% and 65%, resp.  More than 90% of the absorbed drug is excreted in the urine and feces within 48 h.  Thalidomide is minimally metabolized by the liver, but is spontaneously hydrolyzed into numerous renally excreted products.  After a single oral dose of thalidomide 200mg (as the US-approved capsule formulation) in healthy volunteers, absorption is slow and extensive, resulting in a peak concn. (Cmax) of 1-2 mg/L at 3-4 h after administration, absorption lag time of 30 min, total exposure (AUC∞) of 18 mg • h/L, apparent elimination half-life of 6 h and apparent systemic clearance of 10 L/h.  Thalidomide pharmacokinetics are best described by a one-compartment model with first-order absorption and elimination.  Because of the low soly. of the drug in the gastrointestinal tract, thalidomide exhibits absorption rate-limited pharmacokinetics (the "flip-flop" phenomenon), with its elimination rate being faster than its absorption rate.  The apparent elimination half-life of 6 h therefore represents absorption, not elimination.  The "true" apparent vol. of distribution was estd. to be 16L by use of the faster elimination-rate half-life.  Multiple doses of thalidomide 200 mg/day over 21 days cause no change in the pharmacokinetics, with a steady-state Cmax (Cssmax) of 1.2 mg/L.  Simulation of 400 and 800 mg/day also shows no accumulation, with Cssmax of 3.5 and 6.0 mg/L, resp.  Multiple-dose studies in cancer patients show pharmacokinetics comparable with those in healthy populations at similar dosages.  Thalidomide exhibits a dose-proportional increase in AUC at doses from 50 to 400mg.  Because of the low soly. of thalidomide, Cmax is less than proportional to dose, and tmax is prolonged with increasing dose.  Age, sex and smoking have no effect on the pharmacokinetics of thalidomide, and the effect of food is minimal.  Thalidomide does not alter the pharmacokinetics of oral contraceptives, and is also unlikely to interact with warfarin and grapefruit juice.  Since thalidomide is mainly hydrolyzed and passively excreted, its pharmacokinetics are not expected to change in patients with impaired liver or kidney function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqliBDHYhKycbVg90H21EOLACvtfcHk0ljxhtD-jgbPGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFOqtbg%253D&md5=aa199f0c21a3fdb952fccde4059b71ec</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.2165%2F00003088-200443050-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200443050-00004%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DS.%2BK.%26aulast%3DColburn%26aufirst%3DW.%2BA.%26aulast%3DTracewell%26aufirst%3DW.%2BG.%26aulast%3DKook%26aufirst%3DK.%2BA.%26aulast%3DStirling%26aufirst%3DD.%2BI.%26aulast%3DJaworsky%26aufirst%3DM.%2BS.%26aulast%3DScheffler%26aufirst%3DM.%2BA.%26aulast%3DThomas%26aufirst%3DS.%2BD.%26aulast%3DLaskin%26aufirst%3DO.%2BL.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520thalidomide%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2004%26volume%3D43%26spage%3D311%26epage%3D327%26doi%3D10.2165%2F00003088-200443050-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, R.</span></span> <span> </span><span class="NLM_article-title">Ueber das Verhalten von Thalidomid im Organismus</span>. <i>Arzneimittelforschung</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=13970176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A280%3ADyaF387mtF2mug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1963&pages=185-191&author=R.+Beckmann&title=Ueber+das+Verhalten+von+Thalidomid+im+Organismus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">C-14])</span></div><div class="casAuthors">BECKMANN R</div><div class="citationInfo"><span class="NLM_cas:title">Arzneimittel-Forschung</span>
        (<span class="NLM_cas:date">1963</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185-91</span>
        ISSN:<span class="NLM_cas:issn">0004-4172</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkR3GXTV6hukwlCcfExbvbfW6udTcc2ebFJjcTdDwWorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF387mtF2mug%253D%253D&md5=211cb3a294eb7d33c0cfd689bb37d2bc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeckmann%26aufirst%3DR.%26atitle%3DUeber%2520das%2520Verhalten%2520von%2520Thalidomid%2520im%2520Organismus%26jtitle%3DArzneimittelforschung%26date%3D1963%26volume%3D13%26spage%3D185%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kestell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baguley, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tingle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ching, L. M.</span></span> <span> </span><span class="NLM_article-title">Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">5949</span>– <span class="NLM_lpage">5956</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-04-0421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1158%2F1078-0432.ccr-04-0421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=15355928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlyjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=5949-5956&author=F.+Chungauthor=J.+Luauthor=B.+D.+Palmerauthor=P.+Kestellauthor=P.+Browettauthor=B.+C.+Baguleyauthor=M.+Tingleauthor=L.+M.+Ching&title=Thalidomide+pharmacokinetics+and+metabolite+formation+in+mice%2C+rabbits%2C+and+multiple+myeloma+patients&doi=10.1158%2F1078-0432.ccr-04-0421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients</span></div><div class="casAuthors">Chung, Francisco; Lu, Jun; Palmer, Brian D.; Kestell, Philip; Browett, Peter; Baguley, Bruce C.; Tingle, Malcolm; Ching, Lai-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5949-5956</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thalidomide has a variety of biol. effects that vary considerably according to the species tested.  The authors sought to establish whether differences in pharmacokinetics could form a basis for the species-specific effects of thalidomide.  Mice and rabbits were administered thalidomide (2 mg/kg) p.o. or i.v., and plasma concns. of thalidomide were measured after drug administration using high performance liq. chromatog.  Plasma samples from five multiple myeloma patients over 24 h after their first dose of thalidomide (200 mg) were similarly analyzed and all data were fitted to a one-compartment model.  Metabolites of thalidomide in plasma were identified simultaneously using liq. chromatog.-mass spectrometry.  Plasma concn.-time profiles for the individual patients were very similar to each other, but widely different pharmacokinetic properties were found between patients compared with those in mice or rabbits.  Area under the concn. curve values for mice, rabbits, and multiple myeloma patients were 4, 8, and 81 μmol/L · hour, resp., and corresponding elimination half-lives were 0.5, 2.2, and 7.3 h, resp.  Large differences were also obsd. between the metabolite profiles from the three species.  Hydrolysis products were detected for all species, and the proportion of hydroxylated metabolites was higher in mice than in rabbits and undetectable in patients.  Our results show major interspecies differences in the pharmacokinetics of thalidomide that are related to the altered degree of metab.  The authors suggest that the interspecies differences in biol. effects of thalidomide may be attributable, at least in part, to the differences in its metab. and hence pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_L7cwpcdbcLVg90H21EOLACvtfcHk0lgSi3UeIbtSlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlyjtLw%253D&md5=51bea71546be92322a511405e004aa80</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-04-0421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-04-0421%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DKestell%26aufirst%3DP.%26aulast%3DBrowett%26aufirst%3DP.%26aulast%3DBaguley%26aufirst%3DB.%2BC.%26aulast%3DTingle%26aufirst%3DM.%26aulast%3DChing%26aufirst%3DL.%2BM.%26atitle%3DThalidomide%2520pharmacokinetics%2520and%2520metabolite%2520formation%2520in%2520mice%252C%2520rabbits%252C%2520and%2520multiple%2520myeloma%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D5949%26epage%3D5956%26doi%3D10.1158%2F1078-0432.ccr-04-0421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Hydrolyzed metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1248/cpb.55.651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1248%2Fcpb.55.651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=17409565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1arsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2007&pages=651-654&author=T.+Nakamuraauthor=T.+Noguchiauthor=H.+Miyachiauthor=Y.+Hashimoto&title=Hydrolyzed+metabolites+of+thalidomide%3A+synthesis+and+TNF-alpha+production-inhibitory+activity&doi=10.1248%2Fcpb.55.651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrolyzed metabolites of thalidomide: synthesis and TNF-α production-inhibitory activity</span></div><div class="casAuthors">Nakamura, Takanori; Noguchi, Tomomi; Miyachi, Hiroyuki; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">651-654</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Putative hydrolyzed metabolites of thalidomide (I) were prepd. and characterized, and their inhibitory activity on tumor necrosis factor (TNF)-α prodn. in the human monocytic leukemia cell line THP-1 was evaluated.  α-(2-Carboxybenzamido)glutarimide (II) was a more potent TNF-α prodn. inhibitor than I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW3FV9YCmOprVg90H21EOLACvtfcHk0lgSi3UeIbtSlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1arsLc%253D&md5=32f1066b688a9de33e9dbf5da42ec514</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1248%2Fcpb.55.651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.55.651%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DNoguchi%26aufirst%3DT.%26aulast%3DMiyachi%26aufirst%3DH.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DHydrolyzed%2520metabolites%2520of%2520thalidomide%253A%2520synthesis%2520and%2520TNF-alpha%2520production-inhibitory%2520activity%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2007%26volume%3D55%26spage%3D651%26epage%3D654%26doi%3D10.1248%2Fcpb.55.651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Otogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asahi, T.</span></span> <span> </span><span class="NLM_article-title">Structural and thermal analyses of a hydrolysis compound of thalidomide</span>. <i>Acta Crystallogr., Sect. A: Found. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">C113</span>, <span class="refDoi"> DOI: 10.1107/s2053273314098866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1107%2Fs2053273314098866" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2014&pages=C113&author=K.+Otogawaauthor=Y.+Oginoauthor=K.+Ishikawaauthor=M.+Tanakaauthor=M.+Shiroauthor=T.+Osakaauthor=T.+Asahi&title=Structural+and+thermal+analyses+of+a+hydrolysis+compound+of+thalidomide&doi=10.1107%2Fs2053273314098866"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2Fs2053273314098866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs2053273314098866%26sid%3Dliteratum%253Aachs%26aulast%3DOtogawa%26aufirst%3DK.%26aulast%3DOgino%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DShiro%26aufirst%3DM.%26aulast%3DOsaka%26aufirst%3DT.%26aulast%3DAsahi%26aufirst%3DT.%26atitle%3DStructural%2520and%2520thermal%2520analyses%2520of%2520a%2520hydrolysis%2520compound%2520of%2520thalidomide%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Adv.%26date%3D2014%26volume%3D70%26spage%3DC113%26doi%3D10.1107%2Fs2053273314098866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B. L.</span></span> <span> </span><span class="NLM_article-title">Lenalidomide induces degradation of IKZF1 and IKZF3</span>. <i>OncoImmunology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e941742</span> <span class="refDoi"> DOI: 10.4161/21624011.2014.941742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.4161%2F21624011.2014.941742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=25610725" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&author=J.+Kr%C3%B6nkeauthor=S.+N.+Hurstauthor=B.+L.+Ebert&title=Lenalidomide+induces+degradation+of+IKZF1+and+IKZF3&doi=10.4161%2F21624011.2014.941742"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.4161%2F21624011.2014.941742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F21624011.2014.941742%26sid%3Dliteratum%253Aachs%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26aulast%3DHurst%26aufirst%3DS.%2BN.%26aulast%3DEbert%26aufirst%3DB.%2BL.%26atitle%3DLenalidomide%2520induces%2520degradation%2520of%2520IKZF1%2520and%2520IKZF3%26jtitle%3DOncoImmunology%26date%3D2014%26volume%3D3%26doi%3D10.4161%2F21624011.2014.941742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringheim, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span> <span> </span><span class="NLM_article-title">Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1516</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2017-212916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1136%2Fannrheumdis-2017-212916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=29945920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVektbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2018&pages=1516-1523&author=P.+H.+Schaferauthor=Y.+Yeauthor=L.+Wuauthor=J.+Kosekauthor=G.+Ringheimauthor=Z.+Yangauthor=L.+Liuauthor=M.+Thomasauthor=M.+Palmisanoauthor=R.+Chopra&title=Cereblon+modulator+iberdomide+induces+degradation+of+the+transcription+factors+Ikaros+and+Aiolos%3A+immunomodulation+in+healthy+volunteers+and+relevance+to+systemic+lupus+erythematosus&doi=10.1136%2Fannrheumdis-2017-212916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus</span></div><div class="casAuthors">Schafer, Peter H.; Ye, Ying; Wu, Lei; Kosek, Jolanta; Ringheim, Garth; Yang, Zhihong; Liu, Liangang; Thomas, Michael; Palmisano, Maria; Chopra, Rajesh</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1516-1523</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">ObjectivesIKZF1 and IKZF3 (encoding transcription factors Ikaros and Aiolos) are susceptibility loci for systemic lupus erythematosus (SLE).  The pharmacol. of iberdomide (CC-220), a cereblon (CRBN) modulator targeting Ikaros and Aiolos, was studied in SLE patient cells and in a phase 1 healthy volunteer study.  MethodsCRBN, IKZF1 and IKZF3 gene expression was measured in peripheral blood mononuclear cells (PBMC) from patients with SLE and healthy volunteers.  Ikaros and Aiolos protein levels were measured by Western blot and flow cytometry.  Anti-dsDNA and anti-phospholipid autoantibodies were measured in SLE PBMC cultures treated for 7 days with iberdomide.  Fiftysix healthy volunteers were randomised to a single dose of iberdomide (0.03-6mg, n=6 across seven cohorts) or placebo (n=2/cohort).  CD19+ B cells, CD3+ T cells and intracellular Aiolos were measured by flow cytometry.  Interleukin (IL)-2 and IL-1β prodn. was stimulated with anti-CD3 and lipopolysaccharide, resp., in an ex vivo whole blood assay.  Results SLE patient PBMCs expressed significantly higher CRBN (1.5-fold), IKZF1 (2.1-fold) and IKZF3 (4.1- fold) mRNA levels compared with healthy volunteers.  Iberdomide significantly reduced Ikaros and Aiolos protein levels in B cells, T cells and monocytes.  In SLE PBMC cultures, iberdomide inhibited anti-dsDNA and anti-phospholipid autoantibody prodn. (IC50 ≈10 nM).  Single doses of iberdomide (0.3-6mg) in healthy volunteers decreased intracellular Aiolos (min. mean per cent of baseline: ≈12%-28% (B cells); ≈0%-33% (T cells)), decreased abs. CD19+ B cells, increased IL-2 and decreased IL-1β prodn. ex vivo.  Conclusions These findings demonstrate pharmacodynamic activity of iberdomide and support its further clin. development for the treatment of SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRD6MltUiWQ7Vg90H21EOLACvtfcHk0ljnwDCsfrQu9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVektbw%253D&md5=200098adf4787ee935df528d18a5508d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2017-212916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2017-212916%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DKosek%26aufirst%3DJ.%26aulast%3DRingheim%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DPalmisano%26aufirst%3DM.%26aulast%3DChopra%26aufirst%3DR.%26atitle%3DCereblon%2520modulator%2520iberdomide%2520induces%2520degradation%2520of%2520the%2520transcription%2520factors%2520Ikaros%2520and%2520Aiolos%253A%2520immunomodulation%2520in%2520healthy%2520volunteers%2520and%2520relevance%2520to%2520systemic%2520lupus%2520erythematosus%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2018%26volume%3D77%26spage%3D1516%26epage%3D1523%26doi%3D10.1136%2Fannrheumdis-2017-212916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matyskiela, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baculi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBrun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagarigan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmel, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, P. P.</span></span> <span> </span><span class="NLM_article-title">A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1KqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=535-542&author=M.+E.+Matyskielaauthor=W.+Zhangauthor=H.-W.+Manauthor=G.+Mullerauthor=G.+Khambattaauthor=F.+Baculiauthor=M.+Hickmanauthor=L.+LeBrunauthor=B.+Pagariganauthor=G.+Carmelauthor=C.-C.+Luauthor=G.+Luauthor=M.+Rileyauthor=Y.+Satohauthor=P.+Schaferauthor=T.+O.+Danielauthor=J.+Carmichaelauthor=B.+E.+Cathersauthor=P.+P.+Chamberlain&title=A+Cereblon+Modulator+%28CC-220%29+with+Improved+Degradation+of+Ikaros+and+Aiolos&doi=10.1021%2Facs.jmedchem.6b01921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos</span></div><div class="casAuthors">Matyskiela, Mary E.; Zhang, Weihong; Man, Hon-Wah; Muller, George; Khambatta, Godrej; Baculi, Frans; Hickman, Matthew; LeBrun, Laurie; Pagarigan, Barbra; Carmel, Gilles; Lu, Chin-Chun; Lu, Gang; Riley, Mariko; Satoh, Yoshitaka; Schafer, Peter; Daniel, Thomas O.; Carmichael, James; Cathers, Brian E.; Chamberlain, Philip P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">535-542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The drugs lenalidomide and pomalidomide bind to the protein cereblon, directing the CRL4-CRBN E3 ligase toward the transcription factors Ikaros and Aiolos to cause their ubiquitination and degrdn.  Here we describe CC-220 (compd. 6), a cereblon modulator in clin. development for systemic lupus erythematosis and relapsed/refractory multiple myeloma.  Compd. 6 binds cereblon with a higher affinity than lenalidomide or pomalidomide.  Consistent with this, the cellular degrdn. of Ikaros and Aiolos is more potent and the extent of substrate depletion is greater.  The crystal structure of cereblon in complex with DDB1 and compd. 6 reveals that the increase in potency correlates with increased contacts between compd. 6 and cereblon away from the modeled binding site for Ikaros/Aiolos.  These results describe a new cereblon modulator which achieves greater substrate degrdn. via tighter binding to the cereblon E3 ligase and provides an example of the effect of E3 ligase binding affinity with relevance to other drug discovery efforts in targeted protein degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGropbvYIxr5j7Vg90H21EOLACvtfcHk0ljnwDCsfrQu9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1KqsLs%253D&md5=8358ae8563f8f2c09dbf68683e5e4008</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01921%26sid%3Dliteratum%253Aachs%26aulast%3DMatyskiela%26aufirst%3DM.%2BE.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMan%26aufirst%3DH.-W.%26aulast%3DMuller%26aufirst%3DG.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DBaculi%26aufirst%3DF.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DLeBrun%26aufirst%3DL.%26aulast%3DPagarigan%26aufirst%3DB.%26aulast%3DCarmel%26aufirst%3DG.%26aulast%3DLu%26aufirst%3DC.-C.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DRiley%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DSchafer%26aufirst%3DP.%26aulast%3DDaniel%26aufirst%3DT.%2BO.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DChamberlain%26aufirst%3DP.%2BP.%26atitle%3DA%2520Cereblon%2520Modulator%2520%2528CC-220%2529%2520with%2520Improved%2520Degradation%2520of%2520Ikaros%2520and%2520Aiolos%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D535%26epage%3D542%26doi%3D10.1021%2Facs.jmedchem.6b01921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capitosti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. L.</span></span> <span> </span><span class="NLM_article-title">Facile synthesis of an azido-labeled thalidomide analogue</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2865</span>– <span class="NLM_lpage">2867</span>, <span class="refDoi"> DOI: 10.1021/ol034906w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol034906w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1Cgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=2865-2867&author=S.+M.+Capitostiauthor=T.+P.+Hansenauthor=M.+L.+Brown&title=Facile+synthesis+of+an+azido-labeled+thalidomide+analogue&doi=10.1021%2Fol034906w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Synthesis of an Azido-Labeled Thalidomide Analogue</span></div><div class="casAuthors">Capitosti, Scott M.; Hansen, Todd P.; Brown, Milton L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2865-2867</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A five-step synthesis of an azido-thalidomide analog I is presented.  The sequence requires cheap and readily available starting materials and reagents, and only two steps require purifn.  Addnl., I possesses activity comparable to that of thalidomide in inhibiting the proliferation of human microvascular endothelial cells, thus providing impetus for its use as a potential photoaffinity label of thalidomide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquqM8L-K7ZtrVg90H21EOLACvtfcHk0lgNNhwF1ccUUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1Cgs70%253D&md5=fdefbdcf05d15f638e322bc9e5687ebb</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fol034906w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol034906w%26sid%3Dliteratum%253Aachs%26aulast%3DCapitosti%26aufirst%3DS.%2BM.%26aulast%3DHansen%26aufirst%3DT.%2BP.%26aulast%3DBrown%26aufirst%3DM.%2BL.%26atitle%3DFacile%2520synthesis%2520of%2520an%2520azido-labeled%2520thalidomide%2520analogue%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D2865%26epage%3D2867%26doi%3D10.1021%2Fol034906w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambeir, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haemers, A.</span></span> <span> </span><span class="NLM_article-title">Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2411</span>– <span class="NLM_lpage">2413</span>, <span class="refDoi"> DOI: 10.1021/jm0499209</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0499209" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisl2it7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2411-2413&author=J.+Joossensauthor=P.+Van+der+Vekenauthor=A.-M.+Lambeirauthor=K.+Augustynsauthor=A.+Haemers&title=Development+of+irreversible+diphenyl+phosphonate+inhibitors+for+urokinase+plasminogen+activator&doi=10.1021%2Fjm0499209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Irreversible Diphenyl Phosphonate Inhibitors for Urokinase Plasminogen Activator</span></div><div class="casAuthors">Joossens, J.; Van der Veken, P.; Lambeir, A.-M.; Augustyns, K.; Haemers, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2411-2413</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report the synthesis and biochem. evaluation of selective, irreversible di-Ph phosphonate inhibitors for urokinase plasminogen activator (uPA).  A di-Ph phosphonate group was introduced on the substrate-like peptide Z-D-Ser-Ala-Arg, and modification of the guanidine side chain was investigated.  A guanylated benzyl group appeared the most promising side chain modification.  A kapp value in the 103 M-1 s-1 range for uPA was obtained, together with a selectivity index higher than 240 toward other trypsin-like proteases such as tPA, thrombin, plasmin, and FXa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreVabGd76ZqrVg90H21EOLACvtfcHk0lgNNhwF1ccUUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisl2it7k%253D&md5=a5e0eb9791dc09a1ac71b6cf8415af29</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm0499209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0499209%26sid%3Dliteratum%253Aachs%26aulast%3DJoossens%26aufirst%3DJ.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26aulast%3DLambeir%26aufirst%3DA.-M.%26aulast%3DAugustyns%26aufirst%3DK.%26aulast%3DHaemers%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520irreversible%2520diphenyl%2520phosphonate%2520inhibitors%2520for%2520urokinase%2520plasminogen%2520activator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2411%26epage%3D2413%26doi%3D10.1021%2Fjm0499209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omodera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funakoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3307</span>– <span class="NLM_lpage">3319</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.12.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1016%2Fj.bmc.2005.12.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=16434202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtFGjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=3307-3319&author=K.+Kanumaauthor=K.+Omoderaauthor=M.+Nishiguchiauthor=T.+Funakoshiauthor=S.+Chakiauthor=Y.+Nagaseauthor=I.+Iidaauthor=J.-i.+Yamaguchiauthor=G.+Sempleauthor=T.-A.+Tranauthor=Y.+Sekiguchi&title=Identification+of+4-amino-2-cyclohexylaminoquinazolines+as+metabolically+stable+melanin-concentrating+hormone+receptor+1+antagonists&doi=10.1016%2Fj.bmc.2005.12.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists</span></div><div class="casAuthors">Kanuma, Kosuke; Omodera, Katsunori; Nishiguchi, Mariko; Funakoshi, Takeo; Chaki, Shigeyuki; Nagase, Yasuko; Iida, Izumi; Yamaguchi, Jun-ichi; Semple, Graeme; Tran, Thuy-Anh; Sekiguchi, Yoshinori</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3307-3319</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of the distance between two key pharmacophore features within our first hit compds. led to the identification of a new class of potent non-peptidic antagonists for the MCH-R1, based around 4-amino-2-cyclohexylaminoquinazolines.  In particular, ATC0065, N 2-[cis-4-({2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl}amino)cyclohexyl]-N4,N4-dimethylquinazoline-2,4-diamine dihydrochloride, bound with high affinity to the MCH-R1 (IC50 value of 16 nM) and showed good metabolic stability in liver microsomes from human and rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5kEHF1eMMQrVg90H21EOLACvtfcHk0lgNNhwF1ccUUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtFGjtb4%253D&md5=99bcc1d1e058b4c8e5baa2efcbae7447</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.12.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.12.052%26sid%3Dliteratum%253Aachs%26aulast%3DKanuma%26aufirst%3DK.%26aulast%3DOmodera%26aufirst%3DK.%26aulast%3DNishiguchi%26aufirst%3DM.%26aulast%3DFunakoshi%26aufirst%3DT.%26aulast%3DChaki%26aufirst%3DS.%26aulast%3DNagase%26aufirst%3DY.%26aulast%3DIida%26aufirst%3DI.%26aulast%3DYamaguchi%26aufirst%3DJ.-i.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DT.-A.%26aulast%3DSekiguchi%26aufirst%3DY.%26atitle%3DIdentification%2520of%25204-amino-2-cyclohexylaminoquinazolines%2520as%2520metabolically%2520stable%2520melanin-concentrating%2520hormone%2520receptor%25201%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D3307%26epage%3D3319%26doi%3D10.1016%2Fj.bmc.2005.12.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nouch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abid, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diéguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pàmies, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, W.</span></span> <span> </span><span class="NLM_article-title">Enantioselective synthesis of 6,6-disubstituted pentafulvenes containing a chiral pendant hydroxy group</span>. <i>Chem.—Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">17195</span>– <span class="NLM_lpage">17198</span>, <span class="refDoi"> DOI: 10.1002/chem.201704247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1002%2Fchem.201704247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=29083067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKmurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=17195-17198&author=R.+Nouchauthor=M.+Ciniauthor=M.+Magreauthor=M.+Abidauthor=M.+Di%C3%A9guezauthor=O.+P%C3%A0miesauthor=S.+Woodwardauthor=W.+Lewis&title=Enantioselective+synthesis+of+6%2C6-disubstituted+pentafulvenes+containing+a+chiral+pendant+hydroxy+group&doi=10.1002%2Fchem.201704247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Synthesis of 6,6-Disubstituted Pentafulvenes Containing a Chiral Pendant Hydroxy Group</span></div><div class="casAuthors">Nouch, Ryan; Cini, Melchior; Magre, Marc; Abid, Mohammed; Dieguez, Montserrat; Pamies, Oscar; Woodward, Simon; Lewis, William</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">68</span>),
    <span class="NLM_cas:pages">17195-17198</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Simple enantioselective synthesis of 6,6-disubstituted pentafulvenes bearing chiral pendant hydroxy groups are attained by cascade reactivity using com. available proline-based organocatalysts.  Condensation of cyclopentadiene with the acetyl function of a 1,2-formylacetophenone, followed by cyclization of a resulting fulvene-stabilized carbanion with the formyl group, generates bicyclic chiral alcs. with initial er values up to 94:6.  Exceptional enantio-enrichment of the resultant alcs. results upon crystn.-even near racemic samples spontaneously de-racemize.  This enables new families of substituted cyclopentadienes that are both enantiomerically and diastereomerically pure to be rapidly attained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_gTS4C30u6LVg90H21EOLACvtfcHk0lgIZ9mAXjaOAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKmurjI&md5=ed815c390637d2d2ca7c6322180f583b</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fchem.201704247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201704247%26sid%3Dliteratum%253Aachs%26aulast%3DNouch%26aufirst%3DR.%26aulast%3DCini%26aufirst%3DM.%26aulast%3DMagre%26aufirst%3DM.%26aulast%3DAbid%26aufirst%3DM.%26aulast%3DDi%25C3%25A9guez%26aufirst%3DM.%26aulast%3DP%25C3%25A0mies%26aufirst%3DO.%26aulast%3DWoodward%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DW.%26atitle%3DEnantioselective%2520synthesis%2520of%25206%252C6-disubstituted%2520pentafulvenes%2520containing%2520a%2520chiral%2520pendant%2520hydroxy%2520group%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D17195%26epage%3D17198%26doi%3D10.1002%2Fchem.201704247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Tripodal tris-tacn and tris-dpa platforms for assembling phosphate-templated trimetallic centers</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">17366</span>– <span class="NLM_lpage">17369</span>, <span class="refDoi"> DOI: 10.1021/ja108212v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja108212v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVGksbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=17366-17369&author=R.+Caoauthor=P.+M%C3%BCllerauthor=S.+J.+Lippard&title=Tripodal+tris-tacn+and+tris-dpa+platforms+for+assembling+phosphate-templated+trimetallic+centers&doi=10.1021%2Fja108212v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Tripodal Tris-tacn and Tris-dpa Platforms for Assembling Phosphate-Templated Trimetallic Centers</span></div><div class="casAuthors">Cao, Rui; Muller, Peter; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">17366-17369</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidentate tripodal ligands, N(CH2-m-C6H4-CH2tacn)3 (L1) and N(CH2-o-C6H4-CH2N(CH2py)2)3 (L2), were devised for assembling high-nuclearity metal clusters.  By using the same tripodal platform with different ligand appendages, either triazacyclononanes or dipicolylamines, and functionalizing either the ortho or the meta positions on the tris(xylyl) linker arms, discrete trimetal phosphate units of relevance to phosphate-metabolizing trimetallic centers in biol. were prepd.  Four such compds., [(CuIICl)3(HPO4)L1](PF6) (1), [(CuIICl)3(HAsO4)L1](PF6) (2), Na2[MnIII6MnII2(H2O)2(HPO4)6(PO4)4(L1)2] (3), and [CoII3(H2PO4)Cl2(MeCN)L2](PF6)3 (4), all contg. three metal centers bound to a central phosphate or arsenate unit bridging oxygen atoms, were synthesized and structurally characterized.  These results demonstrate the propensity of this novel tripodal ligand platform, in the presence of phosphate or arsenate, to assemble {M3(EO4)} units and thus structurally mimic trimetallic active sites of proteins involved in phosphate metab.  Reactivity studies reveal that the tricopper complex 1 is more efficient than monocopper analogs in catalyzing the hydrolysis of 4-nitrophenyl phosphate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNiyoN_nHxgLVg90H21EOLACvtfcHk0lgIZ9mAXjaOAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVGksbzJ&md5=26ced8d2ad3686926092f1940b96a9cc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fja108212v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja108212v%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DR.%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DTripodal%2520tris-tacn%2520and%2520tris-dpa%2520platforms%2520for%2520assembling%2520phosphate-templated%2520trimetallic%2520centers%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D17366%26epage%3D17369%26doi%3D10.1021%2Fja108212v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinebach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udeshi, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehm, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köpff, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gütschow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krönke, J.</span></span> <span> </span><span class="NLM_article-title">Homo-PROTACs for the chemical knockdown of cereblon</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2782</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFejsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2771-2782&author=C.+Steinebachauthor=S.+Lindnerauthor=N.+D.+Udeshiauthor=D.+C.+Maniauthor=H.+Kehmauthor=S.+K%C3%B6pffauthor=S.+A.+Carrauthor=M.+G%C3%BCtschowauthor=J.+Kr%C3%B6nke&title=Homo-PROTACs+for+the+chemical+knockdown+of+cereblon&doi=10.1021%2Facschembio.8b00693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Homo-PROTACs for the Chemical Knockdown of Cereblon</span></div><div class="casAuthors">Steinebach, Christian; Lindner, Stefanie; Udeshi, Namrata D.; Mani, Deepak C.; Kehm, Hannes; Koepff, Simon; Carr, Steven A.; Guetschow, Michael; Kroenke, Jan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2771-2782</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide, all approved for the treatment of multiple myeloma, induce targeted ubiquitination and degrdn. of Ikaros (IKZF1) and Aiolos (IKZF3) via the cereblon (CRBN) E3 ubiquitin ligase.  IMiD-based proteolysis-targeting chimeras (PROTACs) can efficiently recruit CRBN to a protein of interest, leading to its ubiquitination and proteasomal degrdn.  By linking two pomalidomide mols., we designed homobifunctional, so-called homo-PROTACs and investigated their ability to induce self-directed ubiquitination and degrdn.  The homodimerized compd. I was characterized as a highly potent and efficient CRBN degrader with only minimal effects on IKZF1 and IKZF3.  The cellular selectivity of I for CRBN degrdn. was confirmed at the proteome level by quant. mass spectrometry.  Inactivation by compd. I did not affect proliferation of different cell lines, prevented pomalidomide-induced degrdn. of IKZF1 and IKZF3, and antagonized the effects of pomalidomide on multiple myeloma cells.  Homobifunctional CRBN degraders will be useful tools for future biomedical investigations of CRBN-related signaling and may help to further elucidate the mol. mechanism of thalidomide analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosUoD-BkTUibVg90H21EOLACvtfcHk0lgIZ9mAXjaOAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFejsLrO&md5=71bf2d53ad23c2b873f754de5144883c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00693%26sid%3Dliteratum%253Aachs%26aulast%3DSteinebach%26aufirst%3DC.%26aulast%3DLindner%26aufirst%3DS.%26aulast%3DUdeshi%26aufirst%3DN.%2BD.%26aulast%3DMani%26aufirst%3DD.%2BC.%26aulast%3DKehm%26aufirst%3DH.%26aulast%3DK%25C3%25B6pff%26aufirst%3DS.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26aulast%3DKr%25C3%25B6nke%26aufirst%3DJ.%26atitle%3DHomo-PROTACs%2520for%2520the%2520chemical%2520knockdown%2520of%2520cereblon%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D2771%26epage%3D2782%26doi%3D10.1021%2Facschembio.8b00693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boichenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bär, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez
Alvarez, B.</span></span> <span> </span><span class="NLM_article-title">A FRET-based assay for the identification and characterization of cereblon ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">770</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01735</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01735" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1yktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=770-774&author=I.+Boichenkoauthor=S.+Deissauthor=K.+B%C3%A4rauthor=M.+D.+Hartmannauthor=B.+Hernandez%0AAlvarez&title=A+FRET-based+assay+for+the+identification+and+characterization+of+cereblon+ligands&doi=10.1021%2Facs.jmedchem.5b01735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands</span></div><div class="casAuthors">Boichenko, Iuliia; Deiss, Silvia; Baer, Kerstin; Hartmann, Marcus D.; Hernandez Alvarez, Birte</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">770-774</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cereblon serves as an ubiquitin ligase substrate receptor that can be tuned toward different target proteins by various cereblon-binding agents.  This offers one of the most promising avenues for targeted protein degrdn. in cancer therapy, but cereblon binding can also mediate teratogenic effects.  We present an effective assay that is suited for high-throughput screening of compd. libraries for off-target cereblon interactions but also can guide lead optimization and rational design of novel cereblon effector mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzkRpBLlhlVbVg90H21EOLACvtfcHk0liG1IwGXXtEyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1yktg%253D%253D&md5=f0400506428f439e81f579204e0bd39d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01735%26sid%3Dliteratum%253Aachs%26aulast%3DBoichenko%26aufirst%3DI.%26aulast%3DDeiss%26aufirst%3DS.%26aulast%3DB%25C3%25A4r%26aufirst%3DK.%26aulast%3DHartmann%26aufirst%3DM.%2BD.%26aulast%3DHernandez%2BAlvarez%26aufirst%3DB.%26atitle%3DA%2520FRET-based%2520assay%2520for%2520the%2520identification%2520and%2520characterization%2520of%2520cereblon%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D770%26epage%3D774%26doi%3D10.1021%2Facs.jmedchem.5b01735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">Xds</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/s0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=Xds&doi=10.1107%2Fs0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0liG1IwGXXtEyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXds%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2Fs0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplyakov, A.</span></span> <span> </span><span class="NLM_article-title">Molecular replacement with MOLREP</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1107/s0907444909042589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1107%2Fs0907444909042589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=20057045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Kktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=22-25&author=A.+Vaginauthor=A.+Teplyakov&title=Molecular+replacement+with+MOLREP&doi=10.1107%2Fs0907444909042589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular replacement with MOLREP</span></div><div class="casAuthors">Vagin, Alexei; Teplyakov, Alexei</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-25</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">MOLREP is an automated program for mol. replacement that utilizes a no. of original approaches to rotational and translational search and data prepn.  Since the first publication describing the program, MOLREP has acquired a variety of features that include weighting of the X-ray data and search models, multi-copy search, fitting the model into electron d., structural superposition of two models and rigid-body refinement.  The program can run in a fully automatic mode using optimized parameters calcd. from the input data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzj5SzYvyu_7Vg90H21EOLACvtfcHk0liG1IwGXXtEyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Kktw%253D%253D&md5=820d114719aca209994ffb0403e3b20d</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1107%2Fs0907444909042589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252Fs0907444909042589%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DTeplyakov%26aufirst%3DA.%26atitle%3DMolecular%2520replacement%2520with%2520MOLREP%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D22%26epage%3D25%26doi%3D10.1107%2Fs0907444909042589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of <i>Coot</i></span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/s0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2Fs0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0liG1IwGXXtEyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2Fs0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Schrodinger,
LLC</span>.  <i>The PyMOL Molecular Graphics
System</i>, Version 2.2.1.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schrodinger%2C%0ALLC.+The+PyMOL+Molecular+Graphics%0ASystem%2C+Version+2.2.1."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%250ASystem" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0Q" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0Q','PDB','6R0Q'); return false;">PDB: 6R0Q</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0S" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0S','PDB','6R0S'); return false;">PDB: 6R0S</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0V','PDB','6R0V'); return false;">PDB: 6R0V</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0U" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0U','PDB','6R0U'); return false;">PDB: 6R0U</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R11" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R11','PDB','6R11'); return false;">PDB: 6R11</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V2Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4V2Y','PDB','4V2Y'); return false;">PDB: 4V2Y</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1X','PDB','6R1X'); return false;">PDB: 6R1X</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R12" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R12','PDB','6R12'); return false;">PDB: 6R12</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1K','PDB','6R1K'); return false;">PDB: 6R1K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1D" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1D','PDB','6R1D'); return false;">PDB: 6R1D</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R13" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R13','PDB','6R13'); return false;">PDB: 6R13</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R18" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R18','PDB','6R18'); return false;">PDB: 6R18</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1C" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1C','PDB','6R1C'); return false;">PDB: 6R1C</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1W','PDB','6R1W'); return false;">PDB: 6R1W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1A','PDB','6R1A'); return false;">PDB: 6R1A</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R19" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R19','PDB','6R19'); return false;">PDB: 6R19</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4v2y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4v2y','PDB','4v2y'); return false;">PDB: 4v2y</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i50"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00454">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_76804"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00454">10.1021/acs.jmedchem.9b00454</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HPLC traces of tested compounds, western blot quantification and normalization IKZF3, concentration response curve for IKZF3 mAb, and <i>K</i><sub>i</sub> values of tested compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_001.pdf">jm9b00454_si_001.pdf (1.73 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00454/suppl_file/jm9b00454_si_002.csv">jm9b00454_si_002.csv (1.18 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Crystal structures have been deposited in the protein data bank (PDB) under the accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0S">6R0S</a> (<b>4a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0V">6R0V</a> (<b>4b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0U">6R0U</a> (<b>5a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R11">6R11</a> (<b>5b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1X">6R1X</a> (<b>7a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R12">6R12</a> (<b>7b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1K">6R1K</a> (<b>7c</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1D">6R1D</a> (<b>7d</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R13">6R13</a> (<b>7f</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R18">6R18</a> (<b>11a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1C">6R1C</a> (<b>12a</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1W">6R1W</a> (<b>16b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R19">6R19</a> (<b>20a</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R1A">6R1A</a> (<b>20b</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6R0Q">6R0Q</a> (CBG). The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00454&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00454%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-14%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00454" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b6ccabb01964","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
